



**Annual Registration Statement / Annual Report 2025**  
**Form 56-1 One Report**  
**(e-One Report)**

**Bangkok Genomics Innovation Public Company Limited**

Fiscal Year End 31 December 2025

# Table of Contents

Page

## Part 1 Business Operations and Performance

### 1. Organizational structure and operation of the group of companies

|                                                      |    |
|------------------------------------------------------|----|
| 1.1 Policy and business overview                     | 1  |
| 1.2 Business Operations                              | 8  |
| 1.3 Shareholding structure                           | 22 |
| 1.4 Number of registered capital and paid-up capital | 28 |
| 1.5 Issuance of other securities                     | 29 |
| 1.6 Dividend payment policy                          | 30 |

### 2. Risk management

|                               |    |
|-------------------------------|----|
| 2.1 Risk mgmt policy and plan | 31 |
| 2.2 Risk factors              | 32 |

### 3. Business sustainability development

|                                                                       |    |
|-----------------------------------------------------------------------|----|
| 3.1 Sustainability Management Policy and Targets                      | 39 |
| 3.2 Management of impacts on stakeholders in the business value chain | 41 |
| 3.3 Management of environmental sustainability                        | 46 |
| 3.4 Social sustainability management                                  | 56 |

### 4. Management Discussion and Analysis (MD&A)

|                                                                                                                                         |    |
|-----------------------------------------------------------------------------------------------------------------------------------------|----|
| 4.1 Operation, financial condition and material changes, accompanied by the causes or factors contributing thereto during the past year | 71 |
| 4.2 Potential factors or incidents that may materially affect the financial condition or the operating results                          | 77 |
| 4.3 Disclose information from the financial statements and significant financial ratios                                                 | 78 |

### 5. General information and other material facts

|                                                                                          |    |
|------------------------------------------------------------------------------------------|----|
| 5.1 General information                                                                  | 91 |
| 5.2 Other material facts                                                                 | 92 |
| 5.3 Legal disputes                                                                       | 93 |
| 5.4 Secondary market                                                                     | 94 |
| 5.5 Financial institution with regular contact (only in case of debt securities offeror) | 95 |

## Table of Contents (continued)

|                                                                                                                                                          | Page |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <b>Part 2 Corporate Governance</b>                                                                                                                       |      |
| <b>6. Corporate governance policy</b>                                                                                                                    |      |
| 6.1 Corporate Governance Policy                                                                                                                          | 96   |
| 6.2 Business code of conduct (if any)                                                                                                                    | 105  |
| 6.3 Material changes and developments regarding policy, guidelines and corporate governance system in the preceding year                                 | 119  |
| <b>7. Corporate governance structure and significant information related to the board of directors, subcommittees, executives, employees, and others</b> |      |
| 7.1 Corporate Governance Structure                                                                                                                       | 121  |
| 7.2 Information on the Board of Directors                                                                                                                | 122  |
| 7.3 Information on subcommittees                                                                                                                         | 132  |
| 7.4 Information on executives                                                                                                                            | 140  |
| 7.5 Information on employees                                                                                                                             | 144  |
| 7.6 Other significant information                                                                                                                        | 148  |
| <b>8. Report on key operating results on corporate governance</b>                                                                                        |      |
| 8.1 Summary of duty performance of the Board of Directors in the past year                                                                               | 150  |
| 8.2 Report on the results of duty performance of the Audit Committee in the past year                                                                    | 168  |
| 8.3 Summary of the results of duty performance of subcommittees                                                                                          | 170  |
| <b>9. Internal control and related party transactions</b>                                                                                                |      |
| 9.1 Internal control                                                                                                                                     | 172  |
| 9.2 Related party transactions                                                                                                                           | 175  |
| <b>Part 3 Financial Statement</b>                                                                                                                        |      |
| Board of Directors' Responsibility Statement for the Financial Report                                                                                    | 206  |
| Auditor's Report                                                                                                                                         | 209  |
| Financial Statements                                                                                                                                     | 214  |
| Notes to the Financial Statements                                                                                                                        | 223  |
| <b>Back up attachment</b>                                                                                                                                |      |
| Attachment                                                                                                                                               | 258  |

## **Part 1 Business Operations and Performance**



## 1. Organizational structure and operation of the group of companies

### 1.1 Policy and business overview

#### 1.1.1 Overview of the vision, objectives, goals and business strategies

##### Message from the chairman

Dear Shareholders and Stakeholders,

The year 2025 marked another period in which businesses faced continued volatility in the global economy and evolving business environments. Uncertainty in international trade, trade policies of key partner countries, and the increase in import tariffs remained key factors exerting pressure on global trade. Nevertheless, the healthcare and medical sector continues to play a vital role in improving people's quality of life and is expected to maintain its growth trajectory, driven by increasing global demand for healthcare services. This trend is further supported by the growing emphasis on preventive healthcare as well as government initiatives promoting the development of the medical and health technology industries. At the same time, Thailand is experiencing a continuous decline in its birth rate, which represents a structural factor that may affect the demand for certain healthcare services in the long term. As a result, industry operators need to adapt their business strategies and broaden their service offerings to align with the changing demographic structure.

Bangkok Genomics Innovation Public Company Limited (BKGI) remains committed to continuously enhancing its capabilities in genetic and genomic testing services. Over the past year, the Company has invested in new technologies and further developed its analytical processes to improve efficiency and accuracy in response to the growing demand for healthcare services and to support the advancement of precision medicine in Thailand. The Company operates a standardized medical laboratory and provides comprehensive genetic testing services covering all stages of life from prenatal screening to genetic analysis for adult and elderly healthcare. At the same time, the Company continues to strengthen its organizational capabilities by enhancing the expertise of its personnel and adopting internationally recognized technologies to reinforce its competitiveness. In addition, BKGI views the ongoing industry changes as an opportunity to refine its business strategy, particularly through supportive policies from the National Health Security Office (NHSO), which have increased access to Down syndrome screening for pregnant women. This has led to a significant increase in testing volumes, thereby improving equipment utilization and reducing the cost per test. The Company therefore aims to expand its genetic testing platforms to develop into a comprehensive genomics solutions provider for hospitals as well as public and private healthcare organizations. This strategy will help diversify the Company's revenue structure, including income from the sale and installation of laboratory instruments and recurring revenue from the supply of diagnostic reagents over the long term.

Finally, on behalf of the Board of Directors, the management team, and all employees of the Company, I would like to express my sincere appreciation to our shareholders, customers, business partners, and all stakeholders for their continued support and trust. The Company remains committed to strengthening collaboration with organizations across the healthcare industry to develop solutions that effectively respond to market needs. At the same time, we uphold strong corporate governance principles with transparency and accountability, while pursuing sustainable business operations by minimizing environmental impacts from laboratory operations and promoting efficient resource utilization. Through our services, we also strive to support preventive healthcare and contribute to improving public health. BKGI will continue to move forward with determination to achieve sustainable growth, create value for society, and deliver long-term returns to our shareholders.

##### Vision

Using professional and scientific expertise, making quality of life accessible for all.

## Objectives

### SCOPEs

We are dedicated to becoming a leader in the healthcare business, driving improvements in quality of life through our core mission:

S – Support Medical Institutions, Research Institutions, Pharmaceutical Companies, and other public and private partners.

C – Cooperate with referral laboratory centers across the territory.

O – Obtain ISO certificates related to business scopes.

P – Provide quality data with outstandingly competitive pricing using our expertise and scalable platform.

E – Ecosystem health and sustainability focused.

s – Support the development and implementation of the National Public Health Data Analysis to help optimize health treatment and services for the public.

## Goals

To become a leader in providing innovative solutions for personal and public health using advanced technologies and to create lasting impacts for a healthier future.

## Business strategies

- Differentiation – Competitive advantage through quality service, reduced waiting times, and reasonable pricing.
- Recommend – Encouraging repeat purchases, word-of-mouth referrals, and expansion of new products and services to both existing and new customers.
- People – A team of highly knowledgeable, skilled, and experienced professionals in our core business.
- Technology – Cost efficiency driven by proprietary BGI & Branding technology. Customer
- Satisfaction – Trusted by customers and medical professionals, with direct distribution ensuring quality and reliability.

Business Partner – Strong and strategic partnerships.

### 1.1.2 Material changes and developments

#### Details regarding material changes and developments

| years | Material changes and developments |
|-------|-----------------------------------|
|-------|-----------------------------------|

| years | Material changes and developments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2025  | <ul style="list-style-type: none"> <li>● Signed a Memorandum of Understanding (MoU) with Eisai (Thailand) Marketing Co., Ltd. to enhance Alzheimer's disease screening and treatment, with the aim of developing a comprehensive Alzheimer's patient care ecosystem in Thailand.</li> <li>● Signed a Memorandum of Understanding (MoU) with MGI Tech Co., Ltd. to expand the utilization and accessibility of the Next Generation Sequencing (NGS) platform, enhancing the capability of genetic and genomic testing services in Thailand.</li> <li>● Signed a Letter of Intent (LOI) with the Agricultural Research Development Agency (Public Organization) (ARDA) to strengthen collaboration in agricultural innovation and sustainable development.</li> <li>● Signed an agreement on research and innovation rights and management with the Research Affairs, Faculty of Medicine, Chulalongkorn University, for a project on the development of CAR-T cell products for the treatment of hematologic cancers, aimed at enhancing Thailand's competitiveness in the advanced medical products industry.</li> <li>● Signed a laboratory testing service agreement with the Health Intervention and Technology Assessment Program, Department of Medical Services, for the research project titled "Assessment of Biological Age Using Telomere Length and Physical Performance among Thai Population Aged 50 and Above in Health Region 5."</li> <li>● Signed a contract for the lease of a high-throughput Next Generation Sequencer and related equipment, including reagent kits for Non-Invasive Prenatal Testing (NIPT) for Down syndrome screening, with the Department of Medical Sciences, Ministry of Public Health.</li> <li>● Signed a service contract with Lopburi Cancer Hospital for a research project on genetic variation analysis between lung cancer patients and non-cancer individuals using a 188-gene panel through Next Generation Sequencing (NGS) technology.</li> <li>● Signed an agreement for the lease of a high-performance Next Generation Sequencer and related equipment, including reagent kits for Non-Invasive Prenatal Testing (NIPT) for Down syndrome screening with the Department of Medical Sciences.</li> <li>● Capital increase in the subsidiary "OmicsSphere Co., Ltd.", in which the Company holds 99.99% of the registered capital, on 20 August 2025.</li> <li>● OmicsSphere Co., Ltd., a subsidiary of Bangkok Genomics Innovation Public Company Limited, signed a Memorandum of Understanding (MoU) on Advanced Therapy Medicinal Products (ATMPs) with the Department of Medical Services and Healgen Bio Pharmaceutical (Thailand) Co., Ltd. to promote the development of advanced medical technologies for clinical applications and national research advancement.</li> </ul> |

| years | Material changes and developments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2024  | <ul style="list-style-type: none"> <li>• Bangkok Genomics Innovation Public Company Limited was registered on the Stock Exchange of Thailand on March 20, 2024.</li> <li>• Signed a Memorandum of Understanding (MOU) with Bumrungrad Hospital and BGI Shenzhen to strengthen genomics medical services.</li> <li>• Signed a Memorandum of Understanding (MOU) with the Department of Medical Sciences and BGI Health (Hong Kong) to exchange academic knowledge in medical fields, including clinical whole exome sequencing, fetal chromosomal abnormalities screening (NIPT), and genetic screening for thalassemia in Thailand.</li> <li>• Established a 99.994% owned subsidiary named "Omics Sphere Co., Ltd." on November 1, 2024.</li> <li>• Established a 99.996% owned subsidiary named "Comprehensive Care Limited." on November 5, 2024.</li> <li>• Established a 25.000% owned joint venture named "Edge Medical (Thailand) Co., Ltd." on November 7, 2024.</li> <li>• Established a 50.998% owned subsidiary named "Biovision Tech Co., Ltd." on December 23, 2024.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                            |
| 2023  | <ul style="list-style-type: none"> <li>• Successfully passed proficiency testing for BRCA1/BRCA2 gene testing for hereditary cancers using NGS technology.</li> <li>• Signed an MOU with BGI Shenzhen Co., Ltd. and INNOBIC (Asia) Co., Ltd., the biotechnology division of PTT Public Company Limited, to jointly establish an international life sciences innovation center and promote a colorectal cancer prevention project in its early stages in Thailand using the "COLOTECT" testing kit under BGI technology in March 2023.</li> <li>• Certified for ISO/IEC 27001:2022 Information Security Management System (ISMS) in March 2023.</li> <li>• Collaborated on research and development with NSTDA on the "Microbial Study Process in the Gut using NGS Technology with the DNBSEQ-G50 Machine, covering library preparation, genetic code verification, and data analysis through Bioinformatics Software" to study human gut microbiota in April 2023.</li> <li>• Signed an MOU with the Faculty of Medicine Siriraj Hospital, Mahidol University, BGI Health (HK) Co., Ltd., and Hemogen Hongkong Alpha Technology Limited (HGI) to jointly develop, study, and find methods to prevent and treat thalassemia in Thailand.</li> <li>• Became a network healthcare provider under the NHSO's Lab Anywhere project, and BRCA1/BRCA2 genetic testing for breast cancer patients at high risk and first-degree relatives with a family history of mutation detection in June 2023.</li> </ul> |
| 2022  | <ul style="list-style-type: none"> <li>• BGI Tech Solutions (HK) transferred shares to BGI Health (HK), and BGI Health (HK) purchased shares from existing shareholders, increasing its ownership to 51%.</li> <li>• The extraordinary shareholders' meeting no. 2/2022 approved a capital increase of 340 million shares: <ul style="list-style-type: none"> <li>- 180 million shares allocated to existing shareholders in proportion.</li> <li>- 160 million shares to be offered for sale to the public.</li> </ul> </li> <li>• Opened the second medical technology clinic.</li> <li>• Began offering basic health check-up services.</li> <li>• Expanded service offerings to include cancer gene screening, PGT-A testing, and COLOTECT screening.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2021  | <ul style="list-style-type: none"> <li>• Joined as one of the referral service units with the National Health Security Office (NHSO).</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2020  | <ul style="list-style-type: none"> <li>• Set up a laboratory and provide services related to COVID-19 pathogen testing.</li> <li>• Received accreditation for laboratory standards ISO 15189 and ISO 15190.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

| years | Material changes and developments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2019  | <ul style="list-style-type: none"> <li>Received Technology Transfer to provide NIFTY services from the BGI Group.</li> <li>Began offering genetic decoding services to government agencies such as NSTDA, Chulabhorn Royal Academy, etc.</li> <li>Started providing full-scale NIFTY testing and analysis services.</li> </ul>                                                                                                                                                                                                                                                                           |
| 2018  | <ul style="list-style-type: none"> <li>Registered as a medical equipment importer and began importing key medical devices and genetic sequencing readers from companies in the BGI Group.</li> <li>Restructured shareholding, with BGI Tech Solutions (Hong Kong), a company in the BGI Group, acquiring a 49% share.</li> <li>Received an investment promotion certificate from the BOI for scientific testing services.</li> <li>Obtained a license for a healthcare facility that does not admit patients for overnight stays under the name "Bangkok Genomics Medical Technology Clinic."</li> </ul> |
| 2017  | <ul style="list-style-type: none"> <li>Registered on September 11, 2017, as Bangkok Genomics Innovation Co., Ltd. to engage in laboratory operations and provide medical diagnostic services.</li> <li>Began offering fetal chromosomal abnormality screening from maternal blood under the NIFTY brand of BGI Genomics Co., Ltd. ("BGI Genomics"), a company in the BGI Group, by collecting customer samples and sending them for analysis at BGI Group's laboratories abroad.</li> </ul>                                                                                                              |

### 1.1.3 Spending of the raised fund to serve the objectives declared in the registration statement for securities offering

Is there an issuance of equity securities or debt securities? : Yes

#### Spending of the money obtained from each offering of equity or debt securities

| List of spending of the money obtained from each offering of equity or debt securities                                |                        |                            |                        |
|-----------------------------------------------------------------------------------------------------------------------|------------------------|----------------------------|------------------------|
| Item 1                                                                                                                |                        |                            |                        |
| Types of securities used for fundraising                                                                              |                        |                            | Amount of funds raised |
| Equity Instruments                                                                                                    |                        |                            | 245.57 Million Baht    |
| Spending objectives                                                                                                   | Duration (approximate) | Amount of money as planned | Amount of spent money  |
| Working capital for business operations                                                                               | Dec 2026               | 245.57                     | 74.39                  |
| Implementation according to objectives                                                                                |                        |                            |                        |
| Achieve objectives                                                                                                    |                        |                            |                        |
| Progress of fund utilization / reasons and measures taken in case the funds are not spent according to the objectives |                        |                            |                        |
| -                                                                                                                     |                        |                            |                        |

**Related links**

<https://www.set.or.th/en/market/news-and-alert/newsdetails?id=100962800&symbol=BKGI>

**1.1.4 The obligations to which the company has committed in the registration statement, including the compliance with such obligations or conditions in the following years**

Are there any issued securities with obligations or : No  
conditions?

**1.1.5 Company information**

Company name : Bangkok Genomics Innovation Public Company Limited

Symbol : BKGI

Address : 3689 Rama IV Road, Phra Khanong Sub-district, Khlong  
Toei District

Province : Bangkok

Postcode : 10110

Business : Laboratory business and provide medical diagnosis  
services

Registration number : 0107565000671

Telephone : 0-2261-2638

Facsimile number : 0-2261-2639

Website : <https://www.bangkokgenomics.com/>

Email : BKGI\_IR@bangkokgenomics.com

Total shares sold

Common stock : 600,000,000

Preferred stock : 0



## 1.2 Nature of business

### 1.2.1 Revenue structure

#### Revenue structure by product line or business group

|                                                             | 2023       | 2024       | 2025       |
|-------------------------------------------------------------|------------|------------|------------|
| <b>Total revenue from operations (thousand baht)</b>        | 245,389.66 | 337,592.90 | 379,511.13 |
| Reproductive Health service (thousand baht)                 | 207,107.38 | 233,135.70 | 232,966.54 |
| Infectious Disease Service (thousand baht)                  | 22,807.94  | 227.80     | 93.00      |
| Other Screening Test Services (thousand baht)               | 1,868.94   | 17,942.09  | 22,317.15  |
| Tech- Solution Services (thousand baht)                     | 9,597.72   | 5,196.59   | 8,604.38   |
| Advanced Therapy Medicinal Product Services (thousand baht) | 0.00       | 0.00       | 3,663.55   |
| Sale sequencers and reagent (thousand baht)                 | 4,007.68   | 80,106.45  | 100,774.41 |
| Sale of Advanced Therapy Medicinal Products (thousand baht) | 0.00       | 0.00       | 9,158.88   |
| Sale other (thousand baht)                                  | 0.00       | 984.27     | 1,933.22   |
| Others (thousand baht)                                      | 0.00       | 0.00       | 0.00       |
| <b>Total revenue from operations (%)</b>                    | 100.00%    | 100.00%    | 100.00%    |
| Reproductive Health service (%)                             | 84.40%     | 69.06%     | 61.39%     |
| Infectious Disease Service (%)                              | 9.30%      | 0.07%      | 0.02%      |
| Other Screening Test Services (%)                           | 0.76%      | 5.31%      | 5.88%      |
| Tech- Solution Services (%)                                 | 3.91%      | 1.54%      | 2.27%      |
| Advanced Therapy Medicinal Product Services (%)             | 0.00%      | 0.00%      | 0.97%      |
| Sale sequencers and reagent (%)                             | 1.63%      | 23.73%     | 26.55%     |



|                                                 | 2023  | 2024  | 2025  |
|-------------------------------------------------|-------|-------|-------|
| Sale of Advanced Therapy Medicinal Products (%) | 0.00% | 0.00% | 2.41% |
| Sale other (%)                                  | 0.00% | 0.29% | 0.51% |
| Others (%)                                      | 0.00% | 0.00% | 0.00% |

By geographical area or market

|                               | 2023       | 2024       | 2025       |
|-------------------------------|------------|------------|------------|
| Total revenue (thousand baht) | 245,389.66 | 337,592.90 | 379,511.13 |
| Domestic (thousand baht)      | 243,513.22 | 336,308.72 | 376,875.64 |
| International (thousand baht) | 1,876.44   | 1,284.18   | 2,635.49   |
| Total revenue (%)             | 100.00%    | 100.00%    | 100.00%    |
| Domestic (%)                  | 99.24%     | 99.62%     | 99.31%     |
| International (%)             | 0.76%      | 0.38%      | 0.69%      |

Other income as specified in the financial statements

|                                                  | 2023     | 2024     | 2025     |
|--------------------------------------------------|----------|----------|----------|
| Total other income (thousand baht)               | 1,954.54 | 8,272.95 | 7,216.84 |
| Other income from operations (thousand baht)     | 0.00     | 0.00     | 0.00     |
| Other income not from operations (thousand baht) | 1,954.54 | 8,272.95 | 7,216.84 |

Share of profit of joint ventures and associates accounted for using equity method

|                                 | 2023 | 2024   | 2025    |
|---------------------------------|------|--------|---------|
| Share of profit (thousand baht) | 0.00 | -84.75 | -324.16 |

## 1.2.2 Information on products and services

### 1.2.2.1 Product/service information and business innovation development

#### Provision of services

#### 1.Reproductive Health Testing Services

##### 1.1. Non-Invasive Prenatal Testing (NIPT) under the "NIFTY" Brand

Non-Invasive Prenatal Testing (NIPT), also known as Non-Invasive Prenatal Screening (NIPS), is a screening test that detects chromosomal abnormalities in a fetus by analyzing fetal DNA fragments (cell-free fetal DNA) present in the mother's bloodstream. This test assesses chromosomal abnormalities by comparing the ratio of chromosome pairs to normal population values. NIPT is suitable for pregnant women between 10 and 24 weeks of gestation. It requires only 8–10 ml of maternal blood, posing no risk of miscarriage, unlike amniocentesis. Results are available within 5–7 days. Our company offers NIPT under the "NIFTY" brand, authorized by the BGI Group. Using Next-Generation Sequencing (NGS) technology and advanced bioinformatics from BGI, this test provides highly accurate and reliable results.

##### 1.2. Preimplantation Genetic Testing for Aneuploidies (PGT-A)

Preimplantation Genetic Testing for Aneuploidies (PGT-A) is a genetic screening technique used during in vitro fertilization (IVF) to select embryos with normal chromosomal composition before implantation. This increases the chances of a successful pregnancy. The test employs Next-Generation Sequencing (NGS) to analyze all 23 chromosome pairs with high precision. It detects genetic abnormalities that may affect fetal development, including duplications and deletions that conventional methods might miss. NGS is a modern, highly effective option for individuals seeking to reduce the risks of failed pregnancies and genetic disorders that could impact the baby's long-term health.

##### 1.3. Carrier Screening for Genetic Disorders

Our Carrier Screening test, offered under the "VISTA" brand (authorized by the BGI Group), utilizes Next-Generation Sequencing (NGS) to identify genetic mutations that could be passed to offspring. Many individuals are unaware they are carriers of hereditary diseases until their child exhibits symptoms. This screening detects mutations in over 1,200 genes associated with more than 1,200 genetic conditions, including sex chromosome-linked disorders. It follows the guidelines of The American College of Obstetricians and Gynecologists (ACOG) and can be performed before or during pregnancy. It is particularly recommended for couples planning to conceive. In the Thai population, this screening covers prevalent genetic conditions such as:

- **Thalassemia:** A common inherited blood disorder in Thailand, affecting hemoglobin production and causing anemia. Approximately 30–40% of the population are carriers, with around 1% affected by the disease. Symptoms include pale skin, enlarged liver and spleen, and bone deformities.
- **Spinal Muscular Atrophy (SMA):** A disorder caused by the degeneration of motor neurons, leading to muscle weakness and, in severe cases, respiratory failure. About 1.8% of the Thai population are carriers.
- **Congenital Hearing Loss:** A genetic disorder affecting auditory function due to protein abnormalities in the inner ear. In Thailand, about 1.7 per 1,000 newborns are affected.

##### 1.4. Thalassemia Genetic Screening (Thalassemia-Seq)

Thalassemia is the most common inherited blood disorder in Thailand, with 30–40% of the population being carriers. It results from defective hemoglobin production, causing red blood cells to break down easily. Severe cases may require regular blood transfusions and iron-chelating medication. The VISTA Thalassemia-Seq test by BGI detects over 508 mutations in alpha- and beta-globin genes, along with more than 1,200 hemoglobin abnormalities. This screening is recommended for couples planning to conceive, helping prevent the inheritance of thalassemia in future generations.

#### Diagram of Provision of services



NIFTY



VISTA

## 2. Infectious Related Testing Services

Our infectious disease testing services provide screening and diagnostic solutions to help control and reduce the spread of pathogens. We utilize internationally certified equipment and reagents that meet CE-IVD standards (which ensure quality and safety compliance under European Union regulations for in vitro diagnostic devices) and are approved by Thailand's Food and Drug Administration (FDA). All tests are conducted in accredited laboratories, which meet proficiency testing standards for detecting genetic material of SARS-CoV-2 (COVID-19), including screening for cervical

cancer-causing pathogens using a self-collection kit (HPV DNA test - self collection kit) from the Department of Medical Sciences, Ministry of Public Health. The service details are as follows:

**2.1 COVID-19 Detection via Real-Time PCR:** This test detects SARS-CoV-2 using a nasopharyngeal (nose) and throat swab, analyzed in a laboratory. Results are available within 3 to 24 hours.

**2.2 Cervical Cancer Screening with Self-Collection HPV DNA Test:** This test detects Human Papillomavirus (HPV), the primary cause of cervical cancer in over 95% of cases. It screens for 14 high-risk HPV DNA strains with a sensitivity of 91.9% for detecting precancerous lesions. Patients can self-collect samples at home using a self-sampling kit and send them to our laboratory for expert analysis. Results are reported within five business days.

### **3. Other Testing Services**

#### **3.1 Cancer Screening Services**

Our company offers cancer screening services under the "SENTIS" brand, authorized by BGI Group. These services include Hereditary Cancer Screening, which detects genetic mutations that increase the risk of cancer. This test can be performed before any symptoms appear to assess genetic predisposition using Next-Generation Sequencing (NGS) technology. The screening covers 79 genes in men, associated with 22 types of cancer, and 74 genes in women, associated with 23 types of cancer. It includes commonly inherited cancers such as breast cancer, ovarian cancer, colorectal cancer, prostate cancer, and gastric cancer. In addition to hereditary cancer screening, the Cancer+ Discovery Panel identifies genes related to the response to more than 200 cancer drugs, helping optimize personalized treatment plans.

For patients already diagnosed with cancer, our company provides testing under the "OncoPress" brand, authorized by Beijing GenePlus, China. This service offers genetic testing for cancer patients to guide personalized treatment options using NGS technology. The OncoPress Key package screens 188 genes, while the OncoPress Premium package screens 1,021 genes. These tests are applicable to various solid tumors, including lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, and skin cancer. Additionally, for monitoring Minimal Residual Disease (MRD) after cancer treatment, we offer OncoPress Monitoring, which tracks remaining cancer cells to help assess treatment effectiveness.

Our company also provides early colorectal cancer screening under the "COLOTECT" brand, authorized by BGI Group. This test is non-invasive and highly sensitive in detecting abnormalities associated with colorectal cancer. It uses Multiplex Methylation-Specific PCR to analyze DNA methylation levels from stool samples. Individuals can perform self-sampling at home and send the sample back to our laboratory for analysis by specialists. The test has a sensitivity of approximately 89% for colorectal cancer detection, with results available in 5 to 7 business days.

#### **3.2 Whole Exome Sequencing (WES)**

Our company offers Whole Exome Sequencing (WES) under the "BGI-XOME" brand, authorized by BGI Group. This service detects genetic mutations linked to diseases using high coverage sequencing technology. The test helps researchers and physicians analyze specific genes efficiently, leading to faster clinical diagnosis. Since genetic disorders often respond better to early intervention, this test allows for timely diagnosis and treatment, improving patient outcomes.

#### **3.3 Individual Genetic Testing**

Our company provides detailed personal genetic analysis using Microarray and Next-Generation Sequencing (NGS) technology under the "DNALL" brand. This test analyzes an individual's genetic profile, providing insights into ancestry, optimal exercise regimens, metabolism, nutritional requirements, disease risk predictions, personality traits, and skin

health. The information obtained from this test can be used to customize lifestyle choices, improve diet and supplementation, optimize fitness plans, and tailor medical care based on genetic predispositions.

### **3.4 Cardiovascular Disease Risk Screening: TMAO**

Our company offers a cardiovascular disease (CVD) risk screening service by measuring Trimethylamine-N-oxide (TMAO) levels in the bloodstream using Mass Spectrometry. This screening follows CE-IVD standards to assess heart and vascular disease risks. Research has shown a strong correlation between TMAO levels and cardiovascular risk, making this test a faster and more effective way to evaluate risk compared to basic health check-ups.

### **3.5 Alzheimer's & Dementia Risk Screening**

Our company provides blood-based biomarker testing for Alzheimer's disease and other dementias. This non-invasive method offers an alternative to PET scans and cerebrospinal fluid (CSF) analysis by detecting protein accumulation linked to neurodegenerative diseases. The test can identify Alzheimer's risk up to 10 to 20 years before symptoms appear, allowing individuals to take preventive measures or seek early treatment. This test can also be used to monitor treatment effectiveness in patients undergoing therapy.

### **3.6 Immune System & Inflammation Testing**

Our immune system and inflammation testing evaluates chronic inflammation, immune deficiencies, and immune-related disorders by analyzing T cells, B cells, and NK cells, which play crucial roles in immune response. The test also measures cytokine levels, which are key inflammatory molecules. These insights help in diagnosing immune-related conditions and optimizing treatment plans.

### **3.7 Gut Microbiome Analysis & Probiotics Selection**

Our gut microbiome analysis examines microorganisms in the digestive system using stool samples. This test helps assess gut health, digestion, immunity, and metabolism. The results can be used to select personalized probiotics and dietary modifications to enhance overall well-being.

### **3.8 APOE Genotyping (Alzheimer's Genetic Risk Test)**

Our company offers APOE genotyping, a genetic test that analyzes Apolipoprotein E (APOE) variants. This test helps assess the risk of Alzheimer's disease and abnormal cholesterol metabolism. It can be performed at any age to aid in early prevention and disease management. Additionally, APOE genotyping plays a role in determining the suitability of Alzheimer's treatments.

### **3.9 Telomere Length Test**

Our telomere length test measures the length of telomeres, which are protective structures at the ends of chromosomes. Telomere shortening is associated with aging and chronic diseases. This test helps assess cellular health, providing insights into biological aging and potential health risks.

### **3.10 Biological Age Testing with Epigenetics - Methylation Panel**

Developed by True Diagnostics in the U.S., this test uses Epigenetic Clocks to determine Biological Age, which differs from Chronological Age. It analyzes DNA methylation, a key process influencing cellular aging. The panel includes assessments of biological age, aging rate, immune system health, telomere length, and personalized lifestyle recommendations for slowing aging.

### **Diagram of 3. Other Testing Services**



The cancer screening services under the "SENTIS" brand





#### 4.Tech Solution Services

All living organisms share the same fundamental process for transferring and utilizing genetic information, known as the Central Dogma. This process involves three key components: DNA, RNA, and protein. Initially, DNA is transcribed into a new strand called RNA, which is then translated into protein that the body can use. These steps occur in a specific sequence and are closely connected, forming a continuous process. Studying each step in detail leads to a deeper understanding of the biological mechanisms that occur within living organisms.

Recognizing the importance of this field, our company offers comprehensive biological analysis services, also known as Omics studies. These analyses examine biological systems as a whole by studying DNA, RNA, and proteins. Our services include Genomics, which investigates the genetic makeup (DNA) of organisms, Transcriptomics, which examines gene expression at the RNA level, Proteomics, which analyzes protein expression, and Metabolomics, which studies biochemical compounds and metabolites. Under the "Omics for All" initiative, our company provides a wide range of Omics-related analytical services to support researchers in various medical and scientific studies. We collaborate with research institutions and universities across Thailand to advance scientific discovery in both medical and non-medical fields.

## **Provision of advanced medical services.**

The Company provides advanced medical solutions, with a focus on manufacturing systems for Advanced Therapy Medicinal Products (ATMPs) in compliance with Good Manufacturing Practice (GMP) standards. These systems utilize closed automated technologies to support the production of cell therapy and gene therapy products.

Such solutions are designed to enhance efficiency and consistency in manufacturing processes, reduce the risk of contamination, and support quality control at every stage of production, which are critical factors for highly complex medical products. In addition, closed automated systems enhance scalability to meet both clinical and commercial demands, while supporting the operations of hospitals, research institutions, and participants in the life sciences industry.

## **Sale and distribution of equipment and products**

Our company imports and distributes legally authorized medical devices and products related to our services. These include comprehensive genetic testing kits, Beta-thalassemia real-time PCR (qPCR) test kits, cell-free DNA (cfDNA) collection tubes, and Yumeta Probiotics Powder supplements. In the future, we plan to expand our product range to offer more genetic testing solutions. The details of our current products are as follows:

### **1. Comprehensive Genetic Testing Solutions**

We offer a full set of equipment and reagents for genetic screening, including a genetic sequencer, DNA extraction and preparation systems, genetic data processing and analysis software, DNA extraction reagents, sequencing preparation reagents, and genetic sequencing reagents.

### **2. Beta-thalassemia Real-Time PCR (qPCR)**

- Test Kit This Beta-thalassemia test kit covers 23 genetic variants and uses blood samples from individuals undergoing screening.
- The test has been certified by CE-IVD and Thailand's Food and Drug Administration (FDA).

### **3. Cell-Free DNA (cfDNA) Collection Tubes**

- These tubes are designed for blood collection and transportation.
- They contain EDTA as an anticoagulant and a special stabilizing agent that prevents nuclease activity in plasma and inhibits the release of genomic DNA from cells.

### **4. Yumeta Probiotics Powder Supplements**

- This probiotic supplement contains three strains of Lactobacillus with a high concentration of 18 billion CFUs per serving. It is formulated with cranberry extract, vitamin C, and prebiotics.

The product is certified by Thailand's Food and Drug Administration (FDA).

### **5. Distribution of Solutions for Cell and Gene Therapy Manufacturing**

The Company distributes solutions for the manufacturing of cell and gene therapies, covering CAR T and other types of cell therapies. The distributed solutions are designed to support standardized and traceable manufacturing processes, as well as to facilitate systematic production management, ranging from sample preparation and cell culture or modification to quality control.

In addition, the Company distributes end-to-end automated biobank solutions to support the efficient storage and management of biological samples. These solutions help reduce human error, enhance accuracy in sample storage and tracking, and support research, drug development, and precision medicine.

In this regard, in the future (from 2027 onwards), the Company plans to provide automated biobanking services for biological sample storage and to distribute other ATMP products.



Research and development policy in various areas, and details regarding innovation development in processes, products and/or services, or business models.

Research and development (R&D) policy : No

**R&D expenses in the past 3 years**

|                                                                              | 2023 | 2024 | 2025 |
|------------------------------------------------------------------------------|------|------|------|
| Research and development (R&D) expenses over the past 3 years (Million Baht) | 0.70 | 1.28 | 1.72 |

**1.2.2.2 Marketing policies of the major products or services during the preceding year**

**Policy on Marketing Activity Organization to Stimulate Revenue**

- 1) The company will allocate a budget and develop a plan for marketing activities aimed at stimulating revenue and enhancing the company's image.
- 2) The establishment of promotions must be documented in a memorandum, specifying the details of the products and services, conditions for the promotion, the start and end dates, budget, and expected outcomes. Written approval must be obtained from the authorized personnel.
- 3) The sales department is responsible for overseeing all promotions. A control register must be created, detailing the name of the event, duration, and the criteria used for organizing the activity.
- 4) Once the sales department has organized the activity, a summary report detailing the event, budget spent, comparison with the original plan, and the outcome must be prepared. This report must be submitted to the authorized personnel for review and signed off, and a copy must be sent to the Chief Officer for the relevant department for acknowledgment after the completion of the activity.
- 5) In cases where a promotion is extended, a memorandum requesting written approval from the authorized personnel must be prepared.

**The industry competition during the preceding year**

The laboratory industry in 2025 continues to face intense competition driven by rapid technological advancements, increasingly stringent regulatory requirements, and the growing demand for laboratory testing services. Domestic operators also face challenges related to limitations in investment capital, technological capabilities, and marketing strategies when compared with multinational and foreign companies that possess stronger financial resources and technological advantages.

In addition, medical equipment manufactured domestically has not yet been widely accepted among medical professionals. As a result, the industry continues to rely on imported advanced technologies for service delivery and production processes, which may lead to higher costs of products and services in line with the increasing complexity of such technologies. Key factors affecting competitive conditions in the industry include:

**1. Advancements in Medical Technology and Digital Transformation**

Advancements in laboratory technologies, such as Next Generation Sequencing (NGS), automation systems, and bioinformatics data analysis, require operators to continuously invest in modern equipment and technologies to enhance accuracy, efficiency, and turnaround time. In addition, the adoption of advanced technologies such as Artificial Intelligence (AI), advanced analytics, and Laboratory Information Management Systems (LIMS), as well as emerging digital health trends including Telemedicine and At-home Diagnostic Kits, play an important role in improving service quality and operational efficiency, thereby strengthening the competitiveness of industry operators.

**2. Regulatory Requirements and Laboratory Standards**

The medical laboratory industry is subject to regulatory oversight and must comply with relevant standards and requirements, particularly international standards such as ISO 15189 for medical laboratories and ISO 17025 for testing and calibration laboratories. These standards serve as key indicators of the quality, accuracy, and reliability of laboratory results. Laboratories that consistently maintain high standards of quality and effective quality control systems are better positioned to build trust and confidence among physicians and service users, which represents an important competitive advantage.

**3. Technology Costs and Competition in Pricing and Service Quality**

Advanced medical equipment and technologies are largely imported, resulting in operational costs that may fluctuate in line with technology prices, exchange rates, and equipment complexity. At the same time, the laboratory industry faces competition in terms of pricing, quality of test results, turnaround time, and service standards. Operators therefore need to manage costs efficiently while continuously improving service quality and differentiating their services to maintain competitiveness and strengthen trust among physicians and service users.

**4. Mergers, Acquisitions, and Strategic Partnerships**

Trends in mergers, acquisitions, and strategic collaborations among laboratories, hospitals, research institutions, and healthcare partners have continued to increase as operators seek to expand service capabilities, develop new diagnostic services, and create additional business opportunities. Larger operators generally benefit from economies of scale, modern infrastructure, and broader service networks, which support business growth and enhance their competitive position within the industry.

**5. Development of Specialized Professionals**

Laboratory services require personnel with specialized knowledge, expertise, and professional experience. Operators therefore place significant emphasis on the continuous development of employee skills and professional competencies to keep pace with technological advancements and evolving industry requirements. Such efforts are essential to maintaining service quality and sustaining long-term competitiveness.

**1.2.2.3 Procurement of products or services**

The company procures tools, equipment, and related products used in its operations by importing them from companies within the BGI group, as well as from other manufacturers/suppliers both domestically and internationally. The selection process focuses on choosing suppliers that meet high standards, offer reliable products, and are certified for quality assurance.

**1.2.2.4 Assets used in business undertaking**

**Core permanent assets**

The company’s property, plant, and equipment used in its business operations have a net book value, after depreciation, as shown in the financial statements as of December 31, 2025, amounting to 56.24 million Baht.

**The appraisal price of core permanent assets**

| List of assets | Book value /<br>Appraised value | Ownership | Obligations | Additional details |
|----------------|---------------------------------|-----------|-------------|--------------------|
|----------------|---------------------------------|-----------|-------------|--------------------|

| List of assets                 | Book value /<br>Appraised value | Ownership                    | Obligations | Additional details                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------|---------------------------------|------------------------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Building improvements          | 7.09                            | Owner of the property rights | No          | <ul style="list-style-type: none"> <li>- Building Improvements - Office Building (5th and 6th Floors): Net book value of 0.50 million Baht.</li> <li>- Building Improvements - Single-Story Laboratory (Branch 2) : Net book value of 3.64 million Baht.</li> <li>- Building Improvements - Four-Story Laboratory (Branch 1) : Net book value of 2.65 million Baht.</li> <li>- Building Improvements - Warehouse : Net book value of 0.30 million Baht.</li> </ul> |
| Office equipment and furniture | 5.11                            | Owner of the title           | No          | <ul style="list-style-type: none"> <li>- Computer Equipment and Server Systems: 2.39 million Baht</li> <li>- Telecommunications and Internet Hardware: 0.70 million Baht</li> <li>- Air conditioning units: 0.36 million Baht</li> <li>- Others: 1.66 million Baht</li> </ul>                                                                                                                                                                                      |

| List of assets                     | Book value /<br>Appraised value | Ownership          | Obligations | Additional details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------------|---------------------------------|--------------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Laboratory equipment and furniture | 41.17                           | Owner of the title | No          | <ul style="list-style-type: none"> <li>- Genetic material packaging machine: 1.17 million Baht</li> <li>- Quality Control - QC: 4.21 million Baht</li> <li>- Library Preparation System: 6.39 million Baht</li> <li>- Genetic material amplification machine: 4.11 million Baht</li> <li>- Genetic sequencing machine: 15.82 million Baht</li> <li>- Advanced Immunoassay Analyzer: 2.26 million Baht</li> <li>- Bioinformatics &amp; Data Management: 1.20 million Baht</li> <li>- Others: 6.01 million Baht</li> </ul> |
| Vehicle                            | 2.87                            | Owner of the title | No          | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

#### Core intangible assets

As of December 31, 2025, the Company's intangible assets used in business operations amounted to 22.94 million Baht.

#### The appraisal price of core intangible assets

| List of assets                         | Types                                           | Book value / Appraised value | Additional details |
|----------------------------------------|-------------------------------------------------|------------------------------|--------------------|
| Software Computer                      | Software                                        | 2.88                         | -                  |
| Patents and Project Development Costs. | Others : Patents and Project Development Costs. | 20.06                        | -                  |

#### Investment policy in the subsidiaries and associated companies

Investment policy in the subsidiaries and associated : Yes

companies

Bangkok Genomics Innovation Public Company Limited (“the Company”) invests in both publicly listed and privately held companies. The Company's investments include equity, hybrid financial instruments, and debt securities.

### 1. Target Companies and Entities

1.1 Newly established companies and/or entities, both domestically and internationally.

1.2 Existing companies and/or entities, both domestically and internationally. Investment Methods The Company employs various investment approaches, including: Greenfield Projects (newly initiated investments) Joint Ventures Mergers & Acquisitions (M&A) Amalgamations Asset Purchases Asset Swaps

### 2. Investment Returns

The Company seeks investment returns in the form of profits, capital gains, dividends, and/or interest income.

### 3. Investment Criteria

3.1 Aligns with the Company's goals, vision, and strategic growth plan by investing in businesses with sustainable revenue generation and stable long-term growth.

3.2 Focuses on businesses with growth potential that aligns with the Company's core competencies. These businesses should be capable of self-funding in the medium and long term without relying on financial support from the Company.

3.3 Ensures a minimum Return on Investment (ROI) of 20% per year, averaged over five years. If the ROI falls below this threshold, an investment plan must be presented to the Board of Directors for review and approval.

3.4 Establishes clear investment boundaries and manages risks by diversifying into businesses with strong operational advantages while assessing regional and country-specific investment risks.

3.5 Focuses on medium to long-term investments that enhance and add value to the Company.

### 4. Risk Management and Control

4.1 Regularly provide investment status reports to the Board of Directors for acknowledgment and approval.

4.2 Prepare periodic financial reports, including performance results, budgets, and forecasts at both the company and project levels.

4.3 Comply with relevant regulations, including:

(1) Adherence to applicable laws and regulations in each jurisdiction.

(2) Compliance with applicable accounting standards.

(3) Adherence to the Company's Delegation of Authority (DOA) guidelines.

#### 1.2.2.5 Under-construction projects

Under-construction projects : No

#### Details of under-construction projects

Total projects : N/A

Values of total ongoing projects : N/A

Realized value : N/A

Unrealized value of remaining projects : N/A

Additional details : -

## 1.3 Shareholding structure

### 1.3.1 Shareholding structure of the group of companies

#### Policy on operational organization within the group of companies


The Company has established an investment policy for subsidiaries or associated companies. The Company will invest in companies that have the same business objectives as the Company's core businesses or similar businesses, or businesses that support the Company's businesses, which will enable the Company to increase its operating results or profits. Or invest in businesses that benefit the Company by supporting the Company's core businesses to be more comprehensive in order to increase the Company's competitiveness. In overseeing subsidiaries or associated companies, the Company will send directors or executives with appropriate qualifications and experience in business operations to be directors or executives in subsidiaries and/or associated companies at least in proportion to the shareholding in each company to represent the management of such subsidiaries and associated companies. To set important policies and control the business operations of subsidiaries and/or associated companies, including establishing a supervisory mechanism through the disclosure of financial information, acquisitions and disposals, and intercompany transactions with such subsidiaries by using the relevant criteria for information disclosure and transactions in accordance with the rules and regulations of the relevant authorities. In this regard, the directors who are representatives of the Company must perform their duties in overseeing subsidiaries and/or associated companies to manage or operate in accordance with the policies set by the Company. In addition, monitoring to assess and examine prudently through adequate and appropriate internal control systems, including the use of discretion in accordance with the resolutions of the Board of Directors and/or the Shareholders' Meeting of the Company that approves important matters of subsidiaries and/or associated companies in order to maximize the benefits to the Company and for the sustainable growth of the Company.

#### Shareholding diagram of the group of companies

Does your company have any shareholdings in other : Yes

companies?

#### Shareholding diagram



## Subsidiaries

| Company name                   | Juristic person who holds shares of the company    | Shareholding proportion (%) | Voting right proportion (%) |
|--------------------------------|----------------------------------------------------|-----------------------------|-----------------------------|
| Omicsphere Company Limited     | Bangkok Genomics Innovation Public Company Limited | 99.99%                      | 99.99%                      |
| Comprehensive Care Limited     | Bangkok Genomics Innovation Public Company Limited | 99.99%                      | 99.99%                      |
| Biovision Tech Company Limited | Bangkok Genomics Innovation Public Company Limited | 50.99%                      | 50.99%                      |
|                                | Lanray Group Company Limited                       | 48.99%                      | 48.99%                      |

## Associated companies

| Company name                            | Juristic person who holds shares of the company    | Shareholding proportion (%) | Voting right proportion (%) |
|-----------------------------------------|----------------------------------------------------|-----------------------------|-----------------------------|
| Edge Medical (Thailand) Company Limited | Bangkok Genomics Innovation Public Company Limited | 25.00%                      | 25.00%                      |
|                                         | Edge Medical (Hongkong) Company Limited            | 25.00%                      | 25.00%                      |

### Company that holds 10% or more of the total shares sold

| Name and the location of the head office                                                                                                                   | Type of business                                                                                                                                                                                        | Type of shares | The number of shares | The number of shares sold |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------------------|---------------------------|
| Omicsphere Company Limited<br>3689 Rama 4 Road, Phra Khanong, Khlong Toei District<br>Bangkok 10110<br>Telephone : -<br>Facsimile number : -               | Trading, distributing, selling, exporting tools, equipment, raw materials, ingredients, components, and chemicals for laboratory use, such as Titrators and Magnetic Stirrers.                          | Common shares  | 299,982              | 299,982                   |
| Comprehensive Care Limited<br>3689 Rama 4 Road, Phra Khanong, Khlong Toei District<br>Bangkok 10110<br>Telephone : -<br>Facsimile number : -               | Advanced Therapy Medicinal Products related to Cell                                                                                                                                                     | Common shares  | 49,998               | 49,998                    |
| Biovision Tech Company Limited<br>3689 Rama 4 Road, Phra Khanong, Khlong Toei District<br>Bangkok 10110<br>Telephone : -<br>Facsimile number : -           | Providing consulting services in management and administration for all types of businesses, including individuals, groups of individuals, juristic persons, government agencies, and state enterprises. | Common shares  | 20,399               | 20,399                    |
| Edge Medical (Thailand) Company Limited<br>3741 Rama IV Road, Phra Khanong, Khlong Toei District<br>Bangkok 10110<br>Telephone : -<br>Facsimile number : - | Engaging in the import and distribution of pharmaceuticals, chemicals, medical instruments, and all types of medical equipment (upon receiving permission from relevant authorities).                   | Common shares  | 10,000               | 10,000                    |

### 1.3.2 Shareholding by a person with a potential conflict of interest holding exceeding 10 percent of the voting shares in a subsidiary or associated company

Does the company have a person with potential conflicts : No  
of interest holding shares in a subsidiary or associated  
company?

### 1.3.3 Relationship with major shareholders' business



Does the company have a relationship with a business : Yes

group of a major shareholder?

BGI Group is a leading genomics and biotechnology research institute and one of the internationally recognized organizations in the life sciences field. The group possesses comprehensive expertise in genomic technologies, covering the entire value chain from basic research and technology development to applications in precision medicine, public health, agriculture, and environmental science. As a result, BGI plays an important role in driving advanced life science innovation and maintains collaborative networks with research institutions, universities, hospitals, and healthcare organizations in many countries, including Thailand. BGI is also ranked in the Nature Index, a global indicator that measures the research strength of leading life science institutions. The group has consistently ranked No. 1 in the Asia-Pacific region and was ranked 4th globally in the Life Sciences category in 2025, based on both the quantity and quality of research publications in leading international scientific journals (source: [www.nature.com/nature-index](http://www.nature.com/nature-index)). With such capabilities, BGI is recognized as a global leader in genomic research and the application of genetic sequencing technologies. The group continues to advance high-throughput sequencing technologies, such as Next-Generation Sequencing (NGS), together with bioinformatics, to improve human health and quality of life. Its research outcomes are applied across a wide range of fields, including precision medicine, personalized treatment, agriculture, forensic science, and the development of the bioeconomy. Currently, BGI operates offices and laboratories in several regions worldwide and maintains research collaborations with more than 2,000 partner institutions globally, supporting continuous advancement in genomics and biotechnology innovation.

As of 31 October 2022, BGI Health (HK), a subsidiary within the BGI Group, held 51.00% of the Company's issued and paid-up share capital. Subsequently, on 20 March 2024, the Company completed its initial public offering (IPO), resulting in the shareholding of BGI Health (HK) being reduced to 37.40% of the issued and paid-up share capital, while remaining the Company's largest shareholder. Through the Company's operations to date, genetic testing services offered under the trademarks of the BGI Group have gained increasing recognition and acceptance in Thailand. Following the Company's listing on the Stock Exchange of Thailand, the Company continues to receive strong support from the BGI Group. The Company serves as the flagship of BGI Genomics in Thailand, and BGI remains committed to supporting the Company's business operations in order to strengthen the development of genomic medicine services and promote sustainable growth in Thailand's genomics and precision medicine sector.

BGI Group's position as the Company's major shareholder not only reflects strong financial backing but also enables the transfer of knowledge, advanced technologies, and international operational standards to Thailand. This includes laboratory standards, advanced genomic technologies, research-based genetic testing services, and the development of human resources through global expert networks. The Company receives support from the BGI Group in several key areas as follows:

- **Procurement of instruments, equipment, and reagents**

The Company has entered into agreements to procure laboratory instruments, equipment, and reagents from the BGI Group on a continuous basis in order to support its genetic testing services in Thailand.

- **Technology transfer and personnel development**

BGI provides technology transfer and professional training programs for the Company's personnel to ensure readiness in operating advanced genomic technologies. In addition, personnel exchange and training programs are conducted between the Company and BGI laboratories, including overseas study visits, to enhance technical knowledge and experience in genomic technologies.

- **Research and development of innovations**

With BGI's strong global research capabilities and continuous development of genomic innovations, the Company, as part of the BGI network, is able to introduce new technologies and innovations to develop genetic testing services and healthcare solutions in Thailand on an ongoing basis.

- **Trademark licensing**

The Company has been granted the right to use trademarks owned by the BGI Group for services provided in Thailand, including NIFTY, VISTA, NOVA, BGI-XOME, COLTECT, and SENTIS, without any royalty fee, provided that the Company continues to procure relevant reagents and products from the BGI Group for its services.

In addition, the Company has entered into an agreement with BGI Group to define the scope of business operations. Under this agreement, BGI Group confirms that it will not conduct any business in Thailand that competes with the Company, nor authorize any third party to use BGI trademarks within Thailand, which is the territory where the Company has been granted the rights to operate.

### 1.3.4 Shareholders

#### List of major shareholders

| Group/List of major shareholders   | Number of shares<br>(shares) | % of<br>shares |
|------------------------------------|------------------------------|----------------|
| 1. BGI HEALTH (HK) COMPANY LIMITED | 190,802,560                  | 31.80          |
| 2. MR. PREECHA LAOHAPONGCHANA      | 73,638,000                   | 12.27          |
| 3. Mr.Pongpachara Thanaboonyawat   | 44,000,000                   | 7.33           |
| 4. MR. RATCHAPHOL ASVINVICHIT      | 37,508,500                   | 6.25           |
| 5. BGI HEALTH (HK) COMPANY LIMITED | 33,597,440                   | 5.60           |
| 6. MR. APICHET CHALERMWUTINAN      | 22,000,000                   | 3.67           |
| 7. MISS KORNCANOK CHALERMWUTINAN   | 22,000,000                   | 3.67           |
| 8. MR. CHALERMDEJ LEEWONGCHAROEN   | 5,945,900                    | 0.99           |
| 9. Mr. Sunput Chaisiriphan         | 4,439,000                    | 0.74           |
| 10. MR. WATUS SAKDEJAYONT          | 4,420,800                    | 0.74           |

#### Major shareholders' agreement

Does the company have major shareholders' agreements? : Yes

The Company has entered into a Non-compete agreement with a related person of the Counterparty who is a major shareholder and/or controller and/or executive of the Company. The Counterparty shall:

- Conduct business, provide consultation, be a business partner, establish a new company with a person or juristic person, or have the power to manage a business that is similar/identical to or competitive with the Company in Thailand, or
- Provide support or advice to other persons engaged in a business similar/identical to or competitive with the Company in Thailand, or
- Commit any act that results in the resignation of the Company's directors and/or employees, or
- Interfere with the relationship between the Company and its suppliers or customers (as the case may be).

#### Remarks :

- In the event that BGI Genomics wishes to engage in or participate in a business related to laboratory business, medical diagnostic services, or other healthcare businesses in Thailand, which is not similar to or competitive with the Company,

BGI Genomics agrees to grant the Company the right of first refusal to select BGI Genomics' services before offering them to other service providers.

- The business within the restricted scope includes WGS testing services, medical laboratory services (Clinical Services), related Genomics and Personal Training services, and the territory is limited to Thailand only.
- Major shareholder means a shareholder of the Company, whether directly or indirectly, holding in aggregate more than 10.00 percent of the total number of shares entitled to vote. The number of shares shall include shares held by related persons.
- When the Company is delisted from the Stock Exchange of Thailand or the related person no longer holds the position of director and/or is not a major shareholder of the Company, whether directly or indirectly.
- Related Person means any person or juristic person in which the Counterparty has the right to issue shares of 30.00 percent or more and/or has the power to propose and/or remove more than half of the directors and/or has the ability to determine significant policies and/or determine financial policies.

## 1.4 Amounts of registered capital and paid-up capital

### 1.4.1 Registered capital and paid-up capital

#### Registered capital and paid-up capital

Registered capital (Million Baht) : 300,000,000.00

Paid-up capital (Million Baht) : 300,000,000.00

Common shares (number of shares) : 300,000,000

Value of common shares (per share) (baht) : 0.50

#### Has the company listed in other stock exchange?

Has the company listed in other stock exchange? : No

### 1.4.2 Other types of share whose rights or terms differ from those of ordinary share

Other types of share whose rights or terms differ from : No

those of ordinary share

### 1.4.3 Shareholding by Thai NVDR Company Limited (NVDR)

Are shares held by Thai NVDR Company Limited (NVDR)? : No

## 1.5 Issuance of other securities

### 1.5.1 Convertible securities

Convertible securities : No

### 1.5.2 Debt securities

Debt securities : No

## 1.6 Dividend policy

### The dividend policy of the company

The Company has a policy of paying dividends to its shareholders at a rate of not less than 40.00% of the net profit based on the Company's separate financial statements for each fiscal year, after deduction of corporate income tax and allocation to the statutory reserve as required by law.

However, the Company may consider paying dividends at a rate different from the stated policy depending on various factors, including the Company's operating results, financial position, liquidity, working capital requirements for business operations, future business expansion plans, as well as overall economic conditions.

### The dividend policy of subsidiaries

The Company has a policy to pay dividends to its shareholders at a rate of not less than 40.00% of the net profit based on the Company's separate financial statements for each year, after deduction of corporate income tax and allocation to the statutory reserve as required by law.

However, the Company may pay dividends at a rate different from the stated policy, depending on various factors, including the Company's operating results, financial position, liquidity, the need for working capital for business operations and management, as well as future business expansion plans.

### Historical dividend payment information

|                                                                   | 2021      | 2022         | 2023            | 2024            | 2025            |
|-------------------------------------------------------------------|-----------|--------------|-----------------|-----------------|-----------------|
| Net profit per share ( baht : share)                              | N/A       | N/A          | 0.0700          | 0.0880          | 0.0760          |
| Dividend per share ( baht : share)                                | N/A       | N/A          | 0.0545          | 0.0500          | 0.0500          |
| Ratio of stock dividend payment (existing share : stock dividend) | N/A : N/A | 0.0000 : N/A | 0.0000 : 0.0000 | 0.0000 : 0.0000 | 0.0000 : 0.0000 |
| Value of stock dividend per share (baht : share)                  | N/A       | N/A          | 0.0000          | 0.0000          | 0.0000          |
| Total dividend payment ( baht : share)                            | N/A       | N/A          | 0.0000          | 0.0000          | 0.0000          |
| Dividend payout ratio compared to net profit (%) )                | N/A       | N/A          | 74.67           | 59.79           | 66.15           |

## 2. Risk management

### 2.1 Risk management policy and plan

#### Risk management policy and plan

##### **Risk Management Policy and Practices**

1. The company is committed to becoming an organization that fosters progress for the benefit of all stakeholders, including shareholders, employees, and other relevant parties. The company places significant importance on risk management, which is a crucial element of good corporate governance
2. The company will plan, implement systems, and establish risk management processes across the organization to align with its business strategies and goals. It will operate in accordance with internationally recognized risk management standards. The risk management process must be conducted systematically and continuously, with clear communication and understanding at every stage for all employees, making risk management an integral part of the organization's work culture.
3. The Audit Committee has the authority to oversee the company's risk management and provide guidance to the Board and Risk Management Committee to ensure that risk management is conducted effectively and efficiently.
4. The Risk Management Committee is responsible for performing its duties and responsibilities, as well as carrying out tasks assigned by the Audit Committee or the Board. It must report the results of its activities to the Audit Committee. For risks that are high or critical and may significantly impact the company's operations and strategies, these must be reported to the Audit Committee, and a risk management plan must be developed with progress reports within the specified time frame.
5. Executives and all employees are required to comply with the company's risk management systems and processes. This includes identifying and assessing risks in their respective areas of responsibility, analyzing risks, impacts, and opportunities, and jointly determining appropriate measures to manage risks at an acceptable level.
6. The company will communicate its risk management policies, organize workshops, and provide training to all employees to ensure knowledge, understanding, and awareness of the benefits of risk management, enabling practical application in their work.

## 2.2 Risk factors

### 2.2.1 Risk that might affect the company's business, including environmental, social and corporate governance issues

#### Risk 1 Risk of misdiagnosis

Related risk topics : Strategic Risk

- Damage to company image and reputation

Compliance Risk

- Legal risk

#### Risk characteristics

Genetic and disease screening tests help increase the likelihood of detecting abnormalities or potential health risks at an early stage. However, these tests are designed to assess risk and do not constitute definitive diagnostic confirmation of diseases or genetic abnormalities due to the limitations of current medical technologies. Examples include prenatal genetic screening, preimplantation genetic testing for aneuploidy (PGT-A), and cancer screening tests such as COLOTECT. Although these tests generally demonstrate high accuracy, false positive or false negative results may still occur. Therefore, if screening results indicate a high risk, individuals are typically advised to undergo additional diagnostic testing under a physician's supervision to confirm the findings.

Furthermore, laboratory testing services depend on the accuracy of analytical processes, instruments, equipment, reagents, and the expertise of personnel. Errors at any stage—such as sample collection, preparation, analysis, or reporting—may lead to inaccurate results, which could affect medical decision-making and potentially impact the confidence of patients, physicians, and business partners, as well as the Company's reputation.

#### Risk-related consequences

If errors or inaccuracies occur in laboratory testing or limitations arise in interpreting screening results, patients or physicians may rely on incorrect information for medical decision-making, which could potentially affect patients' health.

In addition, such incidents may undermine the confidence of patients, physicians, and business partners, and may adversely affect the Company's image and reputation. In certain cases, they may also lead to complaints, claims for damages, or legal proceedings, which could impact the Company's business operations and financial position.

#### Risk management measures

To manage the aforementioned risks, the Company has established the following key measures:

##### 1. Provision of Adequate Information and Informed Consent

Prior to undergoing screening services, customers are provided with clear explanations regarding the objectives, limitations, and conditions of the tests, including factors that may affect the accuracy of the results. Such information is specified in the Consent Form to ensure that customers can make well-informed decisions. In addition, certain screening services may include a test result guarantee, under which customers may receive financial support for additional diagnostic testing if a high-risk result is detected, subject to the terms and conditions of the selected service package.

##### 2. Quality Control and Standardized Testing Procedures

The Company has established standardized operating procedures covering all stages of the laboratory process, by ISO15189:2022 and ISO15190:2020, from sample collection and preparation to analysis and reporting. The Company also utilizes standardized instruments, equipment, and reagents, and conducts regular calibration, maintenance, and both internal and external quality control to ensure the accuracy and reliability of test results.



### 3. Personnel Development and Service Quality Monitoring

The Company places strong emphasis on enhancing the capabilities of its personnel by providing continuous training and development in relevant scientific knowledge and technologies. In addition, the Company regularly monitors and reviews service quality to effectively manage risks and maintain appropriate standards of service.

## **Risk 2 The risk of non-compliance with laws, regulations, and other applicable rules related to the business.**

Related risk topics : Compliance Risk

- Change in laws and regulations
- Laws and regulations is not favorable for doing business
- Violations of laws and regulations

### **Risk characteristics**

The Company operates a laboratory business providing laboratory testing services and genetic disease screening; therefore, it is exposed to compliance risks related to laws, regulations, and requirements imposed by regulatory authorities. The Company's operations require obtaining licenses from relevant authorities and strict compliance with applicable laws and standards, such as the Healthcare Facility Act B.E. 2541 (1998) and its amendments, the Medical Device Act B.E. 2551 (2008) and its amendments, and the Ministry of Public Health Notification on Standards for Genomic Medicine Services in Healthcare Facilities B.E. 2564 (2021), among others. Risks may arise from operating without the required licenses or failing to renew expired licenses, non-compliance with regulatory conditions, laboratory testing processes or quality management systems that do not meet required standards, improper management of chemicals and hazardous waste, inadequate occupational safety measures for personnel, as well as risks related to personal data protection and the accuracy of laboratory test reporting.

### **Risk-related consequences**

If the Company fails to comply with applicable laws, standards, or regulatory requirements, it may result in the suspension or cessation of its operations, revocation or suspension of its operating licenses, as well as fines or legal proceedings. In addition, the Company's laboratory accreditation may be suspended or revoked, which could affect the reliability of test results and potentially cause damage to clients or organizations relying on such results. Non-compliance may also lead to accidents, contamination, or adverse impacts on the environment and the health and safety of laboratory personnel, as well as potential violations of clients' personal data. Ultimately, these issues could adversely affect the Company's reputation, credibility, and the confidence of customers and stakeholders in the long term.

### **Risk management measures**

The Company places importance on compliance with applicable laws, regulations, and requirements, and has established policies to manage risks related to legal and regulatory compliance as follows:

#### 1. Governance and Monitoring of Legal and Regulatory Compliance

The Company regularly monitors and reviews relevant laws, regulations, and requirements imposed by regulatory authorities. Changes in laws and regulations are monitored through various channels, such as official websites of relevant government agencies, participation in academic conferences, and professional associations. In addition, the risk management working group is assigned to periodically review relevant laws and regulatory requirements to ensure that the Company's operations remain in compliance.

#### 2. Quality Control and Laboratory Operational Standards

The Company maintains quality control over its laboratory testing processes in accordance with relevant laboratory

standards. This includes regular calibration and maintenance of equipment, as well as maintaining and reviewing quality management documentation to ensure the accuracy and reliability of laboratory test results.

### 3. Personnel Development, Safety Measures, and Data Protection

The Company emphasizes enhancing personnel knowledge and understanding of operational procedures, regulations, and applicable laws. The Company also implements safety measures for laboratory operations and establishes measures to protect clients' personal data, in order to support business operations in compliance with applicable laws and standards.

## Risk 3 Business competition risks

Related risk topics : Strategic Risk

- Changes in technologies
- Business operations of partners in the supply

chain

- Competition risk
- Economic risk

Operational Risk

- Delays in the development of future projects

### Risk characteristics

The operation of a laboratory business providing medical and genetic testing services is exposed to increasing industry competition, driven by the entry of new market participants and rapid advancements in medical and diagnostic technologies. In addition, the growing focus on precision medicine has attracted greater interest in this sector, which may intensify competition in terms of pricing, service quality, and continuous technological development. Furthermore, the Company's operations depend on business partners and participants within the supply chain, such as manufacturers and suppliers of medical equipment, reagents, and laboratory consumables. Any changes in pricing, supply shortages, or procurement constraints may affect the Company's operations. Moreover, uncertainty in economic conditions may impact consumers' purchasing power and demand for services, which could in turn affect the Company's revenue and operating performance in the future.

### Risk-related consequences

If the Company is unable to adapt effectively to increasing competition, technological changes, or fluctuations in the supply chain, it may result in a loss of market share, reduced competitiveness, or higher operating costs. In addition, shortages of laboratory equipment, instruments, or reagents used in testing may affect the continuity of the Company's services. Furthermore, uncertainty in economic conditions may reduce demand for such services, which could adversely affect the Company's revenue, operating performance, and growth prospects in the future.

### Risk management measures

To maintain its competitiveness and respond to changes in the industry, the Company has established the following risk management measures:

#### 1. Continuous Development of Technology and Service Capabilities

The Company closely monitors advancements in genomic medicine and laboratory testing technologies and continuously enhances its equipment, technologies, and service processes. Leveraging the innovations and technologies of the BGI Group, supported by one of the world's largest genetic research databases, the Company is able to deliver accurate and reliable testing results. In addition, the Company performs laboratory testing within Thailand, which helps

reduce turnaround time, lower transportation costs, and enhance flexibility in developing products and service packages that meet customer needs.

## 2. Strengthening Personnel Capabilities and Service Readiness

The Company continuously develops the capabilities of its laboratory personnel and maintains standardized laboratory systems and equipment to support the rapid development and provision of new testing services. During the outbreaks of COVID-19 and Monkeypox Virus, the Company was able to promptly provide testing services after being approved as a network laboratory and successfully passing proficiency testing by the Department of Medical Sciences. The Company also maintains readiness to support testing services for emerging infectious diseases or new virus strains in the future.

### **Risk 4 The risk of fluctuations in foreign exchange rates.**

Related risk topics : Strategic Risk

- Government policy

Financial Risk

- Fluctuation in exchange rates, interest rates, or the inflation rate

#### **Risk characteristics**

The Company is exposed to foreign exchange risk due to fluctuations in exchange rates. This is because most of the Company's purchases of medical equipment, reagents, and laboratory consumables are imported from overseas and must be paid in U.S. dollars (USD), while the majority of the Company's service revenue is denominated in Thai Baht (THB). Therefore, fluctuations in exchange rates may affect the Company's operating costs.

#### **Risk-related consequences**

If the Thai Baht (THB) depreciates against the U.S. dollar (USD), the cost of purchasing goods and equipment may increase, which could adversely affect the Company's profit margins and operating results.

#### **Risk management measures**

The Company closely monitors exchange rate trends and manages its purchasing and payment schedules in line with exchange rate conditions to mitigate potential impacts on its operations. In addition, the Company has a policy to utilize financial instruments for managing foreign exchange risk, such as entering into forward exchange contracts, and coordinates with financial institutions to obtain information and closely monitor exchange rate fluctuations on an ongoing basis.

### **Risk 5 Information Technology Systems and Cybersecurity Risk**

Related risk topics : Strategic Risk

- Damage to company image and reputation

Operational Risk

- Systems or internal control system
- Information security and cyber-attack
- System disruption risk

Compliance Risk

- Legal risk

### **Risk characteristics**

The Company is exposed to risks from cyberattacks and unauthorized access to data, as its operations involve medical and genetic information, which are highly sensitive and critical. In addition, the provision of services through information systems and online platforms may increase exposure to external threats, such as system intrusion, network attacks, or data breaches.

### **Risk-related consequences**

If a data security incident occurs, it may result in the unauthorized disclosure or misuse of customer information, which could adversely affect customer confidence. The Company's operations may be disrupted, and such incidents may also lead to financial losses, legal liabilities, and damage to the Company's reputation and corporate image.

### **Risk management measures**

The Company has established comprehensive information security measures as follows:

#### **1. Technical Measures**

The Company has implemented cybersecurity prevention and detection systems, such as a Next-Generation Firewall (NGFW), to monitor and protect against both external and internal threats in real time. In addition, the Company utilizes additional website protection services to restrict access to internal systems and mitigate cyberattack risks.

#### **2. Policy and Procedural Measures**

The Company has established an Information Security Policy in accordance with international standards such as ISO 27001 and conducts regular IT risk assessments. Real-time alert systems are also in place to enable prompt response and mitigation of any abnormal incidents.

#### **3. Personnel Measures**

The Company emphasizes the development of employees' cybersecurity awareness by providing regular training programs. It also enhances specialized skills for IT personnel to strengthen readiness in preventing and responding to potential cyber threats.

## **2.2.2 Risk to securities holders**

Are there any risk factors affecting securities holders? : Yes

Risk 1 The company's shareholders may face limitations in exercising their rights to purchase additional common shares in the future.

Related risk topics : Risk to Securities Holder

- Risk of the company having a majority

shareholder holding > 25% of shares

### **Risk characteristics**

Shareholders of the Company may be subject to limitations in exercising their rights to subscribe for the Company's securities in the future. This is because the Company may, from time to time, issue and offer additional securities, such as newly issued ordinary shares, warrants, transferable subscription rights (TSR), or convertible debentures, which may be allocated to existing shareholders in proportion to their shareholding (Rights Offering).

In this regard, in the event that such offerings or rights are granted to existing shareholders, the Company may, at its discretion, choose not to offer subscription rights to certain shareholders residing outside Thailand (Restricted Countries) if such offering would require the Company to comply with the laws or regulatory requirements of those jurisdictions. As a result, such shareholders may not be able to fully exercise their rights.

### **Risk-related consequences**

Compliance with securities laws or regulatory requirements in certain jurisdictions may result in some investors being unable to exercise their rights to subscribe for securities on a pro rata basis, which may lead to a dilution of their shareholding (Dilution Effect).

### **Risk management measures**

The Company carefully considers applicable legal and regulatory requirements in each jurisdiction when conducting securities offerings, and may appoint legal advisors or relevant experts to assess constraints and determine appropriate approaches. In addition, the Company will clearly and transparently disclose information regarding the terms and limitations of shareholders' rights to enable investors to make informed decisions. The Company will also consider appropriate measures to mitigate potential impacts on shareholders within the scope permitted by applicable laws.

Risk 2 Risk from Industry-Specific Factors in Genomic Medicine and Laboratory Services Affecting Investment

Related risk topics : Risk to Securities Holder

- Risk of the company having a majority shareholder holding > 25% of shares

### **Risk characteristics**

Investment in the Company's securities, as a provider of laboratory and genomic medicine services, may be affected by industry-specific factors, including changes in medical and genetic testing technologies, increasing competition, reliance on imported instruments, reagents, and equipment, as well as regulatory requirements and standards related to medical services and personal data protection.

### **Risk-related consequences**

These factors may affect the Company's competitiveness, operating costs, revenue, and overall performance, which could lead to volatility in the Company's share price and result in investors receiving returns that may not meet their expectations.

### **Risk management measures**

The Company focuses on continuously developing its technology and service quality, alongside effective cost management and supply chain management. It also ensures strict compliance with relevant laws and standards, as well as accurate, transparent, and adequate disclosure of information to support investors in making informed decisions.

## **2.2.3 Risk to securities holders from investing in foreign securities (applicable to only foreign companies)**

Are there any risk factors affecting securities holders from : No  
investing in foreign securities?

### 3. Business sustainability development

#### 3.1 Policy and goals of sustainable management

##### Sustainability Policy

Sustainability Policy : Yes

The company's board is committed to being a responsible corporate entity that adheres to economic, social, and environmental responsibilities. They recognize the importance of driving business towards sustainability, with a focus on fulfilling duties and responsibilities to stakeholders, including shareholders, customers, business partners, employees, communities, and the society at large. The company is dedicated to operating as a model for ethical business practices and good corporate governance, aiming to create benefits for society, the environment, and sustainable growth. To guide its operations, the company has adopted the relevant Sustainable Development Goals (SDGs) of the United Nations, aligning its direction with these global objectives. The company has also built a structure and management system aimed at becoming a sustainable entity, referencing the Environment, Social, and Governance (ESG) framework. It is committed to applying good governance as a key driver for creating balanced and sustainable benefits for the economy, society, and the environment. The board has established an organizational sustainability development policy to serve as the company's operational guidelines.

The company is committed to sustainable growth and operations, guided by good corporate governance throughout its value chain, considering the impact on stakeholders, society, and the environment. The company firmly believes that conducting business on a foundation of sustainability is essential for fostering long-term, stable growth. Furthermore, the company is determined to create positive change for communities, the environment, and the economy, ensuring its operations benefit all stakeholders and align with sustainable development objectives. The core aspects of the company's commitment to sustainability are outlined as follows:

- 1) Commitment to Fair Business Practices: The company prioritizes human rights, equality, and fairness in its dealings with customers, business partners, competitors, and employees. It takes responsibility for consumer protection, emphasizing health and safety in the workplace and fostering environmental awareness and community development to improve the quality of life for all.
- 2) Corporate Culture of Sustainability: The company encourages board members, executives, employees, and workers at all levels to support, promote, and carry out tasks in alignment with sustainability policies, creating a work culture focused on balancing economic, social, and environmental benefits.
- 3) Fair Competition: The company commits to competing fairly within the boundaries of good practices and will not seek confidential information from competitors through dishonest means.
- 4) Awareness and Responsibility for Sustainable Development: The company raises awareness of sustainable development practices, ensuring that economic progress aligns with social and environmental benefits. It promotes responsible operations throughout the organization's value chain and mandates that all employees and stakeholders support and act in accordance with the company's sustainability policy. This approach is designed to foster a culture of balance between economic, social, and environmental aspects.

##### Sustainability management goals

Does the company set sustainability management goals : No

##### Review of policy and/or goals of sustainable management over the past year

Has the company reviewed the policy and/or goals of : Yes

sustainable management over the past year

Has the company changed and developed the policy and/ : No  
or goals of sustainable management over the past year



## **3.2 Management of impacts on stakeholders in the business value chain**

### **3.2.1 Business value chain**

The company conducts its business with a focus on stakeholder engagement while considering the management of sustainability throughout the value chain, from upstream to downstream. This process begins with the adoption of technology from the BGI group for verification, research, and development, procurement of equipment and reagents for analysis, marketing and sales, laboratory testing services, and post-sales support. All activities are carried out under the principles of good corporate governance, ensuring that the business operates in compliance with the law, with integrity, transparency, and accountability, with a shared objective of providing high-quality and efficient services throughout the entire process. Additionally, the company has established a framework to promote the sustainability of the value chain, alongside the continuous development of economic growth, societal contributions, and environmental conservation. The company aims to maintain balance in economic development, social creation, and environmental sustainability across its business operations. Below are the details of the main activities and supporting activities within the company's value chain:

#### **1) Primary Activities**

##### **1.1 Research and Development**

The company utilizes both concepts and advanced technologies transmitted from the BGI group to enhance its services. These technologies are also used for planning the research and development of other diagnostic tests, as well as to support clients requiring services for both public and private sector research and development activities. The goal is to extend the limits of genetic studies for researchers from both government and private sectors in Thailand. The company provides comprehensive research services in genetics, including Multi-Omics studies, to meet the objectives of various research projects. As an expert in genetic research and applying genetics technology alongside BGI's bioinformatics system, the company promotes the competitive potential of genetic research in Thailand, both currently and in the future. The knowledge gained from these research activities can be applied to medicine, precision disease treatment, the biotechnology industry, agriculture, and other fields.

##### **1.2 Procurement of Equipment, Instruments, and Reagents**

The company emphasizes the procurement of high-quality, standardized, and reasonably priced equipment, instruments, reagents, and products from transparent sources. By verifying the quality of products and assessing the credibility of suppliers, the company ensures sustainable business development. The company sources equipment, instruments, and reagents both from BGI group companies and other domestic and international suppliers. The selected suppliers must meet high standards and quality and be certified according to international manufacturing standards to ensure safety and compliance with regulations, providing customers with confidence in the safety of the services.

##### **1.3 Marketing and Sales**

The company markets its products by participating in medical exhibitions, academic events, and seminars, targeting laboratory customers, hospitals, clinics, medical staff, and nurses. These events are designed to educate clients about products and services in collaboration with product specialists, ensuring that customers can select the most suitable and accurate products and services for their specific needs. The company also engages in online marketing, offering various channels for public relations and brand awareness. Online marketing is designed to stimulate sales and reach target audiences more effectively, with content that is diverse, engaging, measurable, and reliable.

##### **1.4 Diagnostic Testing Services**

The company offers screening services for chromosomal abnormalities in unborn infants, such as NIFTY, and other genetic abnormalities. The goal is to make genetic screening tests more accessible for Thai people in terms of both

service delivery and cost, with the primary objective of reducing the incidence of birth defects, extending the lives of cancer patients, controlling infectious diseases, and promoting genomic research. The company applies advanced technologies and concepts in medical services in Thailand to develop an efficient healthcare system. Furthermore, genetic data is utilized for precise and personalized treatments, enabling better diagnosis, treatment selection, and prevention. Once test results are verified by medical technologists for accuracy, the results are delivered to the clients or healthcare facilities via secure channels, ensuring the protection of personal data as per the Personal Data Protection Act.

### **1.5 Post-Sales Services**

The company places a high value on customer satisfaction. To ensure this, the company conducts customer satisfaction surveys, where clients can provide suggestions or complaints. This feedback allows the company to address issues and better meet customer needs in the future. Medical technologists explain test results and provide advice both before and after the service, along with consistent follow-up to build trust and satisfaction among medical personnel. One of the quality assurance measures is the NIFTY test result guarantee, which allows clients to claim reimbursement for diagnostic testing. If the screening reveals a high risk of chromosomal abnormalities, clients can undergo further diagnostic testing and submit the receipt for reimbursement according to the designated amount, thus ensuring comprehensive service and promoting client confidence in the services.

## **2) Support Activities**

To ensure the effective and efficient execution of primary activities and drive the business forward, the company prioritizes support activities in areas such as sales, service provision, and employee management. These support activities are as follows:

### **2.1 Human Resources Management**

The Company continually recognizes that its employees are its most valuable asset. It places strong emphasis on human resource development and fair labor practices as essential elements for achieving long-term and sustainable corporate success, as follows:

#### **2.2.1 Respect for Human Rights**

- The Company complies with labor laws, relevant regulations, and internationally recognized principles of fundamental human rights. It emphasizes equality and freedom without discrimination based on race, gender, age, skin color, religion, disability, social status, ancestry, educational background, or any other unrelated status. It also respects individuality and human dignity.
- The Company treats employees and workers without discrimination, providing equal opportunities and assigning responsibilities according to individual capabilities. This principle also extends to business partners and other stakeholders.
- The Company respects the rights and dignity of all employees, workers, and business partners, treating everyone equally and fairly in accordance with human dignity.

#### **2.1.2 Fair Labor Practices**

- The Company manages compensation and benefits with the aim of motivating employees to perform at their best. The system is fair, legally compliant, and structured with standardized practices. Compensation is evaluated and aligned with current responsibilities, competitive within the industry, and consistent with business operations.
- In terms of employee development, the Company emphasizes enhancing knowledge, capabilities, and management skills through training programs, seminars, and field visits. It is committed to establishing a continuous framework for talent development at all levels.

- For career advancement, the Company applies non-discriminatory practices in line with applicable laws, providing equal opportunities regardless of gender, race, religion, origin, age, disability, socioeconomic status, or educational background.
- The Company is committed to the well-being and health of its employees. It prioritizes occupational safety and a healthy work environment by ensuring protection and safety for all employees, workers, and company assets, without compromising others' rights and safety. It also upholds the protection of personal rights, data privacy, confidentiality, and appropriate use of personal information.

## 2.2 Information Technology Management

The company provides IT services to support its business operations, including key services such as:

### 2.2.1 IT Services:

- Core Application
- Internet Services
- Security
- Network Services
- Server Services
- IT Support

### 2.2.2 Information Systems:

- BGI group information systems include BGI Lims, a system for managing sample registration and test result reporting, and HALOS, an automated system for analyzing test results linked to DNA sequencing machines and other lab equipment for genetic data interpretation and report generation.
- The company's information system includes Smart Lab Sky, a database management system for health-related data and test results for detecting the genetic material of the SARS-CoV-2 virus or the COVID-19 pathogen. , DEV, a database management system for laboratory operations., Readyport, a system that consolidates the entire workflow, from sample collection and delivery via messenger service to test result issuance, billing, and payment processing., Express, a system for warehouse management and financial accounting data.

### Business value chain diagram



The value chain of a business

## 3.2.2 Analysis of stakeholders in the business value chain

### Details of stakeholder analysis in the business value chain

| Group of stakeholders | Stakeholders' expectations | Responses to stakeholder expectations | Channels for engagement and communication |
|-----------------------|----------------------------|---------------------------------------|-------------------------------------------|
| Internal stakeholders |                            |                                       |                                           |

| Group of stakeholders                                          | Stakeholders' expectations                                                                                                                                                                                                                                                                                                                                                      | Responses to stakeholder expectations                                                                                                                                                                                                                                                                                                                                                                                           | Channels for engagement and communication                                                                                   |
|----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> <li>Shareholders</li> </ul> | <ol style="list-style-type: none"> <li>Legal rights and entitlements</li> <li>Equal treatment of all shareholders, including accurate and timely information disclosure.</li> <li>Compliance with all applicable laws in a transparent, accountable, and well-governed manner.</li> <li>Strong financial performance and stability, with a focus on business growth.</li> </ol> | <ol style="list-style-type: none"> <li>Shareholders' Meeting</li> <li>Quarterly Earnings Announcement</li> <li>Investor Site Visit</li> <li>Dissemination of Information: Announcing shareholder meetings, publishing financial statements, and dividend announcements through various channels.</li> <li>Disclosure of Information to the Stock Exchange</li> <li>Establishing a Complaint or Whistleblower Channel</li> </ol> | <ul style="list-style-type: none"> <li>Online Communication</li> <li>Annual General Meeting (AGM)</li> </ul>                |
| <b>Internal stakeholders</b>                                   |                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                             |
| <ul style="list-style-type: none"> <li>Employees</li> </ul>    | <ol style="list-style-type: none"> <li>Receive appropriate compensation and benefits.</li> <li>Employees have equal rights.</li> <li>Receive support for career advancement.</li> <li>Have safety at work.</li> <li>Training and development plan.</li> </ol>                                                                                                                   | <ol style="list-style-type: none"> <li>Organize events for executives to meet with employees, such as monthly or quarterly meetings.</li> <li>Receive feedback or complaints from employees through various channels designated by the company.</li> <li>Provide training and development programs according to the annual plan.</li> </ol>                                                                                     | <ul style="list-style-type: none"> <li>Internal Meeting</li> <li>Complaint Reception</li> <li>Training / Seminar</li> </ul> |
| <b>External stakeholders</b>                                   |                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                             |

| Group of stakeholders                                                                  | Stakeholders' expectations                                                                                                                                                                                                                                     | Responses to stakeholder expectations                                                                                                                                                                                                                                                                 | Channels for engagement and communication                                                                                        |
|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> <li>Customers</li> </ul>                            | <ol style="list-style-type: none"> <li>Customer Focus</li> <li>Responsibility for Services and Products</li> <li>Service Delivery in Accordance with Relevant Standards</li> <li>Quality of Services and Products</li> <li>Customer Confidentiality</li> </ol> | <ol style="list-style-type: none"> <li>Customer Satisfaction Survey</li> <li>Communication through medical personnel, which is the company's primary channel</li> </ol>                                                                                                                               | <ul style="list-style-type: none"> <li>Online Communication</li> <li>Complaint Reception</li> <li>Satisfaction Survey</li> </ul> |
| <b>External stakeholders</b>                                                           |                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       |                                                                                                                                  |
| <ul style="list-style-type: none"> <li>Suppliers</li> <li>Business partners</li> </ul> | <ol style="list-style-type: none"> <li>Adhere to agreements and fair payment terms.</li> <li>Engage in fair and transparent price competition.</li> <li>Utilize goods and services from partners consistently.</li> </ol>                                      | <ol style="list-style-type: none"> <li>Comply with regulations regarding the Company's procurement process.</li> <li>Conduct business with transparency, fairness, and equality.</li> <li>Communicate through meetings between executives and discussions between company representatives.</li> </ol> | <ul style="list-style-type: none"> <li>External Meeting</li> </ul>                                                               |
| <b>External stakeholders</b>                                                           |                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       |                                                                                                                                  |
| <ul style="list-style-type: none"> <li>Community</li> <li>Society</li> </ul>           | Being a good neighbor to the communities located near the company's operations and considering the potential impacts on society and communities.                                                                                                               | <ol style="list-style-type: none"> <li>Gathering feedback from society and communities.</li> <li>Communicating through channels that can reach society and communities.</li> </ol>                                                                                                                    | <ul style="list-style-type: none"> <li>Social Event</li> <li>Complaint Reception</li> </ul>                                      |

### 3.3 Management of environmental sustainability

#### 3.3.1 Environmental policy and guidelines

##### Environmental policy and guidelines

Environmental policy and guidelines : Yes

Environmental guidelines : Electricity management,  
Water resources and water quality management,  
Waste management,  
Greenhouse gas and climate change management,

##### 1. Environmental Management

The Company places importance on environmental stewardship by aiming to minimize the impact of its operations on natural resources and ecosystems. This is aligned with the Sustainable Development Goals (SDGs) of the United Nations to create shared value across economic, social, and environmental dimensions. In line with its commitment to responsible business practices, the Company has established environmental management goals and guidelines covering four key areas: (1) energy management, (2) water management, (3) waste and pollution management, and (4) greenhouse gas management. Environmental management is incorporated as a key focus under the Company's Environmental, Social, and Governance (ESG) policy to support sustainable growth and reduce environmental impact in a tangible manner.

##### Short-term and Long-term Targets

###### 1) Energy and Water Management

The Company assigns its Human Resources Department to promote awareness among employees regarding efficient resource utilization. The Company has set targets to reduce energy and water consumption by 5% by 2024 and 10% by 2026, compared to the defined baseline year.

###### 2) Waste, Effluent, and Pollution Management

The Company has a policy to prevent the discharge of waste or pollutants that may adversely affect communities and the environment. The Company has engaged Recycle Engineering Co., Ltd., a certified Green Industry Level 3 operator in systematic environmental management, to treat and dispose of wastewater generated from laboratory service processes, which may contain chemical contaminants from equipment cleaning and product handling procedures.

For infectious waste management, the Company has appointed Krungthep Thanakom Co., Ltd. to manage infectious waste disposal in compliance with sanitary standards and relevant regulations. Infectious waste from laboratories or medical facilities (with no overnight patients) is securely sealed and disposed of in designated infectious waste containers to prevent leakage and minimize environmental and social risks.

###### 3) Greenhouse Gas Management

The Company places importance on systematic greenhouse gas management. In 2024, the Company conducted training and capacity building on greenhouse gas inventory preparation and carried out an assessment of its Carbon Footprint for Organization (CFO). This serves as baseline data for setting long-term targets and measures to reduce greenhouse gas emissions.

The Company has also been awarded the "Carbon Footprint for Organization (CFO)" certification for the second consecutive year by the Thailand Greenhouse Gas Management Organization (Public Organization) (TGO), which has developed carbon labeling certification systems since 2009. This initiative encourages all sectors to assess and disclose greenhouse gas emissions from products, services, organizations, events, and activities, contributing to carbon offsetting and the achievement of net-zero emissions goals.

##### 2. Greenhouse Gas Management

The Company is committed to continuously implementing measures to reduce greenhouse gas emissions across multiple dimensions. These include improving energy efficiency, promoting behavioral changes in resource consumption within the organization, encouraging the adoption of environmentally friendly technologies, and developing a concrete system for monitoring greenhouse gas emissions. These efforts aim to drive the Company toward sustainable growth while upholding its Environmental, Social, and Governance (ESG) responsibilities. The Company conducts a review of its environmental targets and performance at least once annually, while strictly complying with all applicable environmental laws, regulations, and requirements.

In addition, the Company promotes efficient resource utilization, reduces unnecessary consumption, and strives to minimize negative environmental impacts across all aspects, including energy, water, waste, pollution, and greenhouse gas emissions throughout its value chain. Appropriate technologies are applied to prevent and control environmental and ecological impacts. The Company also manages environmental quality and biodiversity in accordance with relevant legal requirements, while continuously investing in, developing, and improving its environmental management systems. Furthermore, the Company actively seeks new approaches and measures to enhance the effectiveness of environmental control and management.

The Company focuses on reducing resource and energy consumption, minimizing emissions, waste, and greenhouse gases, and preventing and mitigating impacts on the environment, communities, and society. Examples of such initiatives include reducing paper usage, encouraging employees to switch off lights and air conditioning during lunch breaks, and promoting responsible resource consumption behaviors across the organization.

#### **Review of environmental policies, guidelines, and/or goals over the past year**

Review of environmental policies, guidelines, and/or goals : Yes  
over the past year

### **3.3.2 Environmental operating results**

#### **Information on energy management**

##### **Energy management plan**

The company's energy management plan : Yes

The Company recognizes the importance of efficient electricity consumption alongside minimizing environmental impacts. Accordingly, it has established energy management guidelines that focus on both the adoption of high-efficiency equipment and the promotion of appropriate energy usage behavior within the organization.

##### **1. Enhancement of Electrical Equipment Efficiency**

The Company utilizes air conditioners with Thailand's No. 5 energy efficiency label, representing 82.00% of its total air conditioning units. In addition, 65.00% of the units use R32 refrigerant, which is a high-efficiency refrigerant that does not deplete the ozone layer and has a lower Global Warming Potential (GWP) compared to R410A and R22 refrigerants. The Company has set a target to gradually replace all remaining air conditioning units with R32-based systems within three years, in order to enhance energy efficiency and reduce climate impact.

##### **2. Energy Conservation Campaign and Internal Control Measures**

The Company has implemented appropriate electricity control measures, including:

- Establishing schedules for operating air conditioning and lighting systems, particularly during lunch breaks
- Setting air conditioning temperatures at appropriate levels
- Promoting awareness among employees to use energy only as necessary

The Human Resources Department is responsible for continuously promoting and raising awareness among employees regarding energy conservation practices.

### 3. Energy Reduction Targets

The Company has set targets to reduce electricity consumption by 5.00% by 2025 and 10.00% by 2027, compared to the established baseline year. These targets aim to enhance operational efficiency and align with the Company's sustainable development approach.

#### Setting goals for managing electricity and/or oil and fuel

Does the company set goals for electricity and/or fuel : Yes  
management

#### Details of setting goals for electricity and/or fuel management

| Target(s)                                          | Base year(s)                                                          | Target year(s)                                   |
|----------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------------|
| Reduction of electricity purchased for consumption | 2023 : purchased electricity for consumption 355,474.00 Kilowatt-hour | 2026 : Reduced by 10% or 35,547.40 Kilowatt-hour |
| Reduction of fuel consumption                      | 2023 : fuel consumption 9,334.47 Litres                               | 2026 : Reduced by 5% or 466.72 Litres            |

#### Performance and outcomes of energy management

Performance and outcomes of energy management : Yes

#### Energy Management Performance and Results

Through the continuous implementation of energy management measures, the Company has been able to effectively control and reduce energy consumption. These efforts focus on improving equipment efficiency, managing energy usage, and promoting awareness of responsible resource consumption within the organization. In 2025, the Company's electricity consumption showed a declining trend compared to the 2023 baseline, in line with implemented measures such as the adoption of energy-efficient equipment, optimization of air conditioning systems, control of operating hours for electrical systems, and ongoing employee awareness campaigns. As a result, the Company has been able to manage its energy consumption in accordance with its short-term targets.

In addition, the Company has begun implementing its plan to gradually replace air conditioning systems with R32 refrigerant, which offers higher efficiency and a lower Global Warming Potential (GWP). This initiative has contributed to continuous improvement in the Company's overall energy efficiency. Regarding fuel consumption, the Company has implemented measures to control and reduce usage through efficient route planning, promotion of online meetings to minimize unnecessary travel, and proper management of company vehicles, resulting in a decreasing trend in fuel consumption in line with the established targets.

Overall, the Company's performance is aligned with its energy management plan and targets. The Company remains committed to continuously enhancing its measures to achieve its goals of reducing electricity consumption by 10% and fuel consumption by 5% by 2026.

#### Energy management: Fuel consumption

|                   | 2023     | 2024     | 2025      |
|-------------------|----------|----------|-----------|
| Gasoline (Litres) | 9,334.47 | 9,687.32 | 18,109.82 |



## Energy management: Electricity consumption

|                                                                                          | 2023       | 2024       | 2025       |
|------------------------------------------------------------------------------------------|------------|------------|------------|
| <b>Total electricity consumption within the organization (Kilowatt-Hours)</b>            | 355,474.00 | 327,645.79 | 371,344.00 |
| Electricity purchased for consumption from non-renewable energy sources (Kilowatt-Hours) | 355,474.00 | 327,645.79 | 371,344.00 |

## Information on water management

### Water management plan

The Company's water management plan : Yes

The Company places importance on responsible and efficient water resource management by promoting awareness among employees and management at all levels regarding the value of water and the potential impacts of water scarcity. These efforts aim to encourage efficient water usage and minimize environmental impacts. Since 2022, the Company has established clear internal water management practices as follows:

#### 1) Promotion of Responsible Water Use

The Company encourages employees and management to turn off taps immediately when not in use and to use water only as necessary. Awareness of water conservation is continuously promoted through internal communication and organizational activities.

#### 2) Water Reduction Targets

The Company has assigned the Human Resources Department to lead awareness campaigns and monitor performance. Targets have been set to reduce water consumption by 5.00% by 2025 and 10.00% by 2026, compared to the established baseline year, in order to support efficient long-term resource utilization.

#### 3) Wastewater Management and Water Pollution Prevention

To prevent impacts on external water sources and the environment, the Company has engaged Recycle Engineering Co., Ltd., a certified Green Industry Level 3 operator in systematic environmental management, to treat and dispose of wastewater generated from laboratory service processes. Such wastewater may contain chemical contaminants from equipment cleaning and product handling processes. All operations are conducted in strict compliance with relevant environmental laws and standards.

The Company regularly monitors and reviews its water management performance on an annual basis to assess progress against targets and improve measures in alignment with business operations. This supports sustainable growth and helps minimize long-term environmental impacts.

### Setting goals for water management

Does the company set goals for water management : Yes

### Details of setting goals for water management

| Target(s)                      | Base year(s)                                      | Target year(s)                                  |
|--------------------------------|---------------------------------------------------|-------------------------------------------------|
| Reduction of water withdrawal  | 2023 : Water withdrawal<br>1,510.00 Cubic meters  | 2025 : Reduced by 5% or 75.50<br>Cubic meters   |
| Reduction of water consumption | 2023 : Water consumption<br>1,510.00 Cubic meters | 2026 : Reduced by 10% or<br>151.00 Cubic meters |

### Performance and outcomes of water management

Performance and outcomes of water management : Yes

The Company promotes awareness of the value of water resources among employees and management at all levels, focusing on both education and the establishment of clear guidelines for efficient water usage.

In 2025, the Company implemented key measures as follows:

#### 1. Water Conservation Campaign

The Company encourages employees to turn off taps immediately when not in use and to use water only as necessary. Continuous communication and campaigns on water conservation are carried out within the organization.

#### 2. Short-term and Long-term Water Reduction Targets

The Company has set targets to reduce water consumption by 5.00% by 2025 and 10.00% by 2026, compared to the established baseline year.

#### 3. Wastewater Management and Water Pollution Prevention

To prevent impacts on external water sources, the Company has engaged Recycle Engineering Co., Ltd., a certified Green Industry Level 3 operator in systematic environmental management, to treat and dispose of wastewater generated from laboratory operations that may contain chemical contaminants. All processes are conducted in strict compliance with applicable laws and standards.

As a result of these measures, the Company has been able to effectively control and manage water consumption, with no incidents of wastewater discharge causing impacts on communities or the environment.

### Water management: Water withdrawal by source

|                                                         | 2023     | 2024     | 2025     |
|---------------------------------------------------------|----------|----------|----------|
| <b>Total water withdrawal (Cubic meters)</b>            | 1,510.00 | 1,382.00 | 1,317.00 |
| Water withdrawal by third-party water<br>(cubic meters) | 1,510.00 | 1,382.00 | 1,317.00 |

### Water management: Water consumption

|                                        | 2023     | 2024     | 2025     |
|----------------------------------------|----------|----------|----------|
| Total water consumption (Cubic meters) | 1,510.00 | 1,382.00 | 1,317.00 |

## Information on waste management

### Waste management plan

The company's waste management plan : Yes

The company has implemented a systematic waste and hazardous material management plan for its medical laboratory operations. This includes proper waste segregation at the source, safe storage, and disposal in compliance with sanitation standards and relevant laws to minimize risks to personnel, the community, and the environment.

#### 1. Regular Waste Management

Waste is collected and disposed of regularly to prevent accumulation. Designated disposal points are clearly defined, and waste is properly sorted.

#### 2. Waste Segregation

Waste is classified into four categories:

- General Waste (black bags): Non-contaminated items such as paper, packaging, and plastics.
- Infectious Waste (red bags): Contaminated materials (e.g., PPE, test materials); disposal in sinks is prohibited.
- Sharps (non-infectious): Items like broken glass and blades, stored in puncture-resistant containers.
- Infectious Sharps (red containers): Contaminated sharps (e.g., needles, filter tips); must be disposed of in puncture-proof containers, with no needle recapping and double containment for filter tips.

#### 3. Disposal of Hazardous Waste

Infectious and hazardous waste is handled by licensed contractors for proper disposal in accordance with environmental regulations.

### Setting goals for waste management

Does the company set goals for waste management : No

### Performance and outcomes of waste management

Performance and outcomes of waste management : Yes

The company, through the Bangkok Genomics Medical Technology Laboratory, implements a systematic waste and hazardous material management system. This covers waste segregation, storage, contamination control, and disposal in compliance with relevant regulations to minimize environmental impact and ensure personnel safety.

#### 1. Performance in Waste Segregation and Control

The company strictly enforces waste segregation at the source by classifying waste into four categories: general waste, infectious waste, sharps, and infectious sharps. Clear disposal procedures are in place to ensure proper segregation. As a result, there is no accumulation of waste within the laboratory, no incidents of improper disposal that pose serious risks, and reduced risk of sharps-related injuries to personnel.

#### 2. Control and Disposal of Infectious Waste

Infectious waste is clearly separated from other waste types and stored in designated holding areas. It is contained in red bags and sealed containers without leakage, and labeled with biohazard symbols. The company transfers infectious waste to legally authorized external contractors, who handle collection and disposal in strict compliance with the Ministerial Regulation on Infectious Waste Disposal B.E. 2545 (2002).

#### 3. Reduction of Environmental Impact from Biological Waste

For used equipment or infectious waste from pathogen testing (e.g., SARS-CoV-2-related work), the company performs decontamination through autoclaving under appropriate time and temperature conditions prior to disposal. This reduces risks to public health and the environment.

#### 4. Outcomes and Regulatory Compliance

From these practices, the company fully complies with infectious waste management regulations. No incidents of leakage or non-compliant waste handling were reported during the reporting year. Environmental and safety risks associated with infectious waste are effectively controlled.

## Waste management: Waste Generation

|                                      | 2023     | 2024     | 2025     |
|--------------------------------------|----------|----------|----------|
| Total waste generated (Kilograms)    | 3,751.00 | 3,167.00 | 8,520.80 |
| Total hazardous waste (kilograms)    | 3,751.00 | 3,167.00 | 8,520.80 |
| Hazardous waste – Others (kilograms) | 3,751.00 | 3,167.00 | N/A      |

## Information on greenhouse gas management

### Greenhouse gas management plan

The company's greenhouse gas management plan : Yes

### Management to Mitigate Greenhouse Gas Emissions

The company operates its business under the principle of environmental responsibility, recognizing the importance of greenhouse gas (GHG) management, which is a key factor affecting climate change. Accordingly, the company has established systematic guidelines for managing and reducing greenhouse gas emissions to support both Thailand's policies and international commitments under the framework of the United Nations Framework Convention on Climate Change (UNFCCC).

#### 1.Assessment of Greenhouse Gas Emission Sources

Based on the assessment of business operations, the company does not have industrial-scale fuel-consuming processes and does not generate significant direct greenhouse gas emissions. The main sources of emissions within the organization include, Electricity consumption within office buildings (Scope 2) and Fuel usage from staff vehicles (Scope 1)

#### 2.Measures for Managing and Reducing Greenhouse Gas Emissions

The company has implemented key measures as follows:

- Regular maintenance of air conditioning systems and electrical equipment according to the energy conservation plan
- Promotion of the use of low-carbon-labeled electrical appliances
- Campaigns and awareness-raising among employees regarding energy conservation
- Fostering a corporate culture aligned with a low-carbon society (Low-Carbon Organization)
- These measures aim to increase energy efficiency, reduce resource consumption, and continuously control greenhouse gas emissions.

#### 3. Verification and Certification of Organizational Carbon Footprint

The company conducted verification of organizational-level greenhouse gas emissions and removals in 2025 (using 2024 as the baseline year). This verification was carried out by the Office of Quality System Certification (SOR), Thailand Institute of Scientific and Technological Research (TISTR), an independent body with expertise in auditing and standard certification.

The verification ensures the accuracy, transparency, and credibility of greenhouse gas emission data and serves as a fundamental basis for developing future GHG reduction plans. The company has received organizational carbon footprint labels and certificates, reflecting its commitment and achievement in effectively managing greenhouse gas emissions.

#### 4. Future Goals and Direction

The company aims to focus on controlling greenhouse gas emissions and will set targets aligned with business growth while reasonably controlling emission volumes. This approach ensures consistency with international guidelines and supports the transition to a sustainable low-carbon organization.

#### **Compliance with principles and standards for greenhouse gas or climate change management**

Principles and standards for greenhouse gas or climate : Thailand Greenhouse Gas Management Organization  
change management (TGO)

#### **Setting greenhouse gas emission goals**

Does the company set greenhouse gas management goals : No

#### **Performance and outcomes of greenhouse gas management**

Performance and outcomes of greenhouse gas : Yes  
management

Managing Greenhouse Gas Emissions reflects a commitment to reducing the impacts of global warming and promoting sustainable business practices. The company has received the Carbon Footprint Label and Certificate, which signifies its success in managing greenhouse gas (GHG) emissions within the organization. The company conducted a verification of its greenhouse gas emissions and removals at the organizational level in 2025 (based on 2024 verification data) by Bureau Veritas Certification (Thailand) Co., Ltd., a company specializing in auditing and certifying various standards, including carbon footprint verification. This verification is crucial for ensuring the accuracy of data and the management of greenhouse gas emissions within the organization, enabling the company to develop an effective greenhouse gas reduction plan. The receipt of the Carbon Footprint Label and Certificate highlights the company's responsibility and dedication to minimizing environmental impact while promoting sustainable organizational development.

#### **Diagram of Performance and outcomes of greenhouse gas management**

Certificate Number:  
TGO CFO FY25-02-804



THAILAND GREENHOUSE GAS  
MANAGEMENT ORGANIZATION  
(Public Organization)



## CERTIFICATE

Awarded to

BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED

Company address verified: 3689 Rama IV Road, Phra Khanong Subdistrict, Khlong Toei District, Bangkok 10110

Thailand Greenhouse Gas Management Organization certifies that the quantity of Greenhouse Gas of the above organization has been verified by Thailand Institute of Scientific and Technological Research and found to be in accordance with the requirements of the standard detailed below.

Standard

TGO Guidance of the Carbon Footprint for Organization

Verification Period: [01/01/2024 - 31/12/2024]

Total Greenhouse Gas Emission (Scope 1&2): 206 tonCO<sub>2</sub>e/year

|                               |                               |
|-------------------------------|-------------------------------|
| Direct GHG emissions          | 42 tonCO <sub>2</sub> e/year  |
| Energy Indirect GHG emissions | 164 tonCO <sub>2</sub> e/year |
| Other Indirect GHG emissions  | 93 tonCO <sub>2</sub> e/year  |

The agreed level of assurance is: Limited, at materiality of 5%

Registration Date: 22 August 2025

*Nakorn.*

Mr. Nakorn Tangavirapat  
Executive Director

Thailand Greenhouse Gas Management Organization (Public Organization)

Carbon Footprint for Organization (CFO) Certificate

Greenhouse gas management : Corporate greenhouse gas emission

|                                                                                       | 2023   | 2024   | 2025   |
|---------------------------------------------------------------------------------------|--------|--------|--------|
| Total greenhouse gas emissions (Metric tonnes of carbon dioxide equivalent)           | 222.00 | 209.00 | 342.00 |
| Total greenhouse gas emissions - Scope 1 (Metric tonnes of carbon dioxide equivalent) | 44.00  | 45.00  | 63.00  |
| Total greenhouse gas emissions - Scope 2 (Metric tonnes of carbon dioxide equivalent) | 178.00 | 164.00 | 186.00 |
| Total greenhouse gas emissions - Scope 3 (Metric tonnes of carbon dioxide equivalent) | 0.00   | 0.00   | 93.00  |

Greenhouse gas management: Verification of the company's greenhouse gas emissions over the past year

Verification of the company's greenhouse gas emissions : Yes

List of greenhouse gas verifier entity : Thailand Institute of Scientific and Technological  
Research (TISTR)

Information on incidents related to legal violations or negative environmental impacts

Number of cases and incidents of legal violations or negative environmental impacts

|                                                                                             | 2023 | 2024 | 2025 |
|---------------------------------------------------------------------------------------------|------|------|------|
| Number of cases or incidents of legal violations or negative environmental impact ((cases)) | 0    | 0    | 0    |

### 3.4 Social sustainability management

#### 3.4.1 Social policy and guidelines

Social and human rights policy and guidelines : Yes

Social and human rights guidelines : Employee rights, Consumer/customer rights, Community and environmental rights, Safety and occupational health at work, Non-discrimination, Supplier rights

#### **Social Policy and Practices**

Bangkok Genomics Innovation Public Company Limited conducts its business with a focus on sustainable growth and creating shared value for all stakeholders. The company prioritizes improving quality of life, economic well-being, and social development in surrounding communities, based on participation, transparency, equality, and social responsibility. In 2025, the company maintained its commitment to good corporate governance, business ethics, human rights, and fair stakeholder treatment. Social policies are aligned with the company's strategy, business operations, and the science, technology, and medical industry, focusing on creating shared value across economic, social, and environmental dimensions. Key practices include:

- Promoting research and knowledge development in science, technology, and medicine in collaboration with researchers, institutions, and relevant organizations to benefit the public, support innovation, and strengthen national competitiveness.
- Developing employee capabilities through training, learning, and skill-building, while ensuring a safe and supportive work environment
- Meeting customer needs by delivering reliable, high-quality, standardized products and services in a fair, transparent manner.
- Engaging communities and stakeholders through open communication, consultation, respect for diversity, and support for initiatives that enhance well-being and resilience.
- Collaborating with partners including government, professional associations, business partners, and civil society to share knowledge, apply sustainability standards, and generate tangible positive social impact.

#### **Human Rights Policy and Practices**

The company places great importance on respecting, protecting, and promoting the human rights of all stakeholders across the business value chain. This commitment is guided by principles of equality, non-discrimination, and equal opportunity, in line with the United Nations Sustainable Development Goals (SDGs) and international human rights standards.

The company has established a human rights policy and practices to serve as a framework for the Board of Directors, management, and all employees to adhere to strictly, respecting the dignity, cultural differences, traditions, values, and diversity of all stakeholders, including employees, customers, business partners, communities, and society at large. Additionally, the company has developed a Business Code of Conduct Handbook, aligned with its corporate governance policy. The handbook covers business ethics, human rights and labor, safety, occupational health, environment, personal data protection, and business continuity, providing guidance for responsible and sustainable operations.

##### **1. Respect for Human Rights**

The company recognizes employees as valuable resources and key factors in organizational success, emphasizing human resource development and fair treatment to support sustainable growth.

1.1 The company complies with laws, regulations, and basic human rights principles under international standards, adhering to equality, freedom, and non-discrimination regardless of race, gender, age, skin color, religion, disability,



social or economic status, ancestry, education, or other factors unrelated to work performance, while respecting individual dignity.

1.2 The company treats employees, workers, business partners, and stakeholders fairly, providing equal opportunities and assigning work based on knowledge, skills, and suitability without discrimination.

1.3 The company respects and honors employees, workers, and partners, fostering a workplace environment that values human dignity and mutual respect.

## 2. Fair Labor Practices

2.1 The company manages compensation and benefits fairly and appropriately, ensuring motivation and compliance with relevant laws. The system and standards are applied consistently across the organization and are reviewed and adjusted to reflect responsibilities, business operations, and industry competitiveness.

2.2 The company emphasizes continuous employee development at all levels through training, seminars, knowledge sharing, and study visits to enhance knowledge, professional skills, and managerial capabilities.

2.3 The company promotes career advancement based on non-discrimination and compliance with applicable laws, providing equal opportunities to all employees regardless of gender, race, religion, age, place of origin, disability, socioeconomic status, or educational background.

2.4 The company prioritizes employee life, health, safety, and quality of work-life by managing occupational safety, health, and work environment appropriately. It protects employees, workers, and company assets without violating others' rights, while ensuring personal data protection, confidentiality, proper disclosure, and lawful use of information.

## **Compliance with human rights principles and standards**

Human rights management principles and standards : Thai Labour Standard: Corporate Social Responsibility of Thai Businesses (TLS 8001-2010) by the Ministry of Labour

## **Review of social and human rights policies, guidelines, and/or goals over the past year**

Review of social and human rights policies, guidelines, and/ : Yes  
or goals over the past year

Changes in social and human rights policies, guidelines, : Employee rights, Consumer/customer rights,  
and/or goals Community and environmental rights, Safety and  
occupational health at work, Non-discrimination,  
Supplier rights

The company places great importance on responsible labor management, strictly complying with Thai labor laws and related regulations. It also adopts the Thai Labor Standards and Thai Business Social Responsibility Guidelines (TBS 8001-2533) as a framework for its human resources policies and practices. These are designed to promote fair employment, respect labor rights, and uphold the dignity of employees at all levels.

The company ensures non-discriminatory treatment, supports equality and fair work opportunities, and provides appropriate compensation and benefits in accordance with labor laws, job nature, and responsibilities. Occupational health and safety are prioritized to maintain a safe and suitable working environment.

Furthermore, the company promotes continuous employee development through training and skill-building aligned with its medical and genomics business operations. Employees are encouraged to provide feedback appropriately, and fair, transparent, and verifiable labor grievance mechanisms are in place. The company is committed to conducting business responsibly with respect to labor, adhering to legality, fairness, and labor rights. These efforts support sustainable organizational growth and foster confidence among shareholders, investors, and all stakeholders.

Does the company have an HRDD process : No

### 3.4.2 Social operating results

#### Information on employees and labor

##### Employees and labor management plan

The company's employee and labor management plan : Yes

Employee and labor management plan implemented by : Fair employee compensation, Employee training and development, Promoting employee relations and participation, Migrant/foreign labor, Safety and occupational health at work

##### Fair Compensation

The company strictly adheres to human rights principles and Thai labor laws to create a fair, safe, and supportive working environment. This includes fair employment, appropriate compensation, continuous employee training and development, and comprehensive benefits such as social security, provident fund, funeral assistance for employees' family members, annual health check-ups, and group health/accident insurance.

The company manages human resources based on fairness, equality, and non-discrimination in employment, compensation, promotions, and skill development opportunities, regardless of gender, age, educational background, race, or religion. The company also supports employment for disadvantaged groups, including persons with disabilities, ensuring equal access to career opportunities and personal development.

The company ensures effective human resource management, including workforce planning to meet operational needs and strengthen organizational competitiveness. It also promotes a corporate culture of collaboration, responsibility, and employee engagement, fostering a work environment conducive to the long-term growth of both employees and the organization.

##### Employee Training and Engagement

Recognizing the importance of human capital in driving sustainable growth, the company continuously supports employee learning and skill development through role-specific training programs. These include:

- Specialized training for positions such as product specialists, scientists, medical technicians, bioinformatics specialists, and R&D staff to ensure up-to-date knowledge and professional competence.
- General skills development such as communication, management, and teamwork to improve collaboration and efficiency.
- Technology and innovation training to enhance adaptability to new technologies and industry changes.
- In addition to training, the company promotes employee engagement and relationships through activities that strengthen unity and commitment, including:
  - Physical exercise and sports to promote health and positive relationships.
  - Recreational activities and social events to foster a friendly and enjoyable work environment.
  - Volunteer and social contribution programs to cultivate social responsibility and organizational pride.
- The company strives to create a work environment where employees can grow alongside the organization, enjoy job security, and have opportunities for career advancement.

The company strictly complies with labor, immigration, and related laws, including BOI regulations when applicable. Work permits and relevant visas are obtained through government procedures, including the Single Window system or BOI-designated channels, ensuring foreign employees work legally. Foreign workers receive fair and equal compensation and benefits, in line with Thai employees in comparable positions, without discrimination.

The company does not support or engage in illegal labor, forced labor, or child labor and adheres to human rights principles throughout recruitment, hiring, and labor management to align with good governance and organizational sustainability practices.

### **Occupational Safety, Health, and Environment**

The company's medical laboratories comply with ISO 15190:2020 safety standards. It continuously develops and improves safety management practices to reduce health risks and safeguard the well-being of employees and workers, including maintaining laboratory safety standards.

### **Setting employee and labor management goals**

Does the company set employee and labor management : Yes

goals

## Details of setting goals for employee and labor management

| Target(s)                                                                               | Indicator(s)                                                                                                                                                                                                                   | Base year(s)                                                                                                                                                                                                                         | Target year(s)                                                                                                                                                                                                                            |
|-----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Fair employee compensation                                                            | Employee Turnover Related to Compensation                                                                                                                                                                                      | 2023: Employee turnover related to compensation must be 0%.                                                                                                                                                                          | 2024: The employee turnover rate related to compensation is 0%.                                                                                                                                                                           |
| • Fair employee compensation                                                            | Number of complaints regarding compensation received and resolution                                                                                                                                                            | 2024: The company offers competitive salary and benefits packages that are aligned with the labor market. This is evidenced by the number of compensation-related complaints received and addressed.                                 | 2025: The company offers competitive salary and benefits packages that are aligned with the labor market. This is evidenced by the number of compensation-related complaints received and addressed.                                      |
| • Employee training and development<br>• Promoting employee relations and participation | The company supports employees in continuously developing their skills and abilities. This is evidenced by the fact that over 75% of employees have participated in development programs, and over 75% have received training. | 2023: The company supports employees in continuously developing their skills and abilities. This is evidenced by the fact that over 75% of employees have participated in development programs, and over 75% have received training. | 2024: The company supports employees in continuously developing their skills and abilities. This is evidenced by the fact that more than 75% of employees have participated in development programs, and over 75% have received training. |
| • Safety and occupational health at work                                                | Work-related accident rate, number of days and working hours lost due to work-related accidents or illnesses resulting in at least 3 days of absence                                                                           | 2025: Reduce accidents and injuries resulting in more than 3 days of work absence to zero.                                                                                                                                           | 2027: Reduce accidents and injuries resulting in more than 3 days of work stoppage to zero.                                                                                                                                               |

## Performance and outcomes for employee and labor management

Performance and outcomes for employee and labor : Yes  
management

### Employees and Workers

The company treats all employees and workers fairly, equally, and without discrimination, in line with human rights principles. This includes employment, fair compensation, promotions, training and development, and providing a supportive work environment, regardless of gender, age, education, race, or religion. The company also supports employment for disadvantaged groups, including persons with disabilities, and provides benefits as required by law, such as social security, as well as additional benefits like a provident fund, funeral assistance for employees' family members, annual health check-ups, and group health/accident insurance.

As part of human resource management, the company plans workforce levels to ensure sufficient staffing to perform duties efficiently. As of 31 December 2025, the company had a total of 109 employees: 29 male, 80 female, and 1 employee with a disability.

### **Employee Training**

The company recognizes the importance of developing personnel to enhance skills and capabilities. Training programs are provided according to employees' roles, such as product specialists, scientists, medical technicians, bioinformatics specialists, and R&D staff, to ensure up-to-date knowledge and professional competency.

### **Occupational Safety, Health, and Work Environment**

The company's medical laboratories comply with ISO 15190:2020 safety standards. It continuously improves safety management practices to reduce health risks and safeguard employees' and workers' well-being. Key safety measures include:

- Biohazard Safety Cabinet Class II, Type A2

Class II Type A2 biosafety cabinets are used in BSL-2 laboratories handling specimens potentially contaminated with Risk Group 3 pathogens. HEPA filters trap infectious particles, while blowers control airflow inside the cabinet. The front air curtain protects both the operator and the environment, ensuring contaminated air is filtered before release.

- Autoclaves

Autoclaves are used to sterilize laboratory samples and equipment. Steam replaces the air in the chamber, and pressure and temperature are increased to sterilize contents effectively.

- Ultraviolet Surface Mobile (UV Surface Mobile)

The Ultraviolet Surface Mobile is a UVC (ultraviolet-C) disinfection device used for sterilization purposes. It is capable of inactivating bacteria, viruses, filamentous fungi, yeasts, and other microorganisms. Its effectiveness depends on the duration of exposure.

In the laboratory, the UV Surface Mobile device is operated for at least 30 minutes before and after laboratory use to ensure proper disinfection and to reduce contamination within the laboratory environment.

In 2025, the Company continued to prioritize operational safety to minimize risks of illness and injury, while ensuring the well-being of employees. From 2022 to 2025, there were no recorded work-related injuries resulting in lost-time incidents.

### **Employee and labor management: Employment**

#### **Hiring employees**

|                                  | 2023 | 2024 | 2025 |
|----------------------------------|------|------|------|
| <b>Total employees</b> (persons) | 98   | 103  | 109  |
| Male employees (persons)         | 27   | 25   | 29   |
| Female employees (persons)       | 71   | 78   | 80   |

#### Employment of workers with disabilities

|                                                                                  | 2023 | 2024 | 2025 |
|----------------------------------------------------------------------------------|------|------|------|
| <b>Total employment of workers with disabilities</b> (persons)                   | 1    | 1    | 1    |
| <b>Total number of employees with disabilities</b> (persons)                     | 1    | 1    | 1    |
| Total male employees with disabilities (persons)                                 | 1    | 1    | 1    |
| Total female employees with disabilities (persons)                               | 0    | 0    | 0    |
| <b>Total number of workers who are not employees with disabilities</b> (persons) | 0    | 0    | 0    |
| <b>Contributions to empowerment for persons with disabilities fund</b>           | No   | No   | No   |

#### Employee and labor management: Remuneration

##### Employee remuneration

|                                           | 2023          | 2024          | 2025          |
|-------------------------------------------|---------------|---------------|---------------|
| <b>Total employee remuneration</b> (baht) | 61,093,723.36 | 59,405,266.78 | 80,527,043.50 |
| Total male employee remuneration (Baht)   | 18,278,564.83 | 15,964,485.71 | 22,133,977.14 |
| Total female employee remuneration (Baht) | 42,815,158.53 | 43,440,781.07 | 58,393,066.36 |

#### Employee and labor management: Employee training and development

|                                                         | 2023       | 2024       | 2025         |
|---------------------------------------------------------|------------|------------|--------------|
| Average employee training hours (hours / person / year) | 10.00      | 27.00      | 52.00        |
| Training and development expenses for employees (baht)  | 312,289.80 | 608,295.00 | 1,584,189.04 |

#### Employee and labor management: Safety, occupational health, and environment at work

## Safety, occupational health, and environment at work

|                                                                 | 2023 | 2024 | 2025 |
|-----------------------------------------------------------------|------|------|------|
| Total number of lost time injury incidents by employees (cases) | 0    | 1    | 0    |

## Employee and labor management: Employee engagement and internal employee groups

### Employee engagement

|                                                                                    | 2023  | 2024  | 2025  |
|------------------------------------------------------------------------------------|-------|-------|-------|
| <b>Total number of employee turnover leaving the company voluntarily</b> (persons) | 43    | 31    | 32    |
| Total number of male employee turnover leaving the company voluntarily (persons)   | 11    | 7     | 10    |
| Total number of female employee turnover leaving the company voluntarily (persons) | 32    | 24    | 22    |
| Proportion of voluntary resignations (%)                                           | 43.88 | 30.10 | 29.36 |
|                                                                                    | 2023  | 2024  | 2025  |
| Evaluation result of employee engagement                                           | No    | Yes   | No    |

### Employee internal groups

Employee internal groups : Yes

Types of employee internal groups : Welfare committee

## Information about customers

### Customer management plan

Company's customer management plan : Yes

Customer management plan implemented by the : Responsible production and services for customers, company over the past year Communication of product and service impacts to customers/consumers, Development of customer satisfaction and customer relationship, Consumer data privacy and protection

The company places great importance on customer management as a process aimed at creating customer satisfaction and building long-term relationships, focusing on understanding customer needs in depth and providing accurate, responsive, and safe services.

1.Accurate, precise, and safe laboratory services and test results

Services and test results are provided accurately, precisely, and safely in accordance with established standards.

2.Transparent and accurate communication of products and services

Information about laboratory products and services is accurate, complete, not exaggerated, and complies with professional standards and applicable laws. All information communicated through documents, the website, and online channels is always verified for accuracy.

3.Continuous customer satisfaction and relationship building

The company emphasizes continuous customer satisfaction and relationship management through regular communication via various channels, including email, phone, and social media. After-sales services include monitoring customer satisfaction and resolving issues promptly and effectively.

4.Strict protection and confidentiality of customer information

Customer data and test results are strictly protected, with regular reviews of confidentiality and security measures.

5.Key processes in customer management

- Survey customer needs and feedback through conversations, questionnaires, or market research.
- Collect key customer information, such as service usage behavior, contact history, and preferences.
- Analyze customer data to improve products or services to better meet their needs.
- Offer promotions or special offers tailored to each customer.
- Maintain continuous communication to build relationships and trust.
- Monitor outcomes to assess customer satisfaction.
- Resolve issues and complaints promptly and effectively.

**Setting customer management goals**

Does the company set customer management goals : Yes



## Details of setting customer management goals

| Target(s)                                                             | Indicator(s)                                                                                                                                                                                                  | Base year(s)                                                                                                                                                                                                                   | Target year(s)                                                                                                                                                                                                                 |
|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Development of customer satisfaction and customer relationship      | Increase customer satisfaction, with a customer satisfaction rate of not less than 95%.                                                                                                                       | 2025: Utilize Customer Satisfaction Surveys and feedback to improve services.                                                                                                                                                  | 2026: Utilizing Customer Satisfaction Surveys and feedback to improve services.                                                                                                                                                |
| • Responsible production and services for customers                   | Provide laboratory services and test results that are accurate, precise, and safe for users.                                                                                                                  | 2024: Test accuracy rate of 99% and error-related complaints at 1%.                                                                                                                                                            | 2026: Test accuracy rate $\geq 99\%$ and error-related complaints $\leq 1\%$ of the total.                                                                                                                                     |
| • Communication of product and service impacts to customers/consumers | Communicate product and service information transparently, without exaggeration, and provide accurate laboratory product and service information in accordance with professional standards and relevant laws. | 2025: All communications or promotional materials through documents, websites, and online channels must be 100% verified for accuracy, and the number of complaints regarding inaccurate information or exaggerated claims = 0 | 2026: All communications or promotional materials through documents, websites, and online channels must be 100% verified for accuracy, and the number of complaints regarding inaccurate information or exaggerated claims = 0 |
| • Consumer data privacy and protection                                | Strictly protect customers' personal data and test results.                                                                                                                                                   | 2025: No incidents of customer data breaches, unauthorized access rate = 0, and measures for confidentiality and security are reviewed at least once a year.                                                                   | 2026: No incidents of customer data breaches, unauthorized access rate = 0, and confidentiality and security measures are reviewed annually.                                                                                   |

## Performance and outcomes of customer management

Performance and outcomes of customer management : Yes

### Customers

The company conducts regular customer satisfaction surveys. In 2021-2025, the company received excellent customer satisfaction ratings of 93.40%, 94.60%, 97.40%, 88.84% and 94.21% respectively. The company has not received any major customer complaints in the past.

### Customer management: Customer satisfaction

#### Customer satisfaction

|                                             | 2023 | 2024 | 2025 |
|---------------------------------------------|------|------|------|
| Evaluation results of customer satisfaction | Yes  | Yes  | Yes  |

## Information on community and society

### Community and social management plan

Company's community and social management plan : Yes

Community and social management plan implemented by : Religion and culture, Sports and recreation  
the company over the past year

The company is committed to creating value alongside improving the quality of life, economy, society, and the environment of the surrounding community. This commitment is grounded in community involvement and social responsibility through continuous projects and activities in collaboration with stakeholders. These efforts are a key factor in contributing to the overall economic and social development of the country. In 2025, the company initiated social policies and practices aligned with its operations, focusing on creating shared value in three dimensions: environmental, economic, and social. The goal is to ensure that the surrounding communities and society grow sustainably alongside the company. More details can be found in the company's governance policies, code of ethics, and sustainability development policies, which are published on the company's website. The company has implemented the following social and community practices:

1. Promote research, development, and academic knowledge in collaboration with researchers, experts, and professors to benefit the public and enhance the company's service image sustainably.
2. Invest in developing employee capabilities by supporting training programs, providing necessary resources, and creating a safe work environment that encourages creativity, allowing employees to work at their full potential and capacity.
3. Respond to customer needs and ensure their satisfaction by delivering products and services that meet both the quantity and quality requirements as per contractual agreements.
4. Enhance and promote community and stakeholder participation by being open to feedback, engaging in transparent and constructive consultations, treating everyone equally, respecting diversity, and supporting the development of the community's quality of life and strength.
5. Cooperate with government agencies, associations, business partners, civil society, and other stakeholders to contribute to the development and/or application of sustainability standards and best practices across various sectors.

### Setting community and social management goals

Does the company set community and social : No  
management goals

### Performance and outcomes of community and social management

Performance and outcomes of community and social : Yes  
management

### Preservation of Religion, Culture, and Traditions

The Company recognizes the importance of preserving, promoting, and sustaining Thai religion, culture, and traditions, which serve as a fundamental foundation for values, ethics, and social harmony. The Company has therefore integrated cultural and religious preservation into its human resource management and organizational culture development to support long-term sustainability.

In 2025, the Company conducted several key activities, including:

- Annual merit-making ceremony, aimed at enhancing auspiciousness for employees and the organization, as well as boosting morale.

- Songkran water-pouring ceremony, to preserve Thai traditions and strengthen relationships between management and employees.
- Cultural promotion activities, such as wearing traditional Thai attire on special occasions and organizing Loy Krathong activities, to encourage participation and foster pride in Thai identity.

In addition, the Company supports employees in participating in religious and cultural activities both within and outside the organization, including volunteer and community support initiatives such as donations to temples and public organizations. These efforts promote social responsibility and strengthen community engagement.

The Company remains committed to conducting its business alongside the preservation of Thai cultural traditions, fostering unity within the organization, and supporting sustainable organizational development in the long term.

### **Donations and Community Support**

The Company is committed to contributing to the improvement of quality of life and well-being in society and local communities. In 2025, the Company donated essential supplies to support flood victims in southern Thailand. Employees actively participated in the donation efforts, reflecting their generosity, collaboration, and strong volunteer spirit.

This support not only helped alleviate the hardship faced by affected communities during difficult times, but also reinforced the Company's commitment to continuously and effectively carrying out social responsibility initiatives.

## **Information on incidents related to legal or social and human rights violations**

#### Number of cases and incidents of significant legal or social and human rights violations

|                                                                                                     | 2023 | 2024 | 2025 |
|-----------------------------------------------------------------------------------------------------|------|------|------|
| Total number of cases or incidents of significant legal or social and human rights violations cases | 0    | 1    | 0    |
| Total number of cases or incidents leading to significant labor disputes (cases)                    | 0    | 0    | 0    |
| Total number of incidents or complaints related to business partner's rights violations (cases)     | 0    | 0    | 0    |
| The total number of cases or complaints related to partner rights violations (Cases)                | 0    | 0    | 0    |
| Total number of cases or incidents leading to disputes with the community/society (cases)           | 0    | 0    | 0    |
| Total number of cases or incidents related to cybersecurity or customer data breaches (cases)       | 0    | 0    | 0    |
| Total number of cases or incidents related to workplace safety and occupational health (cases)      | 0    | 1    | 0    |

#### Details of incidents and corrective measures for significant social and legal violations

| Year of incident | Details  | Progress status                      |
|------------------|----------|--------------------------------------|
| 2024             | Incident | Incident no longer subject to action |
|                  |          |                                      |

| Year of incident | Details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Progress status |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
|                  | <p>As the messenger was riding a motorcycle along the designated route, he observed that the traffic light was green. He then accelerated to pass through the intersection in time. While increasing speed, a car moved out from the left side of a queue of vehicles that were gradually advancing. This resulted in a collision between Messenger's motorcycle and the car. The accident was caused by the car exiting the queue without signaling or adequately checking the surrounding traffic conditions.</p> <p><b>Impact that occurred or is expected to occur</b></p> <p><u>Non-financial impact</u></p> <p>Physical and Health Impacts</p> <ul style="list-style-type: none"> <li>- Accident victims may sustain injuries ranging from minor wounds to severe trauma, which could have long-term health consequences. In cases of serious injury, there is a risk of permanent disability or loss of the ability to perform daily activities as usual. Additionally, the stress and anxiety resulting from the injuries may negatively affect the victim's mental well-being.</li> </ul> <p>Psychological and Emotional Impacts</p> <ul style="list-style-type: none"> <li>- Accident victims may develop fear or anxiety about traveling or driving in the future. In cases of severe accidents, they may experience post-traumatic stress disorder (PTSD), leading to nightmares, heightened fear, or prolonged anxiety. Additionally, the victim's family and close associates may also suffer psychological effects, such as worry, stress, and emotional distress.</li> </ul> <p>Impacts on Work and Career</p> <ul style="list-style-type: none"> <li>- Accident-related injuries may result in temporary or permanent inability to work, affecting the victim's income and financial stability. Extended recovery periods could lead to job loss or career setbacks, especially in physically demanding occupations. Additionally, psychological effects, such as anxiety or PTSD, may reduce work efficiency and productivity. Employers and colleagues may also be affected by increased workloads or disruptions in team operations.</li> </ul> <p><u>Financial impact</u></p> <ul style="list-style-type: none"> <li>• Expected impact on financial statement : 0.00 baht</li> <li>• Actual impact on financial statement : 0.00 baht</li> </ul> <p><b>Corrective or remedial measures</b></p> |                 |

| Year of incident | Details                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Progress status |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
|                  | <p>The company recognizes the importance of rehabilitation and support measures for injured employees. It provides full assistance in accessing medical treatment and has a group insurance policy that covers potential accidents. Additionally, the company offers psychological support by sending care packages to hospitalized employees and reinforces workplace safety by reminding other employees to exercise greater caution in their duties.</p> |                 |

## 4. Management Discussion and Analysis (MD&A)

### 4.1 Operation, financial condition and material changes

#### Operational overview

##### Operating Results Overview for the year 2025

- For the fiscal year 2025, the Group reported total revenues of 386.73 million Baht, an increase of 40.86 million Baht or 11.81% compared to the previous year. The primary driver was the success of the market expansion strategy for laboratory products, which resulted in sales revenue reaching 111.87 million Baht, a growth of 37.96%. Meanwhile, revenue from services continued to expand by 4.34%, despite intense market competition and policy changes by the National Health Security Office (NHSO) regarding fully-funded fetal chromosome screening services. The Group proactively adjusted its strategy by offering products aligned with the aforementioned policy to ensure eligibility for reimbursement at rates specified by the NHSO. This approach enabled the Group to effectively maintain its existing customer base and expand its services to new recipient groups.
- In terms of cost management efficiency, the Group recorded a gross profit of 162.84 million Baht, representing a margin of 42.11% of total revenue. This reflects a robust performance, remaining close to the previous year's margin of 42.89%, despite pricing strategy adjustments made in response to government policies and heightened market competition. Net profit for the year amounted to 45.33 million Baht, a slight decrease of 9.63% from the previous year. This was primarily driven by a strategic decision to increase selling and administrative expenses to strengthen the corporate foundation and enhance the capacity for sustainable long-term revenue growth.
- However, when considering the operating results for the fourth quarter of 2025 compared to the previous quarter (QoQ), the Group demonstrated significant and clear improvement. Total revenue reached 144.23 million Baht, an increase of 60.02%. The most prominent growth signal came from sales revenue, which surged by 280.58% from the previous quarter. These factors led to a net profit for the fourth quarter of 26.00 million Baht, representing an exceptional growth of 275.72% compared to the third quarter. This reflects the Company's agility and swift market responsiveness, which will serve as significant momentum for the performance in the following year.

#### Diagram of operational overview

| Statement of Comprehensive Income              | Consolidated Financial Statement |               |               |               |               |                |               |               |              |               |               |               |
|------------------------------------------------|----------------------------------|---------------|---------------|---------------|---------------|----------------|---------------|---------------|--------------|---------------|---------------|---------------|
|                                                | 12 Months                        |               |               |               |               |                | 3 Months      |               |              |               |               |               |
|                                                | Quarter 4/25                     |               | Quarter 4/24  |               | Changed (YoY) |                | Quarter 4/25  |               | Quarter 3/25 |               | Changed (QoQ) |               |
|                                                | MB                               | %             | MB            | %             | MB            | %              | MB            | %             | MB           | %             | MB            | %             |
| Revenue from sales                             | 111.87                           | 28.93         | 81.09         | 23.45         | 30.78         | 37.96          | 66.64         | 46.20         | 17.51        | 19.43         | 49.13         | 280.58        |
| Revenue from services                          | 267.64                           | 69.20         | 256.50        | 74.16         | 11.14         | 4.34           | 75.62         | 52.43         | 71.41        | 79.23         | 4.21          | 5.90          |
| Other income                                   | 7.22                             | 1.87          | 8.28          | 2.39          | (1.06)        | (12.80)        | 1.97          | 1.37          | 1.21         | 1.34          | 0.76          | 62.81         |
| <b>Total revenues</b>                          | <b>386.73</b>                    | <b>100.00</b> | <b>345.87</b> | <b>100.00</b> | <b>40.86</b>  | <b>11.81</b>   | <b>144.23</b> | <b>100.00</b> | <b>90.13</b> | <b>100.00</b> | <b>54.10</b>  | <b>60.02</b>  |
| Cost of sales                                  | 62.95                            | 16.28         | 56.54         | 16.35         | 6.41          | 11.34          | 36.58         | 25.36         | 10.43        | 11.57         | 26.15         | 250.72        |
| Cost of services                               | 160.94                           | 41.61         | 140.98        | 40.76         | 19.96         | 14.16          | 46.27         | 32.08         | 44.77        | 49.67         | 1.50          | 3.35          |
| <b>Total Costs</b>                             | <b>223.89</b>                    | <b>57.89</b>  | <b>197.52</b> | <b>57.11</b>  | <b>26.37</b>  | <b>13.35</b>   | <b>82.85</b>  | <b>57.44</b>  | <b>55.20</b> | <b>61.24</b>  | <b>27.65</b>  | <b>50.09</b>  |
| <b>Gross profit</b>                            | <b>162.84</b>                    | <b>42.11</b>  | <b>148.35</b> | <b>42.89</b>  | <b>14.49</b>  | <b>9.77</b>    | <b>61.38</b>  | <b>42.56</b>  | <b>34.93</b> | <b>38.76</b>  | <b>26.45</b>  | <b>75.72</b>  |
| Selling expenses                               | 49.08                            | 12.69         | 39.41         | 11.39         | 9.67          | 24.54          | 14.80         | 10.26         | 11.88        | 13.18         | 2.92          | 24.58         |
| Administrative expenses                        | 64.15                            | 16.59         | 56.48         | 16.33         | 7.67          | 13.58          | 17.94         | 12.44         | 15.46        | 17.16         | 2.48          | 16.04         |
| <b>Profit from operating activities</b>        | <b>49.61</b>                     | <b>12.83</b>  | <b>52.46</b>  | <b>15.17</b>  | <b>(2.85)</b> | <b>(5.43)</b>  | <b>28.64</b>  | <b>19.86</b>  | <b>7.59</b>  | <b>8.42</b>   | <b>21.05</b>  | <b>277.34</b> |
| Finance costs                                  | 1.44                             | 0.38          | 1.36          | 0.40          | 0.08          | 5.88           | 0.35          | 0.25          | 0.35         | 0.39          | -             | -             |
| Share of loss from investment from JV          | 0.32                             | 0.08          | 0.08          | 0.02          | 0.24          | 300.00         | -             | -             | 0.09         | 0.10          | (0.09)        | (100.00)      |
| <b>Profit from income tax</b>                  | <b>47.85</b>                     | <b>12.37</b>  | <b>51.02</b>  | <b>14.75</b>  | <b>(3.17)</b> | <b>(6.21)</b>  | <b>28.29</b>  | <b>19.61</b>  | <b>7.15</b>  | <b>7.93</b>   | <b>21.14</b>  | <b>295.66</b> |
| Tax expenses                                   | 2.52                             | 0.65          | 0.86          | 0.25          | 1.66          | 193.02         | 2.29          | 1.58          | 0.23         | 0.25          | 2.06          | 895.65        |
| <b>Profit for the period</b>                   | <b>45.33</b>                     | <b>11.72</b>  | <b>50.16</b>  | <b>14.50</b>  | <b>(4.83)</b> | <b>(9.63)</b>  | <b>26.00</b>  | <b>18.03</b>  | <b>6.92</b>  | <b>7.68</b>   | <b>19.08</b>  | <b>275.72</b> |
| Other comprehensive income for the year        | 1.37                             | 0.35          | -             | -             | 1.37          | 100.00         | 1.37          | 0.94          | -            | -             | 1.37          | 100.00        |
| <b>Total comprehensive income for the year</b> | <b>43.96</b>                     | <b>11.37</b>  | <b>50.16</b>  | <b>14.50</b>  | <b>(6.20)</b> | <b>(12.36)</b> | <b>24.63</b>  | <b>17.09</b>  | <b>6.92</b>  | <b>7.68</b>   | <b>17.71</b>  | <b>255.92</b> |

#### Annual Performance Summary 2025

#### Analysis on the operation and financial condition

## Operating results and profitability

### Revenue Structure

- **The Group reported total revenue of 386.73 million Baht, an increase of 40.86 million Baht or 11.81% compared to the previous year.** This growth was driven by the following key factors:
  - **Revenue from laboratory equipment and reagents sales:** This segment reached 111.87 million Baht, growing by 37.96% year-on-year. This success reflects our strategic focus on laboratory products. We have successfully expanded our market through various models, including direct equipment sales, equipment placement paired with monthly reagent supply, and the distribution of specialized reagents. These efforts have effectively stabilized our income and expanded our customer base.
  - **Revenue from services :** Totaling 267.64 million Baht, this segment grew by 4.34%. Despite intense competition and changes in the National Health Security Office (NHSO) policy which now fully funds fetal chromosome screening and caused a slight 0.07% slowdown in reproductive health revenue, the Group adapted quickly. We introduced products that align with NHSO reimbursement rates to maintain our market share. Notably, our specialized services showed strong growth: Technology-driven services increased by 65.38% due to our technical expertise, Other screening services rose by 24.48%, driven by cancer screening (launched in Q3/2024) and the introduction of Advanced Therapy Medicinal Product (ATMP) services in 2025.
  - **Other income:** Decreased by 1.06 million Baht or 12.80%, mainly due to lower market interest rates for deposits.
- **The Group's revenue for the three-month period ended December 31, 2025, showed clear growth, increasing by 54.10 million Baht or 60.02% compared to the previous quarter (QoQ).** This reflects a strong recovery in business activities and a continuous rise in demand. The growth was significantly supported by sales revenue, which surged by 280.58% due to our aggressive product distribution strategy. At the same time, the core service business continued to expand by 5.90%. Despite the impact of NHSO policy changes, our ability to adjust strategies and offer market-relevant products helped us reach new customers effectively. This performance demonstrates the Group's flexibility and the strong confidence customers have in our service quality.

### Gross Profit and Gross Profit Margin from Sales

- **For the year ended December 31, 2025, the Group's gross profit from sales reached 48.92 million Baht, representing a gross profit margin of 43.73%.** This marks a significant increase of 24.37 million Baht or 99.27% compared to the same period last year. This growth was driven by the successful expansion into the laboratory product segment, including direct equipment sales, equipment placements bundled with monthly reagent supplies, and the distribution of specialized reagents to both public and private sector clients. These initiatives led to a 37.96% increase in sales revenue. Furthermore, improved cost management allowed the Group to raise its gross profit margin from 30.28% in the previous year to 43.73% in the current year.
- **For the three-month period ended December 31, 2025, the Group reported a gross profit from sales of 30.06 million Baht, or a gross profit margin of 45.11%.** This represents an impressive leap of 324.58% compared to the previous quarter (QoQ). The primary driver was the exceptional growth in product sales, which surged by 280.58%. Additionally, the gross profit margin improved slightly from 40.43% in the previous quarter to 45.11%. This improvement reflects the Group's ability to maintain strong profitability while achieving substantial sales growth.

### Gross Profit and Gross Profit Margin from Services



- **For the year ended December 31, 2025, the Group's gross profit from services was 106.70 million Baht, representing a gross profit margin of 39.87%. This is a decrease from 115.52 million Baht, or a 45.04% margin, in the previous year.** This change was primarily due to intensified competition in our core service business and a strategic shift in our product mix to align with the National Health Security Office (NHSO) policy, which now provides fully-funded fetal chromosome screening. Although this strategic move led to a lower profit margin per unit, it effectively allowed the Group to retain its existing customer base and reach new service users. Furthermore, the Group maintained overall profitability stability by expanding into high-growth areas, particularly technology-driven services and cancer screening, which helped offset the margin slowdown in core services. Despite rising service costs partly due to overseas sample analysis for specialized services, our commitment to improving laboratory efficiency and resource management has preserved our technical advantage. This ensures continued customer confidence despite external challenges and shifts in government policy.
- **On a quarter-over-quarter basis, the Group reported a gross profit from services of 29.35 million Baht, an increase of 10.17% compared to the previous quarter (QoQ).** This growth aligns with the 5.90% increase in service revenue during this period. The gross profit margin also improved from 37.31% in the previous quarter to 38.81%. Despite a higher proportion of revenue coming from products aligned with NHSO policy, the Group demonstrated strong resilience in maintaining profit levels and a consistent ability to generate robust total revenue.

### Operating Expenses


- **For the year ended December 31, 2025, the Group's operating expenses totaled 114.67 million Baht, representing 29.66% of operating revenue. This is an increase of 17.42 million Baht, or 17.91%, compared to the previous year.** An analysis of these expenses is as follows:
  - **Selling Expenses:** Increased by 9.67 million Baht, or 24.54%. This was primarily due to the expansion of the sales team to support revenue growth in both laboratory products and new services. Additionally, marketing and promotional activities were intensified as part of our strategy to expand our customer base and promote both existing and newly launched services.
  - **Administrative Expenses:** Increased by 7.67 million Baht, or 13.58%. The main factors included the recognition of director bonuses paid during the year and increased international travel expenses for business networking and sourcing new technologies. Furthermore, depreciation costs rose following investments in IT infrastructure, including high-performance storage systems and servers, to enhance operational stability and support increasing transaction volumes.
- **On a quarter-over-quarter basis, total operating expenses were 33.09 million Baht, an increase of 19.50%.** This was mainly driven by a 24.58% rise in selling expenses due to aggressive promotional activities, public relations, and participation in exhibitions to build brand awareness for our products and services. Notably, the overall increase in expenses remained significantly lower than the total revenue growth of 60.02% in the same quarter. This demonstrates the Group's efficiency in cost management and operational planning.

### **Diagram of operating results and profitability**


## Revenues by product type

| Revenue by product type                     | Consolidated Financial Statement |               |               |               |              |              |               |               |              |               |              |               |
|---------------------------------------------|----------------------------------|---------------|---------------|---------------|--------------|--------------|---------------|---------------|--------------|---------------|--------------|---------------|
|                                             | Quarter 4/25                     |               | Quarter 4/24  |               | Changed      |              | Quarter 4/25  |               | Quarter 3/25 |               | Changed      |               |
|                                             | (12 months)                      |               | (12 months)   |               | (YoY)        |              | (3 months)    |               | (3 months)   |               | (QoQ)        |               |
|                                             | MB                               | %             | MB            | %             | MB           | %            | MB            | %             | MB           | %             | MB           | %             |
| Reproductive health services                | 232.97                           | 60.24         | 233.14        | 67.41         | (0.17)       | (0.07)       | 62.34         | 43.22         | 60.80        | 67.46         | 1.54         | 2.53          |
| Infectious disease services                 | 0.09                             | 0.02          | 0.23          | 0.07          | (0.14)       | (60.87)      | 0.02          | 0.01          | 0.02         | 0.02          | -            | -             |
| Other screening test services               | 22.32                            | 5.77          | 17.93         | 5.18          | 4.39         | 24.48        | 9.19          | 6.37          | 6.98         | 7.74          | 2.21         | 31.66         |
| Tech-solution services                      | 8.60                             | 2.22          | 5.20          | 1.50          | 3.40         | 65.38        | 0.41          | 0.29          | 3.61         | 4.01          | (3.20)       | (88.64)       |
| Advanced Therapy Medicinal Product Services | 3.66                             | 0.95          | -             | -             | 3.66         | 100.00       | 3.66          | 2.54          | -            | -             | 3.66         | 100.00        |
| <b>Total Service Revenue</b>                | <b>267.64</b>                    | <b>69.20</b>  | <b>256.50</b> | <b>74.16</b>  | <b>11.14</b> | <b>4.34</b>  | <b>75.62</b>  | <b>52.43</b>  | <b>71.41</b> | <b>79.23</b>  | <b>4.21</b>  | <b>5.90</b>   |
| Sale sequencers and reagent                 | 100.78                           | 26.06         | 80.11         | 23.16         | 20.67        | 25.80        | 56.92         | 39.46         | 16.35        | 18.14         | 40.57        | 248.13        |
| Sale of Advanced Therapy Medicinal Products | 9.16                             | 2.37          | -             | -             | 9.16         | 100.00       | 9.16          | 6.35          | -            | -             | 9.16         | 100.00        |
| Sale other                                  | 1.93                             | 0.50          | 0.98          | 0.29          | 0.95         | 96.94        | 0.56          | 0.39          | 1.16         | 1.29          | (0.60)       | (51.72)       |
| <b>Total Sale Revenue</b>                   | <b>111.87</b>                    | <b>28.93</b>  | <b>81.09</b>  | <b>23.45</b>  | <b>30.78</b> | <b>37.96</b> | <b>66.64</b>  | <b>46.20</b>  | <b>17.51</b> | <b>19.43</b>  | <b>49.13</b> | <b>280.58</b> |
| <b>Total Operating Revenue</b>              | <b>379.51</b>                    | <b>98.13</b>  | <b>337.59</b> | <b>97.61</b>  | <b>41.92</b> | <b>12.42</b> | <b>142.26</b> | <b>98.63</b>  | <b>88.92</b> | <b>98.66</b>  | <b>53.34</b> | <b>59.99</b>  |
| Other income                                | 7.22                             | 1.87          | 8.28          | 2.39          | (1.06)       | (12.80)      | 1.97          | 1.37          | 1.21         | 1.34          | 0.76         | 62.81         |
| <b>Total Revenue</b>                        | <b>386.73</b>                    | <b>100.00</b> | <b>345.87</b> | <b>100.00</b> | <b>40.86</b> | <b>11.81</b> | <b>144.23</b> | <b>100.00</b> | <b>90.13</b> | <b>100.00</b> | <b>54.10</b> | <b>60.02</b>  |

Note : GP = Gross Profit , GPM = Gross Profit Margin



12-Month Operating Revenue (YoY) - Consolidated Financial Statement




3-Month Operating Revenue (QoQ) - Consolidated Financial Statement


## Comparative Graph of Operating Results Gross Profit and Gross Profit Margin from sale revenue

| Gross Profit and<br>Gross Profit from sale revenue | Consolidated Financial Statement |              |              |              |              |              |              |              |              |              |              |               |
|----------------------------------------------------|----------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|---------------|
|                                                    | Quarter 4/25                     |              | Quarter 4/24 |              | Changed      |              | Quarter 4/25 |              | Quarter 3/25 |              | Changed      |               |
|                                                    | MB                               | %            | MB           | %            | MB           | %            | MB           | %            | MB           | %            | MB           | %             |
| Sale revenues                                      | 111.87                           | 100.00       | 81.09        | 100.00       | 30.78        | 37.96        | 66.64        | 100.00       | 17.51        | 100.00       | 49.13        | 280.58        |
| Cost of sales                                      | 62.95                            | 56.27        | 56.54        | 69.72        | 6.41         | 11.34        | 36.58        | 54.89        | 10.43        | 59.57        | 26.15        | 250.72        |
| <b>Gross Profit</b>                                | <b>48.92</b>                     | <b>43.73</b> | <b>24.55</b> | <b>30.28</b> | <b>24.37</b> | <b>99.27</b> | <b>30.06</b> | <b>45.11</b> | <b>7.08</b>  | <b>40.43</b> | <b>22.98</b> | <b>324.58</b> |

Note : GP = Gross Profit , GPM = Gross Profit Margin




12-Months of Gross Profit and Gross Profit Margin from sale revenue (YoY)



3-Months of Gross Profit and Gross Profit Margin from sale revenue (QoQ)

## Gross Profit and Gross Profit Margin from service revenue

|                                                    | Consolidated Financial Statement |        |              |        |         |        |              |        |              |        |         |       |
|----------------------------------------------------|----------------------------------|--------|--------------|--------|---------|--------|--------------|--------|--------------|--------|---------|-------|
| Gross Profit and Gross Profit from service revenue | Quarter 4/25                     |        | Quarter 4/24 |        | Changed |        | Quarter 4/25 |        | Quarter 3/25 |        | Changed |       |
|                                                    | MB                               | %      | MB           | %      | MB      | %      | MB           | %      | MB           | %      | MB      | %     |
| Service revenue                                    | 267.64                           | 100.00 | 256.50       | 100.00 | 11.14   | 4.34   | 75.62        | 100.00 | 71.41        | 100.00 | 4.21    | 5.90  |
| Cost of service                                    | 160.94                           | 60.13  | 140.98       | 54.96  | 19.96   | 14.16  | 46.27        | 61.19  | 44.77        | 62.69  | 1.50    | 3.35  |
| Gross Profit                                       | 106.70                           | 39.87  | 115.52       | 45.04  | (8.82)  | (7.64) | 29.35        | 38.81  | 26.64        | 37.31  | 2.71    | 10.17 |



## Asset management capability

### Assets

As of December 31, 2025, the Group reported total assets of 701.85 million Baht, an increase of 94.26 million Baht or 15.51% from the end of 2024. This growth was primarily driven by increases in trade receivables and prepaid expenses to prepare for new products launching next year, along with inventory management aligned with sales expansion. Additionally, the Group continued to invest in non-current assets to drive long-term growth. Key investments include: Developing an Automated Biobank system in collaboration with the public sector to support Advanced Therapy Medicinal Products (ATMP), Developing CAR-T Cell products for blood cancer treatment. And investing in technology transfer agreements for the production of prototype immunotherapy cells, specifically Dendritic cells (DCs) and Cytokine-induced killer cells (CIK). These strategic investments are designed to generate significant future benefits for the Group.

## Liquidity and capital adequacy

### Key Financial Ratios

- **The Return on Equity (ROE) for the year ended December 31, 2025, stood at 8.33%, a decrease from 12.98% in the same period of the previous year.** The primary reason for this decline was the decrease in net profit, resulting from competitive pressures in the core service business and higher operating expenses. Despite this, the Company successfully expanded its customer base for new products, which offset the slowdown in core services. Additionally, the average shareholders' equity for this period was higher than in the previous year. This expansion of the equity base also contributed to the decrease in ROE from an accounting perspective.
- **The Current Ratio as of December 31, 2025, stood at 4.58, a decrease from 11.27 in the same period of the previous year. Similarly, the Quick Ratio decreased to 3.42 from 6.39.** Although both ratios declined, they remain at a very high level. This change was primarily a result of an increase in current liabilities, such as trade payables and payables for assets, which is consistent with the Company's business expansion and project investments.
- **The Average Collection Period for the year ended December 31, 2025, was 109.81 days an increase from 56.22 days in the same period of the previous year.** This increase is primarily a result of our strategic market expansion into the public sector, particularly through the reagent-rental model. Public sector clients typically have longer payment terms than their private sector counterparts, which directly resulted in the extended average collection period. However, the level of receivables remains consistent with the strong sales growth observed in the fourth quarter.

- **The Average Inventory Period for the year ended December 31, 2025, was 55.28 days, an increase from 38.56 days in the same period of the previous year.** This was a result of proactive inventory management, where the Company increased its stock of products and raw materials in advance. This strategic move ensures that we can respond to customer demand promptly and maintain a reliable supply of products.
- **The Average Payment Period for the year ended December 31, 2025, stood at 86.53 days, a significant increase from 32.75 days in the same period of the previous year.** This reflects an enhanced ability to manage cash flow and optimize trade terms with suppliers.
- **The Debt-to-Equity Ratio as of December 31, 2025, was 0.27, an increase from 0.13 in the same period of the previous year.** This was a result of increased trade payables to support business expansion. However, the ratio remains at a very low level, reflecting a strong financial structure and low financial risk.

#### Diagram of liquidity and capital adequacy

| Key of financial ratios            | Quarter 4/2025 | Quarter 4/2024 |
|------------------------------------|----------------|----------------|
| Return ratio                       |                |                |
| Return on Equity                   | 8.33           | 12.98          |
| Liquidity ratio (Times)            |                |                |
| Current ratio                      | 4.58           | 11.27          |
| Quick Ratio                        | 3.42           | 6.39           |
| Asset and Debt Management (Days)   |                |                |
| Average collection period          | 109.81         | 56.22          |
| Average inventory period           | 55.28          | 38.56          |
| Average payment period             | 86.53          | 32.75          |
| Debt-Equity ratio Analysis (Times) |                |                |
| Debt to equity ratio               | 0.27           | 0.13           |

#### Key financial ratios

#### Issuance of debt securities with an obligation to maintain financial ratios

Is there an issuance of debt securities with an obligation : No  
to maintain financial ratios?

## 4.2 Potential factors or incidents that may materially affect the financial condition or the operating results

### Significant factors or incidents that may materially affect the future financial condition or the operating results

The laboratory industry in 2025 continues to face intense competition driven by rapid technological advancements, increasingly stringent regulatory requirements, and the growing demand for laboratory testing services. Domestic operators also face challenges related to limitations in investment capital, technological capabilities, and marketing strategies when compared with multinational and foreign companies that possess stronger financial resources and technological advantages.

In addition, medical equipment manufactured domestically has not yet been widely accepted among medical professionals. As a result, the industry continues to rely on imported advanced technologies for service delivery and production processes, which may lead to higher costs of products and services in line with the increasing complexity of such technologies. Key factors affecting competitive conditions in the industry include:

#### 1. Advancements in Medical Technology and Digital Transformation

Advancements in laboratory technologies, such as Next Generation Sequencing (NGS), automation systems, and bioinformatics data analysis, require operators to continuously invest in modern equipment and technologies to enhance accuracy, efficiency, and turnaround time. In addition, the adoption of advanced technologies such as Artificial Intelligence (AI), advanced analytics, and Laboratory Information Management Systems (LIMS), as well as emerging digital health trends including Telemedicine and At-home Diagnostic Kits, play an important role in improving service quality and operational efficiency, thereby strengthening the competitiveness of industry operators.

#### 2. Regulatory Requirements and Laboratory Standards

The medical laboratory industry is subject to regulatory oversight and must comply with relevant standards and requirements, particularly international standards such as ISO 15189 for medical laboratories and ISO 17025 for testing and calibration laboratories. These standards serve as key indicators of the quality, accuracy, and reliability of laboratory results. Laboratories that consistently maintain high standards of quality and effective quality control systems are better positioned to build trust and confidence among physicians and service users, which represents an important competitive advantage.

#### 3. Technology Costs and Competition in Pricing and Service Quality

Advanced medical equipment and technologies are largely imported, resulting in operational costs that may fluctuate in line with technology prices, exchange rates, and equipment complexity. At the same time, the laboratory industry faces competition in terms of pricing, quality of test results, turnaround time, and service standards. Operators therefore need to manage costs efficiently while continuously improving service quality and differentiating their services to maintain competitiveness and strengthen trust among physicians and service users.

#### 4. Mergers, Acquisitions, and Strategic Partnerships

Trends in mergers, acquisitions, and strategic collaborations among laboratories, hospitals, research institutions, and healthcare partners have continued to increase as operators seek to expand service capabilities, develop new diagnostic services, and create additional business opportunities. Larger operators generally benefit from economies of scale, modern infrastructure, and broader service networks, which support business growth and enhance their competitive position within the industry.

#### 5. Development of Specialized Professionals

Laboratory services require personnel with specialized knowledge, expertise, and professional experience. Operators therefore place significant emphasis on the continuous development of employee skills and professional competencies to keep pace with technological advancements and evolving industry requirements. Such efforts are essential to maintaining service quality and sustaining long-term competitiveness.

## 4.3 Information from financial statements and significant financial ratios

### Information from financial statements

#### Summary of financial position statements

|                                                                 | THB         |             |             |
|-----------------------------------------------------------------|-------------|-------------|-------------|
|                                                                 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|                                                                 | Separate    | Consolidate | Consolidate |
|                                                                 | AUDITED     | AUDITED     | AUDITED     |
| <b>Assets</b>                                                   |             |             |             |
| Cash And Cash Equivalents<br>(ThousandTHB)                      | 125,887.33  | 199,910.10  | 121,714.56  |
| Trade And Other<br>Receivables - Current - Net<br>(ThousandTHB) | 36,119.89   | 91,830.61   | 311,574.44  |
| Inventories - Net<br>(ThousandTHB)                              | 10,053.08   | 22,088.79   | 36,085.29   |
| Other Current Financial<br>Assets<br>(ThousandTHB)              | 40,017.25   | 190,102.70  | 100,060.79  |
| Other Current Financial<br>Assets - Others<br>(ThousandTHB)     | 40,017.25   | 190,102.70  | 100,060.79  |
| Income Tax Receivable -<br>Current<br>(ThousandTHB)             | 0.00        | 11.18       | 0.22        |
| Other Current Assets<br>(ThousandTHB)                           | 0.00        | 10,981.00   | 10,919.73   |
| Other Current Assets -<br>Others<br>(ThousandTHB)               | 0.00        | 10,981.00   | 10,919.73   |
| <b>Total Current Assets</b><br>(ThousandTHB)                    | 212,077.55  | 514,924.38  | 580,355.03  |
| Restricted Deposits - Non-<br>Current<br>(ThousandTHB)          | 4,120.00    | 6,729.00    | 16,229.00   |

|                                                                                                          | THB         |             |             |
|----------------------------------------------------------------------------------------------------------|-------------|-------------|-------------|
|                                                                                                          | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|                                                                                                          | Separate    | Consolidate | Consolidate |
|                                                                                                          | AUDITED     | AUDITED     | AUDITED     |
| Investment In Subsidiaries, Associates And Joint Ventures Using The Equity Method - Net<br>(ThousandTHB) | 0.00        | 915.25      | 591.09      |
| Investment In Associates<br>(ThousandTHB)                                                                | 0.00        | 915.25      | 591.09      |
| Property, Plant And Equipment - Net<br>(ThousandTHB)                                                     | 46,570.37   | 55,405.40   | 56,236.51   |
| Right-Of-Use Assets - Net<br>(ThousandTHB)                                                               | 23,827.70   | 23,546.10   | 20,498.59   |
| Intangible Assets - Net<br>(ThousandTHB)                                                                 | 1,075.15    | 478.46      | 22,935.17   |
| Intangible Assets - Others<br>(ThousandTHB)                                                              | 1,075.15    | 478.46      | 22,935.17   |
| Deferred Tax Assets<br>(ThousandTHB)                                                                     | 760.44      | 920.67      | 1,269.16    |
| Other Non-Current Assets<br>(ThousandTHB)                                                                | 4,589.75    | 4,676.13    | 3,740.99    |
| Other Non-Current Assets - Others<br>(ThousandTHB)                                                       | 4,589.75    | 4,676.13    | 3,740.99    |
| <b>Total Non-Current Assets</b><br>(ThousandTHB)                                                         | 80,943.41   | 92,671.01   | 121,500.51  |
| <b>Total Assets</b><br>(ThousandTHB)                                                                     | 293,020.96  | 607,595.39  | 701,855.54  |
| <b>Liabilities</b>                                                                                       |             |             |             |
| Trade And Other Payables - Current<br>(ThousandTHB)                                                      | 31,194.23   | 40,960.33   | 119,492.73  |
| Current Portion Of Long-Term Debts<br>(ThousandTHB)                                                      | 4,285.25    | 4,213.37    | 4,867.02    |

|                                                                                  | THB         |             |             |
|----------------------------------------------------------------------------------|-------------|-------------|-------------|
|                                                                                  | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|                                                                                  | Separate    | Consolidate | Consolidate |
|                                                                                  | AUDITED     | AUDITED     | AUDITED     |
| Current Portion Of Long-Term Debts - Others<br>(ThousandTHB)                     | 4,285.25    | 4,213.37    | 4,867.02    |
| Other Tax Or Other Payables Under Law And Regulations - Current<br>(ThousandTHB) | 0.00        | 274.86      | 1,729.13    |
| Other Tax Payables<br>(ThousandTHB)                                              | 83.12       | 274.86      | 1,729.13    |
| Other Current Liabilities<br>(ThousandTHB)                                       | 0.17        | 230.17      | 734.71      |
| <b>Total Current Liabilities</b><br>(ThousandTHB)                                | 35,562.77   | 45,678.73   | 126,823.59  |
| Non-Current Portion Of Lease Liabilities<br>(ThousandTHB)                        | 19,434.92   | 19,791.30   | 16,603.78   |
| Other Non-Current Liabilities<br>(ThousandTHB)                                   | 2,204.75    | 2,972.78    | 5,276.94    |
| <b>Total Non-Current Liabilities</b><br>(ThousandTHB)                            | 21,639.67   | 22,764.08   | 21,880.72   |
| <b>Total Liabilities</b><br>(ThousandTHB)                                        | 57,202.44   | 68,442.81   | 148,704.31  |
| <b>Shareholders' equity</b>                                                      |             |             |             |
| Authorised Share Capital<br>(ThousandTHB)                                        | 300,000.00  | 300,000.00  | 300,000.00  |
| Authorised Ordinary Shares<br>(ThousandTHB)                                      | 300,000.00  | 300,000.00  | 300,000.00  |
| Issued And Paid-Up Share Capital<br>(ThousandTHB)                                | 220,000.00  | 300,000.00  | 300,000.00  |
| Paid-Up Ordinary Shares<br>(ThousandTHB)                                         | 220,000.00  | 300,000.00  | 300,000.00  |
| Premium (Discount) On Share Capital<br>(ThousandTHB)                             | 0.00        | 171,214.29  | 171,214.29  |



|                                                                     | THB         |             |             |
|---------------------------------------------------------------------|-------------|-------------|-------------|
|                                                                     | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|                                                                     | Separate    | Consolidate | Consolidate |
|                                                                     | AUDITED     | AUDITED     | AUDITED     |
| Premium (Discount) On Ordinary Shares<br>(ThousandTHB)              | 0.00        | 171,214.29  | 171,214.29  |
| Retained Earnings (Deficits)<br>(ThousandTHB)                       | 16,124.44   | 66,295.94   | 81,692.53   |
| Retained Earnings - Appropriated<br>(ThousandTHB)                   | 8,460.00    | 11,000.00   | 13,200.00   |
| Legal And Statutory Reserves<br>(ThousandTHB)                       | 8,460.00    | 11,000.00   | 13,200.00   |
| Retained Earnings (Deficits) - Unappropriated<br>(ThousandTHB)      | 7,664.44    | 55,295.94   | 68,492.53   |
| Other Components Of Equity<br>(ThousandTHB)                         | (305.92)    | (305.92)    | (1,680.94)  |
| Other Components Of Equity - Others<br>(ThousandTHB)                | (305.92)    | (305.92)    | (1,680.94)  |
| <b>Equity Attributable To Owners Of The Parent</b><br>(ThousandTHB) | 235,818.52  | 537,204.31  | 551,225.88  |
| Non-Controlling Interests<br>(ThousandTHB)                          | 0.00        | 1,948.27    | 1,925.35    |
| <b>Total Equity</b><br>(ThousandTHB)                                | 235,818.52  | 539,152.58  | 553,151.23  |
| <b>Total Liabilities And Equity</b><br>(ThousandTHB)                | 293,020.96  | 607,595.39  | 701,855.54  |

## Summary of income statement

|                                                          | THB         |             |             |
|----------------------------------------------------------|-------------|-------------|-------------|
|                                                          | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|                                                          | Separate    | Consolidate | Consolidate |
|                                                          | AUDITED     | AUDITED     | AUDITED     |
| Statement of Comprehensive Income                        |             |             |             |
| Revenue From Operations<br>(ThousandTHB)                 | 245,389.66  | 337,592.90  | 379,511.13  |
| Revenue From Sales<br>(ThousandTHB)                      | 4,007.69    | 81,090.72   | 111,866.51  |
| Revenue From Rendering<br>Services<br>(ThousandTHB)      | 241,381.97  | 256,502.18  | 267,644.62  |
| Other Income<br>(ThousandTHB)                            | 1,954.54    | 8,272.96    | 7,216.84    |
| <b>Total Revenue</b><br>(ThousandTHB)                    | 247,344.20  | 345,865.86  | 386,727.97  |
| Costs<br>(ThousandTHB)                                   | 129,285.50  | 197,515.96  | 223,884.71  |
| Cost Of Sales<br>(ThousandTHB)                           | 3,737.89    | 56,535.34   | 62,947.61   |
| Cost Of Rendering<br>Services<br>(ThousandTHB)           | 125,547.61  | 140,980.62  | 160,937.10  |
| Selling And Administrative<br>Expenses<br>(ThousandTHB)  | 85,220.69   | 94,500.76   | 111,356.89  |
| Selling Expenses<br>(ThousandTHB)                        | 28,249.84   | 39,409.50   | 49,077.38   |
| Administrative Expenses<br>(ThousandTHB)                 | 56,970.85   | 55,091.26   | 62,279.51   |
| (Reversal Of) Expected<br>Credit Losses<br>(ThousandTHB) | (746.25)    | 1,384.38    | 1,870.57    |
| <b>Total Cost And Expenses</b><br>(ThousandTHB)          | 213,759.94  | 293,401.10  | 337,112.17  |

|                                                                                                             | THB         |             |             |
|-------------------------------------------------------------------------------------------------------------|-------------|-------------|-------------|
|                                                                                                             | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|                                                                                                             | Separate    | Consolidate | Consolidate |
|                                                                                                             | AUDITED     | AUDITED     | AUDITED     |
| Share Of Profit (Loss) From Investments Accounted For Using The Equity Method<br>(ThousandTHB)              | 0.00        | (84.75)     | (324.16)    |
| <b>Profit (Loss) Before Finance Costs And Income Tax Expense</b><br>(ThousandTHB)                           | 33,584.26   | 52,380.01   | 49,291.64   |
| Finance Costs<br>(ThousandTHB)                                                                              | 1,640.45    | 1,358.76    | 1,441.95    |
| Income Tax Expense<br>(ThousandTHB)                                                                         | (197.92)    | 862.08      | 2,524.16    |
| <b>Profit (Loss) For The Period From Continuing Operations</b><br>(ThousandTHB)                             | 32,141.73   | 50,159.17   | 45,325.53   |
| <b>Net Profit (Loss) For The Period</b><br>(ThousandTHB)                                                    | 32,141.73   | 50,159.17   | 45,325.53   |
| Net Profit (Loss) For The Period / Profit (Loss) For The Period From Continuing Operations<br>(ThousandTHB) | 32,141.73   | 50,159.17   | 45,325.53   |
| <b>Total Comprehensive Income (Expense) For The Period</b><br>(ThousandTHB)                                 | 32,141.73   | 50,159.17   | 43,950.52   |
| Net Profit (Loss) Attributable To : Owners Of The Parent<br>(ThousandTHB)                                   | 32,141.73   | 50,171.50   | 45,349.95   |
| Net Profit (Loss) Attributable To : Non-Controlling Interests<br>(ThousandTHB)                              | 0.00        | (12.33)     | (24.42)     |

|                                                                                                   | THB         |             |             |
|---------------------------------------------------------------------------------------------------|-------------|-------------|-------------|
|                                                                                                   | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|                                                                                                   | Separate    | Consolidate | Consolidate |
|                                                                                                   | AUDITED     | AUDITED     | AUDITED     |
| Total Comprehensive Income (Expense) Attributable To : Owners Of The Parent<br>(ThousandTHB)      | 32,141.73   | 50,171.50   | 43,974.93   |
| Total Comprehensive Income (Expense) Attributable To : Non-Controlling Interests<br>(ThousandTHB) | 0.00        | (12.33)     | (24.42)     |
| <b>Basic Earnings (Loss) Per Share (Baht/Share)</b><br>(ThousandTHB)                              | 0.07300     | 0.08800     | 0.07600     |
| Operating Profit<br>(ThousandTHB)                                                                 | 30,883.47   | 45,576.19   | 44,269.53   |
| Normalize Profit<br>(ThousandTHB)                                                                 | 32,141.73   | 50,159.17   | 45,325.53   |

### Summary of cash flow statement

|                                                                                        | THB         |             |             |
|----------------------------------------------------------------------------------------|-------------|-------------|-------------|
|                                                                                        | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|                                                                                        | Separate    | Consolidate | Consolidate |
|                                                                                        | AUDITED     | AUDITED     | AUDITED     |
| <b>Cash flow statement</b>                                                             |             |             |             |
| Net Profit (Loss) Attributable To Owners Of The Parent For The Period<br>(ThousandTHB) | 32,141.73   | 50,159.17   | 45,325.53   |
| Depreciation And Amortisation<br>(ThousandTHB)                                         | 15,962.51   | 17,787.96   | 21,546.11   |

|                                                                                                      | THB         |             |             |
|------------------------------------------------------------------------------------------------------|-------------|-------------|-------------|
|                                                                                                      | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|                                                                                                      | Separate    | Consolidate | Consolidate |
|                                                                                                      | AUDITED     | AUDITED     | AUDITED     |
| Depreciation<br>(ThousandTHB)                                                                        | 15,398.05   | 17,191.27   | 20,587.91   |
| Amortisation<br>(ThousandTHB)                                                                        | 564.46      | 596.69      | 958.20      |
| (Reversal Of) Expected<br>Credit Losses<br>(ThousandTHB)                                             | (746.25)    | 1,384.38    | 1,870.57    |
| (Reversal Of) Loss From<br>Diminution In Value Of<br>Inventories<br>(ThousandTHB)                    | 2,880.47    | 186.11      | (134.64)    |
| Share Of (Profit) Loss From<br>Investments Accounted For<br>Using The Equity Method<br>(ThousandTHB) | 0.00        | 84.75       | 324.16      |
| (Gains) Losses On Foreign<br>Currency Exchange<br>(ThousandTHB)                                      | (366.65)    | 180.72      | (462.26)    |
| (Gains) Losses On Fair Value<br>Adjustments Of Other<br>Financial Instruments<br>(ThousandTHB)       | 0.00        | (80.10)     | (31.62)     |
| (Gains) Losses On Disposal<br>And Write-Off Of Fixed Assets<br>(ThousandTHB)                         | 26.09       | 0.00        | 9.63        |
| (Gains) Losses On<br>Disposal Of Fixed Assets<br>(ThousandTHB)                                       | (1.36)      | 0.00        | 0.00        |
| Loss On Write-Off Of<br>Fixed Assets<br>(ThousandTHB)                                                | 27.45       | 0.00        | 9.63        |
| (Gains) Losses On Disposal<br>And Write-Off Of Other<br>Assets<br>(ThousandTHB)                      | 1,011.48    | 1,480.44    | 0.00        |

|                                                                                                                             | THB         |             |              |
|-----------------------------------------------------------------------------------------------------------------------------|-------------|-------------|--------------|
|                                                                                                                             | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025  |
|                                                                                                                             | Separate    | Consolidate | Consolidate  |
|                                                                                                                             | AUDITED     | AUDITED     | AUDITED      |
| Loss On Write-Off Of<br>Other Assets<br>(ThousandTHB)                                                                       | 1,011.48    | 1,480.44    | 0.00         |
| Dividend And Interest<br>Income<br>(ThousandTHB)                                                                            | (962.18)    | (4,376.93)  | (3,615.04)   |
| Interest Income<br>(ThousandTHB)                                                                                            | (962.18)    | (4,376.93)  | (3,615.04)   |
| Finance Costs<br>(ThousandTHB)                                                                                              | 1,640.45    | 1,358.76    | 1,441.95     |
| Income Tax Expense<br>(ThousandTHB)                                                                                         | (197.92)    | 862.08      | 2,524.16     |
| Employee Benefit Expenses<br>(ThousandTHB)                                                                                  | 714.56      | 768.03      | 824.59       |
| Other Reconciliation Items<br>(ThousandTHB)                                                                                 | (174.57)    | 0.00        | 0.00         |
| <b>Cash Flows From (Used In)<br/>Operations Before Changes<br/>In Operating Assets And<br/>Liabilities</b><br>(ThousandTHB) | 51,929.72   | 69,795.37   | 69,623.14    |
| (Increase) Decrease In Trade<br>And Other Receivables<br>(ThousandTHB)                                                      | 5,696.32    | (56,448.77) | (222,442.22) |
| (Increase) Decrease In<br>Inventories<br>(ThousandTHB)                                                                      | 7,339.28    | (12,221.81) | (13,861.86)  |
| (Increase) Decrease In Other<br>Operating Assets<br>(ThousandTHB)                                                           | (2,363.16)  | (12,535.41) | 1,015.39     |
| (Increase) Decrease In Other<br>Financial Assets<br>(ThousandTHB)                                                           | 0.00        | 0.00        | 80.10        |
| Increase (Decrease) In Trade<br>And Other Payables<br>(ThousandTHB)                                                         | 11,118.27   | 8,538.97    | 74,087.63    |

|                                                                                                    | THB         |              |             |
|----------------------------------------------------------------------------------------------------|-------------|--------------|-------------|
|                                                                                                    | 31 Dec 2023 | 31 Dec 2024  | 31 Dec 2025 |
|                                                                                                    | Separate    | Consolidate  | Consolidate |
|                                                                                                    | AUDITED     | AUDITED      | AUDITED     |
| Increase (Decrease) In Other Operating Liabilities<br>(ThousandTHB)                                | (21.00)     | 230.00       | 504.54      |
| <b>Cash Generated From (Used In) Operations</b><br>(ThousandTHB)                                   | 73,699.43   | (2,641.65)   | (90,993.28) |
| Income Tax (Paid) Received<br>(ThousandTHB)                                                        | (1,853.89)  | (854.17)     | (1,321.83)  |
| <b>Net Cash From (Used In) Operating Activities</b><br>(ThousandTHB)                               | 71,845.54   | (3,495.82)   | (92,315.11) |
| (Increase) Decrease In Short-Term Investments<br>(ThousandTHB)                                     | (40,001.99) | (150,005.36) | 89,993.43   |
| Payment For Purchase Of Investment In Subsidiaries, Associates And Joint Ventures<br>(ThousandTHB) | 0.00        | (1,000.00)   | 0.00        |
| Proceeds From Disposal Of Fixed Assets<br>(ThousandTHB)                                            | 5.61        | 0.00         | 0.00        |
| Property, Plant And Equipment<br>(ThousandTHB)                                                     | 5.61        | 0.00         | 0.00        |
| Payment For Purchase Of Fixed Assets<br>(ThousandTHB)                                              | (5,084.61)  | (19,964.69)  | (36,266.08) |
| Property, Plant And Equipment<br>(ThousandTHB)                                                     | (4,819.84)  | (19,964.69)  | (15,098.17) |
| Intangible Assets<br>(ThousandTHB)                                                                 | (264.77)    | 0.00         | (21,167.91) |
| (Increase) Decrease In Restricted Deposits<br>(ThousandTHB)                                        | (100.00)    | (2,609.00)   | (9,500.00)  |

|                                                                                     | THB         |              |             |
|-------------------------------------------------------------------------------------|-------------|--------------|-------------|
|                                                                                     | 31 Dec 2023 | 31 Dec 2024  | 31 Dec 2025 |
|                                                                                     | Separate    | Consolidate  | Consolidate |
|                                                                                     | AUDITED     | AUDITED      | AUDITED     |
| Interest Received<br>(ThousandTHB)                                                  | 626.83      | 3,681.47     | 4,234.91    |
| <b>Net Cash From (Used In)<br/>Investing Activities</b><br>(ThousandTHB)            | (44,554.16) | (169,897.58) | 48,462.26   |
| Repayments On Lease<br>Liabilities<br>(ThousandTHB)                                 | (5,656.00)  | (5,616.00)   | (5,776.00)  |
| Proceeds From Issuance Of<br>Equity Instruments<br>(ThousandTHB)                    | 0.00        | 260,800.00   | 0.00        |
| Proceeds From Changes In<br>Interest In Subsidiaries<br>(ThousandTHB)               | 0.00        | 1,960.60     | 1.50        |
| Dividend Paid<br>(ThousandTHB)                                                      | (44,000.00) | 0.00         | (28,082.13) |
| Other Items (Financing<br>Activities)<br>(ThousandTHB)                              | 0.00        | (9,585.71)   | 0.00        |
| <b>Net Cash From (Used In)<br/>Financing Activities</b><br>(ThousandTHB)            | (49,656.00) | 247,558.89   | (33,856.63) |
| <b>Net Increase (Decrease) In Cash<br/>And Cash Equivalent</b><br>(ThousandTHB)     | (22,364.62) | 74,165.49    | (77,709.48) |
| Effect Of Exchange Rate<br>Changes On Cash And Cash<br>Equivalents<br>(ThousandTHB) | (92.45)     | (142.72)     | (486.06)    |
| Cash And Cash Equivalents,<br>Beginning Balance<br>(ThousandTHB)                    | 148,344.40  | 125,887.33   | 199,910.10  |
| <b>Cash And Cash Equivalents,<br/>Ending Balance</b><br>(ThousandTHB)               | 125,887.33  | 199,910.10   | 121,714.56  |



## Key financial ratios

|                                                | 2023   | 2024  | 2025    |
|------------------------------------------------|--------|-------|---------|
| Liquidity ratio                                |        |       |         |
| Current ratio<br>(times)                       | 5.96   | 11.27 | 4.58    |
| Quick ratio<br>(times)                         | 4.37   | 6.39  | 3.42    |
| Cash flow liquidity ratio<br>(times)           | 2.41   | -0.09 | -1.07   |
| Average account receivable turnover<br>(times) | 7.71   | 6.49  | 3.32    |
| Average collection period<br>(days)            | 47.36  | 56.22 | 109.81  |
| Average inventory turnover<br>(times)          | 7.02   | 9.47  | 6.60    |
| Average inventory turnover period<br>(days)    | 52.02  | 38.56 | 55.28   |
| Average account payable turnover<br>(times)    | 18.24  | 11.14 | 4.22    |
| Average payment period<br>(days)               | 20.01  | 32.75 | 86.53   |
| Average cash cycle<br>(days)                   | 79.36  | 62.02 | 78.56   |
| Profitability ratio                            |        |       |         |
| Operating margin<br>(%)                        | 12.89  | 13.09 | 11.17   |
| Other income to total income<br>(%)            | 0.79   | 2.39  | 1.87    |
| Cash from operation to operating profit<br>(%) | 227.15 | -7.91 | -217.73 |

|                                        | 2023   | 2024   | 2025   |
|----------------------------------------|--------|--------|--------|
| Net profit margin<br>(%)               | 13.00  | 14.50  | 11.72  |
| Return on equity (ROE)<br>(%)          | 13.30  | 12.98  | 8.33   |
| Financial policy ratio                 |        |        |        |
| Total debts to total equity<br>(times) | 0.24   | 0.13   | 0.27   |
| Interest coverage ratio<br>(times)     | 30.20  | 51.64  | 49.13  |
| Dividend payout ratio<br>(%)           | 136.89 | 59.81  | 66.19  |
| Efficiency ratio                       |        |        |        |
| Return on asset (ROA)<br>(%)           | 10.83  | 11.14  | 6.92   |
| Return On Fixed Assets<br>(%)          | 99.84  | 133.26 | 119.80 |
| Asset turnover<br>(times)              | 0.83   | 0.77   | 0.59   |

## 5. General information and other material facts

### 5.1 General information

#### General information

#### Securities registrar

**Name of securities registrar :** Thailand Securities Depository Co., Ltd.

Address/location : 93 Ratchadaphisek Road

Subdistrict : Din Daeng

District : Din Daeng

Province : Bangkok

Postcode : 10400

Telephone : 02-009-9000

Facsimile number : 02-009-9991

#### Auditing firm

**Name of auditing firm\* :** DR. VIRACH AND ASSOCIATES COMPANY LIMITED

Address/location : No. 5/1, Supalai Grand Essence Village,  
Ratchadaphisek Road.

Subdistrict : WAT THA PHRA

District : BANGKOK YAI

Province : Bangkok

Postcode : 10600

Telephone : 093-130-8984,093-130-8986,0-2125-0029

**List of auditors :** Mr CHAIYAKORN AUNPITIPONGSA

License number : 3196

## **5.2 Other material facts**

### **5.2.1 Other information that may significantly influence investors' decision making**

Other information that may influence investors' decision : No  
making

### **5.2.2 Restrictions of foreign shareholders**

Are there restrictions on foreign shareholders? : No

## 5.3 Legal disputes

### Legal disputes

Is there any legal dispute? : No

## 5.4 Secondary market

### Secondary market

Has the company's security been listed on a stock : No  
exchange in another country?

## 5.5 Financial institution with regular contact (in case of debt securities offeror)

### Financial institution with regular contact

Are there any debt securities offered? : No

## **Part 2 Corporate Governance**



## 6. Corporate governance policy

### 6.1 Overview of the policy and guidelines

#### Overview of the policy and guidelines

Corporate governance policy and guidelines : Yes

The Board of Directors recognizes the importance of good corporate governance and ethical business conduct as crucial factors in promoting the Company's operational efficiency, transparency, and competitiveness in a changing business environment for sustainable growth. This will lead to confidence among all stakeholders that the operations of the Company and its subsidiaries are conducted fairly and with the best interests of all stakeholders in mind, including employees, investors, shareholders, and other stakeholders.

The Board of Directors has therefore established and implemented this Corporate Governance Policy, adhering to the principles and best practices of the Corporate Governance Code for Listed Companies 2017, prepared by the Securities and Exchange Commission, as a guideline for corporate governance. This aims to build confidence in the operations of the Company and its subsidiaries, ensuring fairness, transparency, and consideration for the best interests of shareholders and all stakeholders. The Board also deems it appropriate to continuously review and update the Corporate Governance Policy to ensure that the Board of Directors, executives, and employees adhere to it as a guideline for their work. This policy consists of 8 principles as follows:

#### **Principle 1 Recognizing the Role and Responsibilities of the Board of Directors as Leaders of the Organization in Creating Sustainable Value for the Business**

1. The Board of Directors understands its role and recognizes its responsibilities as the leader of the organization. The Company will clearly define the roles, authority, duties, and responsibilities of the Board of Directors. The Board of Directors is responsible for overseeing the good governance of the organization, including setting objectives and goals, defining strategies, establishing operating policies, and allocating key resources to achieve objectives and goals. The Board is also responsible for monitoring, evaluating, and overseeing the reporting of the Company's performance.

2. The Company places importance on creating sustainable value for the business. The Company has established a Code of Conduct and Ethics to serve as guidelines for directors, executives, and employees in conducting business. The Company focuses on conducting business ethically, respecting the rights of, and being responsible to shareholders and stakeholders, and helping the Company to be competitive and achieve good operating results. The Company will disclose its good corporate governance policy and the Company's Code of Conduct and Ethics through the Company's website to create a good understanding and promote compliance by directors, executives, employees at all levels, and stakeholders.

3. The Company has appointed an Audit Committee to oversee, monitor, and audit transactions that have a significant impact on the business, related party transactions, and the acquisition or disposal of assets for the benefit of the Company's stakeholders, as well as to build credibility in the Company's operations, which will enable the Company to grow sustainably.

4. The Board of Directors understands the scope of duties and responsibilities of the Board. The Company has established charters for various committees, which clearly define the scope of authority, duties, and responsibilities. The Company will review these charters annually, at least once a year, to ensure they are consistent with the Company's direction.

#### **Principle 2 Setting Objectives and Key Goals of the Business that Lead to Sustainability**

1. The Company has established a clear and appropriate vision, mission, and policies for the organization to communicate to all stakeholders the objectives and key goals of the organization. This is to ensure that personnel at

all levels of the organization adhere to these principles in performing their duties to achieve the established objectives and goals.

2. The Board of Directors has established strategies and annual plans that align with the objectives and key goals of the business. This includes analyzing the environment, factors, and various risks that may impact relevant stakeholders. The Board also recognizes the risks of setting goals that may lead to illegal or unethical conduct. Furthermore, the Board of Directors continuously monitors the implementation of strategies and annual plans to ensure appropriate control of operations according to the established plan.

### **Principle 3 Strengthening Board Effectiveness**

1. The Board of Directors is responsible for determining and reviewing the Board structure, including its composition, size, and an appropriate proportion of independent directors, which is not less than 1/3 of the total number of directors, to balance the Board. The Board also considers diversity in terms of gender, skills, experience, and expertise that are beneficial and sufficient for effective performance of duties. The current structure of the Board of Directors consists of 11 members, comprising executive and non-executive directors. The Company has a policy to appoint an independent director to serve as the Chairman of the Board. In addition, the Board of Directors comprises independent directors not less than 1/3 of the total number of directors.

2. The Board of Directors will appoint the Chairman of the Board by considering and selecting a suitable person and ensuring that the composition and operations of the Board facilitate the exercise of independent judgment in decision-making. The Company has a policy that the Chairman of the Board and the Managing Director are not the same person to ensure clarity in responsibilities between policy setting, oversight, and day-to-day management.

3. The Board of Directors will oversee the recruitment and selection of directors to be transparent and clear to ensure that the Board of Directors has the composition and qualifications in accordance with the provisions of the Board Charter.

4. The Board of Directors will consider and determine the remuneration of directors and executives, taking into account the following criteria:

3.4.1 Appropriateness and consistency with the scope of duties and responsibilities of each director.

3.4.2 The compensation is at a level that can motivate and retain directors with knowledge, abilities, and qualities to perform their duties for the organization.

3.4.3 The elements of compensation are clear and transparent, both in monetary and non-monetary forms.

3.4.4 The rate is comparable to the remuneration of directors in the same or similar industries. After the Company is listed on the Stock Exchange of Thailand, the Company has a policy that the structure and rate of director remuneration, both in monetary and non-monetary forms, must be approved by the shareholders' meeting as required by law or the Company's Articles of Association.

5. The Company has a policy that all directors must comply with the Code of Best Practices for Directors of Listed Companies as outlined by the Stock Exchange of Thailand. Additionally, all directors must dedicate sufficient time to fulfill their responsibilities. The Company will establish a policy requiring each director to attend no less than 75% of all Board of Directors meetings held each year.

6. In establishing the policy for investment in subsidiaries and associated companies, the Company will consider investing in businesses with objectives that align with the Company's core business or similar businesses, or investing in businesses that benefit the Company by supporting the Company's core business to be more comprehensive, thereby enhancing the Company's competitiveness.

7. The Company has a policy to conduct annual performance evaluations of the Board of Directors, subcommittees, and individual directors. The evaluation results should be used for further development of their duties.

8. The Board of Directors has a policy to encourage each director to have knowledge and understanding of their roles, responsibilities, the nature of the business, and laws related to the business. The Board also supports all directors in continuously enhancing their skills and knowledge for performing their duties as directors. The Board will encourage

directors to participate in seminars and training courses organized by various agencies. After the Company is listed on the Stock Exchange of Thailand, the Company has a policy to disclose information on various training courses in the annual report.

9. The Board of Directors schedules meetings at least four times a year and may hold additional special meetings as necessary. Each meeting has a clearly defined agenda, and a notice of meeting with details is sent 7 days in advance of the Board of Directors meeting. Written minutes of the meeting are taken, and the minutes of the meeting, once approved by the Board of Directors, are kept and made available for review by the Board of Directors and relevant individuals.

#### **Principle 4 Recruitment and Development of Senior Executives and Human Resources Management**

1. In recruiting senior executives, the Board of Directors will consider the qualifications, attributes, skills, knowledge, abilities, and experience necessary to lead and drive the organization towards its goals. The Company will clearly define the qualifications, authority, and responsibilities of the Chief Executive Officer. Additionally, the Company has established a policy for CEO succession planning to prepare for the succession of key positions from the level of Deputy Managing Director and above.

2. The Board of Directors will ensure that an appropriate compensation structure and performance evaluation system are in place, taking into account fairness, benchmarking against companies in the same industry of similar size, and providing compensation that can retain qualified executives as required by the Company. It also aims to motivate employees to perform their duties with high quality and good standards, commensurate with their assigned roles and responsibilities.

3. The Board of Directors will consider and understand the shareholder structure and relationships that may affect the management and operations of the business. The Board will oversee such structure and relationships to ensure they do not hinder the performance of the Board's duties. After the Company is listed on the Stock Exchange of Thailand, the Company has a policy to disclose information on agreements that may affect the control of the business.

4. The Board of Directors will oversee the management's development of personnel in terms of knowledge, skills, experience, and appropriate motivation. The Board will also ensure a safe working environment for life, health, and property, and provide communication channels between employees and supervisors or superiors. The Board will also support the process of development and skill enhancement by providing training according to job positions both within and outside the Company as necessary and appropriate.

#### **Principle 5 Promoting Innovation and Responsible Business Conduct**

1. The Board of Directors recognizes and prioritizes building a corporate culture that promotes innovation that benefits all stakeholders. The Company considers the development of product and service quality and human resource development.

2. The Board of Directors recognizes the rights of all stakeholder groups to foster good understanding and cooperation between the Company and its stakeholders. This will benefit the Company's business operations, build confidence, and enhance the Company's long-term competitiveness. Therefore, the Company has established the following policies and practices:

**Shareholders** The Company is committed to conducting business transparently and focusing on developing the organization for sustainable and continuous growth to generate appropriate returns for shareholders and enhance the Company's value, resulting in maximum returns for shareholders. The Company requires directors, executives, and employees to perform their duties responsibly, cautiously, and with honesty and integrity, avoiding any actions that may constitute a conflict of interest.

**Employees** The Company has a policy to treat all employees equally, fairly, and provide fair compensation based on the knowledge and abilities of each employee, as well as appropriate welfare benefits. The Company places importance on developing the knowledge and abilities of employees to enhance their work efficiency. The Company

has also established a provident fund for employees and provides opportunities for employees to develop their skills in various areas.

**Customers** The Company is responsible to its customers, complying with relevant laws and standards. The Company considers the health, safety, fairness, customer data protection, after-sales service throughout the product and service lifecycle, and monitoring and measuring customer satisfaction for product and service improvement. The Company also conducts advertising, public relations, and sales promotion responsibly, avoiding misunderstandings or taking advantage of customer misunderstandings.

**Business Partners and Creditors** The Company is responsible to its business partners, with fair procurement processes, contract terms, or agreements. The Company provides knowledge, develops potential, and enhances production and service capabilities to meet standards. The Company clarifies and ensures that business partners respect human rights and treat their workers fairly, are responsible for society and the environment, and monitors, inspects, and evaluates business partners to develop sustainable business relationships.

**Competitors** The Company has a policy of conducting business transparently and does not seek unfair competitive advantages. The Company adheres to good competitive practices, does not seek confidential information from competitors through dishonest or inappropriate means, and does not damage the reputation of competitors through false accusations.

**Community and Society** The Company emphasizes instilling a sense of awareness and responsibility towards the community and society within the Company continuously, including supporting activities that benefit the public and refraining from any actions that violate or are against the law.

**Environment** The Company will comply with all laws and regulations related to the environment and places importance on continuously controlling environmental impacts.

3. The Board of Directors will determine the Company's policies, business objectives, business plans, and budget. The Board will monitor and ensure that management implements these policies, plans, and budgets for the maximum benefit of the Company and shareholders as a whole. The Board will regularly review and update such business plans and budgets.

4. The Company has an information system security management policy with adequate security standards for the benefit and effectiveness of the Company's business.

#### **Principle 6 Ensuring an Appropriate Risk Management and Internal Control System**

1. The Board of Directors will be responsible for considering and establishing a risk management policy that covers the entire organization. The Board will oversee the implementation of a risk management system or process with supporting measures and control methods to mitigate the impact on the Company's business appropriately.

2. The Board of Directors will appoint an Audit Committee, which will consist of no less than three independent directors who meet the qualifications set by the Securities and Exchange Commission and the Stock Exchange of Thailand. The Audit Committee will have duties as specified in the Audit Committee Charter.

3. The Company will monitor, manage, and address potential conflicts of interest that may arise between the Company, management, the Board of Directors, or shareholders, including preventing the misuse of Company assets, information, and opportunities. The Company has established a related party transaction policy and a conflict of interest policy to serve as guidelines for conduct in the event of related party transactions and conflicts of interest.

4. The Company has established an anti-corruption policy that sets out clear anti-corruption measures and practices to ensure that all levels of the organization and external parties can effectively implement them.

5. The Company has established a whistleblowing and complaint policy, which outlines the mechanisms for receiving complaints, handling whistleblowing cases, and protecting whistleblowers or complainants without any unfair treatment. The Company will not disclose the name, surname, address, or any other information that could identify the whistleblower or complainant.

## **Principle 7 Maintaining Financial Credibility and Disclosure**

1. The Company places importance on disclosing information accurately, completely, and transparently, including financial information and general information, in accordance with the rules and regulations of the SEC and the Stock Exchange of Thailand, as well as important information that may affect the Company's securities prices, which may impact the decision-making process of investors and the Company's stakeholders. The Board of Directors will approve the disclosure of information, taking into account the assessment of the adequacy of the Company's internal control system, the auditor's opinion in the financial statements and observations on the internal control system, the Audit Committee's opinion, and consistency with the Company's objectives, key goals, strategies, and policies.

The Board of Directors will ensure that the disclosure of information, including financial statements, Annual Information Form (Form 56-1), and annual reports, adequately reflects the Company's financial position and operating results. The Board also encourages the Company to prepare Management's Discussion and Analysis (MD&A) to accompany the disclosure of financial statements. This is to enable investors to be informed and understand the changes in the Company's financial position and operating results beyond just the financial figures.

2. The Board of Directors will monitor the adequacy of the Company's financial liquidity and debt repayment ability. The Board will report on the Board's responsibilities for the financial statements, which are presented alongside the auditor's report, management's analysis, general information, and key information in the annual report and Annual Information Form, accurately, completely, timely, and in accordance with the requirements of the Securities and Exchange Commission and the Stock Exchange of Thailand.

3. The Board of Directors prioritizes managing financial problem resolution by considering the rights of all stakeholders. In the event that the business is likely to be unable to pay its debts or faces financial difficulties, the Board of Directors will closely oversee the business to operate with extra caution and take steps to monitor problem resolution by having management report on the status regularly. This ensures that any decision-making in resolving the Company's financial problems, by any means, is reasonable.

4. After the Company is listed on the Stock Exchange of Thailand, the Company will disclose information on legal compliance, code of conduct compliance, anti-corruption policies, and treatment of employees and stakeholders, including fair treatment and respect for human rights, as well as social and environmental responsibility, taking into account recognized reporting frameworks domestically and internationally. The information disclosed will be material and reflect practices that contribute to the creation of sustainable value for the business.

5. After the Company is listed on the Stock Exchange of Thailand, the Company will establish an investor relations department or designate an individual responsible for communicating with shareholders and other stakeholders, such as investors and analysts, appropriately, equally, and timely.

6. After the Company is listed on the Stock Exchange of Thailand, in addition to disclosing information according to the specified criteria and through the channels of the Stock Exchange of Thailand, the Company will disclose information in both Thai and English through the Company's website. The information presented will be kept up-to-date.

## **Principle 8 Supporting Shareholder Participation and Communication**

1. The Company acknowledges and places importance on the various fundamental rights of shareholders, including the right to buy, sell, or transfer shares, the right to receive dividends, the right to receive adequate information about the Company, the right to attend meetings to exercise their rights, the right to vote at shareholder meetings to appoint or remove directors, appoint auditors, and on matters that affect the Company, such as dividend allocation, the establishment or amendment of the Articles of Association and By-laws, capital reduction or increase, etc. The Company will send out notices of meetings along with relevant documents and publish them on the Company's website in advance of the meeting date in accordance with the time period stipulated by relevant laws or regulations to allow shareholders time to consider the details of each agenda item.

2. The Company prioritizes the rights of shareholders and will not take any actions that violate or infringe upon the rights of shareholders. In addition to the fundamental rights of shareholders, such as the right to buy, sell, or transfer

their securities, the right to receive dividends from the Company, and the right to attend shareholder meetings, the Company places importance on the right of shareholders to receive accurate, complete, adequate, timely, and equal information about the Company to make informed decisions on all matters. The Board of Directors has therefore established the following policies:

- (1) The Company will hold shareholder meetings to provide shareholders with the opportunity to consider important matters as required by law or matters that may affect the Company's business operations.
  - (2) The Company will send a notice of meeting along with supporting documents to shareholders in advance of the meeting, within the timeframe stipulated by relevant laws, announcements, or regulations, to allow shareholders to review the information thoroughly before the shareholders' meeting. The Company will also provide an opportunity for shareholders to submit questions in advance of the meeting. The Company will establish criteria for submitting questions and publish such criteria on the Company's website. The Company will compile and address important questions at the meeting.
  - (3) The Company will allow minority shareholders to nominate individuals for consideration as directors or propose additional agenda items before the shareholders' meeting. The Company will establish clear criteria and disclose such criteria to shareholders in advance. The Company will also inform the shareholders' meeting of the reasons for not including the shareholders' proposed agenda items in the meeting agenda.
  - (4) In the event that a shareholder is unable to attend the meeting in person, the Company will facilitate shareholders who are unable to attend the meeting in person by allowing them to appoint a proxy or by having at least one independent director act as a proxy to attend the meeting and vote on behalf of such shareholder. The names and information of such independent directors will be disclosed in the notice of the shareholders' meeting.
  - (5) In the event that the Company has foreign shareholders, the Company will prepare a notice of meeting along with supporting documents for the meeting in English and send them to foreign shareholders along with the Thai version.
  - (6) Increase channels for shareholders to receive information through the Company's website. After the Company is listed on the Stock Exchange of Thailand, the Company will ensure that the notice of the shareholders' meeting is published at least 14 days before the meeting date to allow shareholders to conveniently download complete information on the meeting agenda.
  - (7) The Company will facilitate all shareholders equally in attending the meeting, both in terms of a suitable venue and time.
  - (8) The shareholders' meeting will be conducted in accordance with the law and the Company's Articles of Association. The meeting will consider and vote on agenda items in the order specified, without changing material information or adding unnecessary agenda items. Shareholders will have equal opportunity to ask questions, express opinions, and make suggestions.
  - (9) The Company will use ballot voting on important agenda items and have independent individuals, such as external auditors and legal advisors, act as scrutineers at the meeting.
  - (10) The Company will encourage all directors and relevant executives to attend meetings to answer questions from shareholders.
  - (11) Record the minutes of the meeting completely, accurately, promptly, transparently, and record the names of directors and executives attending the meeting, voting methods, vote counting, meeting resolutions, voting results, including key questions and comments in the minutes of the meeting for shareholders to review, to be completed within 14 days from the date of the shareholders' meeting.
3. The Company will establish working guidelines in accordance with good corporate governance principles and will arrange for the recording of video recordings of meetings for archival and reference purposes. After the Company is listed on the Stock Exchange of Thailand, the Company will submit the minutes of such meetings to the Stock Exchange of Thailand or relevant agencies within the specified timeframe. The Company will also publish the minutes of the shareholders' meeting on the Company's website for shareholders to review.

#### **6.1.1 Policy and guidelines related to the board of directors**

Are there policy and guidelines related to the board of : Yes

directors

Guidelines related to the board of directors : Nomination of directors, Determination of director remuneration, Director development

### **Nomination of directors**

The company recognizes the critical roles, duties, and responsibilities of the Board of Directors, Audit Committee, and Executive Committee in driving business success and ensuring stable, sustainable growth. Therefore, the company has structured its board composition and compensation to align with their responsibilities, providing appropriate incentives to guide the organization toward both short-term and long-term objectives. Director compensation is designed to be consistent with the group's long-term strategy and goals, taking into account experience, responsibilities, scope of duties, and expected contributions. The compensation level is benchmarked against industry standards and requires shareholder approval, ensuring it remains reasonable and reflective of each director's role and responsibilities.

The Board of Directors' practices regarding the recruitment of directors are as follows:

- (1) Establish policies, criteria, and procedures for selecting directors to ensure alignment with the company's specific characteristics.
- (2) Carefully examine whether the person to be nominated has qualifications that do not contradict the laws or regulations of the Stock Exchange of Thailand, the Securities and Exchange Commission, and the company's regulations, including checking the list of nominees for directors with relevant agencies to ensure that they are not blacklisted or removed from the lists prepared by these agencies.
- (3) Approach individuals who meet the specified qualifications to ensure that they are willing to serve as directors of the company if appointed by the shareholders.
- (4) Submit the name for the Board of Directors' consideration and inclusion in the notice of meeting for shareholders to consider the appointment.

### **Determination of director remuneration**

The Company considers structuring and remunerating the Board of Directors at a level commensurate with their responsibilities and to motivate them to lead the organization towards achieving both short-term and long-term goals. The remuneration of the Board of Directors must be in line with the Group's long-term strategies and objectives, the duties, scope of roles and responsibilities, and the expected benefits from each director. It will be comparable to the levels practiced in the same industry. Shareholders will approve the structure and remuneration of the Board of Directors, ensuring it is not excessive. The criteria for determining remuneration will reflect the duties and responsibilities of each director.

### **Director development**

The Company places importance on developing the quality of its directors, as they are crucial personnel who significantly impact the organization's success. Therefore, the Company has established a director development policy that promotes and facilitates knowledge training for those involved in the corporate governance system, including the Board of Directors, Audit Committee, and Executive Committee.

## **6.1.2 Policy and guidelines related to shareholders and stakeholders**

Are there policy and guidelines and measures related to : Yes

shareholders and stakeholders

Guidelines and measures related to shareholders and : Shareholders, Employee, Customer, Other guidelines  
stakeholders and measures related to shareholders and  
stakeholders

### **Shareholders**

The Board of Directors will ensure that shareholders are involved in making decisions on important matters of the company, including ensuring that the conduct of the shareholders' meeting is orderly, transparent, efficient, and facilitates shareholders' exercise of their rights. The Board will strictly adhere to the "8 Principles: Supporting Shareholder Participation and Communication".

### **Employee**

The company places great importance on recruitment and selection as employees are valuable resources that contribute to the organization's success. Therefore, the company has established a systematic recruitment and selection policy, encompassing the planning of recruitment for all levels of employees. This ensures the acquisition of personnel with the vision, values, knowledge, abilities, and qualifications that align with the organization's requirements. This process aims to maintain an adequate and appropriate workforce to support business operations each year. Furthermore, the company recognizes the significance of employee compensation. As all personnel play a crucial role in driving the organization's success, the company has formulated a concrete compensation policy. This policy has been approved by shareholders, the Board of Directors, and the Chief Executive Officer to provide guidelines for fair and appropriate compensation. This approach aligns with the knowledge, abilities, and value of employees, which are essential factors in supporting the company's growth and success.

### **Customer**

The company prioritizes the confidentiality of both company and client information, recognizing its potential impact on both commercial and legal aspects of the business. Therefore, the company has established a policy for safeguarding company and client confidentiality, to serve as a principle and guideline, as follows:

#### **1. Guidelines for Disclosing Insider Information**

The company's board of directors, executives, employees, and related personnel often work with information and documents that cannot be disclosed to others or are considered trade secrets. This includes, but is not limited to, insider information not yet disclosed to the Stock Exchange of Thailand, information regarding bids for the acquisition or disposal of assets, plans, financial data, and inventions. These are considered company property, and protecting this information is crucial to achieving the company's objectives, both present and future, as well as ensuring the job security of all personnel.

All company personnel are responsible for maintaining the confidentiality and security of information, to protect confidential data and prevent its unintentional disclosure.

#### **2. Guidelines for Using Insider Information**

##### **(1) Use of Insider Information**

As the company has a diverse range of stakeholders, it is committed to acting with fairness and equity towards all parties. To prevent illegal activities, all company personnel, including all stakeholders who are or may be aware of non-public information, should refrain from trading in the company's securities where they serve as directors or executives. However, if trading in the company's securities is necessary, it should be conducted with caution, without using insider information that has not yet been disclosed to the Stock Exchange of Thailand. Upon completion of any such transactions, reporting of the securities trading should be carried out in accordance with the regulations of the Stock Exchange of Thailand and the Securities and Exchange Commission.



## (2) Preventive Measures

To ensure the smooth implementation of this policy, the company has established the following preventive measures:

- 1) Restrict access to non-public information, limiting it to the highest level of management possible and disclosing it to company employees only on a need-to-know basis. Employees must be informed that the information is confidential and subject to usage restrictions.
- 2) Implement workplace security systems to protect files, confidential documents, and information not yet disclosed to the public. Owners of such information must ensure that all relevant parties strictly adhere to security procedures.

### **Other guidelines and measures related to shareholders and stakeholders**

#### Responsibility to stakeholders

The Company has a duty to build its business and add value to its stakeholders in the long term. Therefore, it has the following guidelines:

1. Committed to conducting business with good operating results, able to generate profits to grow continuously and sustainably to enhance competitiveness and create long-term value for shareholders.
2. Directors, executives, and employees must perform their assigned duties to the best of their ability, honestly, carefully, and in the best interests of the Company and fairly to all shareholders for maximum benefit, including
3. The Company will treat all persons fairly and avoid any action that may affect the well-being of such persons.
4. The Company must be responsible to its customers by responding to their needs effectively and providing them with sufficient and accurate information to make decisions, without exaggeration or misinformation that may cause customers to misunderstand the Company or its services, including treating business partners and competitors fairly under the rules of competition.
5. The Company must be responsible to the community, society, and the country by providing cooperation and support, as well as accepting and complying with relevant laws. The Company shall adhere to the guidelines to ensure fairness in business conduct, without regard to other benefits that may be derived from improper conduct.
6. The Company shall adhere to the guidelines to ensure fairness in business conduct, without regard to other benefits that may be derived from improper conduct.

## 6.2 Business code of conduct

### Business code of conduct

Business code of conduct : Yes

To ensure that the operations of directors, executives, and employees at all levels are in accordance with the law, requirements, regulations, or rules and respect the rights of the company's vendors or customers, the company has established a business ethics code of conduct for everyone to use as a guideline or framework for work. This is an important foundation for strengthening and enhancing good corporate governance, a key foundation for sustainable business operations, and a guiding principle for the actions of employees throughout the organization. The company conducts business by creating values for employees to uphold and practice until they become a shared organizational culture and support the company in achieving its goals. The company adheres to the following business ethics and conduct policies:

#### 1. Honesty and Integrity

The company should uphold and maintain honesty and integrity as a principle in conducting its business.

#### 2. Compliance with Laws and Regulations

The company will conduct its business in accordance with the law and government regulations and will not engage in or assist, promote, or support any illegal activities or transactions.

#### 3. Use of Knowledge, Expertise, Diligence, and Care

The company should use its knowledge, abilities, expertise, diligence, and care in providing quality services to customers as a professional.

#### 4. Good Management and Effective and Rigorous Internal Control

The company will establish a good management system and risk management system, as well as an effective and rigorous internal control system.

#### 5. Standards Set for Entrepreneurs

The company will comply with the standards related to the business operations of companies engaged in or in the same industry as generally accepted.

#### 6. Treatment of Stakeholders

The company places importance on good treatment of various stakeholders based on cooperation and mutual benefit appropriately, namely:

6.1 The Company shall treat customers, business partners, and competitors with mutual understanding and good cooperation, and shall compete fairly.

6.2 The Company shall offer quality products to customers with friendliness, goodwill, and generosity.

6.3 The Company shall safeguard and protect the interests of its shareholders.

6.4 The Company shall promote and support employees in utilizing their potential, knowledge, and capabilities in performing their duties, as well as appropriately support the development of their potential, knowledge, and skills.

6.5 The Company shall support social responsibilities as appropriate and participate in activities for public benefit, education, and the advancement of the nation.

6.6 The Company recognizes the necessity of resources required for its business operations and acknowledges that the use of each type of resource has interrelated impacts.

#### 7. Conflict of Interest Control

The company will control or prevent, as appropriate, any conflicts of interest that arise or may arise in connection with the company's business and will not seek any benefit that is unlawful or contrary to government regulations.

#### 8. Maintaining Customer Confidentiality

The company will keep and maintain a system to safeguard and manage confidential customer information and will not disclose such confidential information to any other person unless it has obtained the customer's consent or is acting in accordance with the law.

## **9. Communicating Product or Service Information to Customers**

The company will communicate information about the company's products or services adequately so that customers have a correct understanding.

## **10. Providing Advice or Acting on Behalf of Clients**

The company will exercise reasonable care in advising or making any decisions on behalf of its clients, taking into account the appropriateness of the client's circumstances.

## **11. Maintaining Good Relations with Authorities**

The company will promote the establishment and maintenance of good relations with the authorities on a regular basis, such as cooperating with the authorities in accordance with relevant laws and regulations and following the advice of the authorities.

## **12. Data Recording and Reporting**

The company will record information and prepare reports accurately and reliably.

## **13. Service and Performance**

13.1 The company will focus on creating an organizational culture that promotes the use of culture and uses it as part of its strategic planning and development review.

13.2 The company should monitor developments and changes that occur and initiate innovation to add value to its business in accordance with the ever-changing environment to create customer satisfaction, as well as devote its best efforts to its operations.

## **14. Accepting Gifts or Incentives from Customers or Other Persons**

The company will not solicit, request, or accept money, gifts, rewards, or any other consideration from customers or other persons, except as received in accordance with customary practices and of reasonable value in accordance with standards.

## **15. Maintaining a Good Reputation**

The company will maintain its good reputation and refrain from any act that would bring discredit to the company.

## **16. Individual Rights and External Activities**

The company shall respect the rights of individuals as prescribed by law and shall promote and support participation in various external activities. Such activities must:

- 16.1 Does not affect the good reputation and image of the company.
- 16.2 Does not significantly impede or hinder the dedication of time or the dedication of ability to perform duties.
- 16.3 Does not violate policies on business ethics and conduct.
- 16.4 Does not create a conflict of interest.
- 16.5 Does not violate the law and good morals.

## **Policy and guidelines related to business code of conduct**

Guidelines related to business code of conduct : Prevention of conflicts of interest, Anti-corruption, Whistleblowing and Protection of Whistleblowers, Preventing the misuse of inside information, Gift giving or receiving, entertainment, or business hospitality, Compliance with laws, regulations, and rules, Anti-unfair competitiveness, Information and IT system security, Environmental management, Human rights, Safety and occupational health at work

## **Prevention of conflicts of interest**

The company recognizes the importance of conducting business with honesty, integrity, transparency, and accountability, which are principles of good corporate governance and enhance organizational effectiveness. The company has therefore established a policy that directors, executives, and employees shall refrain from any actions that may be detrimental to the interests of the company, which may arise from:

- (1) Dealing with the company's business associates, such as customers and partners.
- (2) Exploiting opportunities or using the company's inside information for personal gain.
- (3) Entering into transactions with the company.
- (4) Engaging in businesses that compete with the company.
- (5) Others.

This ensures that the company is not disadvantaged. In cases where it is necessary and unavoidable to enter into such transactions, the company will ensure that they are conducted with transparency, fairness, and on an arm's length basis, taking into account the best interests of the company and fairness to all parties involved.

To prevent conflicts of interest, the company has established the following guidelines:

- The company must not provide loans or guarantees to directors or businesses in which directors hold more than 50% of the shares, unless it is part of the company's welfare program.
- Directors must not engage in businesses that compete with the company unless approved by the shareholders' meeting prior to their appointment as directors.
- Directors and executives must not exploit the company's opportunities or information for their own benefit or the benefit of others, including engaging in businesses that compete with the company or related businesses.
- Directors and executives must not participate in meetings or vote on matters in which they have a personal interest that may give rise to a conflict of interest with the company. If it is necessary to act in the best interests of the company, such transactions must be conducted on an arm's length basis.
- Directors and executives must disclose their interests in any contracts entered into by the company.
- Directors and executives must submit an annual or ad hoc report disclosing any conflicts of interest.
- Transactions such as the purchase or sale of goods or other assets by directors with the company must be disclosed to and approved by the Board of Directors in advance.
- The consideration of conflicts of interest and transactions that may present a conflict of interest must always involve the participation and deliberation of independent directors.
- Directors, executives, and employees of the company who are privy to inside information should refrain from using such information for personal gain or disclosing it to others for improper benefit.

In addition, the company places great importance on the transparent consideration of all matters in the best interests of the company. Therefore, it prioritizes the prevention of conflicts of interest, related party transactions, or intergroup transactions, with the following key principles:

1. Directors and executives must inform the company of any relationships or related party transactions that may give rise to a conflict of interest.
2. Avoid related party transactions with directors, executives, or related persons that may give rise to conflicts of interest with the company. If such transactions are necessary, they must be presented to the Audit Committee for consideration before being submitted for approval to the Board of Directors and/or the shareholders' meeting (as the case may be), in accordance with the rules on related party transactions set forth by the Stock Exchange of Thailand, the Securities and Exchange Commission, and the Office of the Securities and Exchange Commission (SEC), and in line with good corporate governance principles.
3. Executives and employees must comply with the company's regulations and code of business ethics, which are considered crucial for strict adherence. This ensures that the company is trusted and reliable by all stakeholders. The company shall disseminate information and understanding of these practices throughout the organization.

## **Anti-corruption**

The Company is committed to conducting business with honesty, integrity, transparency, fairness, and in accordance with good corporate governance principles and applicable laws. The Company does not tolerate corruption in any form, both directly and indirectly. The Company requires the Board of Directors, executives, and employees at all levels to strictly comply with the Anti-Corruption Policy. The Company aims to declare its intention to join the Thai Private Sector Collective Action Against Corruption (“CAC”) in the future. The Company has anti-fraud and anti-corruption practices in accordance with the Anti-Fraud and Anti-Corruption Policy, which are summarized as follows:

1. Directors, executives, and employees must comply with the Anti-Fraud and Anti-Corruption Policy and the laws of Thailand on anti-corruption. Failure to comply with this policy will result in disciplinary action and legal action as appropriate.
2. Directors, executives, and employees must not engage in or be involved in corruption, both directly and indirectly.
3. The Board of Directors, executives, and employees of the Company shall not ignore or disregard any act of corruption related to the Company. They must report it to the designated unit/person or inform their supervisor, and cooperate in the investigation of the facts. If there are any doubts or questions, please consult the designated unit/person responsible for monitoring compliance with the Company's Code of Conduct or the supervisor through the designated channels.
4. The Company will provide fairness and protection to persons who refuse to engage in corruption or report corruption related to the Company by using measures to protect whistleblowers or those who cooperate in reporting corruption as determined by the Company. The Company will also provide fairness to employees who report information or provide clues about corruption or non-compliance with laws, regulations, rules, and the Company's Code of Conduct.
5. The Company will disseminate and raise awareness among external parties who have business relationships with the Company on the need to comply with the Anti-Corruption Policy.
6. The Company communicates anti-corruption measures, including whistleblowing channels or complaint channels, to persons within the Company through various channels such as orientation programs for directors and employees, seminars and training sessions, and intranet announcements, in order to ensure that the measures are effectively implemented and that the Company's personnel understand, agree with, and comply with the anti-corruption policies and measures.
7. The Company communicates anti-corruption measures, including whistleblowing channels or complaint channels, to the public, subsidiaries, affiliates, other companies under control (if any), business representatives, relevant business partners, and stakeholders through various channels such as the Company's website and annual report, in order to create understanding and ensure that the measures are effectively implemented.
8. Employees sign an acknowledgement of the Anti-Corruption Policy to ensure that all employees are aware of, understand, and are prepared to implement the principles of the Anti-Corruption Policy in their work with strictness throughout the organization.
9. The Company has a disbursement procedure in place that specifies the authority matrix and approval limits. Disbursements must be supported by clear documentation to prevent improper conduct, including political contributions, and to ensure that charitable donations are not made for corrupt purposes and that business support funds are not used as a pretext for corruption.
10. The Board of Directors, executives, and employees of the Company shall not accept or give gifts, entertainment, or any other expenses that are unnecessary and inappropriate to government officials or persons doing business with the Company. If they receive gifts of unusual value on customary occasions, the directors, executives, or employees shall refuse and not accept such gifts and shall report to their supervisors accordingly. The internal audit process must be carried out regularly.
11. The Company has an audit process and internal control system in place to prevent corruption. These processes cover sales, marketing, procurement, human resource management, finance, accounting, data recording, operations, and other internal processes related to anti-corruption measures. The audit process must be carried out regularly by the internal auditors.

12. The Company has a human resource management process that reflects the Company's commitment to anti-corruption measures from recruitment, training, performance appraisal, compensation, and promotion.

13. The Company has risk management measures in place to prevent corruption by identifying high-risk events of corruption that may arise from business operations, assessing the level of risk both in terms of likelihood and impact, and monitoring the progress of risk management to prevent corruption on a regular basis. The risk management measures will be reviewed to ensure that they are appropriate to mitigate the risk to an acceptable level.

14. The Company has an internal audit function to ensure that the risk management system in place enables the Company to achieve its objectives, as well as to ensure that the Company's internal operations comply with the Company's rules and regulations.

### **Whistleblowing and Protection of Whistleblowers**

The Board of Directors has established measures for whistleblowing or reporting violations of laws, ethics, or conduct that may indicate fraud or misconduct by individuals within the organization, including employees and other stakeholders. Such conduct includes inaccurate financial reporting or inadequate internal control systems, and the Company must have mechanisms in place to protect whistleblowers or complainants in order for stakeholders to participate in overseeing the Company's interests more effectively.

#### Matters to be reported or complained about

- Illegal acts, fraud, violation of company regulations, or ethical violations by the Board of Directors and employees.
- Irregularities in financial reporting, inadequate internal control systems.
- Matters that affect the interests or reputation of the Company.

#### Whistleblowing or Complaint Channels

The Committee provides an opportunity for stakeholders to communicate with the Committee and will protect the rights of stakeholders who report or complain about various issues. Communication channels are available through the Audit Committee to proceed according to the Company's procedures and report to the Committee accordingly. The contact channels are as follows:

#### **(1) Within the Company**

If you witness any action suspected of violating or not complying with the Company's Code of Conduct and work practices, you can report it at

Channel 1: Report to the supervisor accordingly and/or the department responsible for overseeing compliance with the Code of Conduct and work practices.

Channel 2: Suggestion Box

Channel 3: Email: [auditcommittee@bangkokgenomics.com](mailto:auditcommittee@bangkokgenomics.com)

#### **(2) Outside the Company**

Channel 1: By mail to

Chairman of the Audit Committee

Bangkok Genomics Innovation Public Company Limited

3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei District, Bangkok 10110

Channel 2: By email to

[auditcommittee@bangkokgenomics.com](mailto:auditcommittee@bangkokgenomics.com)

To ensure the confidence of whistleblowers or complainants, the Company prioritizes the confidentiality of whistleblowing information or complaints and has established written procedures for receiving and investigating complaints. Such complaints will only be known to the designated and involved individuals. If such confidential information is disclosed, the Company will investigate and identify the person who disclosed such information and will take disciplinary action against such person.

### **Preventing the misuse of inside information**

The Company places great importance on governing the use of the Company's inside information. The Company has a policy prohibiting directors, executives, employees, and staff of the Company from disclosing information not yet disclosed to the public, which may affect the price or value of the Company's securities ("Inside Information") to any person, directly or indirectly, whether or not in return for remuneration. Therefore, the Company has established the following:

1. Directors, executives, employees, and staff of the Company and subsidiaries are prohibited from disclosing or exploiting the confidential and/or inside information of the Company and subsidiaries for their own benefit or for the benefit of any other person, directly or indirectly, whether or not in return for any benefit.
2. Directors, executives, employees, and staff of the Company and subsidiaries, including their spouse or those who cohabit as husband and wife, and their unemancipated children, are prohibited from using the Company's and subsidiaries' inside information that has or may have an impact on the price of the Company's securities, which has not yet been disclosed to the public, whether such action is for their own benefit or for the benefit of others, or for others to do so in return for their benefit. Violators will be subject to disciplinary action by the Company and its subsidiaries.
3. The Company and its subsidiaries have informed the directors and executives to understand and acknowledge their duties to report their shareholdings, as well as those of their spouse or those who cohabit as husband and wife, and their unemancipated children, including juristic persons in which they, their spouse or those who cohabit as husband and wife, and their unemancipated children hold more than 30 percent of the total shares of such juristic person. This includes reporting changes in shareholdings to the Office of the Securities and Exchange Commission in accordance with Section 59 and the penalties stipulated in the Securities and Exchange Act (No. 5) B.E. 2559.
4. The Company and its subsidiaries have stipulated that directors and executives of the Company and its subsidiaries, including their spouse or those who cohabit as husband and wife, and their unemancipated children, as well as juristic persons in which such persons, including their spouse or those who cohabit as husband and wife, and their unemancipated children hold more than 30 percent of the total shares of such juristic person, are prohibited from trading in the Company's securities during the period of 1 month prior to the disclosure of the financial statements to the public.

#### **Gift giving or receiving, entertainment, or business hospitality**

Improper gifts, hospitality, and other expenses can lead to corruption risks and create opportunities for fraud by paying expenses to the Company's directors, executives, or employees for bribery. In addition, the Company's provision of inappropriate gifts, hospitality, or other expenses to customers may be a violation of the policies of some customers, causing the Company to lose business opportunities.

The Company recognizes the importance of building good relationships with business partners in order to bring about the continued success of the Company and, at the same time, to maintain the Company's reputation, which conducts business with honesty, integrity, and in accordance with the law. The Company has established the following guidelines for gifts, hospitality, entertainment, and other expenses:

- 1) The Board of Directors, executives, and employees of the Company may receive/give gifts, hospitality, or other expenses, such as hosting or being hosted by others, on various occasions in accordance with generally accepted customs, traditions, or social etiquette. This must be done transparently and openly. Such receiving/giving must not result in any advantage being gained through improper conduct or being an explicit or implicit exchange for assistance or benefits, resulting in undue leniency in inappropriate business agreements, influencing business decisions, and must comply with relevant laws. The giving of gifts by the Company must be in the name of the Company, not in a personal capacity, and may be in the form of gifts bearing the Company's logo, appropriate to the occasion, such as giving gifts during the New Year, Chinese New Year, or Songkran festivals. They must not be in the form of cash or cash equivalents, such as checks, gift certificates, or gift vouchers (unless given in the form of a sales promotion, which has clearly defined criteria and is treated in the same manner as everyone else).

- 2) The Board of Directors, executives, and employees of the Company shall not solicit or accept gifts, hospitality, or other expenses from customers, partners, or those involved in the Company's business under any circumstances that would influence their decision-making in the performance of their duties with bias, difficulty, or conflict of interest.
- 3) The Board of Directors, executives, and employees of the Company must not accept any gifts or compensation that are excessive due to the performance of their normal duties. For example, in a tender process, they must not accept gifts or hospitality from companies participating in the tender or related companies. However, the Board of Directors, executives, and employees of the Company may accept gifts and/or hospitality and/or other expenses if they are in accordance with normal festivals or customs and do not exceed 3,000 Baht (Three Thousand Baht) in value, such as calendars, pens, notebooks, glasses, etc. Such gifts must not be in the form of cash or cash equivalents, such as gift vouchers or gift certificates.
- 4) It is prohibited to accept gifts, hospitality, or other benefits worth more than 3,000 Baht (Three Thousand Baht) or gifts in the form of cash or cash equivalents, such as gift vouchers or gift certificates, when it is not possible to refuse such gifts or benefits at that time, such as during a meeting with a client. The recipient may accept the gift or benefit first, but must immediately notify their supervisor and submit a gift receipt report to the Administration Department. The Company will consider donating the received items/gifts to public charities for the benefit of the public as appropriate.
- 5) The giving and receiving of other benefits, such as entertainment and hospitality, must be confirmed that such hospitality is not excessive in terms of expenditure or frequency to the extent that it creates an obligation to the host, whether directly or indirectly.
- 6) The Company will communicate to the Board of Directors, executives, and employees of the Company the guidelines for gifts, hospitality, and other expenses of the Company through annual meetings and other communication channels available to the Company. The Company will publicize or inform customers, partners, or those involved in the Company's business of the Company's policies and guidelines for gifts, hospitality, and other expenses through company brochures or leaflets used to publicize the Company's activities.

#### **Compliance with laws, regulations, and rules**

The company monitors the issuance of laws, acts, ministerial regulations, announcements, and relevant professional standards that have been additionally announced, with details as follows:

- 1) The healthcare provider, laboratory manager, and medical technologist are members of the Medical Technology Council and regularly attend academic conferences organized by the Medical Technologist Association of Thailand to stay updated on regulations and announcements. There will be an annual meeting where various agencies will update and announce new or upcoming regulations. In addition, there is participation in Line groups, Facebook, or other channels of members to exchange knowledge, share training, consult on problems related to the profession, and publicize relevant announcements.
- 2) Laboratory staff are also members of other related associations, including the Human Genetics Society, the Medical Technologist Association, the Genetics Society, the Medical Genetics and Genomics Association, and continuously update on activities, announcements, and other details related to laws and regulations.
- 3) Send representatives to attend academic conferences organized by government agencies, universities, or various institutions to stay updated on academic information, regulations, and relevant practices.
- 4) The project and product team will be responsible for reviewing the tariff codes to be used in the customs clearance process for imported goods. The Customs Department of Thailand will review the tariff codes of goods and start using the new codes on January 1st of every year. The project and product team will coordinate with the customs broker to regularly review the codes of imported goods to prevent errors in the customs clearance process, resulting in timely release and delivery of goods to the company or laboratory in a timely manner, while maintaining the condition of the goods, including the storage temperature.

If there are any changes in laws or regulations, the recipient of such information must notify the secretary of the risk management working group in order to proceed with the review measures.



### **Review Measures**

- 1) The secretary of the risk management working group is responsible for preparing a register summarizing relevant laws.
- 2) Organize a risk management working group meeting to review relevant laws every quarter, with the person in charge of each department presenting. The secretary of the risk management working group will update the summary of relevant laws to be current.
- 3) Present the risk management working group report to the audit committee every quarter.

### **Measures to promote knowledge and understanding**

- 1) Announce relevant laws to the departments that need to comply in order to comply correctly. Every time there is an update to the summary of relevant laws, it will be announced to all department managers at the monthly management planning meeting.
- 2) There is a legal advisor who is a jurist from the Legal Division, Department of Health Service Support, Ministry of Public Health, who is an expert in laws related to hospitals and medical devices. Employees will receive training on relevant laws or announcements as requested, help check various contracts to ensure they do not violate the law, provide advice and answer questions, as well as represent the company in discussions on various legal issues as requested by the company.
- 3) Submit inquiries to relevant agencies that issue regulations and rules in case of ambiguity or unclear issues, such as inquiries regarding the consideration of tariff codes for medical devices.

### **Anti-unfair competitiveness**

The company is committed to conducting business with integrity, transparency, and responsibility, treating customers, business partners, and competitors with respect and fairness. The company focuses on building strong relationships based on cooperation and mutual understanding and conducts business competition in a fair manner in accordance with applicable laws and professional standards. To prevent unfair competition, the company avoids practices or actions that may take advantage of competitors or other stakeholders, such as providing false information, distorting facts, infringing on intellectual property rights, or creating unfair obstacles for competitors.

The company promotes innovation and the quality of its products and services through its own capabilities and efforts, without using unfair methods to gain business benefits. All employees are required to strictly adhere to these principles to maintain the company's reputation and ensure sustainable competition in the market.

### **Information and IT system security**

#### **1.Information Technology Risk Assessment (IT Risk Assessment Policy)**

The company must establish an information technology risk management process that covers risk identification, risk assessment, and risk control to a level acceptable to the company, including the assignment of appropriate responsibility for information technology risk management.

#### **2.Information Technology Resource Management (Acceptable Use Policy)**

The company must establish a process for managing information technology resources in accordance with the company's strategic plan that is sufficient for information technology operations, including managing key risks in the event that resources cannot be allocated sufficiently for information technology operations.

#### **3.Information Security Policy**

The company must establish information security practices that are consistent with the published information security policy and communicate these practices to stakeholders. The information security practices must cover 14 items, including:

#### **Section 1 Organization Security Policy**

To provide direction and support for the implementation of information security for the organization to comply with or be consistent with business requirements, laws, and relevant regulations, including primarily protecting the organization's information. Information in this policy refers to information in electronic format, documents, publications,

films, or even conversations. However, the protection of information in electronic form will be discussed in detail as most of the organization's information is in electronic form.

## Section 2 Information Security

To provide a framework for managing and administering the organization's information security from initiation and control of operations to ensure security, the organization has established an information security structure, including the definition of roles and responsibilities for information security management within the organization.

## Section 3 Human Resource Security

To ensure that employees and contractors understand their responsibilities and are appropriate for the roles and responsibilities for which they are employed by the organization.

## Section 4 Asset Management

Assets refer to assets related to information such as data, software, or equipment involved in processing. In addition, the organization should designate asset owners to be responsible for those assets. Asset owners may delegate the care and control of assets to others, but the asset owner remains ultimately responsible for those assets. To ensure that the organization's assets are identified and that responsibilities for asset protection are appropriately assigned.

## Section 5 Access Control

To control access to information and information systems to ensure security and to reduce the risk of unauthorized access, it is necessary to control access to information systems by considering the appropriateness of access to the system based on business needs and requirements.

## Section 6 Data Encryption

To ensure that data is encrypted appropriately and effectively and to protect the confidentiality, integrity, and availability of information.

## Section 7 Physical and Environmental Security

To serve as a standard for maintaining physical security related to the location and area of use of information technology systems, as well as computer equipment, data, and information, which are assets of the company.

## Section 8 Operational Security

To ensure the proper and secure operation of information processing equipment.

## Section 9 Data Communication Security

To protect information on the network and to protect the infrastructure that supports the company's network.

## Section 10 Information System Acquisition, Development, and Maintenance

To ensure that information security is built into information systems throughout the system development lifecycle, including information security requirements for services provided over public networks.

## Section 11 Relationships with External Service Providers

To ensure the protection of organizational assets accessed by external service providers.

## Section 12 Information Security Incident Management

To ensure that incidents and vulnerabilities related to the security of the company's information system are properly addressed in a timely manner and to provide a consistent and effective approach to information security incident management.

#### Section 13 Business Continuity Management

To prevent disruption to the office's operations resulting from system failures or outages, whether due to accidents, natural disasters, or unforeseen events that cause damage to the organization. Therefore, a business continuity plan should be developed to mitigate the severity of the impact of such events to an acceptable level and to enable the organization to continue its core business.

#### Section 14 Compliance

To avoid violating criminal/civil laws, royal decrees, regulations, and contracts.

- Review and update information security policies and practices at least annually.
- Require all personnel under the company to strictly comply with information security regulations. Violators will be guilty and subject to disciplinary action in accordance with the company's disciplinary guidelines.

#### **Environmental management**

The Company is committed to operating and creating sustainable business growth under good corporate governance throughout the value chain, taking into account the impact on stakeholders, society, and the environment. The Company believes that doing business based on sustainability is an important foundation to help strengthen the organization to grow steadily and sustainably. In addition, the Company is committed to operating on the basis of creating positive changes for the community, environment, and economy to ensure that operations are in the right direction and benefit stakeholders at all levels. This intention will help promote sustainable operations, with the following essence:

- 1) Adhere to conducting business with fairness, giving importance and respect to human rights, treating customers, partners, competitors, and employees equally and fairly, being responsible to consumers, giving importance to occupational health and safety of employees, creating awareness, and encouraging employees to protect the environment, along with developing the community and society to have a better quality of life.
- 2) Aim to ensure that the Board of Directors, executives, employees, and employees at all levels are responsible for supporting, promoting, and performing their duties in accordance with the sustainable development policy until it becomes a work culture that takes into account the balance of economic, social, and environmental benefits.
- 3) In terms of dealing with competitors, the Company will treat competitors fairly within the framework of fair competition and will not seek confidential information of competitors by dishonest means.
- 4) Raise awareness and responsibility for the sustainable development approach to ensure that the Company will develop the economy in line with the interests of society, the environment, and stakeholders, including promoting responsible operations throughout the organization's value chain on an ongoing basis. The Board of Directors, executives, employees, and employees at all levels are responsible for supporting, promoting, and performing their duties in accordance with this Corporate Sustainability Development Policy and Guidelines until it becomes a culture that takes into account the balance of economic, social, and environmental aspects.

The Company has established a management framework to drive organizational sustainability development, covering all 3 dimensions: Environment, Social, and Governance, as follows:

#### **Environment Dimension**

##### **1. Environmental Care**

- 1) The Company places importance on environmental care. The Company operates and controls its operations to comply with relevant environmental laws and regulations. The objective is to care for and avoid environmental damage.

- 2) The Company encourages the appropriate use of resources and reduces waste. The Company is also committed to reducing negative environmental impacts in various areas such as energy, water, waste, pollution, and greenhouse gas management.
- 3) Sustainable management of natural resources and the environment. Give importance to the use of natural resources, environmental care throughout the business process. Use appropriate technology to prevent environmental/ecosystem impacts that may arise from business operations.
- 4) Manage environmental quality and biodiversity in accordance with relevant laws and regulations, as well as invest, develop, and improve environmental management systems, including seeking new measures and methods to enhance the efficiency of environmental management and control for the better.
- 5) Invent and seek ways and means to reduce the use of resources and energy, as well as reduce the release of pollutants, waste, and greenhouse gases to prevent, control, and minimize impacts on the environment, communities, and society, such as reducing paper use, reducing electricity consumption by turning off lights and air conditioners during lunch breaks for office staff.
- 6) Exercise caution in carrying out any activities that result in greenhouse gas emissions. Seek measures to reduce greenhouse gas emissions into the atmosphere and ways to respond to climate change so that the business can grow steadily and sustainably.

## **2. Greenhouse Gas Management**

The Company recognizes global warming and the increasingly severe climate change. The Company is committed to cooperating and promoting various activities to help mitigate global warming to the fullest extent. The Company focuses on communicating to employees to understand and be aware of the impact of global warming and to jointly create an organizational culture that transitions into a low-carbon society. In addition, the Company uses electrical appliances with low-carbon labels and campaigns for everyone to save electricity, which is one of the resources that emit greenhouse gases. The Company will also support and promote greenhouse gas management for the benefit of the organization, society, and the country's environment, leading the organization into a low-carbon society to respond to Thailand's policy in reducing greenhouse gases, in line with government policies and agreements under the United Nations Framework Convention on Climate Change (UNFCCC).

Currently, the Company has systematically compiled greenhouse gas emissions and absorption data to be used for monitoring, inspecting, and assessing the environmental impact of the Company's operations. This is to support sustainable business development and align with the approach of reducing environmental impact.

## **3. Environmental Performance Results**

### **3.1. Energy Consumption**

The Company places importance on using electricity properly and avoiding waste. The Company has communicated knowledge to employees within the organization to make them aware of the value of electricity and to use it with maximum efficiency. The Company has therefore established energy-saving measures such as setting time periods for turning lights on and off, turning off employee computers during lunch breaks, and using energy-saving air conditioners and light bulbs to help reduce energy consumption within the organization for maximum efficiency and lead to sustainable business development.

### **3.2. Water Usage**

The Company communicates to employees to appreciate the value of water and use it economically to prevent waste. In addition, the Company also has a system for managing wastewater from the service process. Wastewater that may be contaminated with chemicals generated from laboratory processes will be collected in a container with a tight-fitting lid and no leaks for disposal by a specialized external company.

3.3. Waste, Hazardous Waste, and Pollution Management Bangkok Genomics Medical Laboratory has a consistent waste management system, does not accumulate waste for many days, and disposes of waste in the correct category. The waste bins are divided into 4 types as follows:

- (1) General waste (black bag) for general waste such as paper scraps, plastic bottles, etc.
- (2) Infectious waste (red bag) for specimens or suspected contaminated specimens, gloves, personal protective equipment (PPE). Do not pour or dispose of specimens in the sink.
- (3) Sharps disposal bins, such as broken glass, blades, etc.
- (4) Infectious sharps disposal bins (red bins), such as filter tips, syringes. When the infectious sharps disposal bin is full, pack it in a double container before disposing of it in a red garbage bag. The laboratory separates infectious waste from other types of waste and collects infectious waste bags in a designated area. Place in a container with a tight-fitting lid and no leaks, with a label attached to the outside of the container to indicate that it is infectious waste (Biohazard) for disposal by an external company specializing in the collection and disposal of infectious waste according to the "Ministerial Regulations on Infectious Waste Disposal, B.E. 2545". Used equipment or infectious waste from the SARS-CoV2 laboratory will be decontaminated by autoclaving for an appropriate period of time before being disposed of according to the system to reduce the potential environmental impact of infectious waste.

### **Social Dimension**

#### **Community Aspects**

- 1) Promote research and development of academic knowledge in collaboration with researchers, specialists, and professors for public benefit and to enhance the sustainable service image of the company.
- 2)b Invest in developing employee potential by supporting training, providing knowledge, and necessary resources, as well as creating a safe work environment, stimulating creativity, and enabling employees to work to their full potential and capabilities.
- 3) Respond to the needs and create customer satisfaction in terms of both the quantity and quality of goods and services in accordance with the contract.
- 4) Enhance and promote the participation of communities and relevant stakeholders by being open to opinions, consulting transparently and creatively, treating each other equally, and respecting differences, as well as supporting the development of quality of life and community strength.
- 5) Collaborate with government agencies, associations, business partners, civil society, and other stakeholders to participate in the development and/or application of good sustainability standards and practices from various sectors.

#### **Human rights**

The company recognizes that its employees are its most valuable asset and acknowledges the importance of human resource development and fair labor practices as key factors in achieving sustainable business success. The company's commitment to these principles is demonstrated through the following:

- 1) Legal Compliance and Human Rights: The company complies with all applicable labor laws and regulations, as well as international human rights principles. The company upholds the principles of equality, equal opportunity, and non-discrimination based on race, gender, age, skin color, religion, disability, social status, family background, educational institution, or any other status not directly related to job performance. The company respects individuality and human dignity.
- 2) Non-Discriminatory Treatment: The company treats all employees and workers fairly and provides equal opportunities, assigning tasks based on individual capabilities. This principle extends to employees, partners, and stakeholders.
- 3) Respect for Rights and Dignity: The company respects the rights, dignity, and treats all employees, workers, and business partners with equality and consideration for human dignity.

#### **Fair Labor Practices**

- 1) Compensation and Benefits: The company's compensation and benefits system is designed to motivate employees to perform to their fullest potential. The system is fair, complies with legal requirements, and follows standardized procedures. The company regularly evaluates and analyzes performance indicators to ensure they are up-to-date, appropriate for each job level and responsibility, aligned with business operations, and competitive with industry standards.
- 2) Employee Development: The company prioritizes the development of employee knowledge, skills, and management capabilities through training programs, seminars, and study tours. The company is committed to creating a framework for continuous employee development at all levels to enhance their capabilities.
- 3) Work Practices and Career Advancement: The company's practices are based on the principle of non-discrimination and compliance with all relevant laws, providing equal opportunities for all, regardless of gender, race, religion, ethnicity, age, disability, socioeconomic status, or educational qualifications.
- 4) Employee Well-being and Safety: The company cares for the well-being and health of all employees and prioritizes safety and environmental management in the workplace. The company ensures the safety and health of employees, workers, and company assets without compromising the rights and safety of others. The company also protects personal data privacy, including data storage, disclosure, and utilization.

### **Safety and occupational health at work**

The company recognizes that the safety, occupational health, and work environment system is essential for business operations. Therefore, the company aims to reduce and control the risks and dangers to employees, business partners, service recipients, contractors, and visitors. The company also aims to increase the efficiency of health operations to ensure safety and promote the image of corporate responsibility to society. Therefore, the company has established the following safety, occupational health, and work environment policy:

1. The company will manage the safety, occupational health, and work environment management system in accordance with the law and international standards, including other requirements that the company applies to ensure workplace safety. The company aims to create a culture of workplace safety for employees, business partners, service recipients, contractors, and visitors on a continuous and sustainable basis.
2. The company considers workplace safety to be the duty and responsibility of all employees. Supervisors at all levels must be good role models, leaders, and supporters, promoting employee awareness of working safely. They must also oversee the work of employees, business partners, service recipients, contractors, and visitors to ensure strict compliance with the established occupational health, safety, and work environment policies. This is to ensure maximum safety at every stage of the operation.
3. The company promotes and encourages employees, business partners, service recipients, contractors, and visitors to participate in safety, occupational health, and work environment operations.
4. The company recognizes the importance of safety, occupational health, and work environment policies. The company develops operational plans to assess hazards and environmental impacts to ensure that risk prevention and mitigation systems are effectively implemented under the law and international standards.
5. The company prioritizes and promotes knowledge development by providing training, reviews, rehearsals, and various activities to enhance awareness among employees at all levels of the importance of safety, occupational health, and work environment.
6. The company will monitor and evaluate the performance of the safety, occupational health, and work environment policies defined in the annual plan to ensure effective implementation and maximum efficiency.
7. The company supports and promotes continuous improvement of the work environment, including safe work practices, by adhering to the 5S principles (Sort, Set in Order, Shine, Standardize, Sustain) for the good hygiene of all employees. The company also utilizes appropriate personal protective equipment to prevent accidents, occupational illnesses, work-related illnesses, dangerous communicable diseases, and fires.

8. The company will provide appropriate resources such as budget, time, personnel, tools, and related materials to enable employees to implement the safety, occupational health, and work environment policies smoothly in accordance with international standards.

#### **Promotion of compliance with the business code of conduct**

Promotion for the board of directors, executives, and : Yes

employees to comply with the business code of conduct

The company has established processes that promote the proper conduct of the Board of Directors, executives, and employees at all levels in compliance with laws, regulations, and guidelines, while respecting the rights of the company's suppliers and customers. To this end, the company has developed a corporate governance policy to provide a framework for all individuals within the organization to follow. The business ethics code, which has been implemented, serves as a crucial foundation for sustainable business practices. It is a guiding principle for employees throughout the organization, shaping the way the company operates and fostering a corporate culture based on shared values. This, in turn, helps the company achieve its goals and mission, elevating the organization toward long-term sustainability.

The Board of Directors is committed to conducting business in a fair and transparent manner. The company has formalized its business ethics code (Code of Conduct) in writing to serve as a guideline for employees' actions and to promote responsible business practices. The code reflects the company's commitment to integrity, accountability to stakeholders, and consideration for society and the environment. It is communicated through training and various internal communication channels, ensuring that all employees understand and adhere to the company's values and the prescribed code of conduct.

The code covers various aspects, such as the treatment of shareholders, responsibilities to stakeholders, and the channels for reporting violations of business ethics. The company has announced and ensured that all employees are aware of and strictly follow the business ethics code. In 2024, no complaints regarding violations of the company's business ethics code were filed with the Audit Committee.

#### **Participation in anti-corruption networks**

Participation or declaration of intent to join anti-corruption : No

networks

## 6.3 Material changes and developments in policy and corporate governance system

over the past year

### 6.3.1 Material changes and developments related to the review of policy and guidelines in corporate governance system or board of directors' charter

In the past year, did the company review the corporate : Yes

governance policy and guidelines, or board of directors'

charter

Material changes and developments in policy and : Yes

guidelines over the past year

The Company established a Code of Conduct, including a good corporate governance policy in accordance with the Corporate Governance Code for Listed Companies 2017 (Corporate Governance Code or CG Code) of the SEC. It is made in writing for the Board of Directors, executives, and employees to acknowledge, understand, and comply with the policies stipulated in the Code of Conduct and the Corporate Governance Policy strictly.

To ensure that the policies/working procedures/manuals are accurate and consistent with the current operations of the department, and to enhance the effectiveness of supervision, the Company has established a policy for reviewing the Company's policies and working procedures. The Human Resources Department is assigned to be responsible for surveying and collecting information from executives and all relevant departments to review and examine policies/working procedures/manuals at least once a year. The review is scheduled to be conducted in November of each year, and a summary of the revised/changed information is to be prepared for submission to the authorized person for consideration of the policies/working procedures/manuals, which will be reviewed and approved by December of each year.

At the Board of Directors Meeting No. 4/2025, held on November 10, 2025, in accordance with the policy on reviewing policies and operational regulations, which requires a review at least once a year, the management and relevant personnel have reviewed all 49 policies. The review was conducted to assess their appropriateness and alignment with actual operations. To ensure continuous operations in line with the organizational structure, it is proposed that the meeting consider revising one policy as follows:

1.P-HO-21 Policy on the Review of Policies and Operational Regulations

### 6.3.2 Implementation of the CG Code for listed companies

Implementation of the CG Code as prescribed by the SEC : Fully implement

The Company has complied with the key principles of the Corporate Governance Code (CG Code) across all eight categories. A summary of the implementation is as follows:

#### 1. Roles and Responsibilities of the Board of Directors

The Board of Directors has clearly defined its roles, authority, and responsibilities, and is responsible for overseeing the Company's operations to ensure alignment with its objectives, goals, and strategies, as well as regularly monitoring and evaluating performance. In addition, the Company has established a Code of Conduct to serve as a guideline for conducting business with ethics, transparency, and responsibility toward all stakeholders.

#### 2. Establishing Objectives and Goals for Sustainability

The Company has established clear vision, mission, and corporate policies to guide its business operations and communicate its objectives to stakeholders. The Board of Directors has set strategies and business plans by considering



environmental factors, risks, and impacts on stakeholders, and continuously monitors performance to achieve sustainable goals.

### 3. Strengthening an Effective Board

The Company has established an appropriate board structure, with independent directors comprising no less than one-third of the total number of directors, and clearly separates the roles of the Chairman of the Board and the Chief Executive Officer. The Company has also established charters for the Board and its sub-committees, conducts annual performance evaluations of the Board, and promotes continuous development of directors' knowledge and skills.

### 4. Nomination and Development of Executives and Personnel

The Company has a transparent process for recruiting and selecting senior executives, considering their qualifications, knowledge, capabilities, and experience. A succession plan has been established, and the Company continuously promotes the development of personnel capabilities.

### 5. Promotion of Innovation and Responsible Business Conduct

The Company conducts its business with consideration for all stakeholder groups, including shareholders, employees, customers, business partners, competitors, communities, and the environment. Policies and practices have been established to ensure corporate social responsibility, customer data protection, fair competition, and environmental sustainability.

### 6. Risk Management and Internal Control

The Company has established a comprehensive enterprise-wide risk management policy and appropriate internal control systems. This includes the establishment of an Audit Committee, policies on conflict of interest prevention, anti-corruption measures, and whistleblowing mechanisms.

### 7. Disclosure and Transparency

The Company places importance on accurate, complete, timely, and transparent disclosure in accordance with the regulations of the Securities and Exchange Commission and the Stock Exchange of Thailand. This covers both financial and non-financial information, including the Management Discussion and Analysis (MD&A), for the benefit of investors.

### 8. Shareholder Engagement


The Company recognizes the equal rights of shareholders and ensures transparent shareholder meetings, providing opportunities for shareholders to propose agenda items and raise questions. The Company also facilitates shareholder participation, proxy appointments, and ensures adequate advance disclosure of information.

## 7. Corporate governance structure and significant information related to the board of directors, subcommittees, executives, employees, and others

### 7.1 Corporate governance structure

#### Corporate governance structure diagram

Corporate governance structure diagram



Corporate Governance Structure

## 7.2 Information on the board of directors

### 7.2.1 Composition of the board of directors

|                                                                       | Number (persons) | Percent (%)   |
|-----------------------------------------------------------------------|------------------|---------------|
| <b>Total directors</b>                                                | <b>11</b>        | <b>100.00</b> |
| Male directors                                                        | 10               | 90.91         |
| Female directors                                                      | 1                | 9.09          |
| Executive directors                                                   | 2                | 18.18         |
| Non-executive directors                                               | 9                | 81.82         |
| Independent directors                                                 | 4                | 36.36         |
| Non-executive directors who have no position in independent directors | 5                | 45.45         |

### 7.2.2 The information on each director and controlling person

#### List of the board of directors

| List of directors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Position                                                                                                                                                                                             | First appointment date of director | Skills and expertise                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-----------------------------------------------------------------------------|
| <p>1. Mr. THOSAPORN SIRISUMPHAND</p> <p>Gender: Male</p> <p>Age : 65 years</p> <p>Highest level of education : Doctoral degree</p> <p>Study field of the highest level of education : Political Science</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p> <p>Family relationship between directors and executives : Doesn't Have</p> <p>Legal offenses in the past 5 years <sup>(*)</sup> : Doesn't Have</p> <p>DAP course : No</p> <p>DCP course : Yes</p> <p><b>Shareholding in a company</b></p> <ul style="list-style-type: none"> <li>Direct shareholding : 300,000 Shares (0.050000 %)</li> </ul> | <p>Director</p> <p>(Non-executive directors, Independent director)</p> <p>Authorized directors as per the company's certificate of registration : No</p> <p>Type of director : Existing director</p> | 28 Jan 2022                        | <p>Business Administration, Corporate Management, Public Administration</p> |

| List of directors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Position                                                                                                                                                                        | First appointment date of director | Skills and expertise                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|----------------------------------------|
| <p>2. Mr. PREECHA LAOHAPONGCHANA</p> <p>Gender: Male</p> <p>Age : 71 years</p> <p>Highest level of education : Master's degree</p> <p>Study field of the highest level of education : Law</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p> <p>Family relationship between directors and executives : Doesn't Have</p> <p>Legal offenses in the past 5 years <sup>(*)</sup> : Doesn't Have</p> <p>DAP course : Yes</p> <p>DCP course : No</p> <p><b>Shareholding in a company</b></p> <ul style="list-style-type: none"> <li>• Direct shareholding : 73,638,000 Shares (12.273000 %)</li> <li>• Shareholding by persons related to directors, executives according to Section 59 <sup>(**)</sup> : 0 Shares (0.000000 %)</li> </ul> | <p>Director</p> <p>(Non-executive directors)</p> <p>Authorized directors as per the company's certificate of registration : Yes</p> <p>Type of director : Existing director</p> | 11 Sep 2017                        | Business Administration, Law, Commerce |

| List of directors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Position                                                                                                                                                                     | First appointment date of director | Skills and expertise                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|---------------------------------------------|
| <p>3. Mr. GOANPOT ASVINVICHIT</p> <p>Gender: Male</p> <p>Age : 69 years</p> <p>Highest level of education : Master's degree</p> <p>Study field of the highest level of education : Business Administration</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p> <p>Family relationship between directors and executives : Doesn't Have</p> <p>Legal offenses in the past 5 years <sup>(*)</sup> : Doesn't Have</p> <p>DAP course : Yes</p> <p>DCP course : Yes</p> <p><b>Shareholding in a company</b></p> <ul style="list-style-type: none"> <li>• Direct shareholding : 100,000 Shares (0.016667 %)</li> </ul> | <p>Director<br/>(Non-executive directors)</p> <p>Authorized directors as per the company's certificate of registration : Yes</p> <p>Type of director : Existing director</p> | 25 Jun 2020                        | Business Administration, Economics, Banking |
| <p>4. Mr. NING LI</p> <p>Gender: Male</p> <p>Age : 44 years</p> <p>Highest level of education : Doctoral degree</p> <p>Study field of the highest level of education : Science</p> <p>Thai nationality : No</p> <p>Residence in Thailand : No</p> <p>Family relationship between directors and executives : Doesn't Have</p> <p>Legal offenses in the past 5 years <sup>(*)</sup> : Doesn't Have</p> <p>DAP course : Yes</p> <p>DCP course : No</p>                                                                                                                                                                              | <p>Director<br/>(Non-executive directors)</p> <p>Authorized directors as per the company's certificate of registration : Yes</p> <p>Type of director : Existing director</p> | 25 Jun 2020                        | Health Care Services                        |

| List of directors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Position                                                                                                                                                                                                                                                             | First appointment date of director | Skills and expertise                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|---------------------------------------------------------------------------|
| <p>5. Mr. SUJIE CAO</p> <p>Gender: Male</p> <p>Age : 39 years</p> <p>Highest level of education : Bachelor's degree</p> <p>Study field of the highest level of education : Science</p> <p>Thai nationality : No</p> <p>Residence in Thailand : No</p> <p>Family relationship between directors and executives : Doesn't Have</p> <p>Legal offenses in the past 5 years <sup>(*)</sup> : Doesn't Have</p> <p>DAP course : Yes</p> <p>DCP course : No</p> <p><b>Shareholding in a company</b></p> <ul style="list-style-type: none"> <li>• Direct shareholding : 2,450,000 Shares (0.408333 %)</li> </ul>                        | <p>Director<br/>(Non-executive directors)</p> <p>Authorized directors as per the company's certificate of registration : Yes</p> <p>Type of director : Existing director</p>                                                                                         | 25 Jun 2020                        | Health Care Services                                                      |
| <p>6. Mr. VICHATE TANTIWANICH</p> <p>Gender: Male</p> <p>Age : 64 years</p> <p>Highest level of education : Master's degree</p> <p>Study field of the highest level of education : Business Administration</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p> <p>Family relationship between directors and executives : Doesn't Have</p> <p>Legal offenses in the past 5 years <sup>(*)</sup> : Doesn't Have</p> <p>DAP course : No</p> <p>DCP course : Yes</p> <p><b>Shareholding in a company</b></p> <ul style="list-style-type: none"> <li>• Direct shareholding : 52,600 Shares (0.008767 %)</li> </ul> | <p>Director<br/>(Non-executive directors, Independent director)</p> <p>Authorized directors as per the company's certificate of registration : No</p> <p>Type of director : Continuing director (Full term of directorship and being re-appointed as a director)</p> | 28 Jan 2022                        | Risk Management, Audit, Business Administration, Economics, IT Management |

| List of directors                                                                                                                                                                                                                                                                                                                                                                                                                                         | Position                                                                                                                                                                                                                                           | First appointment date of director | Skills and expertise |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|----------------------|
| <p>7. Mr. VICHYA KREANGAM</p> <p>Gender: Male</p> <p>Age : 44 years</p> <p>Highest level of education : Doctoral degree</p> <p>Study field of the highest level of education : Law</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p> <p>Family relationship between directors and executives : Doesn't Have</p> <p>Legal offenses in the past 5 years <sup>(*)</sup> : Doesn't Have</p> <p>DAP course : Yes</p> <p>DCP course : No</p> | <p>Director</p> <p>(Non-executive directors, Independent director)</p> <p>Authorized directors as per the company's certificate of registration : No</p> <p>Type of director : Existing director</p>                                               | 28 Jan 2022                        | Law                  |
| <p>8. Mr. ZONGZE WU</p> <p>Gender: Male</p> <p>Age : 42 years</p> <p>Highest level of education : Doctoral degree</p> <p>Study field of the highest level of education : Science</p> <p>Thai nationality : No</p> <p>Residence in Thailand : No</p> <p>Family relationship between directors and executives : Doesn't Have</p> <p>Legal offenses in the past 5 years <sup>(*)</sup> : Doesn't Have</p> <p>DAP course : Yes</p> <p>DCP course : No</p>     | <p>Director</p> <p>(Non-executive directors)</p> <p>Authorized directors as per the company's certificate of registration : Yes</p> <p>Type of director : Continuing director (Full term of directorship and being re-appointed as a director)</p> | 28 Jan 2022                        | Health Care Services |

| List of directors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Position                                                                                                                                                                     | First appointment date of director | Skills and expertise                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-----------------------------------------------|
| <p>9. Ms. SAOWALAK DANSAKUL</p> <p>Gender: Female</p> <p>Age : 46 years</p> <p>Highest level of education : Doctoral degree</p> <p>Study field of the highest level of education : Science</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p> <p>Family relationship between directors and executives : Doesn't Have</p> <p>Legal offenses in the past 5 years <sup>(*)</sup> :<br/>Doesn't Have</p> <p>DAP course : Yes</p> <p>DCP course : Yes</p> <p><b>Shareholding in a company</b></p> <ul style="list-style-type: none"> <li>• Direct shareholding : 2,200,000 Shares (0.366667 %)</li> </ul> | <p>Director<br/>(Executive Directors)</p> <p>Authorized directors as per the company's certificate of registration :<br/>Yes</p> <p>Type of director : Existing director</p> | 28 Jan 2022                        | Health Care Services, Agribusiness            |
| <p>10. Mr. XIAOHAN WANG</p> <p>Gender: Male</p> <p>Age : 35 years</p> <p>Highest level of education : Bachelor's degree</p> <p>Study field of the highest level of education : Science</p> <p>Thai nationality : No</p> <p>Residence in Thailand : No</p> <p>Family relationship between directors and executives : Doesn't Have</p> <p>Legal offenses in the past 5 years <sup>(*)</sup> :<br/>Doesn't Have</p> <p>DAP course : Yes</p> <p>DCP course : No</p> <p><b>Shareholding in a company</b></p> <ul style="list-style-type: none"> <li>• Direct shareholding : 2,250,000 Shares (0.375000 %)</li> </ul>        | <p>Director<br/>(Executive Directors)</p> <p>Authorized directors as per the company's certificate of registration :<br/>Yes</p> <p>Type of director : Existing director</p> | 28 Jan 2022                        | Business Administration, Health Care Services |



| List of directors                                                                                                                                                                                                                                                                                                                                                                                              | Position                                                                                                                                                                                                                                                     | First appointment date of director | Skills and expertise |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|----------------------|
| 11. Mr. JEDSADA CHOKDAMRONGSUK<br>Gender: Male<br>Age : 67 years<br>Highest level of education : Bachelor's degree<br>Study field of the highest level of education : Medicine<br>Thai nationality : Yes<br>Residence in Thailand : Yes<br>Family relationship between directors and executives : Doesn't Have<br>Legal offenses in the past 5 years (*) : Doesn't Have<br>DAP course : No<br>DCP course : Yes | Director<br>(Non-executive directors, Independent director)<br><br>Authorized directors as per the company's certificate of registration : No<br><br>Type of director : Continuing director (Full term of directorship and being re-appointed as a director) | 22 Jun 2023                        | Health Care Services |

Additional explanation :

(\*) Any offense under the Securities and Exchange Act B.E. 2535 (1992) or the Derivatives Act B.E. 2546 (2003), only in the following cases:

(1) Dishonest act or gross negligence

(2) Disclosure or dissemination of false information or statements that may be misleading or conceal material facts that should be notified, which may affect decision making of shareholders, investors or other parties involved

(3) Unfair acts or exploitation of investors in trading securities or derivatives, or participation in, or support to, such acts.

(\*\*) Shareholdings by persons related to directors or executives as prescribed in Section 59 of the Securities and Exchange Act B.E. 2535 (1992), such as spouses or cohabiting couple (unmarried couples living together openly), minor children, etc.

### Diagram of the board of directors



List of the board of directors by position

| List of the board of directors  | Position | Executive directors | Non-executive directors | Independent directors | Non-executive directors who have no position in independent directors | Authorized directors as per the company's certificate of registration |
|---------------------------------|----------|---------------------|-------------------------|-----------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
| 1. Mr. THOSAPORN SIRISUMPHAND   | Director |                     | ✓                       | ✓                     |                                                                       |                                                                       |
| 2. Mr. PREECHA L AOHAPONGCHANA  | Director |                     | ✓                       |                       | ✓                                                                     | ✓                                                                     |
| 3. Mr. GOANPOT ASVINVICHIT      | Director |                     | ✓                       |                       | ✓                                                                     | ✓                                                                     |
| 4. Mr. NING LI                  | Director |                     | ✓                       |                       | ✓                                                                     | ✓                                                                     |
| 5. Mr. SUJIE CAO                | Director |                     | ✓                       |                       | ✓                                                                     | ✓                                                                     |
| 6. Mr. VICHATE TANTIWANICH      | Director |                     | ✓                       | ✓                     |                                                                       |                                                                       |
| 7. Mr. VICHYA KREANGAM          | Director |                     | ✓                       | ✓                     |                                                                       |                                                                       |
| 8. Mr. ZONGZE WU                | Director |                     | ✓                       |                       | ✓                                                                     | ✓                                                                     |
| 9. Ms. SAOWALAK DANSAKUL        | Director | ✓                   |                         |                       |                                                                       | ✓                                                                     |
| 10. Mr. XIAOHAN WANG            | Director | ✓                   |                         |                       |                                                                       | ✓                                                                     |
| 11. Mr. JEDSADA C HOKDAMRONGSUK | Director |                     | ✓                       | ✓                     |                                                                       |                                                                       |
| <b>Total (persons)</b>          |          | <b>2</b>            | <b>9</b>                | <b>4</b>              | <b>5</b>                                                              | <b>7</b>                                                              |

## Overview of director skills and expertise

| Skills and expertise        | Number (persons) | Percent (%) |
|-----------------------------|------------------|-------------|
| 1. Economics                | 2                | 18.18       |
| 2. Agribusiness             | 1                | 9.09        |
| 3. Banking                  | 1                | 9.09        |
| 4. Commerce                 | 1                | 9.09        |
| 5. Health Care Services     | 6                | 54.55       |
| 6. Law                      | 2                | 18.18       |
| 7. IT Management            | 1                | 9.09        |
| 8. Corporate Management     | 1                | 9.09        |
| 9. Risk Management          | 1                | 9.09        |
| 10. Audit                   | 1                | 9.09        |
| 11. Public Administration   | 1                | 9.09        |
| 12. Business Administration | 5                | 45.45       |

## Information about the other directors

The chairman of the board and the highest-ranking : No  
executive are from the same family

Chairman is a member of the executive board or taskforce : No

The company appoints at least one independent director : Yes  
to determine the agenda of the board of directors'  
meeting

## The measures for balancing the power between the board of directors and the Management

The measures for balancing the power between the board : Yes  
of directors and the Management

Methods of balancing power between the board of : Appointing an independent director to jointly  
directors and Management consider the agenda of the board of directors'  
meeting

The Company has appointed four independent directors, accounting for 36.36% of the total 11 directors, and nine non-executive directors, representing 81.82% of the total board members. This composition ensures a balance of power between executive directors and management. Regarding the board meeting agenda setting, an independent director or the chairman, who is also an independent director, must be involved in the agenda-setting process. If the chairman is unable to attend or participate in setting the agenda, the chairman of the audit committee or an appointed

representative acting as the meeting chairman will be responsible for determining the agenda. Additionally, those involved in the agenda-setting process must not be executive directors.

### 7.2.3 Information on the roles and duties of the board of directors

Board charter : Yes

Scope of Authority, Duties, and Responsibilities of the Board of Directors are as follows;

1. Define the objectives, key business goals, vision, mission, policies, strategies, business plans, organizational structure, approval authority, and budget of the Company. Supervise the allocation of key resources and review, examine, and approve the Company's policies, strategies, business plans, and operational direction, including those of its subsidiaries, as proposed by the management.
2. Monitor and supervise the Company's performance, management, and operations, ensuring alignment with the Company's objectives, vision, mission, strategies, business plans, and budget to maximize value for the Company and its shareholders effectively and efficiently.
3. Oversee the Company's management and operations to ensure compliance with its policies, corporate governance principles, securities laws, and related regulations issued by the Securities and Exchange Commission (SEC) and the Stock Exchange of Thailand (SET), including related-party transactions and significant asset acquisitions or disposals, provided that they do not conflict with other laws.
4. Establish a comprehensive risk management policy covering the entire organization and oversee the implementation of appropriate risk management systems and control measures to mitigate business risks effectively.
5. Ensure the implementation of an appropriate and effective accounting system, including an internal control system and internal audit process, and conduct regular assessments of the adequacy of the Company's internal control system.
6. Define the management structure, including the authority to appoint subcommittees, the Chief Executive Officer (CEO), and other committees as deemed appropriate. The delegation of authority must not allow subcommittees, the CEO, or other committees to approve transactions that may involve conflicts of interest unless they comply with the policies and criteria previously approved by the Board.
7. Establish corporate governance policies in written form, ensure their effective implementation, and promote ethical business practices that respect the rights of shareholders and stakeholders, contributing positively to society and the environment while maintaining adaptability to changing business conditions.
8. Manage and address conflicts of interest among stakeholders, including preventing the misuse of the Company's assets, information, and opportunities, as well as improper transactions with related parties. Any director with a personal interest in a transaction involving the Company or a change in shareholding proportion must immediately notify the Company.
9. The Board may delegate authority to one or more directors or other individuals to act on its behalf under the Board's supervision. The Board may revoke, withdraw, modify, or amend such delegation of authority as necessary. However, such delegation must not permit decision-making or approvals of transactions where the delegate has a conflict of interest, personal gain, or other conflicting interests with the Company, as defined by the Capital Market Supervisory Board and/or SET regulations, unless the transactions comply with the policies and guidelines previously approved by the Board.

## 7.3 Information on subcommittees

### 7.3.1 Information on roles of subcommittees

#### Roles of subcommittees

##### Audit Committee

#### Role

- Audit of financial statements and internal controls
- Risk management

#### Scope of authorities, role, and duties

1. Review the Company's financial reports to ensure accuracy and adequate disclosure.
2. Review the Company's internal control system and internal audit system for appropriateness and effectiveness, as well as assess the independence of the internal audit function. This includes approving the appointment, transfer, dismissal, and remuneration of the head of internal audit or any other department responsible for internal audit.
3. Review the Company's risk management policies and implementation to ensure compliance with established guidelines.
4. Ensure the Company's compliance with securities and exchange laws, stock exchange regulations, and other applicable business laws.
5. Evaluate, select, and propose the appointment of an independent auditor and determine their remuneration. Additionally, hold at least one meeting per year with the external auditor without management participation.
6. Review related-party transactions and potential conflict of interest transactions to ensure compliance with securities laws and stock exchange regulations, ensuring that such transactions are reasonable and in the best interest of the Company.
7. Prepare and disclose an Audit Committee Report in the Annual Report, signed by the Chairman of the Audit Committee, including at least the following:
  - 7.1) Opinion on the accuracy, completeness, and reliability of the Company's financial reports.
  - 7.2) Opinion on the adequacy of the internal control system.
  - 7.3) Opinion on compliance with securities laws, stock exchange regulations, and other applicable business laws.
  - 7.4) Opinion on the appropriateness of the external auditor.
  - 7.5) Opinion on transactions that may involve conflicts of interest.
  - 7.6) Number of Audit Committee meetings and attendance records of each committee member.

7.7) Overall observations and recommendations based on duties performed under the Audit Committee Charter.

8. Report any other matters that shareholders and investors should be aware of, within the scope of duties assigned by the Board of Directors, including reviewing and approving the Company's internal audit plan and evaluating the performance of the internal control auditor.

9. The Audit Committee has the authority to seek independent professional opinions when necessary, at the Company's expense.

10. Ensure the Company complies with corporate governance, social responsibility, and anti-corruption policies, including handling fraud and corruption complaints from internal personnel, conducting investigations, and submitting cases to the Board of Directors for disciplinary action and resolution.

11. If the Audit Committee identifies or suspects any of the following issues that may significantly impact the Company's financial position and performance, it must report to the Board of Directors for timely corrective action:

11.1) Transactions that may involve conflicts of interest.

11.2) Fraud, irregularities, or significant deficiencies in internal control systems.

11.3) Violations of securities laws, stock exchange regulations, or other applicable business laws.

12. Perform any other duties assigned by the Board of Directors.

#### Reference link for the charter

-

### Executive Committee

#### Role

- Director and executive nomination
- Remuneration
- Sustainability development

#### Scope of authorities, role, and duties

1. Conduct and manage the Company's operations in accordance with its objectives, articles of association, policies, regulations, resolutions of the Board of Directors and/or shareholder meetings, within the framework of applicable laws.

2. Review and evaluate management proposals regarding organizational structure, vision, mission, goals, policies, business strategies, operational plans, investment expansion, financial planning, annual report, budget allocation, human resource management, and IT investments, before submitting them for Board approval.

3. Appoint working committees for specific tasks, define their roles, responsibilities, and authority, and oversee their performance to ensure alignment with the Company's policies and goals.

4. Provide guidance, advice, and policy direction to the Chief Executive Officer (CEO) and special task forces.

5. Monitor the performance of the Company and its subsidiaries to ensure operations are aligned with approved policies and objectives, maintaining quality and efficiency.
6. Review and approve the annual budget allocation proposed by management before submission to the Board of Directors for approval.
7. Approve financial expenditures for regular business transactions, provided they do not exceed the budget approved by the Board.
8. Assess feasibility and approve participation in new projects, bids, and contracts, ensuring compliance with legal and stock exchange regulations.
9. Approve significant capital expenditures as outlined in the Company's annual budget, as delegated by the Board.
10. Authorize loan transactions, banking and financial operations, including account openings, loan applications, intra-group financing, and credit facilities, within the approved limits. Any exceeding amounts must be submitted to the Board for review in the next meeting. If assets are used as collateral, prior Board approval is required.
11. Monitor the Company's financial performance and propose dividend payments to the Board for approval.
12. Establish the Company's organizational structure, management authority, hiring, promotion, transfer, termination, and compensation policies for executives at the director level or equivalent, excluding the CEO.
13. Delegate authority to individuals or committees to conduct Company operations, ensuring oversight and compliance with governance principles. This authority can be revoked, amended, or modified as deemed necessary.
14. Appoint advisory committees and consultants, including determining remuneration, allowances, benefits, and other related expenses.
15. Appoint executive positions within the Company, except for the CEO, which requires Board approval.
16. Convene Executive Committee meetings and set meeting regulations as deemed necessary.
17. Approve operational authority for executives in line with Company rules and regulations.
18. Ensure the Company maintains an effective internal control system, coordinating with the Audit Committee.
19. Nominate qualified candidates for director and executive positions in subsidiaries and affiliates, ensuring governance compliance before seeking Board approval.
20. Perform any other duties assigned by the Board of Directors.

#### Authority Limitations

The delegation of authority to the Executive Committee shall not include approval for transactions where members have conflicts of interest, personal gains, or related party transactions, as defined by the Securities and Exchange Commission (SEC), Stock Exchange of Thailand (SET), and other relevant regulators. Such matters must be presented to the Board or shareholders for approval, except for transactions conducted under normal business operations and standard commercial terms as defined by the SEC, SET, or other relevant authorities.

**Reference link for the charter**

-

**7.3.2 Information on each subcommittee**



## List of audit committee

| List of directors                                                                                                                                                                                                                                                                                                                                     | Position                                                                                                                                                                                                  | Appointment date of audit committee member | Skills and expertise                                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|---------------------------------------------------------------------------|
| <p>1. Mr. VICHATE TANTIWANICH<sup>(*)</sup></p> <p>Gender: Male</p> <p>Age : 64 years</p> <p>Highest level of education : Master's degree</p> <p>Study field of the highest level of education : Business Administration</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p> <p>Expertise in accounting information review : Yes</p> | <p>Chairman of the audit committee</p> <p>(Non-executive directors, Independent director)</p> <p>Director type : Continuing director (Full term of directorship and being re-appointed as a director)</p> | 28 Jan 2022                                | Risk Management, Audit, Business Administration, Economics, IT Management |
| <p>2. Mr. VICHYA KREANGAM</p> <p>Gender: Male</p> <p>Age : 44 years</p> <p>Highest level of education : Doctoral degree</p> <p>Study field of the highest level of education : Law</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p> <p>Expertise in accounting information review : No</p>                                        | <p>Member of the audit committee</p> <p>(Non-executive directors, Independent director)</p> <p>Director type : Existing director</p>                                                                      | 28 Jan 2022                                | Law                                                                       |
| <p>3. Mr. JEDSADA CHOKDAMRONGSUK</p> <p>Gender: Male</p> <p>Age : 67 years</p> <p>Highest level of education : Bachelor's degree</p> <p>Study field of the highest level of education : Medicine</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p> <p>Expertise in accounting information review : No</p>                          | <p>Member of the audit committee</p> <p>(Non-executive directors, Independent director)</p> <p>Director type : Continuing director (Full term of directorship and being re-appointed as a director)</p>   | 22 Jun 2023                                | Health Care Services                                                      |

Additional explanation :

(\*) Directors with expertise in accounting information review

List of executive committee members

| List of directors                                                                                                                                                                                                                                                               | Position                                | Appointment date of executive committee member |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|------------------------------------------------|
| <p>1. Mr. GOANPOT ASVINVICHIT</p> <p>Gender: Male</p> <p>Age : 69 years</p> <p>Highest level of education : Master's degree</p> <p>Study field of the highest level of education : Business Administration</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p> | The chairman of the executive committee | 28 Jan 2022                                    |
| <p>2. Mr. PREECHA LAOHAPONGCHANA</p> <p>Gender: Male</p> <p>Age : 71 years</p> <p>Highest level of education : Master's degree</p> <p>Study field of the highest level of education : Law</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p>                  | Member of the executive committee       | 28 Jan 2022                                    |
| <p>3. Mr. SUJIE CAO</p> <p>Gender: Male</p> <p>Age : 39 years</p> <p>Highest level of education : Bachelor's degree</p> <p>Study field of the highest level of education : Science</p> <p>Thai nationality : No</p> <p>Residence in Thailand : No</p>                           | Member of the executive committee       | 28 Jan 2022                                    |
| <p>4. Ms. SAOWALAK DANSAKUL</p> <p>Gender: Female</p> <p>Age : 46 years</p> <p>Highest level of education : Doctoral degree</p> <p>Study field of the highest level of education : Science</p> <p>Thai nationality : Yes</p> <p>Residence in Thailand : Yes</p>                 | Member of the executive committee       | 28 Jan 2022                                    |
| <p>5. Mr. XIAOHAN WANG</p> <p>Gender: Male</p> <p>Age : 35 years</p> <p>Highest level of education : Bachelor's degree</p> <p>Study field of the highest level of education : Science</p> <p>Thai nationality : No</p> <p>Residence in Thailand : No</p>                        | Member of the executive committee       | 28 Jan 2022                                    |



## 7.4 Information on the executives

### 7.4.1 List and positions of the executive

List of the highest-ranking executive and the next four executives

| List of executives                                                                                                                                                                                                                                                                                                                                                      | Position                                                                    | First appointment date | Skills and expertise                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|------------------------|-----------------------------------------------|
| <p>1. Ms. SAOWALAK DANSAKUL</p> <p>Gender: Female</p> <p>Age : 46 years</p> <p>Highest level of education : Doctoral degree</p> <p>Study field of the highest level of education : Science</p> <p>Thai nationality : Yes</p> <p>Residing in Thailand : Yes</p> <p>Highest responsibility in corporate accounting and finance : No</p> <p>Accounting supervisor : No</p> | <p>Chief Executive Officer (CEO)</p> <p>(The highest-ranking executive)</p> | 28 Jan 2022            | Health Care Services, Agribusiness            |
| <p>2. Mr. XIAOHAN WANG</p> <p>Gender: Male</p> <p>Age : 35 years</p> <p>Highest level of education : Bachelor's degree</p> <p>Study field of the highest level of education : Science</p> <p>Thai nationality : No</p> <p>Residing in Thailand : No</p> <p>Highest responsibility in corporate accounting and finance : No</p> <p>Accounting supervisor : No</p>        | <p>Deputy Chief Executive Officer (DCEO)</p>                                | 1 Oct 2019             | Business Administration, Health Care Services |

| List of executives                                                                                                                                                                                                                                                                                                                                                                                                         | Position                       | First appointment date | Skills and expertise |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|------------------------|----------------------|
| <p>3. Mr. Kittikun Rodrangnok<sup>(*)(**)</sup></p> <p>Gender: Male</p> <p>Age : 35 years</p> <p>Highest level of education : Bachelor's degree</p> <p>Study field of the highest level of education : Accounting</p> <p>Thai nationality : Yes</p> <p>Residing in Thailand : Yes</p> <p>Highest responsibility in corporate accounting and finance : Yes</p> <p>Accounting supervisor : Yes</p>                           | Chief Financial Officer (CFO)  | 23 Sep 2021            | Accounting           |
| <p>4. Mr. Porntep Tanyut</p> <p>Gender: Male</p> <p>Age : 39 years</p> <p>Highest level of education : Master's degree</p> <p>Study field of the highest level of education : Department of Immunology</p> <p>Thai nationality : Yes</p> <p>Residing in Thailand : Yes</p> <p>Highest responsibility in corporate accounting and finance : No</p> <p>Accounting supervisor : No</p>                                        | Chief Laboratory Officer (CLO) | 3 Jan 2024             | Health Care Services |
| <p>5. Mr. Siriyod Denmongkholchai</p> <p>Gender: Male</p> <p>Age : 36 years</p> <p>Highest level of education : Doctoral degree</p> <p>Study field of the highest level of education : Department of Medical Microbiology (Interdisciplinary)</p> <p>Thai nationality : Yes</p> <p>Residing in Thailand : Yes</p> <p>Highest responsibility in corporate accounting and finance : No</p> <p>Accounting supervisor : No</p> | Laboratory Director            | 21 Dec 2023            | Health Care Services |

Additional Explanation :

(\*) Highest responsibility in corporate accounting and finance

(\*\*) Accounting supervisor

(\*\*\*) Appointed after the fiscal year end of the reporting year

## Organization structure diagram of the highest-ranking executive and the next four executives

Organization structure of the highest-ranking executive and : 19 Mar 2026

the next four executives as of date

## Organization structure diagram of the highest-ranking executive and the next four executives from the top executive



Organizational Structure of the Chief Executive Officer and the Four Highest-Ranking Executives

### 7.4.2 Remuneration policy for executive directors and executives

The Company recognizes the significance of the roles, duties, and responsibilities of the Board of Directors, Audit Committee, Executive Committee, and senior management, as they are key figures in driving the business towards its objectives, goals, and sustainable growth. Therefore, the Company carefully considers the structure and remuneration levels for directors to ensure they are appropriate to their responsibilities and serve as an incentive for the Board to lead the organization toward both short-term and long-term success. The remuneration of directors must align with the Company's long-term strategies and goals, their experience, duties, scope of roles and responsibilities, and the expected contributions of each director. The remuneration structure is designed to be comparable to industry standards while being subject to shareholder approval, ensuring that compensation remains reasonable and not excessive. The following criteria are used to determine director and executive compensation:

1. Evaluate and establish appropriate compensation structures and criteria for the remuneration of the Board of Directors, Chief Executive Officer (CEO), and Deputy Chief Executive Officer (Deputy CEO) to ensure fairness and suitability.
2. Determine performance evaluation criteria for the CEO and Deputy CEO, which will be submitted to the Board of Directors for approval.
3. Set annual or quarterly remuneration for directors, the CEO, and the Deputy CEO, considering the CEO's performance evaluation results, and include this matter in the Board meeting agenda for approval.
4. Review conditions and details of new securities offerings or stock options for directors and employees, if applicable.

5. Ensure director compensation is competitive within the industry, reflecting their experience, responsibilities, and expected contributions. Directors with additional roles, such as serving on subcommittees, should receive appropriate additional compensation.

6. Ensure compensation for the CEO, Deputy CEO, and senior executives follows the policies set by the Board within the approved framework from the shareholders' meeting. The salary, bonuses, and long-term incentives should align with the Company's performance and the individual performance of each executive, ensuring the best interests of the Company.

Does the board of directors or the remuneration : Have  
committee have an opinion on the remuneration policy  
for executive directors and executives

The Company determines directors' remuneration based on appropriate criteria and in alignment with the practices of listed companies within the same industry. Key factors considered include the Company's operating performance, business size, responsibilities of the Board of Directors, and net profit.

The Board of Directors is of the view that the remuneration for executive directors and management is appropriate, fair, and consistent with the Company's performance as well as industry practices.

### 7.4.3 Remuneration of executive directors and executives

#### Monetary remuneration of executive directors and executives

|                                                                        | 2023          | 2024          | 2025          |
|------------------------------------------------------------------------|---------------|---------------|---------------|
| <b>Total remuneration of executive directors and executives (baht)</b> | 15,710,574.00 | 13,072,474.00 | 18,494,825.00 |

#### Other remunerations of executive directors and executives

|                                                                                        | 2023       | 2024       | 2025       |
|----------------------------------------------------------------------------------------|------------|------------|------------|
| Company's contribution to provident fund for executive directors and executives (Baht) | 349,000.00 | 395,090.00 | 544,340.00 |
| Employee Stock Ownership Plan (ESOP)                                                   | No         | No         | No         |
| Employee Joint Investment Program (EJIP)                                               | No         | No         | No         |

#### Outstanding remuneration or benefits of executive directors and executives

Outstanding remuneration or benefits of executive : 0.00

directors and executives in the past year

Estimated remuneration of executive directors and : 0.00

executives in the current year



## 7.5 Information on employees

### Information on the company's employees

#### Employees

|                                  | 2023 | 2024 | 2025 |
|----------------------------------|------|------|------|
| <b>Total employees</b> (persons) | 98   | 103  | 109  |
| Male employees (persons)         | 27   | 25   | 29   |
| Female employees (persons)       | 71   | 78   | 80   |

#### Number of employees by position and department

##### Number of male employees by position

|                                                               | 2023 | 2024 | 2025 |
|---------------------------------------------------------------|------|------|------|
| Total number of male employees in operational level (Persons) | 17   | 16   | 21   |
| Total number of male employees in management level (Persons)  | 8    | 5    | 4    |
| Total number of male employees in executive level (Persons)   | 2    | 4    | 4    |

##### Number of female employees by position

|                                                                 | 2023 | 2024 | 2025 |
|-----------------------------------------------------------------|------|------|------|
| Total number of female employees in operational level (Persons) | 58   | 65   | 68   |
| Total number of female employees in management level (Persons)  | 10   | 12   | 11   |
| Total number of female employees in executive level (Persons)   | 3    | 1    | 1    |

#### Significant changes in the number of employees

Significant changes in number of employees over the past : No

3 Years

## Information on employee remuneration

### Employee remuneration

|                                           | 2023          | 2024          | 2025          |
|-------------------------------------------|---------------|---------------|---------------|
| <b>Total employee remuneration</b> (baht) | 61,093,723.36 | 59,405,266.78 | 80,527,043.50 |
| Total male employee remuneration (Baht)   | 18,278,564.83 | 15,964,485.71 | 22,133,977.14 |
| Total female employee remuneration (Baht) | 42,815,158.53 | 43,440,781.07 | 58,393,066.36 |

## Information on provident fund management

### Provident fund management policy

Provident fund management policy : Yes

The company has established a provident fund as a guarantee of security and to motivate employees, managed by SCB Asset Management Company Limited under the name "SCB Provident Fund Master Fund," which is registered with the Securities and Exchange Commission (SEC). The company selects the fund based on its past performance and the fees associated with fund management.

### Overview of methods for determining employee and employer contribution Rates

The Company has established employee contribution rates and employer contribution rates to promote long-term savings and enhance employees' financial security. The details are as follows:

#### 1. Employee Contribution Rate

Employees may choose their contribution rate ranging from 2% to 15% of their salary, based on their voluntary decision and individual savings capacity.

#### 2. Employer Contribution Rate

The Company determines the employer contribution rate within the range of 5% to 10% of salary, which may vary depending on years of service or other conditions specified by the Company, in order to encourage employee motivation and retention.

#### 3. Criteria for Determining Contribution Rates

The determination of employee and employer contribution rates is based on key factors, including:

- Applicable laws and regulations
- Industry practices
- The Company's performance
- Human resources and welfare policies

#### 4. Review and Adjustment

The Company regularly reviews and adjusts the contribution rates to ensure appropriateness in line with economic conditions and the Company's capabilities.

The Company aims for the contribution scheme to serve as a key tool in providing financial security for employees, alongside efficient cost management.

Implementation of Investment Governance Code for : No

Institutional Investors ("I Code") by Company's Provident

Fund Committee

#### Participation in provident fund membership (PVD)

##### Details of provident fund participation (PVD)

##### Number of employees eligible to participate in PVD

|                                                               | 2023  | 2024  | 2025  |
|---------------------------------------------------------------|-------|-------|-------|
| Number of employees eligible to participate in PVD (persons)  | 88    | 87    | 107   |
| Number of employees joining in PVD (persons)                  | 38    | 42    | 42    |
| Total amount of provident fund contributed by the company (%) | 38.78 | 40.78 | 38.53 |
| Number of PVD members / Total eligible employees (%)          | 43.18 | 48.28 | 39.25 |

##### Amount of provident fund

|                                                               | 2023         | 2024         | 2025         |
|---------------------------------------------------------------|--------------|--------------|--------------|
| Total amount of provident fund contributed by employer (baht) | 1,057,533.71 | 1,154,170.61 | 1,372,355.85 |
| Total amount of provident fund contributed by employee (baht) | 0.00         | 0.00         | 1,891,155.51 |

#### Summary of employee PVD participation over the past year

| Company name                                       | Employees participating in PVD (Yes/ No) | Total number of employees (persons) | Number of employees eligible to participate in PVD (persons) | Number of employees joining in PVD (persons) | Number of PVD members / Total employees (%) | Number of PVD members / Total eligible employees (%) |
|----------------------------------------------------|------------------------------------------|-------------------------------------|--------------------------------------------------------------|----------------------------------------------|---------------------------------------------|------------------------------------------------------|
| Bangkok Genomics Innovation Public Company Limited | Yes                                      | 109                                 | 107                                                          | 42                                           | 38.53%                                      | 39.25%                                               |

#### Policy and guidelines on promoting savings through the provident fund for non-participating employees

Policy and guidelines on promoting savings through the : Providing education or information on selecting provident fund for non-participating employees appropriate investment policies

#### Providing education or information on selecting appropriate investment policies

The Company places importance on enhancing employees' knowledge and understanding of investment. It has collaborated with investment professionals from asset management companies to provide information and organize training on investment planning and appropriate risk management.

The implementation guidelines are as follows:

1. Regularly provide communication on investment policies, alternative funds, and risk levels.
2. Support training and provide knowledge on financial planning and investment through online platforms, in order to explain investment policies in a clear and easily understandable manner.
3. Provide employees with the opportunity to adjust their investment policies as appropriate, taking into account their age, investment horizon, and risk tolerance.

The training content covers investment planning, risk profile assessment, selection of appropriate investment policies, and the principles of diversification. This is to enable employees to effectively apply such knowledge in making investment decisions in alignment with their long-term financial goals.

## 7.6 Other significant information

### 7.6.1 Assigned person

List of persons assigned for accounting oversight

| General information        | Email                        | Telephone number |
|----------------------------|------------------------------|------------------|
| 1. Mr. Kittikun Rodrangnok | kittikun@bangkokgenomics.com | -                |

List of the company secretary

| General information         | Email                              | Telephone number |
|-----------------------------|------------------------------------|------------------|
| 1. Ms. Puttarawicha Mhankid | puttarawicha.m@bangkokgenomics.com | 062-1588783      |

List of the head of internal audit or outsourced internal auditor

| General information          | Email                     | Telephone number |
|------------------------------|---------------------------|------------------|
| 1. Mrs. Amornwan Dechkamhang | natthapa.ji@plgroup.co.th | -                |

### 7.6.2 Head of investor relations

Does the Company have an appointed head of investor : Yes  
relations

List of the head of investor relations

| General information        | Email                        | Telephone number |
|----------------------------|------------------------------|------------------|
| 1. Mr. Kittikun Rodrangnok | kittikun@bangkokgenomics.com | 063-0211580      |

### 7.6.3 Company's auditor

Details of the company's auditor

| Audit firms                                                                                                                                                                                                     | Audit fee<br>(Baht) | Other service fees | Names and general<br>information of auditors                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|--------------------|-------------------------------------------------------------------------------------------------|
| DR. VIRACH AND ASSOCIATES<br>COMPANY LIMITED<br>No. 5/1, Supalai Grand Essence Village,<br>Ratchadaphisek Road. WAT THA PHRA<br>BANGKOK YAI Bangkok 10600<br>Telephone<br>093-130-8984,093-130-8986,0-2125-0029 | 1,830,000.00        | -                  | 1. Mr. CHAIYAKORN<br>AUNPITIPONGSA<br>Email:<br>virach_asso@vaaudit.com<br>License number: 3196 |

#### Details of the auditors of the subsidiaries

| Audit firms                                                                                                                                                                                                     | Audit fee<br>(Baht) | Other service fees | Names and general<br>information of auditors                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|--------------------|-------------------------------------------------------------------------------------------------|
| DR. VIRACH AND ASSOCIATES<br>COMPANY LIMITED<br>No. 5/1, Supalai Grand Essence Village,<br>Ratchadaphisek Road. WAT THA PHRA<br>BANGKOK YAI Bangkok 10600<br>Telephone<br>093-130-8984,093-130-8986,0-2125-0029 | 180,000.00          | -                  | 1. Mr. CHAIYAKORN<br>AUNPITIPONGSA<br>Email:<br>virach_asso@vaaudit.com<br>License number: 3196 |

#### 7.6.4 Assigned personnel in case of a foreign company

Does the company have any individual assigned to be : No  
representatives in Thailand

List of designated individuals as representatives in Thailand

## 8. Report on key operating results on corporate governance

### 8.1 Summary of duty performance of the board of directors over the past year

#### Summary of duty performance of the board of directors over the past year

The Board of Directors has performed its duties effectively, demonstrating strong cooperation and consistent attendance at meetings, while fully carrying out its roles and responsibilities. The results of the Board's self-assessment reflect a good level of corporate governance. Nevertheless, the Board places importance on continuous improvement, particularly in strengthening engagement with management, enhancing the capabilities of directors and executives, and improving overall effectiveness in the performance of duties.

In addition, the Board has organized a workshop to collaboratively determine strategic directions prior to the preparation and approval of the annual business plan and budget. This allows directors to participate from an early stage and ensures that the plans are comprehensive and aligned with the perspectives of both the Board and management. The Board has also considered key risk issues, such as cyber risk, and deemed it appropriate to invite external experts to provide insights for further consideration.

Furthermore, the Board has established a systematic approach to enhancing its performance by supporting the implementation of an annual strategic planning process and encouraging joint brainstorming sessions between the Board and management to define the Company's future direction, thereby strengthening corporate governance practices on a continuous basis.

#### 8.1.1 Selection, development and evaluation of duty performance of the board of directors

##### Information about the selection of the board of directors

##### List of directors whose terms have ended and have been reappointed

| List of directors             | Position                                                 | First appointment date of director | Skills and expertise                                                      |
|-------------------------------|----------------------------------------------------------|------------------------------------|---------------------------------------------------------------------------|
| 1. Mr. VICHATE TANTIWANICH    | Director (Non-executive directors, Independent director) | 28 Jan 2022                        | Risk Management, Audit, Business Administration, Economics, IT Management |
| 2. Mr. ZONGZE WU              | Director (Non-executive directors)                       | 28 Jan 2022                        | Health Care Services                                                      |
| 3. Mr. JEDSADA CHOKDAMRONGSUK | Director (Non-executive directors, Independent director) | 22 Jun 2023                        | Health Care Services                                                      |

##### Selection of independent directors

##### Criteria for selecting independent directors

The Board of Directors selects independent directors based on their qualifications, work experience, and other relevant factors. The selected candidates are then presented to the shareholders' meeting for appointment as directors of the Company. The Company has a policy to appoint independent directors at a minimum ratio of one-third (1/3) of the total number of directors, with no fewer than three (3) independent directors. Independent directors must be free from the control of management and major shareholders and must not have any financial or operational interests in the Company. Additionally, they must meet all relevant qualifications prescribed by the Capital Market Supervisory Board (SEC) and other applicable laws. Currently, the Board of Directors consists of 11 members, including four (4) independent directors, which is no less than one-third of the total number of directors. The qualifications of the Company's independent directors can be summarized as follows:

1. Must hold no more than 1% of the total voting shares of the Company, its parent company, subsidiaries, associates, major shareholders, or controlling persons, including shares held by persons related to the independent director.
2. Must not be, nor have ever been, a director involved in management, an employee, a staff member, a salaried advisor, or a controlling person of the Company, its parent company, subsidiaries, associates, subsidiaries of the same tier, major shareholders, or controlling persons. Exceptions apply if such status has been terminated for at least two years before the appointment. However, this restriction does not apply to independent directors who were previously government officials or advisors to a government agency that is a major shareholder or controlling person of the Company.
3. Must not have blood or legal relationships, such as being a parent, spouse, sibling, child, or spouse of a child, of another director, executive, major shareholder, controlling person, or any individual who is nominated to be a director, executive, or controlling person of the Company or its subsidiaries.
4. Must not have or have had any business relationship with the Company, its parent company, subsidiaries, associates, major shareholders, or controlling persons that could interfere with their independent judgment. Additionally, they must not have been a major shareholder or controlling person of the Company unless the relationship ended at least two years before the appointment.
5. May hold directorships in other companies, provided that such positions do not interfere with their responsibilities as an independent director of the Company and comply with the regulations of the Securities and Exchange Commission (SEC) and the Stock Exchange of Thailand (SET).
6. Must not engage in any business that is similar to or competes with the Company's business, whether as a sole proprietor, partner in a general partnership, unlimited liability partner in a limited partnership, director of a private company, or director of another company conducting similar or competing business, whether for their own benefit or the benefit of others, unless they have disclosed such involvement to the shareholders' meeting before their appointment.
7. Must meet the independence criteria as prescribed by the Capital Market Supervisory Board and comply with the same standards applicable to audit committee members as specified by the SEC and SET. They must be able to act in the best interests of all shareholders equally, without conflicts of interest. Additionally, they must be able to attend Board meetings and provide independent opinions.

#### **Business or professional relationships of independent directors over the past year**

Business or professional relationships of independent : No  
directors over the past year

#### **Selection of directors and the highest-ranking executive**

##### **Method for selecting directors and the highest-ranking executive <sup>(1)</sup>**



Method for selecting persons to be appointed as directors : Yes

through the nomination committee

Method for selecting persons to be appointed as the : Yes

highest-ranking executive through the nomination

committee

*Remark : <sup>(1)</sup> Since the company does not have a Nominating Committee, the Executive Committee assumes this responsibility instead.*

### **Number of directors from major shareholders**

Number of directors from each group of major : 5

shareholders over the past year (persons)

### **Rights of minority shareholders on director appointment**

The Board of Directors is responsible for nominating and appointing directors, executives with management authority, and heads of key business units. The board establishes policies for recruiting and selecting qualified individuals to serve as directors, members of subcommittees, or senior executives. Candidates undergo background checks and qualification assessments before being presented to the Shareholders' Meeting for approval. The shareholders determine the structure and compensation of the Board, ensuring that it reflects the duties and responsibilities of each director in accordance with the company's charter, policies, regulations, and applicable laws.

The appointment of directors follows the company's articles of association and relevant laws, utilizing the one-share, one-vote principle for director elections. Shareholders may allocate all of their votes to a single candidate or distribute them among multiple candidates but cannot assign varying vote counts to different candidates. In the case of a tie exceeding the number of available board seats, the Chairman of the meeting shall cast the deciding vote. The appointment process must be transparent, considering the nominee's educational background, experience, and qualifications to ensure an informed decision by the Board and shareholders. Additionally, the right of minority shareholders to nominate individuals for board elections is currently under review.

Method of director appointment : Method whereby each director requires approval

votes more than half of the votes of attending

shareholders and casting votes

## **Information on the development of directors**

### **Development of directors over the past year**

## Details of the development of directors over the past year

| List of directors                                                 | Participation in training in the past financial year | History of training participation                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------------------------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Mr. THOSAPORN SIRISUMPHAND<br>(Director, Independent director) | Participating                                        | Other <ul style="list-style-type: none"> <li>• 2025: Seminar and workshop for the Company's Board of Directors. Cyber risk is a business risk, and the procurement of cyber insurance, by Dr.Prinya Hom-anek, Cybersecurity Expert.</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. The Development of Advanced Therapy Technologies (ATMP / CAR-T Cell) by Prof.Dr. (M.D.) Nattiya Hirankarn, Medical expert.</li> </ul> |
| 2. Mr. PREECHA LAOHAPONGCHANA<br>(Director)                       | Participating                                        | Other <ul style="list-style-type: none"> <li>• 2025: Seminar and workshop for the Company's Board of Directors. Cyber risk is a business risk, and the procurement of cyber insurance, by Dr.Prinya Hom-anek, Cybersecurity Expert.</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. The Development of Advanced Therapy Technologies (ATMP / CAR-T Cell) by Prof.Dr. (M.D.) Nattiya Hirankarn, Medical expert.</li> </ul> |
| 3. Mr. GOANPOT ASVINVICHIT<br>(Director)                          | Participating                                        | Other <ul style="list-style-type: none"> <li>• 2025: Seminar and workshop for the Company's Board of Directors. Cyber risk is a business risk, and the procurement of cyber insurance, by Dr.Prinya Hom-anek, Cybersecurity Expert.</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. The Development of Advanced Therapy Technologies (ATMP / CAR-T Cell) by Prof.Dr. (M.D.) Nattiya Hirankarn, Medical expert.</li> </ul> |

| List of directors                                              | Participation in training in the past financial year | History of training participation                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------------------------------------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4. Mr. NING LI<br>(Director)                                   | Participating                                        | Other <ul style="list-style-type: none"> <li>• 2025: Seminar and workshop for the Company's Board of Directors. Cyber risk is a business risk, and the procurement of cyber insurance, by Dr.Prinya Hom-anek, Cybersecurity Expert.</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. The Development of Advanced Therapy Technologies (ATMP / CAR-T Cell) by Prof.Dr. (M.D.) Nattiya Hirankarn, Medical expert.</li> </ul> |
| 5. Mr. SUJIE CAO<br>(Director)                                 | Participating                                        | Other <ul style="list-style-type: none"> <li>• 2025: Seminar and workshop for the Company's Board of Directors. Cyber risk is a business risk, and the procurement of cyber insurance, by Dr.Prinya Hom-anek, Cybersecurity Expert.</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. The Development of Advanced Therapy Technologies (ATMP / CAR-T Cell) by Prof.Dr. (M.D.) Nattiya Hirankarn, Medical expert.</li> </ul> |
| 6. Mr. VICHATE TANTIWANICH<br>(Director, Independent director) | Participating                                        | Other <ul style="list-style-type: none"> <li>• 2025: Seminar and workshop for the Company's Board of Directors. Cyber risk is a business risk, and the procurement of cyber insurance, by Dr.Prinya Hom-anek, Cybersecurity Expert.</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. The Development of Advanced Therapy Technologies (ATMP / CAR-T Cell) by Prof.Dr. (M.D.) Nattiya Hirankarn, Medical expert.</li> </ul> |

| List of directors                                          | Participation in training in the past financial year | History of training participation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|------------------------------------------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 7. Mr. VICHYA KREANGAM<br>(Director, Independent director) | Participating                                        | Other <ul style="list-style-type: none"> <li>• 2025: Seminar and workshop for the Company's Board of Directors. Cyber risk is a business risk, and the procurement of cyber insurance, by Dr.Prinya Hom-anek, Cybersecurity Expert.</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. The Development of Advanced Therapy Technologies (ATMP / CAR-T Cell) by Prof.Dr. (M.D.) Nattiya Hirankarn, Medical expert.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 8. Mr. ZONGZE WU<br>(Director)                             | Non-participating                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 9. Ms. SAOWALAK DANSAKUL<br>(Director)                     | Participating                                        | Thai Institute of Directors (IOD) <ul style="list-style-type: none"> <li>• 2024: Director Certification Program (DCP)</li> <li>• 2024: Subsidiary Governance Program (SGP)</li> </ul> Other <ul style="list-style-type: none"> <li>• 2025: Certificate Program for Senior Executives, Capital Market Academy Class 36 (CMA 36), 2025, The Stock Exchange of Thailand</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. Cyber risk is a business risk, and the procurement of cyber insurance, by Dr.Prinya Hom-anek, Cybersecurity Expert.</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. The Development of Advanced Therapy Technologies (ATMP / CAR-T Cell) by Prof.Dr. (M.D.) Nattiya Hirankarn, Medical expert.</li> <li>• 2024: Arbitration Procedure Training Program</li> <li>• 2024: Cybersecurity Leadership Certificate Program for Business</li> <li>• 2024: Medical Leadership Certificate, Class 1</li> </ul> |

| List of directors                                                  | Participation in training in the past financial year | History of training participation                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------------------------------------------------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10. Mr. XIAOHAN WANG<br>(Director)                                 | Participating                                        | Other <ul style="list-style-type: none"> <li>• 2025: Seminar and workshop for the Company's Board of Directors. Cyber risk is a business risk, and the procurement of cyber insurance, by Dr.Prinya Hom-anek, Cybersecurity Expert.</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. The Development of Advanced Therapy Technologies (ATMP / CAR-T Cell) by Prof.Dr. (M.D.) Nattiya Hirankarn, Medical expert.</li> </ul> |
| 11. Mr. JEDSADA CHOKDAMRONGSUK<br>(Director, Independent director) | Participating                                        | Other <ul style="list-style-type: none"> <li>• 2025: Seminar and workshop for the Company's Board of Directors. Cyber risk is a business risk, and the procurement of cyber insurance, by Dr.Prinya Hom-anek, Cybersecurity Expert.</li> <li>• 2025: Seminar and workshop for the Company's Board of Directors. The Development of Advanced Therapy Technologies (ATMP / CAR-T Cell) by Prof.Dr. (M.D.) Nattiya Hirankarn, Medical expert.</li> </ul> |

## Information on the evaluation of duty performance of directors

### Criteria for evaluating the duty performance of the board of directors

The company places great importance on good corporate governance policies to foster sustainable growth with a strong emphasis on governance principles. To ensure effective oversight, the company has established charters that define the roles, duties, and responsibilities of the Board of Directors and subcommittees, setting key policies to guide corporate operations. These policies serve as a framework for executives to implement in managing the organization efficiently while adhering to the company's corporate governance standards. To reinforce these governance principles, the Board of Directors and subcommittees conduct self-assessments at least once a year. This evaluation process allows the Board and subcommittees to jointly review their performance, identify areas for improvement, and ensure that their duties, roles, and responsibilities are carried out effectively. The assessment should be conducted at both committee and individual levels to enhance accountability and continuous development.

### Evaluation of the duty performance of the board of directors over the past year

The results of the Board of Directors' self-assessment for the year 2025 reflect that, overall, the Board has performed its duties effectively at a good level, particularly in terms of board structure and composition, performance of duties, and meeting effectiveness. Nevertheless, there remain areas for further improvement, including strengthening engagement with management, enhancing the capabilities of directors and executives, and improving overall effectiveness in the performance of duties, in order to further enhance the Company's corporate governance.

### 8.1.2 Meeting attendance and remuneration payment to each board member

## Meeting attendance of the board of directors

### Meeting attendance of the board of directors

Number of the board of directors meeting over the past : 5

year (times)

Date of AGM meeting : 28 Apr 2025

EGM meeting : No

## Details of the board of directors' meeting attendance

| List of directors                                                  | Number of Board Meeting    |   |                                   | AGM meetings               |   |                                   | EGM meetings               |   |                                   |
|--------------------------------------------------------------------|----------------------------|---|-----------------------------------|----------------------------|---|-----------------------------------|----------------------------|---|-----------------------------------|
|                                                                    | Meeting attendance (times) | / | Meeting attendance rights (times) | Meeting attendance (times) | / | Meeting attendance rights (times) | Meeting attendance (times) | / | Meeting attendance rights (times) |
| 1. Mr. THOSAPORN SIRISUMPHAND<br>(Director, Independent director)  | 5                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |
| 2. Mr. PREECHA LAOHAPONGCHANA<br>(Director)                        | 5                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |
| 3. Mr. GOANPOT ASVINVICHIT<br>(Director)                           | 5                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |
| 4. Mr. NING LI<br>(Director)                                       | 4                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |
| 5. Mr. SUJIE CAO<br>(Director)                                     | 4                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |
| 6. Mr. VICHATE TANTIWANICH<br>(Director, Independent director)     | 5                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |
| 7. Mr. VICHYA KREANGAM<br>(Director, Independent director)         | 5                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |
| 8. Mr. ZONGZE WU<br>(Director)                                     | 2                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |
| 9. Ms. SAOWALAK DANSAKUL<br>(Director)                             | 5                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |
| 10. Mr. XIAOHAN WANG<br>(Director)                                 | 5                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |
| 11. Mr. JEDSADA CHOKDAMRONGSUK<br>(Director, Independent director) | 5                          | / | 5                                 | 1                          | / | 1                                 | N/A                        | / | N/A                               |

### Summary of the board of directors' meeting attendance rate

| List of directors                                                  | Board of directors' meeting attendance rate | AGM meeting attendance rate | EGM meeting attendance rate |
|--------------------------------------------------------------------|---------------------------------------------|-----------------------------|-----------------------------|
| 1. Mr. THOSAPORN SIRISUMPHAND<br>(Director, Independent director)  | 5/5<br>(100.00%)                            | 1/1<br>(100.00%)            | N/A                         |
| 2. Mr. PREECHA LAOHAPONGCHANA<br>(Director)                        | 5/5<br>(100.00%)                            | 1/1<br>(100.00%)            | N/A                         |
| 3. Mr. GOANPOT ASVINVICHIT<br>(Director)                           | 5/5<br>(100.00%)                            | 1/1<br>(100.00%)            | N/A                         |
| 4. Mr. NING LI<br>(Director)                                       | 4/5<br>(80.00%)                             | 1/1<br>(100.00%)            | N/A                         |
| 5. Mr. SUJIE CAO<br>(Director)                                     | 4/5<br>(80.00%)                             | 1/1<br>(100.00%)            | N/A                         |
| 6. Mr. VICHATE TANTIWANICH<br>(Director, Independent director)     | 5/5<br>(100.00%)                            | 1/1<br>(100.00%)            | N/A                         |
| 7. Mr. VICHYA KREANGAM<br>(Director, Independent director)         | 5/5<br>(100.00%)                            | 1/1<br>(100.00%)            | N/A                         |
| 8. Mr. ZONGZE WU<br>(Director)                                     | 2/5<br>(40.00%)                             | 1/1<br>(100.00%)            | N/A                         |
| 9. Ms. SAOWALAK DANSAKUL<br>(Director)                             | 5/5<br>(100.00%)                            | 1/1<br>(100.00%)            | N/A                         |
| 10. Mr. XIAOHAN WANG<br>(Director)                                 | 5/5<br>(100.00%)                            | 1/1<br>(100.00%)            | N/A                         |
| 11. Mr. JEDSADA CHOKDAMRONGSUK<br>(Director, Independent director) | 5/5<br>(100.00%)                            | 1/1<br>(100.00%)            | N/A                         |
| <b>Average meeting attendance rate</b>                             | <b>(90.91%)</b>                             | <b>100.00%</b>              | <b>N/A</b>                  |

### Detailed justification for the Company director's non-attendance at the Board of Directors' meeting

In 2025, certain directors were unable to attend some Board of Directors' meetings due to urgent and important business commitments that directly impacted the Company's direction. Such commitments included meetings and negotiations with key business partners, investors, and strategic partners, which are crucial to the Company's growth and development. Despite their occasional absence, the directors closely followed the meeting agendas and provided input or comments in advance to ensure continuity in the Board's operations. The directors remain committed to performing their duties in accordance with good corporate governance principles and continue to place importance on their oversight responsibilities to the fullest extent.



## Remuneration of the board of directors

### Types of remuneration of the board of directors

At The Annual General Meeting of Shareholders for the year 2025, held on April 28, 2025, resolved to determine the remuneration of the Board of Directors and the sub-committees of the Company as follows:

#### Monthly Remuneration of the Board of Directors (Baht/person)

- Chairman of the Board 50,000 Baht
- Directors 40,000 Baht

#### Meeting Allowance for sub-committees (Audit Committee and Executive Committee) (Baht/person)

- Chairman of the Board 20,000 Baht
- Directors 15,000 Baht

Note: Directors who serve as the company's executive shall receive compensation only in their capacity as executives and will not receive any remuneration in their capacity as board members.

### Remuneration of the board of directors

#### Details of the remuneration of each director over the past year

| Names of directors /<br>Board of directors                                        | Company              |                                   |                   |                                  | Total<br>monetary<br>remuneration<br>from<br>subsidiaries<br>(Baht) |
|-----------------------------------------------------------------------------------|----------------------|-----------------------------------|-------------------|----------------------------------|---------------------------------------------------------------------|
|                                                                                   | Meeting<br>allowance | Other<br>monetary<br>remuneration | Total (Baht)      | Non-<br>monetary<br>remuneration |                                                                     |
| <b>1. Mr. THOSAPORN<br/>SIRISUMPHAND<br/>(Director, Independent<br/>director)</b> |                      |                                   | <b>620,000.00</b> |                                  | <b>0.00</b>                                                         |
| Board of Directors<br>(Director)                                                  | 20,000.00            | 600,000.00                        | 620,000.00        | No                               |                                                                     |
| <b>2. Mr. PREECHA<br/>LAOHAPONGCHANA<br/>(Director)</b>                           |                      |                                   | <b>570,000.00</b> |                                  | <b>0.00</b>                                                         |
| Board of Directors<br>(Director)                                                  | 15,000.00            | 480,000.00                        | 495,000.00        | No                               |                                                                     |
| Executive Committee<br>(Member of the<br>executive committee)                     | 75,000.00            | 0.00                              | 75,000.00         | No                               |                                                                     |

| Names of directors /<br>Board of directors                                     | Company              |                                   |                   |                                  | Total<br>monetary<br>remuneration<br>from<br>subsidiaries<br>(Baht) |
|--------------------------------------------------------------------------------|----------------------|-----------------------------------|-------------------|----------------------------------|---------------------------------------------------------------------|
|                                                                                | Meeting<br>allowance | Other<br>monetary<br>remuneration | Total (Baht)      | Non-<br>monetary<br>remuneration |                                                                     |
| <b>3. Mr. GOANPOT<br/>ASVINVICHIT<br/>(Director)</b>                           |                      |                                   | <b>595,000.00</b> |                                  | <b>0.00</b>                                                         |
| Board of Directors<br>(Director)                                               | 15,000.00            | 480,000.00                        | 495,000.00        | No                               |                                                                     |
| Executive Committee<br>(The chairman of the<br>executive committee)            | 100,000.00           | 0.00                              | 100,000.00        | No                               |                                                                     |
| <b>4. Mr. NING LI<br/>(Director)</b>                                           |                      |                                   | <b>0.00</b>       |                                  | <b>0.00</b>                                                         |
| Board of Directors<br>(Director)                                               | 0.00                 | 0.00                              | 0.00              | No                               |                                                                     |
| <b>5. Mr. SUJIE CAO<br/>(Director)</b>                                         |                      |                                   | <b>570,000.00</b> |                                  | <b>0.00</b>                                                         |
| Board of Directors<br>(Director)                                               | 15,000.00            | 480,000.00                        | 495,000.00        | No                               |                                                                     |
| Executive Committee<br>(Member of the<br>executive committee)                  | 75,000.00            | 0.00                              | 75,000.00         | No                               |                                                                     |
| <b>6. Mr. VICHATE<br/>TANTIWANICH<br/>(Director, Independent<br/>director)</b> |                      |                                   | <b>575,000.00</b> |                                  | <b>0.00</b>                                                         |
| Board of Directors<br>(Director)                                               | 15,000.00            | 480,000.00                        | 495,000.00        | No                               |                                                                     |
| Audit Committee<br>(Chairman of the audit<br>committee)                        | 80,000.00            | 0.00                              | 80,000.00         | No                               |                                                                     |
| <b>7. Mr. VICHYA KREANGAM<br/>(Director, Independent<br/>director)</b>         |                      |                                   | <b>555,000.00</b> |                                  | <b>0.00</b>                                                         |

| Names of directors /<br>Board of directors                                         | Company              |                                   |                   |                                  | Total<br>monetary<br>remuneration<br>from<br>subsidiaries<br>(Baht) |
|------------------------------------------------------------------------------------|----------------------|-----------------------------------|-------------------|----------------------------------|---------------------------------------------------------------------|
|                                                                                    | Meeting<br>allowance | Other<br>monetary<br>remuneration | Total (Baht)      | Non-<br>monetary<br>remuneration |                                                                     |
| Board of Directors<br>(Director)                                                   | 15,000.00            | 480,000.00                        | 495,000.00        | No                               |                                                                     |
| Audit Committee<br>(Member of the audit<br>committee)                              | 60,000.00            | 0.00                              | 60,000.00         | No                               |                                                                     |
| <b>8. Mr. ZONGZE WU<br/>(Director)</b>                                             |                      |                                   | <b>0.00</b>       |                                  | <b>0.00</b>                                                         |
| Board of Directors<br>(Director)                                                   | 0.00                 | 0.00                              | 0.00              | No                               |                                                                     |
| <b>9. Ms. SAOWALAK<br/>DANSAKUL<br/>(Director)</b>                                 |                      |                                   | <b>0.00</b>       |                                  | <b>0.00</b>                                                         |
| Board of Directors<br>(Director)                                                   | 0.00                 | 0.00                              | 0.00              | No                               |                                                                     |
| Executive Committee<br>(Member of the<br>executive committee)                      | 0.00                 | 0.00                              | 0.00              | No                               |                                                                     |
| <b>10. Mr. XIAOHAN WANG<br/>(Director)</b>                                         |                      |                                   | <b>0.00</b>       |                                  | <b>0.00</b>                                                         |
| Board of Directors<br>(Director)                                                   | 0.00                 | 0.00                              | 0.00              | No                               |                                                                     |
| Executive Committee<br>(Member of the<br>executive committee)                      | 0.00                 | 0.00                              | 0.00              | No                               |                                                                     |
| <b>11. Mr. JEDSADA<br/>CHOKDAMRONGSUK<br/>(Director, Independent<br/>director)</b> |                      |                                   | <b>555,000.00</b> |                                  | <b>0.00</b>                                                         |
| Board of Directors<br>(Director)                                                   | 15,000.00            | 480,000.00                        | 495,000.00        | No                               |                                                                     |

| Names of directors /<br>Board of directors            | Company              |                                   |              |                                  | Total<br>monetary<br>remuneration<br>from<br>subsidiaries<br>(Baht) |
|-------------------------------------------------------|----------------------|-----------------------------------|--------------|----------------------------------|---------------------------------------------------------------------|
|                                                       | Meeting<br>allowance | Other<br>monetary<br>remuneration | Total (Baht) | Non-<br>monetary<br>remuneration |                                                                     |
| Audit Committee<br>(Member of the audit<br>committee) | 60,000.00            | 0.00                              | 60,000.00    | No                               |                                                                     |

#### Summary of the remuneration of each committee over the past year

| Names of board members | Meeting allowance | Other monetary<br>remuneration | Total (Baht) |
|------------------------|-------------------|--------------------------------|--------------|
| 1. Board of Directors  | 110,000.00        | 3,480,000.00                   | 3,590,000.00 |
| 2. Audit Committee     | 200,000.00        | 0.00                           | 200,000.00   |
| 3. Executive Committee | 250,000.00        | 0.00                           | 250,000.00   |

#### Remunerations or benefits pending payment to the board of directors

Remunerations or benefits pending payment to the board : 0.00  
of directors over the past year  
(Baht)

### 8.1.3 Supervision of subsidiaries and associated companies

#### Mechanism for overseeing subsidiaries and associated companies

Does the Company have subsidiaries and associated : Yes  
companies

Mechanism for overseeing subsidiaries and associated : Yes  
companies

Mechanism for overseeing management and taking : The appointment of representatives as directors,  
responsibility for operations in subsidiaries and associated executives, or controlling persons in proportion to  
companies approved by the board of directors shareholding, Disclosure of financial condition and  
operating results, Transactions between the company  
and related parties, Other significant transactions

The company has a governance and oversight mechanism for its subsidiaries and affiliated companies by appointing representatives, who are either directors or executives of the company, to serve as directors in all subsidiaries and affiliated companies. This ensures proper supervision and alignment of business operations with the company's core policies while safeguarding the best interests of the subsidiaries and affiliated companies.

#### 8.1.4 The monitoring of compliance with corporate governance policy and guidelines

##### Prevention of conflicts of interest

##### Operations for conflict of interest prevention over the past year

Has the company operated in preventing conflicts of : Yes

interest over the past year

The company recognizes the importance of conducting business with integrity, transparency, and accountability, adhering to good corporate governance principles to enhance organizational efficiency. To ensure fair business operations and prevent conflicts of interest, the company has established a Conflict of Interest Prevention Policy, along with strict operational guidelines as follows:

- The company shall not provide loans or guarantees to directors or businesses in which a director holds more than 50% of shares, except as part of company benefits.
- Directors shall not engage in businesses that compete with the company unless approved by the shareholders' meeting before their appointment.
- Directors and executives must not exploit company opportunities or confidential information for personal or third-party benefit, including engaging in competitive or related businesses.
- Directors and executives must not participate in discussions or voting on matters that involve them and could create a conflict of interest with the company. If a transaction is necessary for the company's benefit, it must be conducted on an Arm's Length Basis as if dealing with an external party.
- Directors and executives must disclose any personal interest in contracts entered into by the company.
- Directors and executives must submit an annual disclosure report on conflicts of interest or whenever a new situation arises.
- Transactions involving the purchase or sale of goods, assets, or other items between a director and the company must be disclosed and approved by the Board of Directors.
- Independent directors must be involved in reviewing and approving conflict-of-interest matters to ensure fair decision-making.
- Directors, executives, and employees who have access to internal information must refrain from misusing such information for personal gain or improperly disclosing it to others.

Ensuring Transparency in Related Transactions, the company places great importance on ensuring transparency and prioritizing the company's best interests when evaluating transactions that may involve conflicts of interest. The company has established the following preventive principles for related-party transactions and intercompany dealings:

1. Directors and executives must disclose to the company any relationships or related transactions that may create a conflict of interest.
2. Avoid engaging in transactions with directors, executives, or related parties that may lead to conflicts of interest with the company. If such transactions are necessary, they must be submitted to the Audit Committee for review before seeking approval from the Board of Directors or the shareholders' meeting (as applicable), in accordance with Securities and Exchange Commission (SEC) and Stock Exchange of Thailand (SET) regulations and good corporate governance principles.

3. Executives and employees must strictly adhere to company regulations and business ethics, ensuring the company maintains its credibility and trustworthiness among all stakeholders. The company actively promotes awareness and compliance among employees through company-wide communication and training.

The company enforces these policies and practices rigorously and transparently to prevent conflicts of interest, ensuring that all business activities are conducted responsibly and in line with the highest ethical standards to build trust among all stakeholders.

#### Number of cases or issues related to conflict of interest

|                                                                         | 2023 | 2024 | 2025 |
|-------------------------------------------------------------------------|------|------|------|
| Total number of cases or issues related to conflict of interest (cases) | 0    | 0    | 0    |

### Prevention of the use of inside information to seek benefits

#### Operations for prevention of the use of inside information to seek benefits over the past year

Has the company operated in preventing the use of inside : Yes

information to seek benefits over the past year

The company conducts its business with a strong focus on shareholders, investors, stakeholders, the economy, and society. To ensure proper governance, the company enforces strict oversight of directors, sub-committee members, executives, and employees in handling non-public internal information and preventing its misuse for personal gain. This is in compliance with the Securities and Exchange Act B.E. 2535 (1992) (including amendments) and the Stock Exchange of Thailand (SET) regulations on information disclosure for listed companies.

Furthermore, the company has implemented an Internal Information Usage Policy, serving as a guideline for managing internal information to ensure that directors, executives, and employees understand and comply with the correct procedures. Over the past year, the company has actively monitored the use of internal information through corporate governance measures, which include: restricting the number of individuals with access to internal information, defining access levels to company information to enhance data security, implementing secure data storage and processing systems. Requiring employees to sign confidentiality agreements, informing directors and executives of their responsibilities regarding internal information handling. These measures reinforce the company's commitment to transparency, data security, and regulatory compliance in managing sensitive corporate information.

#### Number of cases or issues related to the use of inside information to seek benefits

|                                                                                                   | 2023 | 2024 | 2025 |
|---------------------------------------------------------------------------------------------------|------|------|------|
| Total number of cases or issues related to the use of inside information to seek benefits (cases) | 0    | 0    | 0    |

### Anti-corruption action

#### Operations in anti-corruption in the past year

Has the company operated in anti-corruption over the : Yes

past year

Form of operations in anti-corruption : Review of appropriateness in anti-corruption

The company has established an Anti-Corruption and Fraud Policy as a guideline for conducting business with integrity, emphasizing responsibility towards society and all stakeholders. This policy is implemented within the framework of good corporate governance and ethical business practices, ensuring transparency, strong internal controls, and audit mechanisms to minimize opportunities for fraud and corruption within the organization. To demonstrate its commitment to fighting corruption in all forms, as previously outlined in Section 6.1.2: Policies and Practices Regarding Shareholders and Stakeholders, the company requires that directors, sub-committee members, executives, and employees perform their duties without abusing their authority directly or indirectly for personal gain or for the benefit of others through fraudulent means. This includes refraining from soliciting, engaging in, or facilitating corruption in any form that results in undue benefits. The company actively communicates and provides training on its anti-corruption policies and practices to directors, sub-committee members, executives, and employees. Additionally, it has established whistleblowing and complaint channels to report suspected fraudulent or corrupt activities, with confidentiality and protection measures for whistleblowers. If the company detects any bribery, fraud, or corruption, or if any individual is found to have violated the anti-corruption policy, such actions will be considered a serious violation of company regulations and will be subject to disciplinary action. If the act is illegal, the violator may also face legal consequences. As of December 31, 2024, the company has not received any reports of bribery, fraud, or corruption.

#### Number of cases or issues related to corruption

|                                                               | 2023 | 2024 | 2025 |
|---------------------------------------------------------------|------|------|------|
| Total number of cases or issues related to corruption (cases) | 0    | 0    | 0    |

## Whistleblowing

#### Operations related to whistleblowing over the past year

Has the company implemented whistleblowing : Yes  
procedures over the past year

The company has established a policy on complaints and whistleblowing regarding misconduct, applicable to directors, members of sub-committees, executives, employees, customers, contractors, and stakeholders. The company has set up a reliable process, methods, and channels for employees, customers, contractors, and stakeholders to report any misconduct or wrongdoing they have witnessed or become aware of. Such misconduct may involve directors, sub-committee members, executives, employees, representatives, or agents of the company. Additionally, the company has implemented a policy to protect whistleblowers, witnesses, and other informants from disciplinary actions or other adverse consequences from supervisors or executives. All complaints or whistleblowing reports must be made in good faith and must not be intended as retaliation or malicious accusations. The Board of Directors has established channels for reporting concerns or complaints from stakeholders who believe they have been affected by the company's operations or have witnessed employees engaging in fraud or illegal activities. Reports can be submitted through the following channels:

#### (1) Internal Reporting Channels:

Channel 1: Report directly to the supervisor in the chain of command and/or the department responsible for overseeing compliance with the company's code of conduct and ethical standards.

Channel 2: Suggestion Box.

Channel 3: Email: [auditcommittee@bangkokgenomics.com](mailto:auditcommittee@bangkokgenomics.com).

#### (2) External Reporting Channels:

Channel 1: By mail, addressed to:

Chairman of the Audit Committee

Bangkok Genomics Innovation Public Company Limited

3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei District, Bangkok 10110, Thailand

Channel 2: By email: [auditcommittee@bangkokgenomics.com](mailto:auditcommittee@bangkokgenomics.com).

Since the implementation of the whistleblowing policy until December 31, 2024, the company has not received any reports of misconduct or wrongdoing.

**Number of cases or issues related to whistleblowing**

|                                                                                  | 2023 | 2024 | 2025 |
|----------------------------------------------------------------------------------|------|------|------|
| Total number of cases or issues received through whistleblowing channels (cases) | 0    | 0    | 0    |



## 8.2 Report on the results of duty performance of the audit committee in the past year

### 8.2.1 Meeting attendance of audit committee

Meeting attendance of audit committee (times) : 4

| List of Directors                                                | Meeting attendance of audit committee |   |                                  | Average percentage meeting attendance |
|------------------------------------------------------------------|---------------------------------------|---|----------------------------------|---------------------------------------|
|                                                                  | Meeting attendance (times)            | / | Meeting attendance right (times) |                                       |
| 1. Mr. VICHATE TANTIWANICH<br>(Chairman of the audit committee)  | 4                                     | / | 4                                | 4/4<br>(100.00%)                      |
| 2. Mr. VICHYA KREANGAM<br>(Member of the audit committee)        | 4                                     | / | 4                                | 4/4<br>(100.00%)                      |
| 3. Mr. JEDSADA CHOKDAMRONGSUK<br>(Member of the audit committee) | 4                                     | / | 4                                | 4/4<br>(100.00%)                      |
| Average Attendance Rate                                          |                                       |   |                                  | 100.00%                               |

### 8.2.2 The results of duty performance of the audit committee

For the year 2025, ended 31 December 2025, the Audit Committee has fully performed its duties as assigned. The Committee has overseen the Company's risk management processes to ensure appropriateness and alignment with the evolving business environment. In addition, the Committee has reviewed the adequacy of the internal control system and continuously monitored the remediation of identified deficiencies.

The Audit Committee has reviewed significant transactions to ensure compliance with applicable laws and regulations. It has also overseen the establishment of appropriate, transparent, and auditable whistleblowing and complaint-handling mechanisms. The key activities and significant matters are summarized as follows:

1. Reviewed and examined the Company's quarterly and annual financial statements to ensure compliance with applicable accounting standards and financial reporting standards issued and revised by the Federation of Accounting Professions, as well as ensuring adequate, accurate, complete, and timely disclosure of material information for decision-making purposes.

2. Reviewed related party transactions between the Company and its connected persons to ensure that such transactions were conducted under normal commercial terms, without any transfer of benefits, and in the best interest of the Company.

3. Reviewed the adequacy and effectiveness of the Company's internal control and internal audit systems. The Committee monitored the performance of the internal audit function to ensure independence, adherence to professional standards, and effectiveness in providing recommendations to ensure compliance with applicable laws, regulations, policies, and procedures, as well as providing reasonable assurance on the adequacy of the internal control system.

4. Reviewed the adequacy and appropriateness of the Company's risk management system in accordance with the COSO Enterprise Risk Management – Integrated Framework, covering strategic, financial, operational, and compliance risks, including environmental, reputational, and community-related risks.
5. Promoted and ensured compliance with good corporate governance principles. The Company has continuously adhered to the eight CG principles, including shareholders' rights and equitable treatment, stakeholder roles, disclosure and transparency, board responsibilities, internal control and risk management, prevention of conflicts of interest, business ethics and code of conduct, and anti-corruption policy. The Board has reviewed and updated the corporate governance policies and practices in accordance with the SEC's 2018 CG Code, which the Company has implemented effectively, with ongoing improvement plans.
6. Reviewed the Company's Code of Conduct and ethical standards applicable to directors, executives, and employees.
7. Promoted and ensured compliance with the Company's Anti-Corruption Policy by directors, executives, and employees.
8. Promoted and ensured that the Company complies with safety standards and maintains a healthy environment for the organization, surrounding communities, and society.
9. Considered and recommended the appointment of the external auditor and the appropriate audit fee for the year, namely Dr. Virach & Associates Office Co., Ltd.
10. Considered and recommended the appointment of the internal control auditor and the appropriate remuneration, namely P&L Internal Audit Co., Ltd.

In the opinion of the Audit Committee, the Company has established adequate and appropriate internal control, risk management, and corporate governance systems for its business operations. No material issues were identified that would affect the reliability of the financial statements or the Company's operations. The Company's financial statements have been prepared, in all material respects, in accordance with applicable accounting and financial reporting standards, with appropriate disclosure of related party transactions and potential conflicts of interest. The Company has also maintained an effective risk management system and complied with relevant laws and regulations, while adhering to good corporate governance principles.

## 8.3 Summary of the results of duty performance of subcommittees

### 8.3.1 - 8.3.2 Meeting attendance and the results of duty performance of subcommittees

#### Meeting attendance Executive Committee

Meeting Executive Committee (times) : 3

| List of Directors                                                       | Meeting attendance Executive Committee |   |                                  | Average Meeting Attendance |
|-------------------------------------------------------------------------|----------------------------------------|---|----------------------------------|----------------------------|
|                                                                         | Meeting attendance (times)             | / | Meeting attendance right (times) |                            |
| 1. Mr. GOANPOT ASVINVICHIT<br>(The chairman of the executive committee) | 3                                      | / | 3                                | 3 / 3<br>(100.00%)         |
| 2. Mr. PREECHA LAOHAPONGCHANA<br>(Member of the executive committee)    | 3                                      | / | 3                                | 3 / 3<br>(100.00%)         |
| 3. Mr. SUJIE CAO<br>(Member of the executive committee)                 | 3                                      | / | 3                                | 3 / 3<br>(100.00%)         |
| 4. Ms. SAOWALAK DANSAKUL<br>(Member of the executive committee)         | 3                                      | / | 3                                | 3 / 3<br>(100.00%)         |
| 5. Mr. XIAOHAN WANG<br>(Member of the executive committee)              | 3                                      | / | 3                                | 3 / 3<br>(100.00%)         |
| Average Meeting Attendance Rate                                         |                                        |   |                                  | 100.00%                    |

#### The results of duty performance of Executive Committee

The Executive Committee has performed its duties as assigned effectively by overseeing and monitoring the Company's operations to ensure alignment with the policies, business plans, and strategies set by the Board of Directors, while optimizing the use of the Company's resources in accordance with its objectives. The Committee has regularly considered key matters, including the review of annual targets and business plans, monitoring quarterly performance, providing recommendations on management plans, as well as closely monitoring business conditions and market competition.

In addition, the Executive Committee has placed importance on risk management and ensuring that the internal control system is appropriate and adequate. It has also promoted sustainable business development through supporting

innovation, developing products and services, and enhancing operational efficiency, while taking into account all stakeholders in a fair and balanced manner. The Executive Committee is of the opinion that the Company's operations have been conducted in accordance with the established plans and objectives and have supported the Company's continuous growth.

## 9. Internal control and related party transactions

### 9.1 Internal control

#### Summary of the opinion of the board of directors regarding the internal control of the company

The Board of Directors has assessed the adequacy of the Company's internal control system by considering the internal control evaluation form in accordance with the guidelines of the Office of the Securities and Exchange Commission (SEC), together with inquiries made with the management and the review of relevant reports, in order to ensure that the Company has an appropriate and adequate internal control system for its business operations.

Such assessment is based on the framework of the Committee of Sponsoring Organizations of the Treadway Commission (COSO), which comprises five key components as follows:

- Control Environment
- Risk Assessment
- Control Activities
- Information and Communication
- Monitoring Activities

The Board of Directors is of the opinion that the Company has an adequate and appropriate internal control system for its business operations. The Company has established an appropriate organizational structure, systems, and sufficient personnel to effectively implement such internal control system. This supports the Company's operations in accordance with good corporate governance principles, ensuring transparency and accountability.

In addition, the Company has established continuous monitoring and evaluation processes to ensure that its assets are safeguarded against unauthorized or improper use. The Company also has appropriate control measures in place for transactions that may give rise to conflicts of interest, including connected transactions, to ensure compliance with applicable laws and regulations.

In this regard, the Board of Directors has not identified any material weaknesses in the Company's internal control system.

#### 9.1.1 Adequacy and appropriateness of the company's internal control system

Company's internal control system : The Committee of Sponsoring Organizations of the  
Treadway Commission (COSO)

#### The Committee of Sponsoring Organizations of the Treadway Commission (COSO)

The company has considered and assessed the adequacy of its internal control system based on the internal control adequacy evaluation framework of the Securities and Exchange Commission (SEC). Additionally, the company has conducted inquiries with management to evaluate the internal control system across various aspects, following the guidelines of The Committee of Sponsoring Organizations of the Treadway Commission ("COSO"), which includes the following:

1. Control Environment
2. Risk Assessment
3. Control Activities
4. Information and Communication
5. Monitoring Activities

#### 9.1.2 Deficiencies related to the internal control system

|                                                                             | 2023 | 2024 | 2025 |
|-----------------------------------------------------------------------------|------|------|------|
| Total number of deficiencies related to the internal control system (cases) | 0    | 0    | 0    |

### 9.1.3 Opinions of the audit committee and auditor's observations on internal control

Does the audit committee have opinions on internal : No  
control different from the board of directors' opinions?

Does the auditor have any observations on the company's : No  
internal control?

### 9.1.4 Opinions of the audit committee on the position of the head of the internal audit unit

Head of the internal audit unit : Outsourced service

At the Audit Committee meeting on February 14, 2024, the committee resolved to appoint P&L Internal Audit Co., Ltd. and P&L IT Audit Co., Ltd. as the company's internal auditors for the year 2024. These two companies designated Ms. Wannawimon Jongsuriyaphas, an executive director, as the primary person responsible for conducting the company's internal audit operations.

The Audit Committee reviewed the qualifications of both companies and Ms. Wannawimon Jongsuriyaphas and found them highly suitable for the role. The evaluation was based on key factors, including independence in performing duties, extensive experience in internal auditing, as well as relevant professional training and certifications, such as the Internal Auditing Certificate Program (IACP) from the Federation of Accounting Professions under the Royal Patronage of His Majesty the King and the Certified Professional Internal Auditor of Thailand (CPIAT) from the Institute of Internal Auditors of Thailand (IIAT).

Additionally, the committee resolved that any appointment, dismissal, or transfer of the head of the internal audit unit must receive approval or endorsement from the Audit Committee. Further details regarding the qualifications of the internal audit head are provided in Enclosure 3.

### 9.1.5 Appointment, discharge, and transfer of the head of the internal audit unit

Does the appointment, discharge, and transfer of the head : Yes  
of the internal audit unit require the audit committee  
approval?

The Audit Committee is responsible for overseeing that the Company has an effective and independent internal audit function. The guidelines for considering the appointment of the internal auditor are as follows:

#### 1. Qualifications and Independence

The Audit Committee shall consider the qualifications of the internal auditor to ensure that he/she possesses appropriate knowledge, competence, and experience, and is able to perform duties independently without any conflict of interest with the Company.

#### 2. Recruitment and Selection Process

The recruitment of the internal auditor may be carried out through the appointment of internal personnel or the engagement of an external service provider. The Audit Committee shall consider the appropriateness of the Company's organizational structure, business size, and operational complexity.

#### 3. Appointment, Transfer, and Termination

The Audit Committee has the authority to approve the appointment, transfer, or termination of the Head of Internal Audit to ensure independence and freedom from management influence.

#### 4.Scope of Duties and Responsibilities

The Audit Committee shall define and review the scope of duties and responsibilities of the internal audit function to ensure coverage of internal control systems, risk management, and good corporate governance.

#### 5.Reporting and Oversight

The internal auditor shall report audit results directly to the Audit Committee on a regular basis and shall have the authority to meet with the Audit Committee independently to report significant matters without management presence.

#### 6.Performance Evaluation

The Audit Committee shall regularly evaluate the performance of the internal auditor to ensure that the internal audit function operates effectively, complies with professional standards, and supports the Company's corporate governance.

## 9.2 Related party transactions

### Related party transactions

Does the company have any related party transactions? : Yes

### 9.2.1 - 9.2.2 Names of the group of persons who may have a conflict of interest, nature of relationship, and information on related party transactions

#### Persons/entities with potential conflicts

| Name of person or entity/type of business                                                                                                               | Nature of relationship                                                                                                                                          | Information as of date |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| BGI Health (Hong Kong) Co.,Ltd<br>Genetic testing services, including research and development in physical and commercial biotechnology                 | <ul style="list-style-type: none"><li>• Shareholders (holding 37.40 percent of the company's shares)</li><li>• 100.00% owned by BGI Genomics Co., Ltd</li></ul> | 31 Dec 2025            |
| BGI Tech Solutions (Hong Kong) Company Limited<br>Genetic testing services, including research and development in physical and commercial biotechnology | <ul style="list-style-type: none"><li>• Joint shareholder (shares held by BGI Health (HK) Co., Ltd.)</li></ul>                                                  | 31 Dec 2025            |



| Name of person or entity/type of business                                                                                                        | Nature of relationship                                                                                                                                                | Information as of date |
|--------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| <p>BGI Health (AU) Co.,Ltd</p> <p>Genetic testing services, including research and development in physical and commercial biotechnology</p>      | <ul style="list-style-type: none"> <li>Joint shareholder (shares held by BGI Health (HK) Co., Ltd.)</li> </ul>                                                        | <p>31 Dec 2025</p>     |
| <p>Thai Omics Company Limited</p> <p>Provision of services related to genomic medicine</p>                                                       | <ul style="list-style-type: none"> <li>Joint directors</li> </ul>                                                                                                     | <p>31 Dec 2025</p>     |
| <p>MGI Tech Singapore Pte. Ltd.</p> <p>Genetic testing services, including research and development in physical and commercial biotechnology</p> | <ul style="list-style-type: none"> <li>Common shareholder (Mr. Wang Jian, who is the Ultimate Shareholder as well as the Company, holds shares indirectly)</li> </ul> | <p>31 Dec 2025</p>     |

| Name of person or entity/type of business                                                                                                 | Nature of relationship                                                                                                               | Information as of date |
|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| Krung Thai Tractor Company Limited<br>Sale of tractors, hydraulic excavators, wheel loaders, air compressors and various spare parts      | <ul style="list-style-type: none"> <li>Shareholders are individuals who have a relationship with the company's directors.</li> </ul> | 31 Dec 2025            |
| Shenzhen Zaozhidao Technology Co.,Ltd.<br>Technological technique development                                                             | <ul style="list-style-type: none"> <li>Common shareholder (shares held by BGI Genomics Co., Ltd)</li> </ul>                          | 31 Dec 2025            |
| BGI Bio Solutions (Hong Kong) Co., Ltd.<br>Analytical services, genetics, and commercial physical and biological research and development | <ul style="list-style-type: none"> <li>Common shareholder (shares held indirectly by BGI Genomics Co., Ltd.)</li> </ul>              | 31 Dec 2025            |

| Name of person or entity/type of business                                                                              | Nature of relationship | Information as of date |
|------------------------------------------------------------------------------------------------------------------------|------------------------|------------------------|
| Omicsphere Company Limited<br>Distributor of scientific medical device, equipment and chemicals used in laboratories.  | • SUBSIDIARIES         | 31 Dec 2025            |
| Comprehensive Care Limited<br>Business related to medical technology, advanced medical products, and-related equipment | • SUBSIDIARIES         | 31 Dec 2025            |
| Biovision Tech Company Limited<br>Operate as a consultancy service provider for businesses.                            | • Subsidiaries         | 31 Dec 2025            |

| Name of person or entity/type of business                                                                                             | Nature of relationship                                                                                                  | Information as of date |
|---------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|------------------------|
| BGI Health (Hungary) Co.,Ltd<br>Genetic testing services, including research and development in physical and commercial biotechnology | <ul style="list-style-type: none"> <li>Joint shareholder (shares held by BGI Health (HK) Co., Ltd.)</li> </ul>          | 31 Dec 2025            |
| BGI Genomics UK Limited<br>Genetic testing services, including research and development in physical and commercial biotechnology      | <ul style="list-style-type: none"> <li>Joint shareholders (shares held by BGI Genomics Co., Ltd. indirectly)</li> </ul> | 31 Dec 2025            |
| Krung Thai Land Development Company Limited<br>Real Estate Development                                                                | <ul style="list-style-type: none"> <li>Joint director</li> </ul>                                                        | 31 Dec 2025            |
| Genovation Co., Ltd.<br>Health Analytics Management, Health Check                                                                     | <ul style="list-style-type: none"> <li>Joint directors</li> </ul>                                                       | 31 Dec 2025            |

| Name of person or entity/type of business                                                           | Nature of relationship                                       | Information as of date |
|-----------------------------------------------------------------------------------------------------|--------------------------------------------------------------|------------------------|
| Pure Select Company Limited<br>Establish a retail store selling pharmaceutical and medical supplies | • Joint director                                             | 31 Dec 2025            |
| Compound Assets Co.,Ltd.<br>Real Estate Development                                                 | • Joint shareholders                                         | 31 Dec 2025            |
| BGI College<br>Educational institutions provide training.                                           | • Joint shareholders (shares held by BGI Shenzhen Co., Ltd.) | 31 Dec 2025            |
| BGI Specialized Medical solution<br>DMCC<br>Manufacture and distribution of protein products        | • Joint shareholders                                         | 31 Dec 2025            |
| BGI Precision Nutrition Trade Development (Shenzhen) Co., Ltd.<br>Food product import and export    | • Joint shareholders                                         | 31 Dec 2025            |

| Name of person or entity/type of business                                                         | Nature of relationship | Information as of date |
|---------------------------------------------------------------------------------------------------|------------------------|------------------------|
| Edge Medical (Thailand) Co., Ltd.<br>Distributor of medical equipment related to robotic surgery. | • Associate            | 31 Dec 2025            |

#### Details of related party transactions

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Transaction value at the end of the fiscal year (million baht) |       |       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|-------|-------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2023                                                           | 2024  | 2025  |
| BGI Health (Hong Kong) Co.,Ltd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                |       |       |
| <b>Transaction 1</b><br><br><u>Nature of transaction</u><br><br>Purchase Products<br><br><u>Details</u><br><br>The company procures products from BGI Health (HK), with the majority being reagents for laboratory services.<br><br><u>Necessity/reasonableness</u><br><br>The Company purchases goods from BGI Health (HK), primarily reagents for laboratory services, which are standard catalog items. The purchase price for these goods is as stipulated in the contract, which is comparable to prices offered by BGI Health (HK) to other customers, taking into consideration market competition.<br><br><u>Audit committee's opinion</u> | 50.30                                                          | 80.93 | 96.70 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Transaction value at the end of the fiscal year (million baht) |      |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2023                                                           | 2024 | 2025 |
| <p>The Audit Committee has reviewed and is of the opinion that the said list is in accordance with general commercial practices. The purchase price of such goods is as stipulated in the contract and is comparable to the price at which BGI Health (HK) sells to other customers, taking into account additional market competition, which is beneficial and reasonable to the Company.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                |      |      |
| <p><b>Transaction 2</b></p> <p>0.99</p> <p>1.31</p> <p>1.84</p> <p><u>Nature of transaction</u></p> <p>Analysis Service Fee</p> <p><u>Details</u></p> <p>The company, namely BGI Health (HK), is under investigation.</p> <p><u>Necessity/reasonableness</u></p> <p>The Company clarifies that BGI Health (HK) is a service provider for analysis. In accordance with general business practices, the Company sends samples or DNA of its customers to BGI Health (HK) for analysis. The service fee is specified in the contract between the BGI Group and the Company.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the aforementioned list is in accordance with general commercial practices. The service fees specified in the agreement between the BGI Group and the Company's subsidiaries are comparable to prices offered by BGI Health (HK) to other customers, taking into account market competition. This arrangement is beneficial and reasonable for the Company.</p> |                                                                |      |      |
| <p><b>Transaction 3</b></p> <p>10.31</p> <p>18.62</p> <p>68.36</p> <p><u>Nature of transaction</u></p> <p>Trade creditor</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                |      |      |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Transaction value at the end of the fiscal year (million baht) |      |      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 2023                                                           | 2024 | 2025 |
| <p><u>Details</u></p> <p>The company procures products from BGI Health (HK), with the majority being reagents for laboratory services.</p> <p><u>Necessity/reasonableness</u></p> <p>The Company purchases goods from BGI Health (HK), primarily reagents for laboratory services, which are standard catalog items. The purchase price of such goods is the price stipulated in the contract, which is comparable to the price that BGI Health (HK) sells to other customers, taking into account market competition.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the said list is in accordance with general commercial practices. The purchase price of such goods is as stipulated in the contract and is comparable to the price at which BGI Health (HK) sells to other customers, taking into account additional market competition, which is beneficial and reasonable to the Company.</p> |                                                                |      |      |
| <p><b>Transaction 4</b></p> <p>0.00                      4.58                      5.44</p> <p><u>Nature of transaction</u></p> <p>Prepaid Expense</p> <p><u>Details</u></p> <p>The company purchased machine maintenance services (Warranty Sequencer).</p> <p><u>Necessity/reasonableness</u></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                |      |      |



| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Transaction value at the end of the fiscal year (million baht) |      |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 2023                                                           | 2024 | 2025 |
| <p>The company procured maintenance services (Warranty Sequencer) for equipment used within the laboratory. This procurement was conducted as a standard commercial transaction. The purchase price for these services aligns with the terms specified in the contract and is comparable to prices offered by BGI Health (HK) to other customers, taking into account market competition.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the said list is in accordance with general commercial practices. The purchase price of such goods is the price stipulated in the contract and is comparable to the price at which BGI Health (HK) sells to other customers, taking into account additional market competition, which is beneficial and reasonable to the Company.</p> |                                                                |      |      |
| <p><b>Transaction 5</b></p> <p><u>Nature of transaction</u></p> <p>NIFTY PRO and NIFTY FOCUS Screening Test Costs &amp; Insurance Coverage</p> <p><u>Details</u></p> <p>The company pays insurance premiums for the test result guarantee of NIFTY chromosomal analysis services to BGI Health (HK).</p> <p><u>Necessity/reasonableness</u></p> <p>The company pays insurance premiums for the test result guarantee of NIFTY chromosomal analysis services to BGI Health (HK). These premiums are comparable to those charged by BGI Health (HK) to other customers, considering additional market competition factors.</p> <p><u>Audit committee's opinion</u></p>                                                                                                                                                                        | 5.80                                                           | 6.21 | 5.16 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Transaction value at the end of the fiscal year (million baht) |      |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 2023                                                           | 2024 | 2025 |
| <p>The Audit Committee has reviewed and concluded that the transaction is in line with normal commercial terms. The service fees are comparable to those charged by BGI Health (HK) to other customers, taking into account additional market competition. This allows the company to remain competitive with other service providers in Thailand, benefiting the company and ensuring reasonableness.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                |      |      |
| <p><b>Transaction 6</b></p> <p><u>Nature of transaction</u></p> <p>Warranty Sequencer</p> <p><u>Details</u></p> <p>The company purchased machine maintenance services (Warranty Sequencer).</p> <p><u>Necessity/reasonableness</u></p> <p>The company procured maintenance services (Warranty Sequencer) for equipment used within the laboratory. This procurement was conducted as a standard commercial transaction. The purchase price for these services aligns with the terms specified in the contract and is comparable to prices offered by BGI Health (HK) to other customers, taking into account market competition</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the said list is in accordance with general commercial practices. The purchase price of such goods is the price stipulated in the contract and is comparable to the price at which BGI Health (HK) sells to other customers, taking into account additional market competition, which is beneficial and reasonable to the Company.</p> | 0.00                                                           | 2.83 | 5.26 |
| <p><b>Transaction 7</b></p> <p><u>Nature of transaction</u></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 2.68                                                           | 3.00 | 2.95 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Transaction value at the end of the fiscal year (million baht) |      |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 2023                                                           | 2024 | 2025 |
| <p>Purchased Assets</p> <p><u>Details</u></p> <p>The company purchases laboratory instruments and equipment from BGI Health (HK) for use in its business operations.</p> <p><u>Necessity/reasonableness</u></p> <p>The company purchases laboratory instruments and equipment from BGI Health (HK) for its business operations. The acquisition of these assets is conducted under standard commercial terms.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and concluded that this transaction is in line with normal commercial terms. The purchase price of the assets is comparable to the price that BGI Health (HK) charges other customers, which benefits the company and is deemed reasonable.</p> |                                                                |      |      |
| <p><b>Transaction 8</b></p> <p><u>Nature of transaction</u></p> <p>Fixed Asset Payable</p> <p><u>Details</u></p> <p>The Company has outstanding payables for asset acquisition from BGI Health (HK) for laboratory equipment to support operations and enhance laboratory efficiency.</p> <p><u>Necessity/reasonableness</u></p> <p>The company purchases laboratory instruments and equipment from BGI Health (HK) for use in its business operations.</p> <p><u>Audit committee's opinion</u></p>                                                                                                                                                                                                                                           | 0.00                                                           | 0.00 | 2.63 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Transaction value at the end of the fiscal year (million baht) |      |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 2023                                                           | 2024 | 2025 |
| <p>The Audit Committee has reviewed and concluded that this transaction is in line with normal commercial terms. The purchase price of the assets is comparable to the price that BGI Health (HK) charges other customers, which benefits the company and is deemed reasonable.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                |      |      |
| <p><b>Transaction 9</b></p> <p>0.00</p> <p>0.00</p> <p>5.88</p> <p><u>Nature of transaction</u></p> <p>Purchased Intangible Assets</p> <p><u>Details</u></p> <p>The Company acquired intangible assets from BGI Health (HK) as project development costs</p> <p><u>Necessity/reasonableness</u></p> <p>The Company acquired intangible assets from BGI Health (HK) as project development costs, with terms and conditions following general commercial practices</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and concluded that this transaction is in line with normal commercial terms. The purchase price of the assets is comparable to the price that BGI Health (HK) charges other customers, which benefits the company and is deemed reasonable.</p> |                                                                |      |      |
| <p><b>Transaction 10</b></p> <p>2.69</p> <p>0.00</p> <p>0.00</p> <p><u>Nature of transaction</u></p> <p>Revenue from sales and services</p> <p><u>Details</u></p> <p>The company provides chromosome screening services, specifically NIFTY Pro and NIFTY Focus, to BGI Health (HK). BGI Health (HK) sends test samples or DNA from its customers to the company.</p> <p><u>Necessity/reasonableness</u></p>                                                                                                                                                                                                                                                                                                                                                                                      |                                                                |      |      |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Transaction value at the end of the fiscal year (million baht) |      |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 2023                                                           | 2024 | 2025 |
| <p>The company provides chromosome screening services, specifically NIFTY Pro and NIFTY Focus, to BGI Health (HK)</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and opined that the transaction is in line with general commercial practices. The service rates are in accordance with the rates specified in the contract that the company provides to customers within the BGI group.</p>                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                |      |      |
| <p><b>Transaction 11</b></p> <p>0.05                      0.00                      0.00</p> <p><u>Nature of transaction</u></p> <p>Trade receivables</p> <p><u>Details</u></p> <p>The company provides chromosome screening services, specifically NIFTY Pro and NIFTY Focus, to BGI Health (HK). BGI Health (HK) sends test samples or DNA from its customers to the company.</p> <p><u>Necessity/reasonableness</u></p> <p>The company provides chromosome screening services, specifically NIFTY Pro and NIFTY Focus, to BGI Health (HK)</p> <p><u>Audit committee's opinion</u></p> <p>.The Audit Committee has reviewed and opined that the transaction is in line with general commercial practices. The service rates are in accordance with the rates specified in the contract that the company provides to customers within the BGI group.</p> |                                                                |      |      |
| <p><b>Transaction 12</b></p> <p>0.01                      0.29                      0.01</p> <p><u>Nature of transaction</u></p> <p>Other income</p> <p><u>Details</u></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                |      |      |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Transaction value at the end of the fiscal year (million baht) |      |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 2023                                                           | 2024 | 2025 |
| <p>The company has other revenue from providing conference organizing services. In 2022, it received a donation of inventory following Thailand's role as the host of the Asia-Pacific Economic Cooperation (APEC) conference in Q4 2022. During the conference, the BGI Group was exclusively appointed by the People's Republic of China as the COVID-19 testing provider for the delegates. After the conference, the BGI Group had leftover COVID-19 testing reagents from its operations and subsequently donated them to the company.</p> <p><u>Necessity/reasonableness</u></p> <p>The company has other revenue from BGI Health (HK), which is not derived from its core business and opined that the transaction is in line with general commercial practices.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and opined that the transaction is beneficial to the company and is reasonable.</p> |                                                                |      |      |
| <p><b>Transaction 13</b></p> <p><u>Nature of transaction</u></p> <p>Other current receivable</p> <p><u>Details</u></p> <p>Other receivables arise from the company's conference organizing services and insurance claim receivables and opined that the transaction is in line with general commercial practices.</p> <p><u>Necessity/reasonableness</u></p> <p>Other receivables from other income include insurance claim receivables.</p> <p><u>Audit committee's opinion</u></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1.49                                                           | 8.57 | 9.64 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Transaction value at the end of the fiscal year (million baht) |      |      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 2023                                                           | 2024 | 2025 |
| The Audit Committee has reviewed and opined that the transaction is beneficial to the company and is reasonable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                |      |      |
| BGI Tech Solutions (Hong Kong) Company Limited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                |      |      |
| <b>Transaction 1</b><br><br><u>Nature of transaction</u><br><br>Technology Services<br><br><u>Details</u><br><br>The company has contracted BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for studying genetic information, offering services to researchers involved in various projects.<br><br><u>Necessity/reasonableness</u><br><br>The company has contracted BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for studying genetic information, offering services to researchers involved in various projects. This is a transaction based on general trade practices, as it is a specialized service. The service price is determined based on the specifics of each project. The company uses a pricing policy for services provided to customers, calculating the price based on the total service cost plus a markup according to the company's policy.<br><br><u>Audit committee's opinion</u><br><br>The Audit Committee has reviewed and concluded that the transaction is in line with general business practices, with the pricing comparable to that of other clients served by BGI Tech Solutions (Hong Kong) Co., Ltd. The transaction is considered beneficial to the company and reasonable. | 3.36                                                           | 2.89 | 3.64 |
| <b>Transaction 2</b><br><br><u>Nature of transaction</u>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.13                                                           | 0.01 | 0.43 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Transaction value at the end of the fiscal year (million baht) |      |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 2023                                                           | 2024 | 2025 |
| <p>Account Payables and Accrued expense</p> <p><u>Details</u></p> <p>The company has engaged BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for the study of genetic information, in order to serve researchers involved in various projects.</p> <p><u>Necessity/reasonableness</u></p> <p>The company has engaged BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for genetic information studies, offering these services to researchers in various projects. This transaction is in line with general business practices, as it involves a specialized service. The pricing for these services is determined based on the specifics of each project. The company follows a pricing policy that calculates the service cost by adding a markup to the total service cost, in accordance with the company's profit margin policy.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and concluded that the transaction is in line with standard commercial practices, with pricing comparable to that charged by BGI Tech Solutions (Hong Kong) Co., Ltd. for services provided to other clients. This is considered beneficial to the company and reasonable.</p> |                                                                |      |      |
| <p><b>Transaction 3</b></p> <p><u>Nature of transaction</u></p> <p>Prepaid Expense</p> <p><u>Details</u></p> <p>The company has contracted BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for the study of genetic data, aimed at supporting researchers in various projects.</p> <p><u>Necessity/reasonableness</u></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.00                                                           | 0.60 | 0.60 |



| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Transaction value at the end of the fiscal year (million baht) |      |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2023                                                           | 2024 | 2025 |
| <p>The company has engaged BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for the study of genetic data, which will support researchers in various projects. This transaction falls under standard commercial practices, as it is a specialized service. The pricing for these services is determined based on the specific details of each project. The company applies a pricing policy that calculates the service price based on the total service cost plus a markup percentage, in accordance with the company's established pricing guidelines.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that this transaction is in line with standard commercial practices, with pricing comparable to that charged by BGI Tech Solutions (Hong Kong) Co., Ltd. to other customers. This is deemed beneficial and reasonable for the company.</p> |                                                                |      |      |
| BGI Health (AU) Co.,Ltd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                |      |      |
| <p><b>Transaction 1</b></p> <p>0.03</p> <p>0.05</p> <p>0.00</p> <p><u>Nature of transaction</u></p> <p>Service income</p> <p><u>Details</u></p> <p>The company provides DNALL analysis services to BGI Health (AU), where BGI Health (AU) sends samples or DNA from their clients to the company for analysis.</p> <p><u>Necessity/reasonableness</u></p> <p>The company provides DNALL analysis services to BGI Health (AU), where BGI Health (AU) sends samples or DNA from their clients to the company for analysis. The service rate for this is in accordance with the terms outlined in the contract between the company and other entities within the BGI group.</p>                                                                                                                                                                                                                                                          |                                                                |      |      |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Transaction value at the end of the fiscal year (million baht) |      |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2023                                                           | 2024 | 2025 |
| <u>Audit committee's opinion</u><br><br>The Audit Committee has reviewed and is of the opinion that the service provided is beneficial to the company and reasonable. Although the service rate is lower than the rate charged to external customers, the company still makes a profit. Additionally, gaining more clients will help enhance overall business growth.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                |      |      |
| Thai Omics Company Limited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                |      |      |
| <b>Transaction 1</b><br><br><u>Nature of transaction</u><br><br>Purchase Products<br><br><u>Details</u><br><br>The company purchases goods from Thai Omics Co., Ltd., with products for PGT-A testing, which are common trade items.<br><br><u>Necessity/reasonableness</u><br><br>The Company purchases goods from Thai Omics Co., Ltd., including consumables such as films and microtiter plates used in the laboratory for PGT-A testing. These are standard commercial items. The purchase price of such goods is as specified in the contract, which is comparable to the price that Thai Omics Co., Ltd. sells to other customers, taking into account market competition.<br><br><u>Audit committee's opinion</u><br><br>The Audit Committee has reviewed and is of the opinion that the said list is in accordance with general commercial practices. The purchase price of such goods is the price stipulated in the contract and is comparable to the price at which BGI Health (HK) sells to other customers, taking into account additional market competition, which is beneficial and reasonable to the Company. | 0.03                                                           | 0.71 | 0.00 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Transaction value at the end of the fiscal year (million baht) |      |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2023                                                           | 2024 | 2025 |
| <b>Transaction 2</b><br><br><u>Nature of transaction</u><br><br>Analysis Service Fee<br><br><u>Details</u><br><br>The Company hired Thai Omics Co., Ltd. to provide genetic testing services to study genetic information.<br><br><u>Necessity/reasonableness</u><br><br>The Company hired Thai Omics Co., Ltd. to provide genetic testing services to study genetic information. As this is a specialized service, the service fee is determined on a case-by-case basis depending on the specifics of each project. The Company will apply its service pricing policy to customers by calculating the total service cost plus a gross profit margin according to the Company's policy.<br><br><u>Audit committee's opinion</u><br><br>The Audit Committee has reviewed and is of the opinion that the item in question follows the general trade practices, with pricing in line with the company's policy. This is beneficial to the company and reasonable. | 0.44                                                           | 1.67 | 0.31 |
| <b>Transaction 3</b><br><br><u>Nature of transaction</u><br><br>Accounts Payable<br><br><u>Details</u><br><br>The company has engaged Thai Omics Co., Ltd. to provide genetic testing services for the study of genetic information.<br><br><u>Necessity/reasonableness</u>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.07                                                           | 0.04 | 0.03 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Transaction value at the end of the fiscal year (million baht) |      |      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 2023                                                           | 2024 | 2025 |
| <p>The company has hired Thai Omics Co., Ltd. to provide genetic testing services for genetic data analysis. Since this is a specialized service, the pricing for such services depends on the specifics of each project. The company will apply its pricing policy by calculating the total service cost plus the gross profit margin, as per the company's policy.</p> <p><u>Audit committee's opinion</u></p> <p>The audit committee has reviewed and concluded that the transaction is in line with general commercial practices, with the pricing being in accordance with the company's policies. It is beneficial to the company and reasonable.</p>                                                                                      |                                                                |      |      |
| <p><b>Transaction 4</b></p> <p><u>Nature of transaction</u></p> <p>Revenue from Sales</p> <p><u>Details</u></p> <p>The Company generated revenue from the sale of reagent kits to Thai Omics Co., Ltd.</p> <p><u>Necessity/reasonableness</u></p> <p>The transaction is conducted in the ordinary course of business to support group operations. The selling price and commercial terms are based on market prices or comparable to third-party transactions on an arm's length basis.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the transaction is reasonable and follows general commercial practices. The price and terms are consistent with third-party transactions.</p> | 0.00                                                           | 0.00 | 0.34 |
| <p><b>Transaction 5</b></p> <p><u>Nature of transaction</u></p> <p>Trade Receivables</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.00                                                           | 0.00 | 0.36 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Transaction value at the end of the fiscal year (million baht) |      |      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 2023                                                           | 2024 | 2025 |
| <p><u>Details</u></p> <p>The Company has outstanding trade receivables from Thai Omics Co., Ltd., arising from the sale of diagnostic reagent kits in the ordinary course of business.</p> <p><u>Necessity/reasonableness</u></p> <p>The transaction is conducted in the ordinary course of business to support group operations. The selling price and commercial terms are based on market prices or comparable to third-party transactions on an arm's length basis.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the transaction is reasonable and follows general commercial practices. The price and terms are consistent with third-party transactions.</p> |                                                                |      |      |
| <p><b>Transaction 6</b></p> <p>0.00</p> <p>0.00</p> <p>106.50</p> <p><u>Nature of transaction</u></p> <p>Prepaid Expenses</p> <p><u>Details</u></p> <p>The Company has outstanding prepayments to Thai Omics Co., Ltd. for the procurement of customized products, which require specific material sourcing and production lead time according to the Company's specifications.</p> <p><u>Necessity/reasonableness</u></p> <p>The prepayment is a standard commercial term for made-to-order products to guarantee delivery and cover initial production costs, consistent with industry practices.</p> <p><u>Audit committee's opinion</u></p>                                                                                  |                                                                |      |      |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Transaction value at the end of the fiscal year (million baht) |      |      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 2023                                                           | 2024 | 2025 |
| The Audit Committee has reviewed and is of the opinion that the transaction is necessary and reasonable to support business operations. The prepayment terms comply with general commercial practices, with close monitoring of production status and delivery to ensure the Company's best interests.                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                |      |      |
| MGI Tech Singapore Pte. Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                |      |      |
| <b>Transaction 1</b><br><br><u>Nature of transaction</u><br><br>Purchase Products<br><br><u>Details</u><br><br>The company procures goods from MGI Tech (Singapore), primarily laboratory equipment and reagents.<br><br><u>Necessity/reasonableness</u><br><br>The company purchases goods from MGI Tech (Singapore), primarily laboratory equipment and consumables. These purchases are made under normal trade terms.<br><br><u>Audit committee's opinion</u><br><br>The Audit Committee has reviewed and opined that the transaction is considered to be in the ordinary course of business, with a price lower than that offered by other suppliers. Therefore, it is beneficial to the Company and deemed reasonable. | 0.14                                                           | 6.80 | 0.44 |
| <b>Transaction 2</b><br><br><u>Nature of transaction</u><br><br>Asset Purchase<br><br><u>Details</u><br><br>The company purchased laboratory equipment from MGI Tech (Singapore).<br><br><u>Necessity/reasonableness</u>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.68                                                           | 6.26 | 2.05 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Transaction value at the end of the fiscal year (million baht) |      |      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 2023                                                           | 2024 | 2025 |
| <p>The Company purchased machinery and laboratory equipment from MGI Tech Singapore Pte., Ltd. for use in the Company's operations. The purchase of such assets is subject to normal commercial terms.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the aforementioned list is in accordance with general commercial practices. The purchase price of such assets is comparable to the price at which MGI Tech Singapore Pte., Ltd. sells to other customers, which is beneficial and reasonable to the company.</p>                                                                                                                                                                                                                                                                                                                                     |                                                                |      |      |
| <p><b>Transaction 3</b></p> <p>0.00                      0.04                      0.08</p> <p><u>Nature of transaction</u></p> <p>Service Charge</p> <p><u>Details</u></p> <p>The company procures maintenance services for laboratory equipment and devices from MGI Tech Singapore Pte., Ltd.</p> <p><u>Necessity/reasonableness</u></p> <p>The company procured maintenance services for laboratory equipment from MGI Tech Singapore Pte., Ltd. The terms of the asset purchase agreement are in accordance with normal trade practices.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the aforementioned list represents a general trade pricing structure. The purchase price of the assets is comparable to the price offered by MGI Tech Singapore Pte., Ltd. to other customers, which is deemed beneficial and reasonable for the company.</p> |                                                                |      |      |
| <b>Transaction 4</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.00                                                           | 0.28 | 0.14 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Transaction value at the end of the fiscal year (million baht) |      |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 2023                                                           | 2024 | 2025 |
| <p><u>Nature of transaction</u></p> <p>Prepaid expense</p> <p><u>Details</u></p> <p>The company procures maintenance services for laboratory equipment and devices from MGI Tech Singapore Pte., Ltd.</p> <p><u>Necessity/reasonableness</u></p> <p>The company procured maintenance services for laboratory equipment from MGI Tech Singapore Pte., Ltd. The terms of the asset purchase agreement are in accordance with normal trade practices.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the aforementioned list represents a general trade pricing structure. The purchase price of the assets is comparable to the price offered by MGI Tech Singapore Pte., Ltd. to other customers, which is deemed beneficial and reasonable for the company.</p> |                                                                |      |      |
| Krung Thai Tractor Company Limited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                |      |      |
| <p><b>Transaction 1</b></p> <p>5.66</p> <p>5.62</p> <p>5.78</p> <p><u>Nature of transaction</u></p> <p>Rental, Asset, Right of Use, and Building</p> <p><u>Details</u></p> <p>The company leases office space from Krung Thai Tractor for use in conducting its business.</p> <p><u>Necessity/reasonableness</u></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                |      |      |



| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Transaction value at the end of the fiscal year (million baht) |      |      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 2023                                                           | 2024 | 2025 |
| <p>The Company leases office space from Krung Thai Tractor for its business operations. The rental rate is based on an appraisal by an independent appraiser approved by the Securities and Exchange Commission. This appraisal, conducted for public purposes, utilizes the Market Approach, comparing the rental rate to comparable market rates for similar properties in the vicinity.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the aforementioned list is beneficial to the company. The list aligns with general business practices, and the pricing is consistent with market rates.</p>                                      |                                                                |      |      |
| <p><b>Transaction 2</b></p> <p><u>Nature of transaction</u></p> <p>Public utility costs</p> <p><u>Details</u></p> <p>The company pays utility expenses for the use of the office and premises to "Krung Thai Tractor".</p> <p><u>Necessity/reasonableness</u></p> <p>The Company paid utility expenses for the use of the office and premises to Krung Thai Tractor, whereby such expenses were based on actual costs incurred.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the aforementioned list is beneficial to the company. The list aligns with general business practices, and the pricing is consistent with market rates.</p> | 0.93                                                           | 0.93 | 0.94 |
| <p><b>Transaction 3</b></p> <p><u>Nature of transaction</u></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.02                                                           | 0.02 | 0.03 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Transaction value at the end of the fiscal year (million baht) |      |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2023                                                           | 2024 | 2025 |
| <p>Others Account Payable</p> <p><u>Details</u></p> <p>The company leases office space from Krung Thai Tractor for use in conducting its business.</p> <p><u>Necessity/reasonableness</u></p> <p>The Company leases office space from Krung Thai Tractor for its business operations. The rental rate is based on an appraisal by an independent appraiser approved by the Securities and Exchange Commission. This appraisal, conducted for public purposes, utilizes the Market Approach, comparing the rental rate to comparable market rates for similar properties in the vicinity.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and is of the opinion that the aforementioned list is beneficial to the company. The list aligns with general business practices, and the pricing is consistent with market rates.</p> |                                                                |      |      |
| <p><b>Transaction 4</b></p> <p><u>Nature of transaction</u></p> <p>Deposits and guarantees.</p> <p><u>Details</u></p> <p>Deposits and guarantee deposits for leasing office space from Krungthai Tractor, used for the company's operations.</p> <p><u>Necessity/reasonableness</u></p> <p>Deposits and guarantee deposits for leasing office space from Krungthai Tractor, used for the company's operations.</p> <p><u>Audit committee's opinion</u></p>                                                                                                                                                                                                                                                                                                                                                                                                      | 0.24                                                           | 0.24 | 0.24 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Transaction value at the end of the fiscal year (million baht) |      |      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 2023                                                           | 2024 | 2025 |
| The Audit Committee has reviewed and is of the opinion that the aforementioned list is beneficial to the company. The list aligns with general business practices, and the pricing is consistent with market rates.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                |      |      |
| Shenzhen Zaozhidao Technology Co.,Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                |      |      |
| <b>Transaction 1</b><br><br><u>Nature of transaction</u><br><br>Purchase<br><br><u>Details</u><br><br>The company purchases goods from Shenzhen Zaozhidao Technology Co.,Ltd., with most of the items being chemicals for research purposes.<br><br><u>Necessity/reasonableness</u><br><br>The company purchases goods from Shenzhen Zaozhidao Technology Co.,Ltd., with most of the items being chemicals for research purposes. These purchases are made under normal commercial terms.<br><br><u>Audit committee's opinion</u><br><br>The Audit Committee has reviewed and concluded that the transaction follows normal commercial practices. The pricing is lower than other suppliers, benefiting the company and being reasonable. | 0.00                                                           | 1.19 | 0.00 |
| <b>Transaction 2</b><br><br><u>Nature of transaction</u><br><br>Deposit<br><br><u>Details</u><br><br>he company made a deposit payment for the purchase of goods from Shenzhen Zaozhidao Technology Co.,Ltd., with most of the items being chemicals for research purposes.                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.00                                                           | 0.24 | 0.00 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Transaction value at the end of the fiscal year (million baht) |      |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2023                                                           | 2024 | 2025 |
| <u>Necessity/reasonableness</u><br><br>The company made a deposit payment for the purchase of goods from Shenzhen Zaozhidao Technology Co.,Ltd., with most of the items being chemicals for research purposes. The purchase was made under normal commercial terms.                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                |      |      |
| <u>Audit committee's opinion</u><br><br>The Audit Committee has reviewed and concluded that the transaction follows normal commercial practices. The pricing is lower than other suppliers, benefiting the company and being reasonable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                |      |      |
| BGI Bio Solutions (Hong Kong) Co., Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                |      |      |
| <b>Transaction 1</b><br><br><u>Nature of transaction</u><br><br>Purchase goods<br><br><u>Details</u><br><br>The company purchases goods from BGI Bio-Solutions Hongkong Co.,Ltd with most of the items being chemicals for research purposes.<br><br><u>Necessity/reasonableness</u><br><br>The company purchases goods from BGI Bio-Solutions Hongkong Co.,Ltd with most of the items being chemicals for research purposes. These purchases are made under normal commercial terms.<br><br><u>Audit committee's opinion</u><br><br>The Audit Committee has reviewed and concluded that the transaction follows normal commercial practices. The pricing is lower than other suppliers, benefiting the company and being reasonable. | 0.01                                                           | 0.01 | 0.00 |
| <b>Transaction 2</b><br><br><u>Nature of transaction</u>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.04                                                           | 0.04 | 0.00 |

| Related party transactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Transaction value at the end of the fiscal year (million baht) |      |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------|------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 2023                                                           | 2024 | 2025 |
| <p>Analysis Service Fee</p> <p><u>Details</u></p> <p>The company engaged BGI Bio Solutions Hongkong for genetic testing services to analyze genetic data and support researchers in various projects.</p> <p><u>Necessity/reasonableness</u></p> <p>The company engaged BGI Bio Solutions Hongkong for genetic testing services to analyze genetic data and support researchers in various projects. This transaction follows normal commercial practices. As the service is highly specialized, pricing depends on the specific details of each project. The company sets its service pricing based on the total cost of service plus a gross profit margin in accordance with its pricing policy.</p> <p><u>Audit committee's opinion</u></p> <p>The Audit Committee has reviewed and concluded that the transaction follows normal commercial practices. The pricing is lower than other suppliers, benefiting the company and being reasonable.</p> |                                                                |      |      |

### 9.2.3 Policy and future trends of related party transactions and the compliance with the obligations specified in the prospectus of the company

#### Measures and procedures for approving related party transactions or connected transactions

The company has established measures for conducting related party transactions within the group and with individuals who may have a conflict of interest. The Audit Committee is responsible for providing opinions on the necessity and reasonableness of such transactions, as well as the appropriateness of the pricing based on market conditions. These transactions should align with standard commercial practices and market prices, which can be compared with those offered to external parties. In cases where the Audit Committee lacks expertise in reviewing related party transactions, the company will seek advice from independent professionals with specialized knowledge, such as auditors, appraisers, or legal advisors, who are independent from the company and any conflicting parties. Their opinions will be used to assist the Audit Committee's decision-making, and the Committee will then present the matter to the Board of Directors or shareholders, as applicable.

In addition, the company has established measures to prevent executives or stakeholders from participating in the approval of transactions in which they have a direct or indirect interest. The Board of Directors is responsible for

ensuring that the company complies with the Securities and Exchange Act and the regulations, announcements, orders, or requirements set by the Securities and Exchange Commission and the Stock Exchange of Thailand. This includes compliance with disclosure requirements for related party transactions and the acquisition or disposal of significant company assets, as well as adherence to accounting standards set by the Federation of Accounting Professions and licensed auditors in Thailand. The company will disclose related party transactions in the notes to the financial statements, which are audited or reviewed by the company's auditors.

#### **Future trends in related party transactions**

The company may engage in ongoing related party transactions in the future, which will follow the general nature of business practices. Clear policies will be established for such transactions, including prices and terms that are in line with standard business practices, similar to those set with unrelated parties, such as the purchase or sale of goods, the provision or receipt of services, and property leasing. These related party transactions will be necessary for the company's operations and will benefit the company. The Audit Committee will review and assess compliance with these guidelines and provide opinions on the reasonableness of the transactions on a quarterly basis.

For related party transactions that are not in the ordinary course of business and may occur in the future, the company will ensure that the Audit Committee reviews compliance with the relevant criteria and provides justifications for the transaction before the company and its subsidiaries enter into such transactions. The Audit Committee will offer opinions on the necessity, reasonableness, and appropriateness of the pricing of the transaction, considering various conditions to ensure it aligns with standard commercial practices and market prices, which can be compared to those offered to external parties. In cases where the Audit Committee lacks expertise in reviewing potential related party transactions, the company will seek advice from independent experts, such as auditors, appraisers, or legal advisors, who are independent from the company group and any conflicting parties. Their opinions will assist the Audit Committee in its decision-making, which will then be presented to the Board of Directors or shareholders, as applicable. The company will follow the measures and approval procedures for related party transactions as outlined above. However, for related party transactions that could potentially lead to conflicts of interest in the future, the Board of Directors must ensure compliance with the Securities and Exchange Act, regulations, announcements, orders, or requirements from the Securities and Exchange Commission and the Stock Exchange of Thailand. This also includes compliance with disclosure requirements for related party transactions and the acquisition or disposal of assets within the company group or its subsidiaries, as well as adherence to accounting standards set by the Federation of Accounting Professions and licensed auditors in Thailand.

#### **9.2.4 Information on appraised assets and appraisal price in conjunction with the execution of related party transactions**

Can be referred in attachment 4: assets for business undertaking and details of asset appraisal

## Part 3 Financial Statement

## Board of Directors' Responsibility Statement for the Financial Report



## Report of the Board of Directors' Responsibilities for the Financial Statements

The Board of Directors is responsible for the financial statements of Bangkok Genomics Innovation Public Company Limited, its consolidated financial statements, and the financial information presented in the Annual Report. These financial statements have been prepared in accordance with the Financial Reporting Standards prescribed under the Accounting Professions Act B.E. 2547 (2004) and the requirements of the Securities and Exchange Commission regarding the preparation and presentation of financial reports under the Securities and Exchange Act B.E. 2535 (1992).

The financial statements comply with the notification of the Department of Business Development dated October 27, 2023, issued under the Accounting Act B.E. 2543 (2000). The Board has ensured the selection of appropriate and consistently applied accounting policies, exercising prudent judgment and best estimates in their preparation. Furthermore, essential information has been sufficiently disclosed in the notes to the financial statements to ensure transparency for the benefit of shareholders and general investors.

The Board of Directors has established and maintained an appropriate and effective internal control system to provide reasonable assurance that accounting records are accurate, complete, adequate, and timely. This system aims to safeguard the company's assets and prevent fraud or significant irregular operations. To reinforce this, the Board has appointed an Audit Committee, comprised of independent directors, to oversee and review the accounting policies, the quality of financial reports, and the efficiency of internal control and internal audit processes. The Audit Committee's opinion on these matters is detailed in the Audit Committee Report included in this Annual Report.

The separate and consolidated financial statements of the Company and its subsidiaries have been audited by an independent certified public accountant from Dr. Virach & Associates Office Co., Ltd. The Board provided full support, including all necessary information and documentation, to enable the auditor to perform their audit and express an opinion in accordance with Thai Standards on Auditing. The auditor's unqualified opinion is presented in the Independent Auditor's Report within this Annual Report.

The Board of Directors is of the opinion that the Company's internal control system is overall adequate and appropriate, providing reasonable assurance that the financial statements of Bangkok Genomics Innovation Public Company Limited and its consolidated financial statements for the year ended December 31, 2025, are reliable and present fairly, in all material respects, in accordance with Financial Reporting Standards and relevant laws and regulations.

Mr.Thosaporn Sirisumphand

Chairman of the Board of Directors

Bangkok Genomics Innovation Pcl.

## Auditor's Report

เลขที่ 5/1 สุภาลัย แกรนด์ เอสเซนส์  
ถนนรัชดาภิเษก แขวงวัดท่าพระ  
เขตบางกอกใหญ่ กรุงเทพฯ 10600  
โทร. 02-125-0029  
093-130-8984  
093-130-8986  
อีเมล virach\_asso@vaaudit.com  
virach5183@yahoo.com



บริษัท สำนักงาน ดร.วิรัช แอนด์ แอสโซซิเอตส์ จำกัด  
DR.VIRACH & ASSOCIATES OFFICE CO., LTD.

CERTIFIED PUBLIC ACCOUNTANTS  
สำนักงานใหญ่ เลขประจำตัวผู้เสียภาษี 0105556000751

5/1 Supalai Grand Essence Village,  
Rachadapisek Road, Khwaeng Wat Tha Phra,  
Khet Bangkok Yai, Bangkok 10600  
Tel. 66 (0)2-125-0029  
66 (0)93-130-8984  
66 (0)93-130-8986  
Email virach\_asso@vaaudit.com  
virach5183@yahoo.com

## **AUDITOR'S REPORT**

### **To the Shareholders of Bangkok Genomics Innovation Public Company Limited**

#### **Opinion**

I have audited the consolidated financial statements of Bangkok Genomics Innovation Public Company Limited and its subsidiaries, which comprise the consolidated statements of financial position as at December 31, 2025, the related consolidated statements of comprehensive income, changes in shareholders' equity and cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policies information, and have also audited the separate financial statements of Bangkok Genomics Innovation Public Company Limited for the same period.

In my opinions, the financial statements referred to above present fairly, in all material respects, the financial position of Bangkok Genomics Innovation Public Company Limited and its subsidiaries and of Bangkok Genomics Innovation Public Company Limited as at December 31, 2025, their financial performance and cash flows for the year then ended in accordance with Thai Financial Reporting Standards.

#### **Basis for Opinion**

I conducted my audit in accordance with Thai Standards on Auditing. My responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of my report. I am independent of the Group in accordance with the Code of Ethics for Professional Accountants including Independence Standards issued by the Federation of Accounting Professions (Code of Ethics for Professional Accountants) that are relevant to my audit of the financial statements, and I have fulfilled my other ethical responsibilities in accordance with the Code of Ethics for Professional Accountants. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

#### **Key Audit Matters**

Key audit matters are those matters that, in my professional judgment, were of most significance in my audit of the financial statements of the current period. These matters were addressed in the context of my audit of the financial statements as a whole, and in forming my opinion thereon, and I do not provide a separate opinion on these matters.

#### **Revenues recognition**

The Group companies have revenues from sales and revenues from services, which have different conditions for revenues recognition. Additionally, the volume of transactions is quite high, which may affect the accuracy and completeness, as well as the period of revenues recognition.

h

I have understanding and assessed the internal control system design in respect of revenues recognition including tested and complied with the internal control relating to revenues recognition. I have reviewed the conditions of revenues agreement and tested revenues recognition following the financial reporting standard TFRS 15 that are based on the agreed conditions and was recognized in the fiscal accounting period, tested by sampling the accounting documents with revenues and accrued income recognition supporting and checked the cutting off revenues rendering at the period. I performed analytical procedures to detect possible irregularities in revenue transactions throughout the period.

The results of audited are satisfactory, and in my opinions, I did not find unusual items that are material misstatement.

#### **Other Information**

Management is responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and my auditor's report thereon. The annual report of the Group is expected to be made available to me after the date of this auditor's report.

My opinion on the financial statements does not cover the other information and I do not express any form of assurance conclusion thereon.

In connection with my audit of the financial statements, my responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or my knowledge obtained in the audit or otherwise appears to be materially misstated.

When I read the annual report, if I conclude that there is a material misstatement therein, I am required to communicate the matter to those charged with governance for correction of the misstatement.

#### **Responsibilities of Management and Those Charged with Governance for the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Thai Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.



### **Auditor's Responsibilities for the Audit of the Financial Statements**

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Thai Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Thai Standards on Auditing, I exercise professional judgement and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

62

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. I am responsible for the direction, supervision and performance of the group audit. I remain solely responsible for my audit opinion.

I communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

I also provide those charged with governance with a statement that I have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on my independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, I determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. I describe these matters in my auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, I determine that a matter should not be communicated in my report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



(Mr. Chaikorn Aunpitipongsa)

Certified Public Accountant Registration No. 3196

February 25, 2026

## Financial Statements



**BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED AND SUBSIDIARIES**

**STATEMENTS OF FINANCIAL POSITION**

**AS AT DECEMBER 31, 2025**

|                                     |             | BAHT                 |                    |                      |                    |
|-------------------------------------|-------------|----------------------|--------------------|----------------------|--------------------|
|                                     |             | CONSOLIDATED         |                    | SEPARATE             |                    |
|                                     |             | FINANCIAL STATEMENTS |                    | FINANCIAL STATEMENTS |                    |
| Notes                               |             | 2025                 | 2024               | 2025                 | 2024               |
| <b>ASSETS</b>                       |             |                      |                    |                      |                    |
| <b>Current Assets</b>               |             |                      |                    |                      |                    |
| Cash and cash equivalents           | 3.2 and 4   | 121,714,560          | 199,910,102        | 107,472,707          | 185,909,417        |
| Trade and other current receivables | 3.3 and 5   | 311,574,442          | 91,830,612         | 288,903,234          | 91,861,087         |
| Inventories                         | 3.4 and 6   | 36,085,287           | 22,088,786         | 28,251,782           | 22,088,786         |
| Current tax assets                  |             | 218                  | 11,175             | -                    | 11,175             |
| Other current financial assets      | 3.5 and 7   | 100,060,793          | 190,102,706        | 100,060,793          | 190,102,706        |
| Other current assets                |             | 10,919,730           | 10,981,000         | 9,431,175            | 10,981,000         |
| Total Current Assets                |             | 580,355,030          | 514,924,381        | 534,119,691          | 500,954,171        |
| <b>Non-Current Assets</b>           |             |                      |                    |                      |                    |
| Restricted bank deposit             | 8           | 16,229,000           | 6,729,000          | 14,729,000           | 6,729,000          |
| Investments in subsidiaries         | 3.6 and 9   | -                    | -                  | 37,037,900           | 12,039,400         |
| Investments in associate            | 3.6 and 10  | 591,093              | 915,250            | 1,000,000            | 1,000,000          |
| Plant improvement and equipment     | 3.7 and 11  | 56,236,512           | 55,405,402         | 56,236,512           | 55,405,402         |
| Right-of-use assets                 | 3.8 and 12  | 20,498,589           | 23,546,095         | 20,498,589           | 23,546,095         |
| Intangible assets                   | 3.9 and 13  | 22,935,172           | 478,456            | 22,935,172           | 478,456            |
| Deferred tax assets                 | 3.10 and 20 | 1,269,162            | 920,674            | 1,269,162            | 920,674            |
| Other non-current assets            |             | 3,740,987            | 4,676,127          | 3,740,987            | 4,676,127          |
| Total Non-Current Assets            |             | 121,500,515          | 92,671,004         | 157,447,322          | 104,795,154        |
| <b>TOTAL ASSETS</b>                 |             | <b>701,855,545</b>   | <b>607,595,385</b> | <b>691,567,013</b>   | <b>605,749,325</b> |

62

**BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED AND SUBSIDIARIES**  
**STATEMENTS OF FINANCIAL POSITION**  
**AS AT DECEMBER 31, 2025**

|                                                   |             | BAHT                 |                    |                      |                    |
|---------------------------------------------------|-------------|----------------------|--------------------|----------------------|--------------------|
|                                                   |             | CONSOLIDATED         |                    | SEPARATE             |                    |
|                                                   |             | FINANCIAL STATEMENTS |                    | FINANCIAL STATEMENTS |                    |
| Notes                                             |             | 2025                 | 2024               | 2025                 | 2024               |
| <b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>       |             |                      |                    |                      |                    |
| <b>Current Liabilities</b>                        |             |                      |                    |                      |                    |
| Trade and other current payables                  | 14          | 119,492,723          | 40,960,334         | 113,404,162          | 40,915,334         |
| Current portion of lease liabilities              | 3.8 and 15  | 4,867,023            | 4,213,365          | 4,867,023            | 4,213,365          |
| Accrued corporate income taxes                    |             | 1,729,130            | 274,855            | 1,186,420            | 274,855            |
| Other current liabilities                         |             | 734,710              | 230,171            | 464,261              | 230,171            |
| Total Current Liabilities                         |             | 126,823,586          | 45,678,725         | 119,921,866          | 45,633,725         |
| <b>Non-Current Liabilities</b>                    |             |                      |                    |                      |                    |
| Lease liabilities - net of current portion        | 3.8 and 15  | 16,603,784           | 19,791,303         | 16,603,784           | 19,791,303         |
| Provision for long-term employee benefits         | 3.11 and 16 | 5,276,940            | 2,972,778          | 5,276,940            | 2,972,778          |
| Total Non-Current Liabilities                     |             | 21,880,724           | 22,764,081         | 21,880,724           | 22,764,081         |
| <b>TOTAL LIABILITIES</b>                          |             | <b>148,704,310</b>   | <b>68,442,806</b>  | <b>141,802,590</b>   | <b>68,397,806</b>  |
| <b>Shareholders' Equity</b>                       |             |                      |                    |                      |                    |
| Share capital                                     | 18          |                      |                    |                      |                    |
| Registered                                        |             |                      |                    |                      |                    |
| 600,000,000 ordinary shares of Baht 0.50 each     |             | 300,000,000          | 300,000,000        | 300,000,000          | 300,000,000        |
| Issued and paid-up share capital                  |             |                      |                    |                      |                    |
| 600,000,000 ordinary shares of Baht 0.50 each     |             | 300,000,000          | 300,000,000        | 300,000,000          | 300,000,000        |
| Share premium on ordinary shares                  | 18          | 171,214,292          | 171,214,292        | 171,214,292          | 171,214,292        |
| Retained earnings                                 |             |                      |                    |                      |                    |
| Appropriated                                      |             |                      |                    |                      |                    |
| Statutory reserve                                 | 19          | 13,200,000           | 11,000,000         | 13,200,000           | 11,000,000         |
| Unappropriated                                    |             | 68,492,528           | 55,295,940         | 67,031,069           | 55,443,149         |
| Other components of shareholders' equity          |             | (1,680,938)          | (305,922)          | (1,680,938)          | (305,922)          |
| Total Shareholders' Equity of Parent Company      |             | 551,225,882          | 537,204,310        | 549,764,423          | 537,351,519        |
| Non-controlling interests                         |             | 1,925,353            | 1,948,269          | -                    | -                  |
| Total Shareholders' Equity                        |             | 553,151,235          | 539,152,579        | 549,764,423          | 537,351,519        |
| <b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b> |             | <b>701,855,545</b>   | <b>607,595,385</b> | <b>691,567,013</b>   | <b>605,749,325</b> |

h

**BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED AND SUBSIDIARIES**

**STATEMENTS OF COMPREHENSIVE INCOME (1/2)**

**FOR THE YEAR ENDED DECEMBER 31, 2025**

|                                                                        |             | BAHT                 |               |                      |               |
|------------------------------------------------------------------------|-------------|----------------------|---------------|----------------------|---------------|
|                                                                        |             | CONSOLIDATED         |               | SEPARATE             |               |
|                                                                        |             | FINANCIAL STATEMENTS |               | FINANCIAL STATEMENTS |               |
| Notes                                                                  |             | 2025                 | 2024          | 2025                 | 2024          |
| Revenues from sales                                                    |             | 111,866,509          | 81,090,717    | 102,707,631          | 81,090,717    |
| Revenues from services                                                 |             | 267,644,623          | 256,502,180   | 267,252,100          | 256,502,180   |
| Total revenues                                                         |             | 379,511,132          | 337,592,897   | 369,959,731          | 337,592,897   |
| Cost of sale                                                           |             | (62,947,614)         | (56,535,340)  | (57,274,285)         | (56,535,340)  |
| Cost of services                                                       |             | (160,937,098)        | (140,980,617) | (160,937,098)        | (140,980,617) |
| Total costs                                                            |             | (223,884,712)        | (197,515,957) | (218,211,383)        | (197,515,957) |
| Gross profit                                                           |             | 155,626,420          | 140,076,940   | 151,748,348          | 140,076,940   |
| Other incomes                                                          |             | 7,216,843            | 8,272,956     | 7,278,778            | 8,281,641     |
| Profit before expenses                                                 |             | 162,843,263          | 148,349,896   | 159,027,126          | 148,358,581   |
| Selling expenses                                                       |             | (49,077,383)         | (39,409,497)  | (48,616,622)         | (39,409,497)  |
| Administrative expenses                                                |             | (62,279,510)         | (55,091,255)  | (61,403,012)         | (55,025,150)  |
| Profit from operating activities                                       |             | 51,486,370           | 53,849,144    | 49,007,492           | 53,923,934    |
| Finance costs                                                          |             | (1,441,950)          | (1,358,758)   | (1,441,950)          | (1,358,758)   |
| Share of loss from investments in associate                            | 10          | (324,157)            | (84,750)      | -                    | -             |
| Expected credit loss                                                   |             | (1,870,574)          | (1,384,382)   | (1,870,574)          | (1,384,382)   |
| Profit before income tax                                               |             | 47,849,689           | 51,021,254    | 45,694,968           | 51,180,794    |
| Income tax expenses                                                    | 3.12 and 20 | (2,524,158)          | (862,083)     | (1,953,689)          | (862,083)     |
| Profit for the year                                                    |             | 45,325,531           | 50,159,171    | 43,741,279           | 50,318,711    |
| Other comprehensive income (loss) :                                    |             |                      |               |                      |               |
| Items that not reclassified subsequently to profit or loss :           |             |                      |               |                      |               |
| Actuarial loss on re-measurement on defined benefit plans              | 16          | (1,479,577)          | -             | (1,479,577)          | -             |
| Components of income tax                                               |             | 104,561              | -             | 104,561              | -             |
| Actuarial loss on re-measurement on defined benefit plans - net of tax |             | (1,375,016)          | -             | (1,375,016)          | -             |
| Other comprehensive income (loss) for the year                         |             | (1,375,016)          | -             | (1,375,016)          | -             |
| Total comprehensive income for the year                                |             | 43,950,515           | 50,159,171    | 42,366,263           | 50,318,711    |

h

**BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED AND SUBSIDIARIES**

**STATEMENTS OF COMPREHENSIVE INCOME (2/2)**

**FOR THE YEAR ENDED DECEMBER 31, 2025**

|                                                    |             | BAHT                 |             |                      |             |
|----------------------------------------------------|-------------|----------------------|-------------|----------------------|-------------|
|                                                    |             | CONSOLIDATED         |             | SEPARATE             |             |
|                                                    |             | FINANCIAL STATEMENTS |             | FINANCIAL STATEMENTS |             |
| Notes                                              |             | 2025                 | 2024        | 2025                 | 2024        |
| Profit (loss) attributable to                      |             |                      |             |                      |             |
| Equity holders of the parent                       |             | 45,349,947           | 50,171,502  | 43,741,279           | 50,318,711  |
| Non-controlling interests                          |             | (24,416)             | (12,331)    | -                    | -           |
|                                                    |             | 45,325,531           | 50,159,171  | 43,741,279           | 50,318,711  |
| Comprehensive profit (loss) attributable to        |             |                      |             |                      |             |
| Equity holders of the parent                       |             | 43,974,931           | 50,171,502  | 42,366,263           | 50,318,711  |
| Non-controlling interests                          |             | (24,416)             | (12,331)    | -                    | -           |
|                                                    |             | 43,950,515           | 50,159,171  | 42,366,263           | 50,318,711  |
| Earnings per share to equity holders of the parent |             |                      |             |                      |             |
| Basic earnings per share (Baht)                    | 3.13 and 21 | 0.076                | 0.088       | 0.073                | 0.089       |
| The number of weighted average ordinary shares     |             |                      |             |                      |             |
| use in-computation.(shares)                        |             | 600,000,000          | 567,213,115 | 600,000,000          | 567,213,115 |

h

**BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED AND SUBSIDIARIES**

**STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY**

**FOR THE YEAR ENDED DECEMBER 31, 2025**

**CONSOLIDATED FINANCIAL STATEMENTS**

**BAHT**

| Equity attributable to owners of the Company |                                                 |                                  |                               |                                          |                                                        |                                                          |                                               |                            |                                                           |
|----------------------------------------------|-------------------------------------------------|----------------------------------|-------------------------------|------------------------------------------|--------------------------------------------------------|----------------------------------------------------------|-----------------------------------------------|----------------------------|-----------------------------------------------------------|
| Notes                                        |                                                 | Retained earnings                |                               | Other components of shareholders' equity |                                                        | Total equity attributable to Shareholders of the Company | Non-controlling interests of the subsidiaries | Total shareholders' equity |                                                           |
|                                              |                                                 | Issued and paid-up share capital | Share premium ordinary shares | Appropriated Statutory reserve           | Unappropriated re-measurement of defined benefit plans |                                                          |                                               |                            | Actuarial loss on re-measurement of defined benefit plans |
|                                              |                                                 |                                  |                               |                                          |                                                        |                                                          |                                               |                            |                                                           |
| 18                                           | Year 2024                                       |                                  |                               |                                          |                                                        |                                                          |                                               |                            |                                                           |
|                                              | Beginning balances, January 1, 2024             | 220,000,000                      | -                             | 8,460,000                                | 7,664,438                                              | (305,922)                                                | 235,818,516                                   | -                          | 235,818,516                                               |
|                                              | Increased share capital                         | 80,000,000                       | 171,214,292                   | -                                        | -                                                      | -                                                        | 251,214,292                                   | -                          | 251,214,292                                               |
|                                              | Comprehensive income for the year 2024 :-       |                                  |                               |                                          |                                                        |                                                          |                                               |                            |                                                           |
|                                              | Profit for the year 2024                        | -                                | -                             | -                                        | 50,171,502                                             | -                                                        | 50,171,502                                    | (12,331)                   | 50,159,171                                                |
| 19                                           | Other comprehensive income :-                   | -                                | -                             | -                                        | -                                                      | -                                                        | -                                             | -                          | -                                                         |
|                                              | Total comprehensive income for the year 2024    | -                                | -                             | -                                        | 50,171,502                                             | -                                                        | 50,171,502                                    | (12,331)                   | 50,159,171                                                |
|                                              | Transferred to statutory reserve                | -                                | -                             | 2,540,000                                | (2,540,000)                                            | -                                                        | -                                             | -                          | -                                                         |
|                                              | Purchase of investments in subsidiary           | -                                | -                             | -                                        | -                                                      | -                                                        | -                                             | 1,960,600                  | 1,960,600                                                 |
|                                              | Ending balances, December 31, 2024              | 300,000,000                      | 171,214,292                   | 11,000,000                               | 55,295,940                                             | (305,922)                                                | 537,204,310                                   | 1,948,269                  | 539,152,579                                               |
|                                              | Year 2025                                       |                                  |                               |                                          |                                                        |                                                          |                                               |                            |                                                           |
|                                              | Beginning balances, January 1, 2025             | 300,000,000                      | 171,214,292                   | 11,000,000                               | 55,295,940                                             | (305,922)                                                | 537,204,310                                   | 1,948,269                  | 539,152,579                                               |
|                                              | Comprehensive income for the year 2025 :-       |                                  |                               |                                          |                                                        |                                                          |                                               |                            |                                                           |
|                                              | Profit for the year 2025                        | -                                | -                             | -                                        | 45,349,947                                             | -                                                        | 45,349,947                                    | (24,416)                   | 45,325,531                                                |
|                                              | Other comprehensive loss :-                     | -                                | -                             | -                                        | -                                                      | (1,375,016)                                              | (1,375,016)                                   | -                          | (1,375,016)                                               |
| 19                                           | Total comprehensive income for the year 2025    | -                                | -                             | -                                        | 45,349,947                                             | (1,375,016)                                              | 43,974,931                                    | (24,416)                   | 43,950,515                                                |
|                                              | Capital increase from non-controlling interests | -                                | -                             | -                                        | -                                                      | -                                                        | -                                             | 1,500                      | 1,500                                                     |
|                                              | Dividend paid                                   | -                                | -                             | -                                        | (29,953,359)                                           | -                                                        | (29,953,359)                                  | -                          | (29,953,359)                                              |
|                                              | Transferred to statutory reserve                | -                                | -                             | 2,200,000                                | (2,200,000)                                            | -                                                        | -                                             | -                          | -                                                         |
|                                              | Ending balances, December 31, 2025              | 300,000,000                      | 171,214,292                   | 13,200,000                               | 68,492,528                                             | (1,680,938)                                              | 551,225,882                                   | 1,925,353                  | 553,151,235                                               |

Notes to the financial statements form an integral part of these statements.

*m*

**BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED AND SUBSIDIARIES**  
**STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY**

**FOR THE YEAR ENDED DECEMBER 31, 2025**

**SEPARATE FINANCIAL STATEMENTS**

|                                              | Notes | BAHT                             |                               |                                |                   |                                                           |                            |
|----------------------------------------------|-------|----------------------------------|-------------------------------|--------------------------------|-------------------|-----------------------------------------------------------|----------------------------|
|                                              |       | Issued and paid-up share capital | Share premium ordinary shares | Retained earnings              |                   | Other components of shareholders' equity                  | Total shareholders' equity |
|                                              |       |                                  |                               | Appropriated Statutory reserve | Unappropriated    |                                                           |                            |
|                                              |       |                                  |                               |                                |                   | Actuarial loss on re-measurement of defined benefit plans |                            |
| <b>Year 2024</b>                             |       |                                  |                               |                                |                   |                                                           |                            |
| Beginning balances, January 1, 2024          |       | 220,000,000                      | -                             | 8,460,000                      | 7,664,438         | (305,922)                                                 | 235,818,516                |
| Increased share capital                      | 18    | 80,000,000                       | 171,214,292                   | -                              | -                 | -                                                         | 251,214,292                |
| Comprehensive income for the year 2024 :-    |       |                                  |                               |                                |                   |                                                           |                            |
| Profit for the year 2024                     |       | -                                | -                             | -                              | 50,318,711        | -                                                         | 50,318,711                 |
| Other comprehensive income :-                |       | -                                | -                             | -                              | -                 | -                                                         | -                          |
| Total comprehensive income for the year 2024 |       | -                                | -                             | -                              | 50,318,711        | -                                                         | 50,318,711                 |
| Transferred to statutory reserve             | 19    | -                                | -                             | 2,540,000                      | (2,540,000)       | -                                                         | -                          |
| <b>Ending balances, December 31, 2024</b>    |       | <b>300,000,000</b>               | <b>171,214,292</b>            | <b>11,000,000</b>              | <b>55,443,149</b> | <b>(305,922)</b>                                          | <b>537,351,519</b>         |
| <b>Year 2025</b>                             |       |                                  |                               |                                |                   |                                                           |                            |
| Beginning balances, January 1, 2025          |       | 300,000,000                      | 171,214,292                   | 11,000,000                     | 55,443,149        | (305,922)                                                 | 537,351,519                |
| Comprehensive income for the year 2025 :-    |       |                                  |                               |                                |                   |                                                           |                            |
| Profit for the year 2025                     |       | -                                | -                             | -                              | 43,741,279        | -                                                         | 43,741,279                 |
| Other comprehensive loss :-                  |       | -                                | -                             | -                              | -                 | (1,375,016)                                               | (1,375,016)                |
| Total comprehensive income for the year 2025 |       | -                                | -                             | -                              | 43,741,279        | (1,375,016)                                               | 42,366,263                 |
| Dividend paid                                | 19    | -                                | -                             | -                              | (29,953,359)      | -                                                         | (29,953,359)               |
| Transferred to statutory reserve             | 19    | -                                | -                             | 2,200,000                      | (2,200,000)       | -                                                         | -                          |
| <b>Ending balances, December 31, 2025</b>    |       | <b>300,000,000</b>               | <b>171,214,292</b>            | <b>13,200,000</b>              | <b>67,031,069</b> | <b>(1,680,938)</b>                                        | <b>549,764,423</b>         |

Notes to the financial statements form an integral part of these statements.

12

Page 6

**BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED AND SUBSIDIARIES**

**STATEMENTS OF CASH FLOWS (1/2)**

**FOR THE YEAR ENDED DECEMBER 31, 2025**

|                                                                                             | BAHT                 |                    |                      |                    |
|---------------------------------------------------------------------------------------------|----------------------|--------------------|----------------------|--------------------|
|                                                                                             | CONSOLIDATED         |                    | SEPARATE             |                    |
|                                                                                             | FINANCIAL STATEMENTS |                    | FINANCIAL STATEMENTS |                    |
|                                                                                             | 2025                 | 2024               | 2025                 | 2024               |
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>                                                 |                      |                    |                      |                    |
| Profit for the year                                                                         | 45,325,531           | 50,159,171         | 43,741,279           | 50,318,711         |
| Adjustment to reconcile profit for the year to cash provided from (used in) operation :     |                      |                    |                      |                    |
| Income tax expenses                                                                         | 2,524,158            | 862,083            | 1,953,689            | 862,083            |
| Depreciation of plant improvement and equipment                                             | 15,740,216           | 12,367,930         | 15,740,216           | 12,367,930         |
| Depreciation of right-of-use assets                                                         | 4,847,695            | 4,823,342          | 4,847,695            | 4,823,342          |
| Amortization of intangible assets                                                           | 958,198              | 596,693            | 958,198              | 596,693            |
| Expected credit loss                                                                        | 1,870,574            | 1,384,382          | 1,870,574            | 1,384,382          |
| (Reverse) reduction of inventory to net realizable value                                    | (134,637)            | 186,108            | (134,637)            | 186,108            |
| Gain from the change in fair value of forward contract                                      | (31,618)             | (80,099)           | (31,618)             | (80,099)           |
| Loss on write-off of equipment                                                              | 9,633                | -                  | 9,633                | -                  |
| Interest expenses                                                                           | 1,441,950            | 1,358,758          | 1,441,950            | 1,358,758          |
| Interest income                                                                             | (3,615,041)          | (4,376,933)        | (3,563,891)          | (4,374,968)        |
| Write-off withholding tax                                                                   | -                    | 1,480,437          | -                    | 1,480,437          |
| Unrealized (gain) loss on exchanges rates                                                   | (462,261)            | 180,717            | (448,666)            | 180,717            |
| Long-term employee benefits expenses                                                        | 824,585              | 768,031            | 824,585              | 768,031            |
| Share of loss from investments in associate                                                 | 324,157              | 84,750             | -                    | -                  |
| Profit from operation before changes in the composition of operating assets and liabilities | 69,623,140           | 69,795,370         | 67,209,007           | 69,872,125         |
| <b>(INCREASE) DECREASE IN OPERATING ASSETS ITEMS</b>                                        |                      |                    |                      |                    |
| Trade and other current receivables                                                         | (222,442,214)        | (56,448,770)       | (199,740,531)        | (56,479,245)       |
| Inventories                                                                                 | (13,861,864)         | (12,221,811)       | (6,028,359)          | (12,221,811)       |
| Other current financial assets                                                              | 80,099               | -                  | 80,099               | -                  |
| Other current assets                                                                        | 61,270               | (10,981,000)       | 1,549,825            | (10,981,000)       |
| Other non-current assets                                                                    | 954,115              | (1,554,414)        | 954,115              | (1,554,414)        |
| <b>INCREASE IN OPERATING LIABILITIES ITEMS</b>                                              |                      |                    |                      |                    |
| Trade and other current payables                                                            | 74,087,630           | 8,538,971          | 66,820,503           | 8,493,971          |
| Other current liabilities                                                                   | 504,539              | 229,997            | 234,090              | 229,997            |
| Cash used in operation                                                                      | (90,993,285)         | (2,641,657)        | (68,921,251)         | (2,640,377)        |
| Cash paid for income tax                                                                    | (1,321,828)          | (854,170)          | (1,293,851)          | (854,170)          |
| <b>NET CASH USED IN OPERATING ACTIVITIES</b>                                                | <b>(92,315,113)</b>  | <b>(3,495,827)</b> | <b>(70,215,102)</b>  | <b>(3,494,547)</b> |

4

Notes to the financial statements form an integral part of these statements.

Page 7

**BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED AND SUBSIDIARIES**

**STATEMENTS OF CASH FLOWS (2/2)**

**FOR THE YEAR ENDED DECEMBER 31, 2025**

|                                                                           | BAHT                 |                      |                      |                      |
|---------------------------------------------------------------------------|----------------------|----------------------|----------------------|----------------------|
|                                                                           | CONSOLIDATED         |                      | SEPARATE             |                      |
|                                                                           | FINANCIAL STATEMENTS |                      | FINANCIAL STATEMENTS |                      |
|                                                                           | 2025                 | 2024                 | 2025                 | 2024                 |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>                               |                      |                      |                      |                      |
| (Increase) decrease in other current financial assets - Fixed deposit     | 89,993,432           | (150,005,355)        | 89,993,432           | (150,005,355)        |
| Increase in restricted bank deposit                                       | (9,500,000)          | (2,609,000)          | (8,000,000)          | (2,609,000)          |
| Interest received                                                         | 4,234,912            | 3,681,466            | 4,183,762            | 3,679,501            |
| Cash paid for investments in subsidiaries                                 | -                    | -                    | (24,998,500)         | (12,039,400)         |
| Cash paid for investments in associate                                    | -                    | (1,000,000)          | -                    | (1,000,000)          |
| Purchase of plant improvement and equipment                               | (15,098,171)         | (19,964,686)         | (15,098,171)         | (19,964,686)         |
| Purchase of intangible assets                                             | (21,167,914)         | -                    | (19,957,943)         | -                    |
| <b>NET CASH PROVIDED FROM (USED IN) INVESTING ACTIVITIES</b>              | <b>48,462,259</b>    | <b>(169,897,575)</b> | <b>26,122,580</b>    | <b>(181,938,940)</b> |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>                               |                      |                      |                      |                      |
| Proceeds from increase in share capital                                   | -                    | 260,800,000          | -                    | 260,800,000          |
| Proceeds from increase non-controlling interests                          | 1,500                | 1,960,600            | -                    | -                    |
| Cash paid for transaction costs related to share issuance                 | -                    | (9,585,708)          | -                    | (9,585,708)          |
| Cash paid for settle lease liabilities                                    | (5,776,000)          | (5,616,000)          | (5,776,000)          | (5,616,000)          |
| Dividend paid                                                             | (28,082,130)         | -                    | (28,082,130)         | -                    |
| <b>NET CASH PROVIDED FROM (USED IN) FINANCING ACTIVITIES</b>              | <b>(33,856,630)</b>  | <b>247,558,892</b>   | <b>(33,858,130)</b>  | <b>245,598,292</b>   |
| <b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>               |                      |                      |                      |                      |
| BEFORE EFFECT ON EXCHANGE RATES                                           | (77,709,484)         | 74,165,490           | (77,950,652)         | 60,164,805           |
| Effect on exchange rates in cash and cash equivalents                     | (486,058)            | (142,718)            | (486,058)            | (142,718)            |
| <b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>               | <b>(78,195,542)</b>  | <b>74,022,772</b>    | <b>(78,436,710)</b>  | <b>60,022,087</b>    |
| <b>CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</b>                     | <b>199,910,102</b>   | <b>125,887,330</b>   | <b>185,909,417</b>   | <b>125,887,330</b>   |
| <b>CASH AND CASH EQUIVALENTS AT END OF YEAR</b>                           | <b>121,714,560</b>   | <b>199,910,102</b>   | <b>107,472,707</b>   | <b>185,909,417</b>   |
| <b>ADDITIONAL DISCLOSURE ITEMS TO CASH FLOWS STATEMENTS</b>               |                      |                      |                      |                      |
| <b>NON-CASH FLOWS ITEMS COMPRISE</b>                                      |                      |                      |                      |                      |
| Transferred withholding tax over one year to non-current assets           | 18,975               | 12,409               | 18,975               | 12,409               |
| Increase in right-of-use assets from lease liabilities                    | 1,800,189            | 4,541,740            | 1,800,189            | 4,541,740            |
| Other current payables from plant improvement and purchase equipment      | 5,341,606            | 3,858,818            | 5,341,606            | 3,858,818            |
| Other current payables from intangible assets                             | 2,247,000            | -                    | 3,456,971            | -                    |
| Effect of adjustment of actuarial estimates from employee benefit plan :- |                      |                      |                      |                      |
| - Components of income tax                                                | 104,561              | -                    | 104,561              | -                    |
| - Actuarial loss on re-measurement on defined benefit plans               | (1,479,577)          | -                    | (1,479,577)          | -                    |

4



## Notes to the Financial Statements

**BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED AND SUBSIDIARIES**

**NOTES TO THE FINANCIAL STATEMENTS**

**DECEMBER 31, 2025**

**1. GENERAL INFORMATION**

|                                                             |                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.1 Legal status                                            | (1) A juristic person established under Thai law and listed on the Stock Exchange of Thailand.<br><br>(2) An associate of BGI Health (HK) Co.,Ltd. which is a juristic person established in Hong Kong Special Administrative Region.                                                                                                       |
| 1.2 Company location<br><br>- Head office<br><br>- Branch 1 | 3689 Rama 4 Road, Kwaeng Phra Khanong, Khet Klongtoey, Bangkok, Thailand.<br><br>3675 Rama 4 Road, Kwaeng Phra Khanong, Khet Klongtoey, Bangkok, Thailand.                                                                                                                                                                                  |
| 1.3 Type of business                                        | (1) Analysis biosynthetic services , Quality control , Review and verification of correctness including business of hospitals, laboratories and medical diagnostic services which do not admit patients overnight.<br><br>(2) Investment in subsidiaries and associate which is conduct business in accordance with the Note 9 and Note 10. |

**2. BASIS FOR PREPARATION OF FINANCIAL STATEMENTS**

- 2.1 These consolidated and the separate financial statements are prepared in accordance with the Accounting Standards and Financial Reporting Standards issued by the Federation of Accounting Professions under the Accounting Profession Act, B.E. 2547 (2004), and the Accounting Act, B.E. 2543 (2000) and the Notification of the Office of the Securities and Exchange Commission and the Department of Business Development regarding “The Brief Particulars in the Financial Statements B.E. 2566 (2023)”.
- 2.2 These financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies.
- 2.3 These consolidated financial statements included the financial statements of Bangkok Genomics Innovation Public Company Limited with its subsidiaries and associate as follows:

**SUBSIDIARIES**

| COMPANIES                      | PERCENTAGE OF SHAREHOLDING | ESTABLISHED IN |
|--------------------------------|----------------------------|----------------|
| Comprehensive Care Limited     | 99.99                      | THAILAND       |
| Omicsphere Co., Ltd.           | 99.99                      | THAILAND       |
| Biovision Tech Company Limited | 51                         | THAILAND       |

The financial statements of subsidiaries are prepared with same accounting policies of the parent company.

**ASSOCIATE**

| COMPANY                           | % HOLDING | ESTABLISHED IN |
|-----------------------------------|-----------|----------------|
| Edge Medical (Thailand) Co., Ltd. | 25        | THAILAND       |

2.4 Inter-company balances and significant transactions of the Company and its subsidiaries have been eliminated from the consolidated financial statements.

2.5 Accounting standards that became effective in the current accounting period

The Group's has adopted the revised and new financial reporting standards which are effective for fiscal periods beginning on or after January 1, 2025. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards.

The adoption of these financial reporting standards does not have any significant impact on the Group's financial statements.

**Financial reporting standards that will become effective for fiscal years beginning on or after January 1, 2026**

The Federation of Accounting Professions issued a number of revised financial reporting standards, which are effective for fiscal years beginning on or after January 1, 2026. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards.

The management of the Group's believes that the adoption of these financial reporting standards does not have any significant impact on the Group financial statements.

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### 3.1 Revenues and expenses recognition

The Company recognized revenues and expenses from the following bases :

|                                 |                                                                                       |
|---------------------------------|---------------------------------------------------------------------------------------|
| Revenues and cost from services | - Recognized when analysis biosynthetic service has been rendered to the customer.    |
| Revenues and cost from sales    | - Recognized when the Company has transferred control over the goods to the customer. |
| Other income                    | - Recognized on the accrual basis.                                                    |
| Interest income                 | - Recognized on the accrual basis based on effective interest rate.                   |
| Expenses                        | - Recognized on the accrual basis.                                                    |

### **3.2 Cash and cash equivalents**

Cash and cash equivalents are cash on hand, fixed deposits at financial institutions due not more than 3 months from the date of acquisition with no obligation.

### **3.3 Trade receivables and allowance for expected credit loss**

Trade receivables are stated at net realizable value, the Company provides allowance for expected credit loss that may arise from collection of receivables by considering the aging of debt according uses the simplified approach in calculating ECLs. Therefore, the Company instead recognises a loss allowance based on lifetime ECLs at each reporting date. Based on its historical credit loss experience and adjusted for forward-looking factors specific to the debtors and the economic environment.

### **3.4 Inventories**

Cost of work, which is not yet recognized as revenues, is recorded in work in process which will be recognized to cost whenever the services are completed and control transferred.

Chemical and finished goods are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method.

The Group set up provision for diminution in value of inventories whenever the goods are obsolete and deteriorated by considering the current condition of inventories.

### **3.5 Other current financial assets**

Deposit in financial institution more than 3 months but not more than 12 months.

### **3.6 Investments in subsidiaries and associate**

Subsidiaries mean those companies in which the parent in the Group, directly or indirectly, has power more than one half of the total voting rights or power to govern the financial and operating policies of subsidiaries. Investments in subsidiaries in the separate financial statements are stated at cost after deduction of provision for diminution in investments (if any).

Associates mean those companies in which the parent in the Group has shareholding from 20% to 50% of the total voting rights or has significant influence over the associates, that is the parent in the Group has power to participate in determining relating to the financial and operating policies of the enterprise but not up to the level of governing such policies. Investments in associate stated by equity method for consolidation and cost after deduction of provision for diminution in investments (if any) for the separate financial statements.

### **3.7 Plant improvement and equipment**

Plant improvement and equipment are stated at cost less accumulated depreciation and allowance for loss on impairment of assets (if any).

Depreciation is calculated by the straight-line method based on the estimated useful life of the following assets:

|                                |                   |
|--------------------------------|-------------------|
| Plant improvement              | 10 Years          |
| Office equipment and furniture | 3, 5 and 10 Years |
| Lab equipment and furniture    | 3, 5 and 10 Years |
| Vehicle                        | 5 Years           |

Expenditures for additions, renewals or betterments which affected the significant increment in value of assets will be capitalized, considered as capital expenditures. Regarding repair and maintenance costs are recognized as expenses during the accounting periods when incurred.

### **3.8 Leases**

#### **Right-of-use assets**

The Group recognizes right-of-use assets at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses (if any.), the recognized right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term.

The Group assesses the lease term for the non-cancellable period as stipulated in lease contract or the remaining period of active leases together with any period covered by an option to extend the lease if it is reasonably certain to be exercised or any periods covered by an option to terminate the lease if it is reasonably certain not to be exercise by considering

#### **Lease liabilities**

At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of the lease payments to be made over the lease term, discounted by the interest rate implicit in the lease or the Group's incremental borrowing rate.

#### **Short-term leases and leases of low-value assets**

Payments under leases that, have a lease term of 12 months or less at the commencement date, or are leases of low-value assets, are recognized as expenses on a straight-line basis over the lease term.

### **3.9 Intangible assets**

#### **Computer software license**

Acquired right for using computer software which are capitalized based on the acquiring costs incurred and bring to use as intended. These costs are amortized by the straight-line method through the estimated useful life of 3 years and 5 years.

#### **Research and development/internally generated intangible assets**

Research expenditure is recognized as an expense in the statements of comprehensive income at the year incurred.

Expenditure incurred from products development is recognized as an asset when the Company can demonstrate all of the following :

1) The expenditure attributable to its development can be measured reliably and feasibility in technical, financial, commercial, and resource and ;

2) The Company intends to and has the ability to complete the development for the purpose of using or selling.

Development costs previously recognized as expenses are not recognized as assets in a subsequent period.

Expenditure from product development are amortized when the asset is ready to use in production process by the straight-line method over the period of its expected benefit 5 years.

### **3.10 Deferred tax assets/liabilities**

Deferred tax assets/liabilities are recognized for temporary differences arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes as at the statements of financial position date. They will be realised in future period when the income is realised, or the expenses provided for are actually incurred and considered deductible for income tax purposes.

Deferred tax assets are recognized for deductible temporary differences or additional tax are deferred tax liabilities if it is highly probable that the Group will generate sufficient taxable profits from its future operations to utilise these assets.

As each statements of financial position date, the Group reviews and reduces the carrying amount of deferred tax assets/liabilities to the extent that it is no longer probable that sufficient taxable profit be available to allow all or part of the deferred tax asset or deferred tax liabilities to be utilised.

### **3.11 Employee benefits**

#### Short-term employee benefits

The Group recognized salaries, wages, bonuses and contributions to the social security fund as expenses when incurred.

#### Long-term employee benefits

##### Defined contribution plan

The Group provides a provident fund, which is a defined contribution plan, the assets of which are held in a separate trust fund and managed by the external fund manager. Such provident fund is contributed by payments from employees and the Company. Contributions to the provident fund are charged to the statements of comprehensive income in the incurred period.

##### Defined benefit plan

The provision for employee retirement benefits is recognized as an expense of operations over the employee's service period. It is calculated by estimating the amount of future benefit earned by employees in return for service provided to the Company in the current and future periods, with such benefit being discounted to determine the present value. The reference point for setting the discount

rate is the yield rate of government bonds as at the reporting date. The calculation is performed by a qualified actuary using the Projected Unit Credit Method.

### **3.12 Income tax expenses**

Income tax expenses from profit for the year consist of current income tax and deferred tax. Income tax expenses recognized in statements of comprehensive income unless part of transaction recorded in shareholders' equity recorded directly to equity.

### **3.13 Earnings per share**

Basic earnings per share is calculated by dividing profit for the year with the number of ordinary shares held by outsiders by the weighted average method.

### **3.14 Presentation currency**

The financial statements are prepared and presented in Thai Baht. All financial information presented in Thai Baht has been rounded to the nearest Baht unless otherwise stated.

### **3.15 Foreign currency transactions**

Foreign currency transactions incurred during the years are recorded in Baht at the rate ruling on the date of transactions. Outstanding foreign currency assets and liabilities on the statements of financial position date are converted to Baht at the rate of exchange in effect on that date.

Gains or losses on exchange rate fluctuation are credited or charged to operations during the years.

### **3.16 Financial instruments**

#### **Classification and measurement of financial assets**

Financial assets are classified, at initial recognition, as to be subsequently measured at amortized cost, fair value through other comprehensive income ("FVOCI"), or fair value through profit or loss ("FVTPL"). The classification of financial assets at initial recognition is driven by the Group's business model for managing the financial assets and the contractual cash flows characteristics of the financial assets.

#### **Financial assets at amortized cost**

The Group measures financial assets at amortized cost if the financial asset is held in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets at amortized cost are subsequently measured using the effective interest rate ("EIR") method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognized, modified or impaired.

#### **Financial assets designated at FVOCI**

Upon initial recognition, the Group can elect to irrevocably classify its equity investments which are not held for trading as equity instruments designated at FVOCI. The classification is determined on an instrument-by-instrument basis.

Gains and losses recognized in other comprehensive income on these financial assets are never recycled to profit or loss.

Dividends are recognized as other income in profit or loss, except when the dividends clearly represent a recovery of part of the cost of the financial asset, in which case, the gains are recognized in other comprehensive income.

Equity instruments designated at FVOCI are not subject to impairment assessment.

#### **Financial assets designated at FVTPL**

Financial assets measured at FVTPL are carried in the statements of financial position at fair value with net changes in fair value including interest income recognized in profit or loss.

These financial assets include derivatives, security investments held for trading, equity investments which the Group has not irrevocably elected to classify at FVOCI and financial assets with cash flows that are not solely payments of principal and interest.

#### **Classification and measurement of financial liabilities**

Except for derivative liabilities, at initial recognition the Group's financial liabilities are recognized at fair value net of transaction costs and classified as liabilities to be subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the EIR amortization process. In determining amortized cost, the Group takes into account any fees or costs that are an integral part of the EIR. The EIR amortization is included in finance costs in profit or loss.

The Group may elect to measure financial liabilities at FVTPL if doing so eliminates, or significantly reduces a recognition inconsistency.

#### **Recognition and derecognition of financial instruments**

The Group recognizes or derecognizes of financial assets on the transaction date which is the date on which the Group has an obligation to buy or sell the asset for the normal purchase or sale of a financial asset.

A financial asset is primarily derecognized when the right to receive cash flows from the asset has expired or has been transferred and either the Group has transferred substantially all the risks and rewards of the asset.

A financial liability is derecognized when obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in profit or loss.



### **Impairment of financial assets**

For trade accounts receivables, the Group applies a simplified approach in calculating ECLs. Therefore, the Group instead recognises a loss allowance based on lifetime ECLs at each reporting date. Based on its historical credit loss experience and adjusted for forward-looking factors specific to the debtors and the economic environment.

### **Offsetting of financial instruments**

Financial assets and financial liabilities are offset and the net amount is reported in the statements of financial position if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

### **3.17 Derivatives and hedge accounting**

The Group derivatives are initially recognized at fair value on the date on which a derivative contract is entered into and are subsequently remeasured at fair value. The subsequent changes are recognized in profit or loss. Derivatives are carried as financial assets when the fair value is greater than zero and as financial liabilities when the fair value is less than zero.

#### **Hedge accounting**

For the purpose of hedge accounting, The Group hedges are classified as follow :

Cash flow hedges when hedging the exposure to variability in cash flows that is either attributable to a particular risk associated with a recognized asset or liability or a highly probable forecast transaction or the foreign currency risk in an unrecognized firm commitment.

#### **Fair value hedges**

The change in the fair value of a hedging instrument is recognized in profit or loss. The change in the fair value of the hedged item attributable to the risk hedged is recorded as part of the carrying value of the hedged item and is also recognized in profit or loss.

Any adjustment to the carrying value of fair value hedges relating to items carried at amortized cost, is amortized through profit or loss over the remaining term of the hedge using the effective interest method. The amortization may begin as soon as an adjustment exists or no later than when the hedged item ceases to be adjusted for changes in its fair value attributable to the risk being hedged. If the hedged item is derecognized, the unamortized fair value is recognized immediately in profit or loss.

### **3.18 Provisions**

Provisions are recognised when the Group has a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

### **3.19 Fair value measurement**

Fair value is the amount for which an asset could be exchange, or a liabilities settled between knowledgeable, willing parties in an arm's length transaction. The Group applies a quoted market price in an active market to measure their assets and liabilities that are required to be measured at fair

value by relevant financial reporting standards. Except in case of no active market of an identical asset or liability or when a quoted market price is not available, the Group measures fair value using valuation technique that are appropriate in the circumstances and maximizes the use of relevant observable inputs related to assets and liabilities that are required to be measured at fair value.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy into three levels based on categorize of input to be used in fair value measurement as follows:

- Level 1 - Use of quoted market prices in an active market for such assets or liabilities
- Level 2 - Use of other observable inputs for such assets or liabilities, whether directly or indirectly
- Level 3 - Use of unobservable inputs such as estimates of future cash flows

At the end of each reporting period, the Group determines whether transfers have occurred between levels within the fair value hierarchy for assets and liabilities held at the end of the reporting period that are measured at fair value on a recurring basis.

### 3.20 Significant accounting judgments and estimates

In preparation of financial statements in accordance with generally accepted accounting principles requires management to use judgments on various estimates and assumptions that will affect the reported amounts of revenues, expenses, assets and liabilities including the disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

Estimates and assumptions are continually evaluated and based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions of significant accounting relate primarily to allowance for expected credit loss, reduce inventory cost to net realizable value, depreciation of plant improvement and equipment, depreciation of right-of-use assets, amortization of intangible assets, deferred tax assets or liabilities and provision for long-term employee benefits. All other estimates mentioned above are further disclosed in the corresponding notes to the financial statements.

## 4. CASH AND CASH EQUIVALENTS

Unit : Baht

| PARTICULARS                     | CONSOLIDATED<br>FINANCIAL STATEMENTS |             | SEPARATE<br>FINANCIAL STATEMENTS |             |
|---------------------------------|--------------------------------------|-------------|----------------------------------|-------------|
|                                 | 2025                                 | 2024        | 2025                             | 2024        |
| Cash                            | 133,200                              | 2,111,103   | 127,800                          | 150,803     |
| Cash at bank                    | 121,581,360                          | 197,798,999 | 107,344,907                      | 185,758,614 |
| Total cash and cash equivalents | 121,714,560                          | 199,910,102 | 107,472,707                      | 185,909,417 |

## 5. TRADE AND OTHER CURRENT RECEIVABLES

Unit : Baht

| PARTICULARS                                       | CONSOLIDATED<br>FINANCIAL STATEMENTS |             | SEPARATE<br>FINANCIAL STATEMENTS |             |
|---------------------------------------------------|--------------------------------------|-------------|----------------------------------|-------------|
|                                                   | 2025                                 | 2024        | 2025                             | 2024        |
| <b><u>Trade receivables related parties</u></b>   |                                      |             |                                  |             |
| Trade receivables                                 |                                      |             |                                  |             |
| Current                                           | -                                    | -           | 3,500,000                        | -           |
| Overdue between 3 to 6 months                     | 362,903                              | 51,421      | 362,903                          | 51,421      |
| Overdue more than to 12 months                    | 117,774                              | 75,379      | 117,774                          | 75,379      |
| Total                                             | 480,677                              | 126,800     | 3,980,677                        | 126,800     |
| <u>Less</u> Allowance for expected credit loss    | (117,773)                            | (101,343)   | (140,728)                        | (101,343)   |
| Trade receivables related parties - net           | 362,904                              | 25,457      | 3,839,949                        | 25,457      |
| <b><u>Trade receivables unrelated parties</u></b> |                                      |             |                                  |             |
| Accrued income                                    |                                      |             |                                  |             |
| Overdue within 3 months                           | 9,434,612                            | 401,500     | 9,434,612                        | 401,500     |
| Overdue between 3 to 6 months                     | -                                    | 156,100     | -                                | 156,100     |
| Overdue between 6 to 12 months                    | 16,800                               | 9,000       | 16,800                           | 9,000       |
| Overdue more than 12 months                       | 508,150                              | 477,650     | 508,150                          | 477,650     |
| Total                                             | 9,959,562                            | 1,044,250   | 9,959,562                        | 1,044,250   |
| <u>Less</u> Allowance for expected credit loss    | (405,975)                            | (384,885)   | (405,975)                        | (384,885)   |
| Accrued income - net                              | 9,553,587                            | 659,365     | 9,553,587                        | 659,365     |
| Trade receivables                                 |                                      |             |                                  |             |
| Current                                           | 76,018,135                           | 55,807,071  | 62,298,135                       | 55,807,071  |
| Overdue within 3 months                           | 41,645,655                           | 6,670,490   | 41,645,655                       | 6,670,490   |
| Overdue between 3 to 6 months                     | 6,773,907                            | 8,203,262   | 6,773,907                        | 8,203,262   |
| Overdue between 6 to 12 months                    | 16,381,743                           | 1,293,151   | 16,381,743                       | 1,293,151   |
| Overdue more than 12 months                       | 2,366,721                            | 1,714,501   | 2,366,721                        | 1,714,501   |
| Total                                             | 143,186,161                          | 73,688,475  | 129,466,161                      | 73,688,475  |
| <u>Less</u> Allowance for expected credit loss    | (5,038,153)                          | (3,205,099) | (5,015,198)                      | (3,205,099) |
| Trade receivables - net                           | 138,148,008                          | 70,483,376  | 124,450,963                      | 70,483,376  |
| Trade receivables unrelated parties - net         | 147,701,595                          | 71,142,741  | 134,004,550                      | 71,142,741  |
| Total trade receivables - net                     | 148,064,499                          | 71,168,198  | 137,844,499                      | 71,168,198  |

**TRADE AND OTHER CURRENT RECEIVABLES (CONTINUED)**

Unit : Baht

| PARTICULARS                               | CONSOLIDATED<br>FINANCIAL STATEMENTS |            | SEPARATE<br>FINANCIAL STATEMENTS |            |
|-------------------------------------------|--------------------------------------|------------|----------------------------------|------------|
|                                           | 2025                                 | 2024       | 2025                             | 2024       |
| <b><u>Other current receivables</u></b>   |                                      |            |                                  |            |
| Prepaid expenses related parties          | 112,526,241                          | 4,571,563  | 109,628,241                      | 4,571,563  |
| Prepaid expenses unrelated parties        | 32,655,319                           | 7,051,260  | 23,641,630                       | 5,841,289  |
| Other receivables related parties         | 10,312,669                           | 7,292,551  | 10,312,669                       | 8,532,997  |
| Other receivables unrelated parties       | 7,119,408                            | 363,202    | 6,579,889                        | 363,202    |
| Others                                    | 896,306                              | 1,383,838  | 896,306                          | 1,383,838  |
| Total other current receivables           | 163,509,943                          | 20,662,414 | 151,058,735                      | 20,692,889 |
| Total trade and other current receivables | 311,574,442                          | 91,830,612 | 288,903,234                      | 91,861,087 |

The term of credit to customers is usually 15 days to 120 days.

**6. INVENTORIES**

Unit : Baht

| PARTICULARS                                     | CONSOLIDATED<br>FINANCIAL STATEMENTS |             | SEPARATE<br>FINANCIAL STATEMENTS |             |
|-------------------------------------------------|--------------------------------------|-------------|----------------------------------|-------------|
|                                                 | 2025                                 | 2024        | 2025                             | 2024        |
| Work in process                                 | 572,493                              | 472,038     | 572,493                          | 472,038     |
| Packaging                                       | 576,213                              | 463,670     | 576,213                          | 463,670     |
| Chemical                                        | 17,457,929                           | 17,948,884  | 17,457,929                       | 17,948,884  |
| Finished goods                                  | 22,231,617                           | 8,091,796   | 14,398,112                       | 8,091,796   |
| Total inventories                               | 40,838,252                           | 26,976,388  | 33,004,747                       | 26,976,388  |
| <u>Less</u> Reduce cost to net realizable value | (4,752,965)                          | (4,887,602) | (4,752,965)                      | (4,887,602) |
| Total inventories - net                         | 36,085,287                           | 22,088,786  | 28,251,782                       | 22,088,786  |

During the year, the Company reversed reduced cost of inventories by Baht 0.13 million to reflect the net realizable value, which was included in cost of service. (2024 : reduced cost of inventories amount of Baht 0.19 million).

## 7. OTHER CURRENT FINANCIAL ASSETS

Unit : Baht

| PARTICULARS                                           | CONSOLIDATED AND SEPARATE<br>FINANCIAL STATEMENTS |             |
|-------------------------------------------------------|---------------------------------------------------|-------------|
|                                                       | 2025                                              | 2024        |
| Cash at bank                                          | 100,029,175                                       | 190,022,607 |
| Receivables of the purchase forward exchange contract | 31,618                                            | 80,099      |
| Total other current financial assets                  | 100,060,793                                       | 190,102,706 |

## 8. RESTRICTED BANK DEPOSIT

As at December 31, 2025 and 2024, fixed deposit and savings deposit pledged as collateral with financial institutions are as follow :

Unit : Baht

| PARTICULARS                                | CONSOLIDATED<br>FINANCIAL STATEMENTS |           | SEPARATE<br>FINANCIAL STATEMENTS |           |
|--------------------------------------------|--------------------------------------|-----------|----------------------------------|-----------|
|                                            | 2025                                 | 2024      | 2025                             | 2024      |
| For bank gurantee in business operation    | 12,729,000                           | 3,229,000 | 11,229,000                       | 3,229,000 |
| For the purchase forward exchange contract | 3,500,000                            | 3,500,000 | 3,500,000                        | 3,500,000 |
| Total restricted bank deposit              | 16,229,000                           | 6,729,000 | 14,729,000                       | 6,729,000 |

## 9. INVESTMENTS IN SUBSIDIARIES

Unit : Baht

| SUBSIDIARIES                      | PERCENTAGE<br>OF SHAREHOLDING |       | SEPARATE FINANCIAL<br>STATEMENTS (COST METHOD) |            |
|-----------------------------------|-------------------------------|-------|------------------------------------------------|------------|
|                                   | 2025                          | 2024  | 2025                                           | 2024       |
| Comprehensive Care Limited        | 99.99                         | 99.99 | 4,999,800                                      | 4,999,800  |
| Omicsphere Co., Ltd.              | 99.99                         | 99.99 | 29,998,200                                     | 4,999,700  |
| Biovision Tech Company Limited    | 51                            | 51    | 2,039,900                                      | 2,039,900  |
| Total investments in subsidiaries |                               |       | 37,037,900                                     | 12,039,400 |

Unit : Baht

| SUBSIDIARIES                   | NATURE OF BUSINESS                                                                                                           | ISSUED AND PAID-UP<br>SHARE CAPITAL |           | DIVIDENDS RECEIVED<br>DURING THE YEAR |      |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-----------|---------------------------------------|------|
|                                |                                                                                                                              | 2025                                | 2024      | 2025                                  | 2024 |
|                                |                                                                                                                              |                                     |           |                                       |      |
| Comprehensive Care Limited     | Business related to medical technology, advanced medical products, and-related equipment.                                    | 5,000,000                           | 5,000,000 | -                                     | -    |
| Omicsphere Co., Ltd.           | Distributor of scientific medical device, equipment, chemicals used in laboratories and advanced therapy medicinal products. | 30,000,000                          | 5,000,000 | -                                     | -    |
| Biovision Tech Company Limited | Operate as a consultancy service provider for businesses.                                                                    | 4,000,000                           | 4,000,000 | -                                     | -    |
| TOTAL                          |                                                                                                                              |                                     |           | -                                     | -    |

In August 2025, Omicsphere Co., Ltd. increased its registered share capital from 50,000 shares with a par value of Baht 100 each to 300,000 shares with a par value of Baht 100 each. The Company additionally invested in 249,985 shares at a par value of Baht 100 per share, totaling Baht 24,998,500, representing 99.99 percent of the total shares.

#### 10. INVESTMENTS IN ASSOCIATE

Unit : Baht

| CONSOLIDATED AND SEPARATE<br>FINANCIAL STATEMENTS | PERCENTAGE OF<br>SHAREHOLDING |      | EQUITY METHOD |         | COST METHOD |           |
|---------------------------------------------------|-------------------------------|------|---------------|---------|-------------|-----------|
|                                                   | 2025                          | 2024 | 2025          | 2024    | 2025        | 2024      |
| Edge Medical (Thailand) Co., Ltd.                 | 25                            | 25   | 591,093       | 915,250 | 1,000,000   | 1,000,000 |

Unit : Baht

| ASSOCIATE                         | NATURE OF BUSINESS                                           | ISSUED AND PAID- UP<br>SHARE CAPITAL |           | DIVIDENDS RECEIVED<br>DURING THE YEAR |      |
|-----------------------------------|--------------------------------------------------------------|--------------------------------------|-----------|---------------------------------------|------|
|                                   |                                                              | 2025                                 | 2024      | 2025                                  | 2024 |
|                                   |                                                              |                                      |           |                                       |      |
| Edge Medical (Thailand) Co., Ltd. | Distributor of medical equipment related to robotic surgery. | 4,000,000                            | 4,000,000 | -                                     | -    |

The share of loss from investments for using the equity method which are recorded on the consolidated statements of comprehensive income for the year ended December 31, 2025 and 2024 as follows.

Unit : Baht

| SHARE OF LOSS FROM INVESTMENTS<br>FOR USING THE EQUITY METHOD | CONSOLIDATED FINANCIAL STATEMENTS |          |
|---------------------------------------------------------------|-----------------------------------|----------|
|                                                               | 2025                              | 2024     |
| Edge Medical (Thailand) Co., Ltd.                             | (324,157)                         | (84,750) |

#### Summarized financial information of associate

Financial information of the associate is summarized, as follows:

Unit : Thousand Baht

| COMPANY                           | TOTAL ASSETS |       | TOTAL LIABILITIES |      | LOSS FOR THE YEAR |       |
|-----------------------------------|--------------|-------|-------------------|------|-------------------|-------|
|                                   | 2025         | 2024  | 2025              | 2024 | 2025              | 2024  |
| Edge Medical (Thailand) Co., Ltd. | 1,593        | 1,396 | 29                | 15   | (1,297)           | (339) |

## 11. PLANT IMPROVEMENT AND EQUIPMENT

Unit : Baht

| CONSOLIDATED AND<br>SEPARATE FINANCIAL<br>STATEMENTS | Plant<br>improvement | Office equipment<br>and furniture | Lab equipment<br>and furniture | Vehicle   | Total       |
|------------------------------------------------------|----------------------|-----------------------------------|--------------------------------|-----------|-------------|
| <u>Cost</u>                                          |                      |                                   |                                |           |             |
| January 1, 2024                                      | 16,275,293           | 12,753,035                        | 50,080,389                     | 1,717,000 | 80,825,717  |
| Purchases                                            | 145,830              | 2,861,897                         | 16,486,232                     | 1,709,000 | 21,202,959  |
| December 31, 2024                                    | 16,421,123           | 15,614,932                        | 66,566,621                     | 3,426,000 | 102,028,676 |
| Purchases                                            | 148,199              | 1,839,349                         | 14,593,411                     | -         | 16,580,959  |
| Disposal / Write off                                 | -                    | (380,451)                         | (560,870)                      | -         | (941,321)   |
| December 31, 2025                                    | 16,569,322           | 17,073,830                        | 80,599,162                     | 3,426,000 | 117,668,314 |
| <u>Accumulated depreciation</u>                      |                      |                                   |                                |           |             |
| January 1, 2024                                      | 5,906,658            | 5,810,761                         | 22,308,876                     | 229,049   | 34,255,344  |
| Depreciation for the year 2024                       | 1,783,315            | 3,068,898                         | 7,363,096                      | 152,621   | 12,367,930  |
| December 31, 2024                                    | 7,689,973            | 8,879,659                         | 29,671,972                     | 381,670   | 46,623,274  |
| Depreciation for the year 2025                       | 1,795,678            | 3,454,827                         | 10,314,209                     | 175,502   | 15,740,216  |
| Disposal / Write off                                 | -                    | (372,295)                         | (559,393)                      | -         | (931,688)   |
| December 31, 2025                                    | 9,485,651            | 11,962,191                        | 39,426,788                     | 557,172   | 61,431,802  |
| <u>Net book value</u>                                |                      |                                   |                                |           |             |
| December 31, 2024                                    | 8,731,150            | 6,735,273                         | 36,894,649                     | 3,044,330 | 55,405,402  |
| December 31, 2025                                    | 7,083,671            | 5,111,639                         | 41,172,374                     | 2,868,828 | 56,236,512  |

The Company and its subsidiaries have depreciation for plant improvement and equipment presented in the statements of comprehensive income for the years ended December 31, 2025 and 2024 as follows.

Unit : Baht

| PARTICULARS             | CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS |            |
|-------------------------|---------------------------------------------------|------------|
|                         | 2025                                              | 2024       |
| Cost of sales           | 1,966,933                                         | -          |
| Cost of services        | 9,658,562                                         | 8,852,953  |
| Administrative expenses | 4,114,721                                         | 3,514,977  |
| Total                   | 15,740,216                                        | 12,367,930 |

## 12. RIGHT-OF-USE ASSETS

Net book value of right-of-use assets related to building lease for the period of 4 - 10 years are presented as follows :

Unit : Baht

| PARTICULARS                              | CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS |      |
|------------------------------------------|---------------------------------------------------|------|
|                                          | 2025                                              | 2024 |
| <u>Cost</u>                              |                                                   |      |
| January 1, 2024                          | 39,949,727                                        |      |
| Adjustment from lease reassessment       | 4,541,740                                         |      |
| December 31, 2024                        | 44,491,467                                        |      |
| <u>Add Increase during the year 2025</u> | 1,800,189                                         |      |
| December 31, 2025                        | 46,291,656                                        |      |
| <u>Accumulated depreciation</u>          |                                                   |      |
| January 1, 2024                          | 16,122,030                                        |      |
| Depreciation for the year 2024           | 4,823,342                                         |      |
| December 31, 2024                        | 20,945,372                                        |      |
| Depreciation for the year 2025           | 4,847,695                                         |      |
| December 31, 2025                        | 25,793,067                                        |      |
| <b>Net Book value</b>                    |                                                   |      |
| December 31, 2024                        | 23,546,095                                        |      |
| December 31, 2025                        | 20,498,589                                        |      |

The Company and its subsidiaries have depreciation for right-of-use assets presented in the statements of comprehensive income for the years ended December 31, 2025 and 2024 as follows.

Unit : Baht

| PARTICULARS             | CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS |                  |
|-------------------------|---------------------------------------------------|------------------|
|                         | 2025                                              | 2024             |
| Cost of services        | 3,678,542                                         | 3,540,066        |
| Administrative expenses | 1,169,153                                         | 1,283,276        |
| <b>Total</b>            | <b>4,847,695</b>                                  | <b>4,823,342</b> |



### 13. INTANGIBLE ASSETS

Unit : Baht

| PARTICULARS                     | CONSOLIDATED AND SEPARATE FINANCIAL STATEMENTS |                                 |            |
|---------------------------------|------------------------------------------------|---------------------------------|------------|
|                                 | PROGRAMS<br>COMPUTER                           | PATENT AND<br>DEVELOPMENT COSTS | TOTAL      |
| <u>Cost</u>                     |                                                |                                 |            |
| January 1, 2024                 | 1,983,949                                      | -                               | 1,983,949  |
| Purchases                       | -                                              | -                               | -          |
| December 31, 2024               | 1,983,949                                      | -                               | 1,983,949  |
| Purchases                       | 3,134,200                                      | 20,280,714                      | 23,414,914 |
| December 31, 2025               | 5,118,149                                      | 20,280,714                      | 25,398,863 |
| <u>Accumulated amortization</u> |                                                |                                 |            |
| January 1, 2024                 | 908,800                                        | -                               | 908,800    |
| Amortization for the year 2024  | 596,693                                        | -                               | 596,693    |
| December 31, 2024               | 1,505,493                                      | -                               | 1,505,493  |
| Amortization for the year 2025  | 734,636                                        | 223,562                         | 958,198    |
| December 31, 2025               | 2,240,129                                      | 223,562                         | 2,463,691  |
| <b>Net book value</b>           |                                                |                                 |            |
| December 31, 2024               | 478,456                                        | -                               | 478,456    |
| December 31, 2025               | 2,878,020                                      | 20,057,152                      | 22,935,172 |

The Company and its subsidiaries have amortization for intangible assets presented in the statements of comprehensive income for the years ended December 31, 2025 and 2024 as follows.

Unit : Baht

| PARTICULARS             | CONSOLIDATED AND SEPARATE FINANCIAL STATEMENTS |         |
|-------------------------|------------------------------------------------|---------|
|                         | 2025                                           | 2024    |
| Cost of services        | 655,691                                        | 208,481 |
| Administrative expenses | 302,507                                        | 388,212 |
| Total                   | 958,198                                        | 596,693 |

#### 14. TRADE AND OTHER CURRENT PAYABLES

Unit : Baht

| PARTICULARS                                                   | CONSOLIDATED<br>FINANCIAL STATEMENTS |            | SEPARATE<br>FINANCIAL STATEMENTS |            |
|---------------------------------------------------------------|--------------------------------------|------------|----------------------------------|------------|
|                                                               | 2025                                 | 2024       | 2025                             | 2024       |
| Trade payables related parties                                | 70,148,668                           | 15,272,283 | 65,063,073                       | 15,272,283 |
| Trade payables unrelated parties                              | 12,241,208                           | 8,488,305  | 11,350,138                       | 8,488,305  |
| Total trade payables                                          | 82,389,876                           | 23,760,588 | 76,413,211                       | 23,760,588 |
| Other current payables unrelated parties                      | 1,709,422                            | 2,055,889  | 1,128,927                        | 2,055,889  |
| Accrued expenses related parties                              | 1,085,239                            | 554,281    | 1,085,239                        | 554,281    |
| Accrued expenses unrelated parties                            | 11,603,896                           | 3,948,855  | 11,549,416                       | 3,903,855  |
| Unearned revenues                                             | 13,148,972                           | 5,282,172  | 13,148,972                       | 5,282,172  |
| Payables for acquisitions of fixed assets - related parties   | 2,634,719                            | 2,902,418  | 2,634,719                        | 2,902,418  |
| Payables for acquisitions of intangible - related parties     | -                                    | -          | 1,209,971                        | -          |
| Payables for acquisitions of intangible - unrelated parties   | 2,247,000                            | -          | 2,247,000                        | -          |
| Payables for acquisitions of fixed assets - unrelated parties | 2,706,887                            | 956,400    | 2,706,887                        | 956,400    |
| Revenue Department payable                                    | 1,920,775                            | 1,491,722  | 1,233,883                        | 1,491,722  |
| Others                                                        | 45,937                               | 8,009      | 45,937                           | 8,009      |
| Total other current payables                                  | 37,102,847                           | 17,199,746 | 36,990,951                       | 17,154,746 |
| Total trade and other current payables                        | 119,492,723                          | 40,960,334 | 113,404,162                      | 40,915,334 |

#### 15. LEASE LIABILITIES

Lease liabilities as at December 31, 2025 and 2024 are presented as follows :

Unit : Baht

| PARTICULARS                                      | CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS |             |
|--------------------------------------------------|---------------------------------------------------|-------------|
|                                                  | 2025                                              | 2024        |
| Lease payments                                   | 24,384,000                                        | 28,080,000  |
| <u>Less</u> Deferred interest expenses           | (2,913,193)                                       | (4,075,332) |
| Total                                            | 21,470,807                                        | 24,004,668  |
| <u>Less</u> Current portion of lease liabilities | (4,867,023)                                       | (4,213,365) |
| Lease liabilities-net                            | 16,603,784                                        | 19,791,303  |

A maturity analysis of lease payments is disclosed in Note 28.5 to the financial statements under the liquidity risk.

Movements of lease liabilities for the years ended December 31, 2025 and 2024 are summarised below.

Unit : Baht

| PARTICULARS                                                  | CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS |             |
|--------------------------------------------------------------|---------------------------------------------------|-------------|
|                                                              | 2025                                              | 2024        |
| Balances at the beginning of year                            | 24,004,668                                        | 23,720,170  |
| <u>Add</u> Additions during the year                         | 1,800,189                                         | -           |
| Adjustment from lease reassessment<br>and lease modification | -                                                 | 4,541,740   |
| Accretion of interest                                        | 1,441,950                                         | 1,358,758   |
| <u>Less</u> Payments during the year                         | (5,776,000)                                       | (5,616,000) |
| Balances at the end of year                                  | 21,470,807                                        | 24,004,668  |

Expenses for the years ended December 31, 2025 and 2024 relating to the lease are recognized in the following

Unit : Baht

| PARTICULARS                                         | CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS |           |
|-----------------------------------------------------|---------------------------------------------------|-----------|
|                                                     | 2025                                              | 2024      |
| <b>The amounts recognized in profit or loss</b>     |                                                   |           |
| Depreciation of right-of-use assets                 | 4,847,695                                         | 4,823,342 |
| Interest expenses on lease liabilities              | 1,441,950                                         | 1,358,758 |
| Expenses relating to leases of the low value assets | 270,392                                           | 270,392   |

## 16. PROVISION FOR LONG-TERM EMPLOYEE BENEFITS

Unit : Baht

| PARTICULARS                                               | CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS |           |
|-----------------------------------------------------------|---------------------------------------------------|-----------|
|                                                           | 2025                                              | 2024      |
| <u>Defined benefit obligation</u>                         |                                                   |           |
| Beginning balances                                        | 2,972,778                                         | 2,204,747 |
| Actuarial loss on re-measurement of defined benefit plans | 1,479,577                                         | -         |
| <u>Add</u> Current service cost                           | 708,646                                           | 682,046   |
| Interest cost                                             | 115,939                                           | 85,985    |
| Ending balances                                           | 5,276,940                                         | 2,972,778 |

The key assumptions used in determining the employee benefit liabilities are shown as follows:

PERCENTAGE PER ANNUM

| PARTICULARS                                   | CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS |       |
|-----------------------------------------------|---------------------------------------------------|-------|
|                                               | 2025                                              | 2024  |
| Discount rate                                 | 2.44                                              | 3.90  |
| Salary increase rate                          | 6.00                                              | 6.00  |
| Employee turnover rate (depends on the age) : |                                                   |       |
| - Less than 25 years old                      | 22.92                                             | 22.92 |
| - 25 - 29 years old                           | 17.19                                             | 17.19 |
| - 30 - 34 years old                           | 11.46                                             | 11.46 |
| - 35 - 39 years old                           | 7.64                                              | 7.64  |
| - 40 - 44 years old                           | 5.73                                              | 5.73  |
| - 45 - 49 years old                           | 3.82                                              | 3.82  |
| - 50 - 60 years old                           | 1.91                                              | 1.91  |

The result of sensitivity analysis for significant assumptions that affect the present value of the long-term employee benefit obligation as at December 31, 2025 and 2024 are summarized below.

Unit : Baht

| PARTICULARS                         | CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS |           |
|-------------------------------------|---------------------------------------------------|-----------|
|                                     | 2025                                              | 2024      |
| Discount rate decrease 1%           | 1,221,495                                         | 636,199   |
| Discount rate increase 1%           | (968,835)                                         | (509,666) |
| Salary increase rate decrease 1%    | (915,405)                                         | (537,852) |
| Salary increase rate increase 1%    | 1,122,779                                         | 666,775   |
| Employee turnover rate increase 20% | (838,089)                                         | (520,966) |
| Employee turnover rate decrease 20% | 1,045,852                                         | 677,475   |

## 17. EXPENSES BY NATURE

Unit : Baht

| PARTICULARS                                                  | CONSOLIDATED<br>FINANCIAL STATEMENTS |             | SEPARATE<br>FINANCIAL STATEMENTS |             |
|--------------------------------------------------------------|--------------------------------------|-------------|----------------------------------|-------------|
|                                                              | 2025                                 | 2024        | 2025                             | 2024        |
| Service expenses and supplies used                           | 183,227,720                          | 167,187,508 | 177,554,391                      | 167,187,508 |
| Director and management benefit expenses                     | 18,494,825                           | 13,072,474  | 18,494,825                       | 13,072,474  |
| Employee benefit expenses                                    | 63,985,260                           | 51,741,934  | 63,985,260                       | 51,741,934  |
| Depreciation and amortization                                | 21,546,109                           | 17,787,965  | 21,546,109                       | 17,787,965  |
| Expected credit loss                                         | 1,870,574                            | 1,384,382   | 1,870,574                        | 1,384,382   |
| (Reversal) reduction of inventory to<br>net realizable value | (134,637)                            | 186,108     | (134,637)                        | 186,108     |

## 18. SHARE CAPITAL

During March 12-14, 2024, the Company made an initial public offering of 160 million newly issued ordinary shares with a par value of Baht 0.50 each, at an offering price of Baht 1.63 per share, amounting to Baht 260.80 million. Subsequently on March 15, 2024, the Company has received full payment of the additional capital and then registered the increase of its issued and paid-up share capital from Baht 220 million (440 million ordinary shares with a par value of Baht 0.50 each) to Baht 300 million (600 million ordinary shares par value of Baht 0.50 each) with the Ministry of Commerce on March 15, 2024. The Stock Exchange of Thailand approved 600 million ordinary shares with a par value of Baht 0.50 each as securities, with trading permitted on March 20, 2024.

For the offering of such newly ordinary shares, the Company had directly related expense of Baht 9.59 million which had been recorded to net with its share premium ordinary shares. As a result, the Company had a share premium ordinary shares of Baht 171.21 million.

## 19. DIVIDEND PAYMENT AND STATUTORY RESERVE

On April 28, 2025, the Company's Ordinary General Shareholders' Meeting for the year 2025 approved to pay dividends from the operation of the year, at Baht 0.05 per share (600,000,000 shares) the amount of Baht 30.00 million. On May 28, 2025, the Company has paid dividend the amount of Baht 29.95 million.

On February 29, 2024, the Company's Ordinary General Shareholders' Meeting for the year 2024 acknowledge the payment of interim dividend during the year 2023, according to the Board of Directors' meeting on October 31, 2023, which had a resolution to pay interim dividend at Baht 0.0545 per share the amount of Baht 24.00 million. the Company has paid interim dividend on November 7, 2023. And had resolution not paying dividends for the year 2023.

Pursuant to Section 116 of the Public Limited Companies Act, B.E. 2535 (1992), the Company is required to set aside to a statutory reserve at least 5 percent of its net profit after deducting accumulated deficit brought forward (if any) until the reserve reaches to 10 percent of the registered capital. The statutory reserve is not available for dividend distribution.

During the year 2025, the Company approved the allocation of statutory reserve of Baht 2.20 million which combined with the statutory reserve already allocated amounted to Baht 13.20 million. (In 2024, the Company approved the allocation of statutory reserve of Baht 2.54 million. Which combined with the statutory reserve already allocated amounted to Baht 11.00 million.)

## 20. INCOME TAX

Corporate income taxes of the Company and its subsidiaries for the years ended December 31, 2025 and 2024 were calculated from accounting profit or loss and adjusted with other revenues and some expenses which are exempted from income tax, such as allowance for expected credit loss.

Non-BOI business operation or non-taxable privileges, the tax computation was calculated at the rate of 20 percent.

BOI business operation, income tax is calculated according to the privileges which are granted (see also Note 23).

Income tax expenses recognized in statements of comprehensive income consist:

Unit : Baht

| PARTICULARS FOR THE YEARS<br>ENDED DECEMBER 31,                               | CONSOLIDATED<br>FINANCIAL STATEMENTS |                  | SEPARATE<br>FINANCIAL STATEMENTS |                  |
|-------------------------------------------------------------------------------|--------------------------------------|------------------|----------------------------------|------------------|
|                                                                               | 2025                                 | 2024             | 2025                             | 2024             |
| The corporate income tax for the year                                         | (2,768,085)                          | (1,022,320)      | (2,197,616)                      | (1,022,320)      |
| Deferred tax relating to origination<br>and reversal of temporary differences | 243,927                              | 160,237          | 243,927                          | 160,237          |
| <b>Income tax expenses</b>                                                    | <b>(2,524,158)</b>                   | <b>(862,083)</b> | <b>(1,953,689)</b>               | <b>(862,083)</b> |

As at December 31, 2025 and 2024, the deferred tax assets/liabilities arose from the following temporary differences:

Unit : Baht

| PARTICULARS                                                                            | CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS |           |
|----------------------------------------------------------------------------------------|---------------------------------------------------|-----------|
|                                                                                        | 2025                                              | 2024      |
| <b>Tax rate 20%</b>                                                                    |                                                   |           |
| <b>Accumulated temporary differences in the statements<br/>of comprehensive income</b> |                                                   |           |
| Allowance for expected credit loss                                                     | 1,299,673                                         | 638,710   |
| Allowance for diminution in value of inventories                                       | 3,721,145                                         | 3,635,334 |
| Lease liabilities                                                                      | 122,516                                           | (58,979)  |
| Provision for long-term employee benefits                                              | 661,709                                           | 370,343   |
|                                                                                        | 5,805,043                                         | 4,585,408 |
| <b>Accumulated temporary differences in other comprehensive income</b>                 |                                                   |           |
| - recognized in other components of the shareholders' equity                           |                                                   |           |
| Provision for long-term employee benefits                                              | 540,767                                           | 17,961    |
| <b>Total</b>                                                                           | 6,345,810                                         | 4,603,369 |
| <b>Tax rate 0% (BOI – exemption tax 100%)</b>                                          |                                                   |           |
| <b>Accumulated temporary differences in the statements<br/>of comprehensive income</b> |                                                   |           |
| Allowance for expected credit loss                                                     | 4,262,228                                         | 3,052,617 |
| Allowance for diminution in value of inventories                                       | 1,031,820                                         | 1,252,268 |
| Lease liabilities                                                                      | 849,702                                           | 517,552   |
| Provision for long-term employee benefits                                              | 2,826,139                                         | 2,292,920 |
|                                                                                        | 8,969,889                                         | 7,115,357 |
| <b>Accumulated temporary differences in other comprehensive income</b>                 |                                                   |           |
| - recognized in other components of the shareholders' equity                           |                                                   |           |
| Provision for long-term employee benefits                                              | 1,248,325                                         | 291,554   |
| <b>Total</b>                                                                           | 10,218,214                                        | 7,406,911 |
| <b>Deferred tax assets</b>                                                             |                                                   |           |
| Tax rate 20%                                                                           | 1,269,162                                         | 920,674   |
| Tax rate 0% (BOI – exemption tax 100%)                                                 | -                                                 | -         |
| <b>Total deferred tax assets</b>                                                       | 1,269,162                                         | 920,674   |

The reconciliation between accounting profit and tax expenses as follows :

| CONSOLIDATED FINANCIAL STATEMENTS                                                                                           |            |            |            |            |           |            | Unit : Baht |
|-----------------------------------------------------------------------------------------------------------------------------|------------|------------|------------|------------|-----------|------------|-------------|
| 2025                                                                                                                        |            |            |            | 2024       |           |            |             |
|                                                                                                                             | BOI        | Non-BOI    | Total      | BOI        | Non-BOI   | Total      |             |
| Accounting profit before income tax                                                                                         | 36,948,144 | 10,901,545 | 47,849,689 | 47,281,821 | 3,739,433 | 51,021,254 |             |
| Tax rate                                                                                                                    | 0%         | 20%        |            | 0%         | 20%       |            |             |
| Corporate tax applicable to profit                                                                                          | -          | 2,180,309  | 2,180,309  | -          | 747,887   | 747,887    |             |
| Effects of :                                                                                                                |            |            |            |            |           |            |             |
| Non-deductible expenses                                                                                                     | -          | 266,530    | 266,530    | -          | 99,383    | 99,383     |             |
| Expenses deductible at a greater amount for tax                                                                             | -          | (35,819)   | (35,819)   | -          | (17,095)  | (17,095)   |             |
| Tax losses from prior periods that had not been previously recognized and are utilized to reduce current income tax expense | -          | (4,888)    | (4,888)    | -          | -         | -          |             |
| Unused tax loss                                                                                                             | -          | 53,195     | 53,195     | -          | 31,908    | 31,908     |             |
| Other                                                                                                                       | -          | 64,831     | 64,831     | -          | -         | -          |             |
| Tax expenses reported in the statements of comprehensive income                                                             | -          | 2,524,158  | 2,524,158  | -          | 862,083   | 862,083    |             |
| SEPARATE FINANCIAL STATEMENTS                                                                                               |            |            |            |            |           |            | Unit : Baht |
| 2025                                                                                                                        |            |            |            | 2024       |           |            |             |
|                                                                                                                             | BOI        | Non-BOI    | Total      | BOI        | Non-BOI   | Total      |             |
| Accounting profit before income tax                                                                                         | 36,948,144 | 8,746,824  | 45,694,968 | 47,281,821 | 3,898,973 | 51,180,794 |             |
| Tax rate                                                                                                                    | 0%         | 20%        |            | 0%         | 20%       |            |             |
| Corporate tax applicable to profit                                                                                          | -          | 1,749,365  | 1,749,365  | -          | 779,795   | 779,795    |             |
| Effects of :                                                                                                                |            |            |            |            |           |            |             |
| Non-deductible expenses                                                                                                     | -          | 240,143    | 240,143    | -          | 99,383    | 99,383     |             |
| Expenses deductible at a greater amount for tax                                                                             | -          | (35,819)   | (35,819)   | -          | (17,095)  | (17,095)   |             |
| Tax expenses reported in the statements of comprehensive income                                                             | -          | 1,953,689  | 1,953,689  | -          | 862,083   | 862,083    |             |

Page 31



## 21. EARNINGS PER SHARE

Basic earnings per share for the years ended December 31, 2025 and 2024 were calculated by dividing profit for the year attributable to equity with the number of ordinary shares held by outsiders by the weighted average method as follows:

| PARTICULARS<br><br>For the years ended December 31, | CONSOLIDATED<br>FINANCIAL STATEMENTS |             | SEPARATE<br>FINANCIAL STATEMENTS |             |
|-----------------------------------------------------|--------------------------------------|-------------|----------------------------------|-------------|
|                                                     | 2025                                 | 2024        | 2025                             | 2024        |
| Profit for the years (Baht)                         | 45,349,947                           | 50,171,502  | 43,741,279                       | 50,318,711  |
| Number of ordinary shares as of January 1,          | 600,000,000                          | 440,000,000 | 600,000,000                      | 440,000,000 |
| Effect from issued share capital                    | -                                    | 127,213,115 | -                                | 127,213,115 |
| Weighted average number of ordinary shares (Shares) | 600,000,000                          | 567,213,115 | 600,000,000                      | 567,213,115 |
| Basic earnings per share (Baht)                     | 0.076                                | 0.088       | 0.073                            | 0.089       |

Basic earnings per share is calculated by dividing profit for the years attributable to equity holders of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares issued during the years.

## 22. FOREIGN CURRENCY TRANSACTIONS

22.1 As at December 31, 2025 and 2024, the Company and its subsidiaries have assets and liabilities denominated in foreign currencies as follows:

Unit : Million

| CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS | FOREIGN CURRENCIES |      | CONVERTED TO BAHT |       |
|---------------------------------------------------|--------------------|------|-------------------|-------|
|                                                   | 2025               | 2024 | 2025              | 2024  |
| ASSETS                                            |                    |      |                   |       |
| USD                                               | 0.39               | 0.21 | 12.23             | 7.22  |
| LIABILITIES                                       |                    |      |                   |       |
| USD                                               | 2.22               | 0.53 | 70.49             | 18.16 |

22.2 The Group is exposed to foreign currency risk relating to purchases which are denominated in foreign currencies. The Group primarily utilizes forward exchange contracts with maturities of less than one year to hedge such financial assets and liabilities denominated in foreign currencies. The forward exchange contracts entered into at the reporting date also relate to anticipated purchases denominated in foreign currencies, for the subsequent period.

As at December 31, 2025 and 2024, the Company has entered into purchases Forward Exchange Contracts with the local commercial bank for hedging against any risk in exchange rate fluctuation which might affect to Baht payment to import trade accounts payable that can be summarized as follow :

Unit : Million

| CONSOLIDATED AND<br>SEPARATE FINANCIAL STATEMENTS | FOREIGN<br>CURRENCIES | FAIR VALUE<br>IN BAHT | SETTLEMENT<br>DATE |
|---------------------------------------------------|-----------------------|-----------------------|--------------------|
| As at December 31, 2025                           |                       |                       |                    |
| USD                                               | 0.96                  | 30.07                 | March - June 2026  |
| As at December 31, 2024                           |                       |                       |                    |
| USD                                               | 0.20                  | 6.68                  | April 2025         |

### 23.PROMOTIONAL PRIVILEGES

|                                                                                                                                              |                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| 1. Promotional certificates Nos.                                                                                                             | 61-0945-1-00-2-0                          |
| 2. Date of promotional certificates                                                                                                          | 12/02/2018                                |
| 3. The first date of generating income                                                                                                       | 12/02/2018                                |
| 4. The promotional privileges for manufacturing of                                                                                           | Medical testing and analysis services     |
| 5. Important privileges which are granted                                                                                                    |                                           |
| 5.1 Exemption from corporate income tax rate of 100% on net profit from promotional operations, commencing from the generating revenue date. | 8 years<br>(Expired on February 11, 2026) |
| 5.2 Exemption from income tax on dividends from promoted business which was exempted from income tax as 5.1.                                 | 8 years<br>(Expired on February 11, 2026) |

As a promoted industry, the Company must strictly comply with certain terms and conditions stipulated in the promotional certificates.

The Company and its subsidiaries have Exemption Revenues from corporate income tax and Non Exemption Revenues from corporate income tax for the years ended December 31, 2025 and 2024 as follows:-

Unit : Baht

| PARTICULARS                                      | CONSOLIDATED FINANCIAL STATEMENTS |        |             |        |
|--------------------------------------------------|-----------------------------------|--------|-------------|--------|
|                                                  | 2025                              |        | 2024        |        |
|                                                  | AMOUNT                            | %      | AMOUNT      | %      |
| Exemption Revenues from corporate income tax     | 239,235,207                       | 63.04  | 238,099,863 | 70.53  |
| Non Exemption Revenues from corporate income tax | 140,275,925                       | 36.96  | 99,493,034  | 29.47  |
| Total                                            | 379,511,132                       | 100.00 | 337,592,897 | 100.00 |

Unit : Baht

| PARTICULARS                                      | SEPARATE FINANCIAL STATEMENTS |        |             |        |
|--------------------------------------------------|-------------------------------|--------|-------------|--------|
|                                                  | 2025                          |        | 2024        |        |
|                                                  | AMOUNT                        | %      | AMOUNT      | %      |
| Exemption Revenues from corporate income tax     | 239,235,207                   | 64.67  | 238,099,863 | 70.53  |
| Non Exemption Revenues from corporate income tax | 130,724,524                   | 35.33  | 99,493,034  | 29.47  |
| Total                                            | 369,959,731                   | 100.00 | 337,592,897 | 100.00 |

## 24.COMMITMENT AND CONTINGENT LIABILITIES

24.1 As at December 31, 2025, fixed deposit and savings deposit pledged as collateral with financial institutions are as follow: (See Note 8).

Unit : Baht

| PARTICULARS                                | CONSOLIDATED         |           | SEPARATE             |           |
|--------------------------------------------|----------------------|-----------|----------------------|-----------|
|                                            | FINANCIAL STATEMENTS |           | FINANCIAL STATEMENTS |           |
|                                            | 2025                 | 2024      | 2025                 | 2024      |
| For bank gurantee in business operation    | 12,729,000           | 3,229,000 | 11,229,000           | 3,229,000 |
| For the purchase forward exchange contract | 3,500,000            | 3,500,000 | 3,500,000            | 3,500,000 |
| Total restricted bank deposit              | 16,229,000           | 6,729,000 | 14,729,000           | 6,729,000 |

24.2 As at December 31, 2025, the Group has letters of guarantee issued by the commercial banks, outstanding in the consolidated financial statements in the amount of Baht 11,185,150 and in the separate financial statements in the amount of Baht 10,135,150 to ensure the performance under the contract (2024 : the consolidated and separate financial statements in the amount of Baht 800,000).

24.3 As at December 31, 2025, the Group has entered into several lease agreement in respect of the lease of office equipment and office rental contract. The Group has future minimum lease payment under this operating lease contract which cannot be terminated as follow.

Payable within

Unit : Million Baht

Less than 1 year

0.19

1 to 3 years

0.02

24.4 As at December 31, 2025, the Company has commitment capital expenditure related to purchases fixed assets amount of Baht 2.46 million (2024 : Baht 0.05 million).

## 25. TRANSACTIONS WITH RELATED PARTIES

The Company has certain business transactions with its related parties which are related through, directorship or shareholding or having shareholders or some co-directors. The effects of these transactions were reflected in the accompanying financial statements in normal business and general trading conditions.

| RELATED PARTIES                           | ESTABLISHED IN | TYPE OF BUSINESS                                                                      | RELATIONSHIP                                     |
|-------------------------------------------|----------------|---------------------------------------------------------------------------------------|--------------------------------------------------|
| Subsidiaries                              | Thailand       | See Note 9                                                                            | See Note 9                                       |
| Associate                                 | Thailand       | See Note 10                                                                           | See Note 10                                      |
| Related parties                           |                |                                                                                       |                                                  |
| 1. BGI Tech Solutions (Hong Kong) Co.,Ltd | Hong Kong      | Genomics services including physical and commercialization research                   | Co - shareholders                                |
| 2. BGI Health (HK) Co.,Ltd.               | Hong Kong      | Genomics services including physical and commercialization research                   | Shareholders                                     |
| 3. BGI Health Hungary Co., Ltd.           | Hungary        | Genomics services including physical and commercialization research                   | Co - shareholders                                |
| 4. BGI Health (AU) Company Pte.,Ltd.      | Australia      | Genomics services including physical and commercialization research                   | Co - shareholders                                |
| 5. BGI UK Co.,Ltd                         | England        | Genomics services including physical and commercialization research                   | Co - shareholders                                |
| 6. MGI Tech Singapore Pte.,Ltd.           | Singapore      | Genomics services including physical and commercialization research                   | Co - shareholders                                |
| 7. Shenzhen Zaozhidao Technology Co.,Ltd. | China          | Development of biotechnology techniques and selling biological products               | Co - shareholders                                |
| 8. Krungthai Land Development Co.,Ltd.    | Thailand       | Real estate business development                                                      | Co - directors                                   |
| 9. Genovation Co.,Ltd.                    | Thailand       | Health analytic service, medical checkup service                                      | Co - directors                                   |
| 10. Thai Omics Co.,Ltd.                   | Thailand       | Business services related to genomics medicine                                        | Co - directors                                   |
| 11. Pure Select Co.,Ltd.                  | Thailand       | Retail business of pharmaceutical products and medical supplies                       | Co - directors                                   |
| 12. Compound Assets Co.,Ltd.              | Thailand       | Real estate business development                                                      | Co - shareholders                                |
| 13. Krung Thai Tractor Co.,Ltd.           | Thailand       | Selling tractors, hydraulic excavators, wheel loader, air compressors and spare parts | Shareholder is related to the Company's director |
| 14. BGI Bio-Solutions Hongkong Co.,Ltd.   | Hong Kong      | Genomics services including physical and commercialization research                   | Co - shareholders                                |

| RELATED PARTIES                                                    | ESTABLISHED IN       | TYPE OF BUSINESS                                                    | RELATIONSHIP      |
|--------------------------------------------------------------------|----------------------|---------------------------------------------------------------------|-------------------|
| 15. BGI College                                                    | China                | Educational institution provides training services                  | Co - shareholders |
| 16. BGI Specialized Medical Solution DMCC                          | United Arab Emirates | Manufacture and distribution of protein products                    | Co - shareholders |
| 17. BGI Precision Nutrition Trade Development (Shenzhen) Co., Ltd. | China                | Food Import and Export                                              | Co - shareholders |
| 18. Wegene (Hong Kong) Company Limited                             | China                | Genomics services including physical and commercialization research | Co - shareholders |

The significant transactions with related parties are as follows:

Unit : Baht

| The balances of the accounts between the Company and those related parties | CONSOLIDATED FINANCIAL STATEMENTS |            | SEPARATE FINANCIAL STATEMENTS |            |
|----------------------------------------------------------------------------|-----------------------------------|------------|-------------------------------|------------|
|                                                                            | 2025                              | 2024       | 2025                          | 2024       |
| <u>Trade accounts receivables-net and other current receivables</u>        |                                   |            |                               |            |
| - Subsidiaries                                                             | -                                 | -          | 3,477,045                     | 1,240,446  |
| - Related companies                                                        | 123,201,814                       | 11,889,571 | 120,303,814                   | 11,889,571 |
| <u>Right-of-use assets</u>                                                 |                                   |            |                               |            |
| - Related company                                                          | 20,498,589                        | 23,546,095 | 20,498,589                    | 23,546,095 |
| <u>Other non - current assets</u>                                          |                                   |            |                               |            |
| - Related company                                                          | 413,124                           | 2,417,876  | 413,124                       | 2,417,876  |
| <u>Trade and other current payables</u>                                    |                                   |            |                               |            |
| - Subsidiaries                                                             | -                                 | -          | 1,423,971                     | -          |
| - Related companies                                                        | 73,868,626                        | 18,728,982 | 68,569,031                    | 18,728,982 |
| <u>Lease liabilities</u>                                                   |                                   |            |                               |            |
| - Related company                                                          | 21,470,807                        | 24,004,668 | 21,470,807                    | 24,004,668 |

**The significant transactions with related parties are as follows: (Continuous)**

Unit : Baht

| Transactions with related parties for the years ended December 31, | CONSOLIDATED FINANCIAL STATEMENTS |            | SEPARATE FINANCIAL STATEMENTS |            | Transfer pricing policy |
|--------------------------------------------------------------------|-----------------------------------|------------|-------------------------------|------------|-------------------------|
|                                                                    | 2025                              | 2024       | 2025                          | 2024       |                         |
| <u>Revenues from sales</u>                                         |                                   |            |                               |            |                         |
| - Related companies                                                | 339,161                           | -          | 339,161                       | -          | Market price            |
| <u>Revenues from service</u>                                       |                                   |            |                               |            |                         |
| - Subsidiaries                                                     | -                                 | -          | 3,271,028                     | -          | Market price            |
| - Related companies                                                | -                                 | 51,424     | -                             | 51,424     | Market price            |
| <u>Other incomes</u>                                               |                                   |            |                               |            |                         |
| - Subsidiaries                                                     | -                                 | -          | 27,832                        | 10,650     | Contract price          |
| - Related companies                                                | 7,766                             | 292,906    | 7,766                         | 292,906    | Contract price          |
| <u>Purchase goods</u>                                              |                                   |            |                               |            |                         |
| - Related companies                                                | 97,135,000                        | 89,895,073 | 91,822,568                    | 89,895,073 | Contract price          |
| <u>Cost of service</u>                                             |                                   |            |                               |            |                         |
| - Related companies                                                | 17,118,734                        | 14,902,782 | 17,118,734                    | 14,902,782 | Contract price          |
| <u>Selling expenses</u>                                            |                                   |            |                               |            |                         |
| - Related companies                                                | 13,482                            | 280,981    | 13,482                        | 280,981    | Contract price          |
| <u>Administrative expenses</u>                                     |                                   |            |                               |            |                         |
| - Subsidiaries                                                     | -                                 | -          | 214,000                       | -          | Market price            |
| - Related companies                                                | 1,554,614                         | 1,688,082  | 1,554,614                     | 1,688,082  | Market price            |
| <u>Rental fee - Right of use</u>                                   |                                   |            |                               |            |                         |
| - Related companies                                                | 5,776,000                         | 5,616,000  | 5,776,000                     | 5,616,000  | Contract price          |
| <u>Purchase fixed assets</u>                                       |                                   |            |                               |            |                         |
| - Related companies                                                | 4,997,718                         | 9,254,332  | 4,997,718                     | 9,254,332  | Contract price          |
| <u>Purchase intangible assets</u>                                  |                                   |            |                               |            |                         |
| - Related companies                                                | 5,883,705                         | -          | 5,883,705                     | -          | Contract price          |

**Directors and management's benefits**

The Company had employee benefit expenses payable to their director's and management as follows :

Unit : Baht

| PARTICULARS<br>For the years ended December 31, | CONSOLIDATED AND SEPARATE FINANCIAL STATEMENTS |            |
|-------------------------------------------------|------------------------------------------------|------------|
|                                                 | 2025                                           | 2024       |
| Short-term employee benefits                    | 18,213,920                                     | 12,810,320 |
| Post-employment benefits                        | 280,905                                        | 262,154    |
| Total                                           | 18,494,825                                     | 13,072,474 |

## 26. FINANCIAL INFORMATION BY SEGMENT

Operating segment information is reported in a manner consistent with the internal reports that are regularly reviewed by the chief operating decision maker in order to make decisions about the allocation of resources to the segment and assess its performance as follows: 1. Sale of laboratory reagents and related products. 2. Testing and analysis services 3. Sale and advanced therapy medicinal product

The Company financial information by segments in the financial statements for the years ended December 31, 2025 and 2024 are as follows :

Unit : Million Baht

| CONSOLIDATED FINANCIAL STATEMENTS           |                                                     |         |                                  |          |                                                |      |             |          |          |
|---------------------------------------------|-----------------------------------------------------|---------|----------------------------------|----------|------------------------------------------------|------|-------------|----------|----------|
|                                             | Sale of laboratory reagents<br>and related products |         | Testing and analysis<br>services |          | Sale and advanced therapy<br>medicinal product |      | Elimination | Total    |          |
|                                             | 2025                                                | 2024    | 2025                             | 2024     | 2025                                           | 2024 |             | 2025     | 2024     |
| Revenues from operation                     | 102.71                                              | 81.09   | 267.25                           | 256.50   | 12.82                                          | -    | 3.27        | 379.51   | 337.59   |
| Cost from operation                         | (57.27)                                             | (56.53) | (160.94)                         | (140.98) | (8.94)                                         | -    | (3.27)      | (223.88) | (197.51) |
| Segment result                              | 45.44                                               | 24.56   | 106.31                           | 115.52   | 3.88                                           | -    | -           | 155.63   | 140.08   |
| Other income                                |                                                     |         |                                  |          |                                                |      |             | 7.21     | 8.27     |
| Selling expenses                            |                                                     |         |                                  |          |                                                |      |             | (49.08)  | (39.41)  |
| Administrative expenses                     |                                                     |         |                                  |          |                                                |      |             | (62.27)  | (55.10)  |
| Profit from operating activities            |                                                     |         |                                  |          |                                                |      |             | 51.49    | 53.84    |
| Finance costs                               |                                                     |         |                                  |          |                                                |      |             | (1.44)   | (1.36)   |
| Share of loss from investments in associate |                                                     |         |                                  |          |                                                |      |             | (0.33)   | (0.08)   |
| Expected credit loss                        |                                                     |         |                                  |          |                                                |      |             | (1.87)   | (1.38)   |
| Profit before income tax                    |                                                     |         |                                  |          |                                                |      |             | 47.85    | 51.02    |
| Income tax expenses                         |                                                     |         |                                  |          |                                                |      |             | (2.52)   | (0.86)   |
| Profit for the year                         |                                                     |         |                                  |          |                                                |      |             | 45.33    | 50.16    |

Unit : Million Baht

| SEPARATE FINANCIAL STATEMENTS    |                                  |         |                                                     |          |          |          |
|----------------------------------|----------------------------------|---------|-----------------------------------------------------|----------|----------|----------|
|                                  | Testing and<br>analysis services |         | Sale of laboratory reagents<br>and related products |          | Total    |          |
|                                  | 2025                             | 2024    | 2025                                                | 2024     | 2025     | 2024     |
| Revenues from operation          | 102.71                           | 81.09   | 267.25                                              | 256.50   | 369.96   | 337.59   |
| Cost from operation              | (57.27)                          | (56.53) | (160.94)                                            | (140.98) | (218.21) | (197.51) |
| Segment result                   | 45.44                            | 24.56   | 106.31                                              | 115.52   | 151.75   | 140.08   |
| Other income                     |                                  |         |                                                     |          | 7.28     | 8.28     |
| Selling expenses                 |                                  |         |                                                     |          | (48.62)  | (39.41)  |
| Administrative expenses          |                                  |         |                                                     |          | (61.41)  | (55.03)  |
| Profit from operating activities |                                  |         |                                                     |          | 49.00    | 53.92    |
| Finance costs                    |                                  |         |                                                     |          | (1.44)   | (1.36)   |
| Expected credit loss             |                                  |         |                                                     |          | (1.87)   | (1.38)   |
| Profit before income tax         |                                  |         |                                                     |          | 45.69    | 51.18    |
| Income tax expenses              |                                  |         |                                                     |          | (1.95)   | (0.86)   |
| Profit for the year              |                                  |         |                                                     |          | 43.74    | 50.32    |

## **27. PROVIDENT FUND**

The Company and its employees have jointly established a provident fund in accordance with the Provident Fund Act B.E.2530. The Company contributed to the fund monthly at the rate of 5% - 10% of basic salary and employee contributed to the fund monthly at the rate of 2% - 15% of basic salary. The fund, which is managed by SCB Asset Management Co.,Ltd., will be paid to employees upon termination in accordance with the fund rules. The contributions for the year 2025 amounting to Baht 1.37 million (2024 : Baht 1.15 million) were recognised as expenses in the statements of comprehensive income.

## **28. DISCLOSURE OF FINANCIAL INSTRUMENTS**

The Company has information relating to financial instruments both in and off statements of financial position, as follows:

### **28.1 Accounting policies and procedure**

See Note 3.

### **28.2 Risk from breach of contracts**

- Due to the contracting parties do not follow the requirement in the contract which caused damage to the Group.
- Risk from concentration of credit is minimal even most resulting from scientific testing service for large companies and small companies, the Company has closely monitored each trade account receivable business. Thus, the Company does not expect any material damage from this kind of risk.
- For the financial assets shown in the statements of financial position, the book value of such assets is net from various provisions to be estimated fair value. Such provisions are assumed to be the highest value of risk incurred from breach of contracts.

### **28.3 Risk from exchange rate**

The Group has risk from the fluctuation in foreign exchange rates, due to some debtors and creditors arisen from trading in foreign currencies. The Group will prepare the forward exchange contract, in the case of Thai Baht volatility, if the Company deems it appropriate.

### **28.4 Risk relating to interest rate**

Risk from the fluctuation in interest rate may have negative effect to the Group for the current and the following years. Management believes that they can manage the contingent risk, due to the Group has set up a plan and follow up the situation closely.



Risk relating to interest rate (Continuous)

Unit : Million Baht

CONSOLIDATED FINANCIAL STATEMENTS

|                                            | As at December 31, 2025 |            |                   |        | As at December 31, 2024 |               |            |                   |
|--------------------------------------------|-------------------------|------------|-------------------|--------|-------------------------|---------------|------------|-------------------|
|                                            | Floating rate           | Fixed rate | Non-Interest rate | Total  | Interest rate           | Floating rate | Fixed rate | Non-Interest rate |
| <u>Financial assets</u>                    |                         |            |                   |        |                         |               |            |                   |
| Cash and cash equivalents                  | 119.58                  | -          | 2.13              | 121.71 | 0.40% - 1.50%           | 197.71        | -          | 2.20              |
| Other current financial assets             | -                       | 100.03     | -                 | 100.03 | 0.90% - 1.20%           | -             | 190.02     | -                 |
| Restricted bank deposit                    | 15.71                   | 0.52       | -                 | 16.23  | 0.40% - 0.90%           | 6.21          | 0.52       | -                 |
| <u>Financial liabilities</u>               |                         |            |                   |        |                         |               |            |                   |
| Current portion of lease liabilities       | -                       | 4.87       | -                 | 4.87   | 5.72% - 7.15%           | -             | 4.21       | -                 |
| Lease liabilities - net of current portion | -                       | 16.60      | -                 | 16.60  | 5.72% - 7.15%           | -             | 19.79      | -                 |

Unit : Million Baht

SEPARATE FINANCIAL STATEMENTS

|                                            | As at December 31, 2025 |            |                   |        | As at December 31, 2024 |               |            |                   |
|--------------------------------------------|-------------------------|------------|-------------------|--------|-------------------------|---------------|------------|-------------------|
|                                            | Floating rate           | Fixed rate | Non-Interest rate | Total  | Interest rate           | Floating rate | Fixed rate | Non-Interest rate |
| <u>Financial assets</u>                    |                         |            |                   |        |                         |               |            |                   |
| Cash and cash equivalents                  | 105.42                  | -          | 2.05              | 107.47 | 0.40% - 1.50%           | 185.73        | -          | 0.18              |
| Other current financial assets             | -                       | 100.03     | -                 | 100.03 | 0.90% - 1.20%           | -             | 190.02     | -                 |
| Restricted bank deposit                    | 14.21                   | 0.52       | -                 | 14.73  | 0.40% - 0.90%           | 6.21          | 0.52       | -                 |
| <u>Financial liabilities</u>               |                         |            |                   |        |                         |               |            |                   |
| Current portion of lease liabilities       | -                       | 4.87       | -                 | 4.87   | 5.72% - 7.15%           | -             | 4.21       | -                 |
| Lease liabilities - net of current portion | -                       | 16.60      | -                 | 16.60  | 5.72% - 7.15%           | -             | 19.79      | -                 |

## 28.5 Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash, management maintains a level of cash and cash equivalents deemed adequate by management to finance the Group and operations and mitigate the effects of fluctuations in cash flows.

| CONSOLIDATED FINANCIAL STATEMENTS          |                  |                |                         |         |                  | Unit : Million Baht |
|--------------------------------------------|------------------|----------------|-------------------------|---------|------------------|---------------------|
| As at December 31, 2025                    |                  |                | As at December 31, 2024 |         |                  |                     |
| At call                                    | Within 12 months | Over 12 months | Total                   | At call | Within 12 months | Over 12 months      |
| <u>Financial assets</u>                    |                  |                |                         |         |                  |                     |
| Cash and cash equivalents                  | 121.71           | -              | 121.71                  | 199.91  | -                | 199.91              |
| Other current financial assets             | -                | 100.03         | 100.03                  | -       | 190.02           | 190.02              |
| Restricted bank deposit                    | 15.71            | 0.52           | 16.23                   | 6.21    | 0.52             | 6.73                |
| <u>Financial liabilities</u>               |                  |                |                         |         |                  |                     |
| Current portion of lease liabilities       | -                | 4.87           | 4.87                    | -       | 4.21             | 4.21                |
| Lease liabilities - net of current portion | -                | -              | 16.60                   | -       | -                | 19.79               |

| SEPARATE FINANCIAL STATEMENTS              |                  |                |                         |         |                  | Unit : Million Baht |
|--------------------------------------------|------------------|----------------|-------------------------|---------|------------------|---------------------|
| As at December 31, 2025                    |                  |                | As at December 31, 2024 |         |                  |                     |
| At call                                    | Within 12 months | Over 12 months | Total                   | At call | Within 12 months | Over 12 months      |
| <u>Financial assets</u>                    |                  |                |                         |         |                  |                     |
| Cash and cash equivalents                  | 107.47           | -              | 107.47                  | 185.91  | -                | 185.91              |
| Other current financial assets             | -                | 100.03         | 100.03                  | -       | 190.02           | 190.02              |
| Restricted bank deposit                    | 14.21            | 0.52           | 14.73                   | 6.21    | 0.52             | 6.73                |
| <u>Financial liabilities</u>               |                  |                |                         |         |                  |                     |
| Current portion of lease liabilities       | -                | 4.87           | 4.87                    | -       | 4.21             | 4.21                |
| Lease liabilities - net of current portion | -                | -              | 16.60                   | -       | -                | 19.79               |

#### 28.6 Fair value estimation

The carrying amount of cash and cash equivalents, other current financial assets, trade receivables, amounts due from related parties, trade payables, other current payables, amounts due to related parties are assumed to approximate their fair value due to the short maturities of these instruments.

### 29. EVENTS AFTER THE REPORTING PERIOD

On 25 February 2026, the Board of Directors' Meeting No. 1/2026 passed a resolution to propose to the Annual General Meeting of Shareholders for approval of a dividend payment from the annual operating results at the rate of Baht 0.05 per share, totaling Baht 30,000,000. The payment of such dividend is subject to the approval of the Company's Annual General Meeting of Shareholders.

The Board of Directors' Meeting also approved a resolution to acquire additional investment in Biovision Tech Company Limited for 19,599 shares at Baht 100 per share, totaling Baht 1,959,900. Following this transaction, the total investment value in this subsidiary will increase to Baht 3,999,800, representing a shareholding proportion of 99.995% of the registered capital.

In addition, the Board of Directors' Meeting approved a resolution to dispose of investment in Comprehensive Care Company Limited for 24,498 shares at Baht 100 per share, totaling Baht 2,449,800. After the disposal, the Company will retain 25,500 shares, with a remaining investment value of Baht 2,550,000, representing a decreased shareholding proportion of 51.00% of the registered capital.

### 30. FINANCIAL STATEMENTS APPROVAL

These financial statements were authorized for issue by the Company's Board of Directors on February 25, 2026.

Attachment

## Back up attachment

Attachment 1 : Details of directors, executives, controlling persons, the person assigned to take the highest responsibility in Accounting and Finance, the person assigned to take direct responsibility for accounting supervision, the Company's secretary, and the representative for contact and coordination in case of a foreign company

Link to attachment : <https://eonemedia.setlink.set.or.th/report/1828/2025/1774912369584.pdf>



Attachment 2 : Details of the directors of subsidiaries

Link to attachment : <https://eonemedia.setlink.set.or.th/report/1828/2025/1774827363109.pdf>



Attachment 3 : Details of the Heads of the Internal Audit and Compliance Units

Link to attachment : <https://eonemedia.setlink.set.or.th/report/1828/2025/1774827363155.pdf>



Attachment 4 : Assets for business undertaking and details of asset appraisal

Link to attachment : <https://eonemedia.setlink.set.or.th/report/1828/2025/1774571598647.pdf>



Attachment 5 : Unabridged policy and guidelines on corporate governance and unabridged code of business conduct prepared by the Company

Link to attachment : <https://eonemedia.setlink.set.or.th/report/1828/2025/1774827363200.pdf>



Attachment 6 : Report of the Audit Committee

Link to attachment : <https://eonemedia.setlink.set.or.th/report/1828/2025/1774827363204.pdf>

